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THESIS ABSTRACT
Campylobacter spp. are well-established human, veterinary and economic pathogens,
with a broad host range spanning from terrestrial and marine mammalian, avian and
reptilian hosts. The scope of the study includes novel and notorious species within the
genus, with reference to zoonotic agents Campylobacter jejuni and Campylobacter
coli - the leading cause of human bacterial gastroenteritis in the EU and Ireland,
Campylobacter fetus that represents the most common campylobacter causing
bacteraemia and two novel species isolated from pigs not described in the literature
previously.
C. jejuni and C. coli isolates (n = 350) recovered from broiler caecal and neck skin
samples, collected from the three main poultry processing plants in Ireland between
September 2017 and September 2018, were tested for the susceptibility to six clinically
relevant antimicrobials. Overall, 45.1% of Campylobacter spp. isolates tested were
resistant to at least one antimicrobial. Resistance rates were broadly in line with figures
reported nationally over the past 20 years, indicating that resistance is stable and
persistent, and an increasing incidence of tetracycline resistance in C. jejuni was noted.
Known or related antimicrobial resistance genes were identified in all isolates with
phenotypic resistance, and we highlight the importance of clonal expansion of resistant
strains and potential for horizontal gene transfer in Campylobacter.
A C. fetus subsp. fetus (Cff) isolate (CITCf01) recovered from a case of prosthetic
valve endocarditis (2017) was tested for its ability to form a biofilm. Biofilms were
stronger than that of a known Campylobacter jejuni biofilm forming strain and this
was the first report of biofilm formation within the species, using a modified crystal
violet staining method developed in this study.
A second Cff (CITCf02) was isolated from the recurrent case of prosthetic valve
endocarditis in late 2018. Genomic and phenotypic comparisons of the isolates were
performed, and their taxonomic position among previously described Cff isolates from
humans (n = 83) was determined. Cff isolates CITCf01 and CITCf02 were confirmed
to be the same strain and the polymorphic sap island (known to contribute to immune
evasion) defined their temporal separation. These Cff isolates were marked for their
unusual ability to grow aerobically, despite a high degree of genetic relatedness to
viii

other members of the subspecies that are not capable of growth in air. Mutations in
genes putatively involved in stress response were identified in CITCf01 and CITCf02.
Campylobacter isolated from the porcine gastrointestinal tract in the 1980s were
formally classified as novel species in this study, using a polyphasic approach
encompassing biochemical, phenotypic, genomic and taxonomic analyses. The
pathogenic potential of the genus was explored, and factors contributing to their
persistence.
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1.1

Introduction – Campylobacter spp.

Campylobacter spp. are motile, spiral Gram negative Epsilonproteobacteria.
Campylobacter spp. are well-established human and veterinary pathogens and remain
the leading cause of human bacterial gastroenteritis and the most frequently reported
zoonosis in the European Union (EU) and Ireland (European Food Safety Authority
2011; Health Protection Surveillance Centre 2020). Campylobacteraceae have a broad
host range spanning from terrestrial and marine mammalian, avian and reptilian hosts
(McCarthy et al. 2007; Gilbert et al. 2017). Campylobacters can exist in the
environment but are most frequently isolated from the gastrointestinal tract of birds,
reptiles, marine and terrestrial animals and man (Lawson et al. 2001), while their
isolation has largely been limited by conventional culture techniques, historically (On
2001). Campylobacter jejuni predominantly, and Campylobacter coli to a lesser
extent, remain the leading causes of campylobacteriosis, primarily manifesting as
gastroenteritis (European Food Safety Authority 2011).
Campylobacter spp. were first recognised in 1906 in the UK by John McFadyean who
described comma-shaped spiral organisms isolated from aborting ewes (Skirrow
2006). Subsequently, Theobald Smith and Marian Taylor in the United States of
America (USA) isolated an apparently identical organism from aborting cattle and
named it Vibrio fetus (V. fetus) (Smith and Taylor 1919). However, Theodor Escherich
noted nonculturable spiral bacteria in stool specimens from neonates and kittens in
1886, which were probably Campylobacter (Kist 1986). The pathogen was reclassified
as Campylobacter fetus in 1973 (Véron and Chatelain 1973). King (1957) described
V. fetus as a cause of human blood stream infections, but the role of campylobacters
as an enteric pathogen remained undiscovered until the early 1970s (Butzler et al.
1973), primarily due to difficulties isolating these bacteria from faeces (Skirrow
2006).
Members of the genus are typically microaerobic or anaerobic. Notably, thermophilic
Campylobacter spp., among others, are microaerophilic, requiring lower levels of
oxygen, generally at concentrations ranging from 2–10%, being also capnophilic,
requiring higher levels of carbon dioxide, generally at a concentration of 10% reflecting the conditions in the animal gut.
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C. jejuni and C. coli are thermophilic and grow optimally at 42°C (Allos et al. 2008).
The distribution of members of the genus among mammalian, avian and reptilian hosts
likely results from evolutionary adaption to different host body temperatures.
Chickens have a body temperature of 41°C. Optimum temperatures for
Campylobacter spp. growth are within 30-45°C, while optimum growth temperatures
for reptile-associated strains is 25°C (Miller et al. 2016).
Recent expansion of the genus continues, despite the challenges in the successful
isolation of campylobacters from environmental samples, due to the fastidious nature
of Campylobacter spp. (O’Doherty et al. 2014). The taxonomic diversity of
Campylobacter spp. is matched by the diverse habitats in which they are found, and
the variable presentation of disease in different hosts (On 2001). Allopatric speciation
is a significant contributor to the evolution and epidemiology of campylobacteriosis
(Sheppard et al. 2010, 2014; Pascoe et al. 2017; Epping et al. 2021).
Within the Campylobacteraceae family, the genus Campylobacter comprises 47
species/subspecies (in October 2021) (Table 1.1).
Table 1.1. Taxonomy of currently described Campylobacter species and subspecies.
Species

Campylobacter
armoricus

Original isolation
source
(type strain)
River water

Type strain
designations

Year of
isolation

Country of
isolation

Reference

CA656T
(=CIP 111675T;
=CCUG 73571T)
MIT 17-670T
(=LMG 31272T;
=NCTC 14267T)

2019a

Brittany, France

(Boukerb et al.
2019)

2020a

Massachusetts
Institute of
Technology
(MIT), USA
Bologna, Italy

(Bryant et al.
2020)

2017

Utrecht, The
Netherlands

(Gilbert et al.
2018)

Campylobacter
aviculae

Zebra fish
(Taeniopygia
guttata)

Campylobacter
avium

Chicken (Gallus
gallus domesticus),
caecal contents
Common seal
(Phoca vitulina),
faeces
Captive whooping
crane (Grus
americana), cloacal
swab
Pig (Sus scrofa
domesticus), faeces

86/06T
(=CCUG 56292T;
=LMG 24591T)
17S00004-5T
(=LMG 30333T;
=CCUG 71276T)
L266T
(=CCUG 54429T;
=LMG 24001T)

2006

2004

Calgary,
Canada

(Inglis et al.
2007)

ATCC 33559T
(=CCUG 11283T;
=CCUG 14540T;
=CIP 70.80T;
=DSM 4689T;
=JCM 2529T;
=LMG 6440T;
=NCTC 11366T;
=LMG 9860T)

nd

Belgium

Human (gingivitis),
oral cavity lesion
(gingival sulcus)

ATCC 33237T
(=CCUG 13144T;
=CIP 103757T;
=DSM 9716T;
=FDC 484T;

1981a

Forsyth Dental
Center (FDC),
Boston, Georgia
(GA),

(Véron and
Chatelain 1973;
Skerman,
McGowan and
Sneath 1980;
Alderton et al.
1995;
Vandamme et
al. 1997;
Vandamme and
On 2001)
(Tanner et al.
1981)

Campylobacter
blaseri
Campylobacter
canadensis

Campylobacter coli

Campylobacter
concisus

(Rossi et al.
2009)
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Species

Campylobacter
corcagiensis
Campylobacter
cuniculorum

Campylobacter
curvus

Original isolation
source
(type strain)

Captive lion-tailed
macaque (Macaca
Silenus), faeces
Rabbit
(Oryctolagus
cuniculus), caecal
contents
Human, alveolar
abscess

Campylobacter
estrildidarum

Zebra fish

“Campylobacter
faecalis”

Human (acquired
immunodeficiency
syndrome (AIDS))
Goat (Ovis aries)
(aborting), uterine
mucus/foetus brain

Campylobacter
fetus subsp. fetus

Type strain
designations
=LMG 7788T;
=NCTC 11485T)
CIT 045T
(=LMG 27932T;
=CCUG 64942T)
150BT
(=CCUG 56289T;
=LMG 24588T;
=DSM 23162T)
ATCC 35224T
(=CCUG 13146T;
=CIP 103747T;
=DSM 6644T;
=LMG 7609T;
=NCTC 11649T;
=VPI 9584T)
MIT 17-644T
(=LMG 21371T;
=NCTC 14266T)
nd

Year of
isolation

Country of
isolation

2013

United States of
America (USA)
Cork, Ireland

Emilia
Romagna
region, Italy

(Zanoni et al.
2009)

1984a

FSC, Boston,
GA, USA

2020a

MIT), USA

(Tanner,
Listgarten and
Ebersole 1984;
Han, Smibert
and Krieg 1991;
Vandamme et
al. 1991)
(Bryant et al.
2020)

2000a

nd

(Kachler et al.
2000)

NCTC 10842T
(=ATCC 27374T;
=CCUG 6823T;
=CIP 5396T;
=DSM 5361T;
=LMG 6442T)

1919a

nd

(Smith and
Taylor 1919;
Véron and
Chatelain 1973;
Skerman,
McGowan and
Sneath 1980;
Vandamme and
On 2001)
(Fitzgerald et
al. 2014)

Human, blood
culture

03-427T
(=ATCC BAA2539T;
=LMG 27499T)

2003

Campylobacter
fetus subsp.
venerealis

Cow (Bos taurus),
genital sample
(vaginal mucus)

ATCC 19438T
(=CCUG 33899T;
=CCUG 538T ;
=CIP 68.29T ;
=JCM 2528T;
=LMG 6443T;
=NCTC 10354T;
=DSM 18826T)

1959a

National
Campylobacter
and
Helicobacter
Reference
Laboratory at
the Center for
Disease Control
and Prevention
(CDC)
USA
nd

Campylobacter
geochelonis

Western Hermann’s
tortoise (Testudo
hermanni
hermanni), cloacal
swab
Human
(periodontitis), oral
cavity lesion
(gingival sulcus)

RC20T
(=DSM 102159T;
=LMG 29375T)

2011

Northern Italy

ATCC 33236T
(=CCUG 27720T;
=FDC 1084T;
=JCM 8538T;
=NCTC 12738T;
=DSM 19528T)
NCTC 12470T
(=CCUG 30682T;
=CIP 104877T;
=ATCC 51209T;
=LMG 12638T;
=LMG 19528T)
HV10TT
(=NCTC 13823T;
=CIP 111092T)

1981a

FDC, Boston,
GA, USA

1989

Switzerland

2015

Australia

Campylobacter
helveticus

Domestic cat (Felis
catus), diarrhoeic
faeces

Campylobacter
hepaticus

Chicken, livers with
spotty liver disease

(Koziel et al.
2014b)

2005

Campylobacter
fetus subsp.
testudinum

Campylobacter
gracilis

Reference

(Florent 1959;
Véron and
Chatelain 1973;
Skerman,
McGowan and
Sneath 1980;
On 2000;
Vandamme and
On 2001)
(Piccirillo et al.
2016)

(Tanner et al.
1981; Han,
Smibert and
Krieg 1991;
Vandamme et
al. 1995)
(Burnens,
Angéloz‐Wick
and Nicolet
1992; Stanley et
al. 1992)
(Hao Van et al.
2016)
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Species

Campylobacter
hominis

Original isolation
source
(type strain)
Human, faeces

Campylobacter
hyointestinalis
subsp.
hyointestinalis

Pig, (proliferative
enteritis), intestine

Campylobacter
hyointestinalis
subsp. lawsonii

Pig, stomach

Campylobacter
iguaniorum

Bearded dragon
(Pogona vitticeps),
intestinal contents
Common seal
(Phoca vitulina),
rectal swabs and
harbour porpoise
(Phocoena
phocoena), small
intestine
Human
(hospitalised child),
diarrhoeic faeces

Campylobacter
insulaenigrae

Campylobacter
jejuni subsp. doylei

Campylobacter
jejuni subsp. jejuni

Cow, faeces

Campylobacter
lanienae

Human
(asymptomatic
abattoir worker),
faeces
Shellfish

Campylobacter lari
subsp. concheus
Campylobacter lari
subsp. lari

Herring gull
(Larus argentatus),
cloacal swab

“Campylobacter
lawrenceae”

Elephant seal
(Mirounga
angustirostris)
Weaned pig,
intestinal adenoma
mucous membrane

Campylobacter
mucosalis

Type strain
designations

Year of
isolation

Country of
isolation

Reference

NCTC 13146T
(=LMG 19568T;
=CCUG 45161T;
=CH001AT;
=ATCC BAA-381T;
=CIP 107682T;
=DSM 21671T)
80-4577-4T
(=ATCC 35217T;
=NCTC 11608T;
=LMG 7817T;
=CIP 103750T;
=DSM 19053T;
=CCUG 14169T)
CHY 5T
(=CCUG 34538T;
=CIP 104686T;
=LMG 14432T;
=NCTC 12901T)
1485ET
(=LMG 28143T;
=CCUG 66346T)
1485ET
(=NCTC 12927T;
=CCUG 48653T)

1995a

London, United
Kingdom (UK)

1983a

Minnesota
(MN), USA

(Murray and
Stackebrandt
1995; Lawson,
Linton and
Stanley 1998;
Lawson et al.
2001)
(Gebhart et al.
1983, 1985; On
et al. 1995;
Harrington and
On 1999)

1995a

UK

(On et al. 1995;
Harrington and
On 1999)

2003

Utrecht, The
Netherlands

(Gilbert et al.
2015)

1988

Black Isle,
Scotland, UK

(Thompson et
al. 1992; Foster
et al. 2004)

093T
(=ATCC 49349T;
=CCUG 24567T;
=CIP 103751T;
=IMVS 1141;
=NCTC 11951T;
=LMG 8803T;
=LMG 8843T)
ATCC 33560T
(=CCUG 11284T;
=CIP 70.2T;
=DSM 4688T;
=LMG 8841T;
=NCTC 11351T)

1985a

Central
Australia

(Steele,
Sangster and
Lanser 1985;
Steele and
Owen 1988)

1931a

Brussels,
Belgium

CCUG 44467T
(=CIP 106785T;
=NCTC 13004T)

2000a

Switzerland

(Jones, Orcutt
and Little 1931;
Véron and
Chatelain 1973;
Skerman,
McGowan and
Sneath 1980;
Vandamme and
On 2001)
(Logan et al.
2000)

2897RT
(=CCUG 55786T;
=LMG 21009T)
ATCC 35221T;
(=CCUG 23947T;
=CIP 102722T;
=DSM 11375T;
=JCM 2530T;
=LMG 8846T;
=NCTC 11352T;
=WRI 3034/77T;
=LMG 7605T;
=JCM 14870T)
nd

1993

The
Netherlands

(Debruyne et al.
2009)

1980a

Worcestershire,
UK

(Skirrow and
Benjamin 1980;
Benjamin et al.
1983; von
Graevenitz
1990; Debruyne
et al. 2009)

2004a

nd

(Foley et al.
2004)

FS253/72T
(=ATCC 43264T;
=CCUG 6822T;
=CIP 103750T;
=NCTC 11000T;
=DSM 21682T)

1974a

Midlothian,
Scotland, UK

(Lawson and
Rowland 1974;
Rowland and
Lawson 1974)
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Species

Original isolation
source
(type strain)
Mallard (Anas
platyrhynchos),
faeces
Wild bird (likely,
black-faced ibis
(Theristicus
melanopis),
southern lapwing
(Vanellus chilensis)
and chimango
caracara (Mil- vago
chimango), faeces
Large shellfish giant mussel (Pinna
nobilis)

Type strain
designations

Year of
isolation

Country of
isolation

Reference

B423bT
(=NZRM 4741T;
=ATCC TSD-167T)
WBE38T
(=CECT 9147T;
=LMG 29815T)

2008

Palmerston
North, New
Zealand
Valdivia,
southern Chile

(Bloomfield et
al. 2020)

2314BVAT
(=CCUG 55787T;
=LMG 23910T)

1993

The
Netherlands

(Debruyne et al.
2009)

Campylobacter
pinnipediorum
subsp. caledonicus

Juvenile grey seal
(Halichoerus
grypus), pulmonary
abscess

M302/10/6T
(=LMG 29473T;
=CCUG 68650T;
=RM18021T)

2010

Inverness,
Scotland, UK

(Gilbert et al.
2017)

Campylobacter
pinnipediorum
subsp.
pinnipediorum
Campylobacter
portucalensis

California sea lion
(Zalophus
californianus),
abscess
Charolais bull,
preputial mucosa

2013

San Diego, CA,
USA

(Gilbert et al.
2017)

2018

Human
(periodontitis), oral
cavity lesion

Alentejo
province,
Portugal
FDC, Boston,
GA, USA

(Silva et al.
2020)

Campylobacter
rectus

Campylobacter
showae

Human,
gingival crevice

1993a

FDC, Boston,
GA, USA

(Etoh et al.
1993)

Campylobacter
sputorum

Human, gingival
crevice

nd

Virginia
Polytechnic
Institute (VPI),
Blacksburg,
Virginia (VA),
USA

(Véron and
Chatelain 1973;
Roop et al.
1986;
Vandamme and
On 2001)

Campylobacter
subantarcticus

Grey-headed
albatross
(Diomedea
chrysostoma),
faeces
Zebra fish

RM17260T
(=SW130133T;
=LMG 29472T;
=CCUG 69570T)
MV-PI01T
(=LMG 31504T;
=CCUG 73856T)
ATCC 33238T
(=CCUG 20446 BT;
=CIP 103748T;
=DSM 3260T;
=FDC 371T ;
=JCM 6301T;
=NCTC 11489T)
SU A4T
(=ATCC 51146T;
=CCUG 30254T;
=CIP 103970T;
=JCM 12989T;
=LMG 12635T;
=NCTC 12843T)
ER33T
(=ATCC 35980T;
=CCUG 9728T;
=CIP 103749T;
=LMG 7795T;
=NCTC 11528T;
=VPI S:17T)
R-3023T
(=CCUG 38513T;
=LMG 24377T)

1996

South Atlantic,

(Debruyne et al.
2010a)

MIT 10-5678T
(=LMG 30935T;
=NCTC 14187T)
MIT 05-9149T
(=LMG 26485T)

2020a

MIT, USA

(Bryant et al.
2020)

2005

Tanzania

(Kaur et al.
2011)

ATCC 43954T
(=CCUG 14913T;
=CIP 103681T;
=DSM 5365T;
=NCTC 11541T;
=LMG 8850T)
ATCC 33387T
(=CCUG 7319T;
=DSM 20703T;
=LMG 6451T;
=NCTC 10941T)

1979

Uppsala,
Sweden

(Sandstedt and
Ursing 1991)

1978b

Misericordia
Hospital,
Edmonton,
Alberta, Canada

(Henriksen
1948; Eiken
1958; Jackson
and Goodman
1978; Han,

Campylobacter
novaezeelandiae
Campylobacter
ornithocola

Campylobacter
peloridis

Campylobacter
taeniopygiae
“Campylobacter
troglodytis”

Campylobacter
upsaliensis

Campylobacter
ureolyticus

Wild Chimpanzees
(Pan troglodytes
schweinfurthii),
faeces
Canine (Canis
lupus familiaris)
, faeces

Human, amniotic
fluid

2017a

1981a

(Cáceres et al.
2017)

(Tanner et al.
1981)

6

Species

Original isolation
source
(type strain)

Type strain
designations

Year of
isolation

Country of
isolation

Campylobacter
volucris

Black-headed gulls
(Larus ridibundus),
faeces

CCUG 57498T
(=LMG 24380T;
=DSM 25354T)

1999

Sweden

Campylobacter
vulpis

Wild red fox
(Vulpes vulpes)

251/13T
(=CCUG 70587T;
=LMG 30110T)

2013

Northern Italy

Reference

Smibert and
Krieg 1991;
Vandamme et
al. 1995, 2010)
(Debruyne et al.
2010b)

(Parisi et al.
2021)

a

, year of publication; nd, not determined

Despite the dominance of C. jejuni and C. coli, other Campylobacter spp. have
emerged as significant players in human disease and the evolution of the genus (Table
1.2), given that campylobacters are recovered from diverse environmental sources.
Table 1.2. The clinical importance of Campylobacter spp. in humans and animals.
Species/
subspecies

Host/
Source

Immune status

Campylobacter
armoricus

River water

n/a

Campylobacter
infection
manifestation
n/a

Human

n/a

Enteritis

Faeces

Broiler
Turkey
(Meleagris)
Common
seal
Captive
adult
whooping
crane
Human

n/a

n/a

Caecal contents
Caecal contents

n/a

n/a

Faeces

n/a

n/a

Cloacal swab

Pregnant/neonate

Septic abortion
without diarrhoea

Immunocompromised/
neonate
nd

Sepsis with or
without diarrhoea
Acute cholecystitis

Blood cultures,
amniotic fluid and
maternal placenta
Blood culture and
faeces
Gallbladder

Infant

Meningitis without
diarrhoea
Peritonitis with
diarrhoea

cerebrospinal fluid
(CSF)
Dialysate

Enteritis

Faeces

Bacteraemia with
associated
intrauterine growth
restriction
n/a

Blood culture
(faeces not tested)

Campylobacter
avium
Campylobacter
blaseri
Campylobacter
canadensis

Campylobacter
coli

Continuous
ambulatory peritoneal
dialysis
n/a

Pregnant

Caprine

n/a

Isolation source

Reference

River water

(Boukerb et al.
2019
(Boukerb et al.
2019)
(Rossi et al. 2009)
(Rossi et al. 2009)

Unpasteurised milk
Diarrhoeic faeces
Faeces

Ovine

n/a

n/a

Gallbladder
Faeces

Seagull
(Larus)
Ostrich
(Struthio
camelus)

n/a

n/a

nd

n/a

n/a

Cloacal swab

(Gilbert et al.
2018)
(Inglis et al. 2007)

(Kist et al. 1984)

(Blaser et al.
1986)
(Blaser et al.
1986)
(Blaser et al.
1986)
(Wood et al.
1992)
(Lastovica et al.
2000; Bullman et
al. 2011)
(Kuperman-Shani
et al. 2015)

(Hutchinson et al.
1985)
(Chaban, Ngeleka
and Hill 2010)
(Karikari et al.
2017)
(Ertaş et al. 2003)
(Karikari et al.
2017)
(Sekizuka et al.
2004)
(Cuomo et al.
2007)
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Species/
subspecies

Host/
Source
Pheasant
(Phasianus
colchicus)
Bovine

n/a

Campylobacter
infection
manifestation
n/a

n/a

n/a

Immune status

Isolation source

Reference

Cloacal swab

(Dipineto et al.
2008)

Bile

(Enokimoto et al.
2007)
(Lynch et al.
2011)
(Karikari et al.
2017)
(Karikari et al.
2017)
(Nonga and
Muhairwa 2010)

Retail meat
Faeces
Carcass
Domestic
duck
(Cairina
moschata)
Poultry

n/a

n/a

Caecal contents

n/a

n/a

Retail meat

Liver, spleen, caecal
and jejunal content
Porcine

n/a

n/a

Retail meat

Carcass

Caecal
contents/faeces

Campylobacter
concisus

(Lynch et al.
2011; Bellio et al.
2014)
(Müller, Böhland
and Methner
2011)
(Lynch et al.
2011; Scanlon et
al. 2013)
(Scanlon et al.
2013; Karikari et
al. 2017)
(Scanlon et al.
2013; Karikari et
al. 2017)
(Bojanić et al.
2019)
(Tanner et al.
1981)
(Johnson and
Finegold 1987)
(Vandamme et al.
1989; Lauwers et
al. 1991;
Lastovica et al.
2000; Platts-Mills
et al. 2014)
(Cox, Kempsell
and Gaston 2003)

Canine

n/a

n/a

Faeces

Human

n/a

Gingivitis and
periodontitis
Osteomyelitis with
food ulcer
Enteritis

Oral cavity lesions

Psoriatic arthritis
with associated
diarrhoea
Oesophageal
adenocarcinoma/Bar
rett’s oesophagus

Synovial fluid and
faeces
Biopsy tissue

(Macfarlane et al.
2007; Kaakoush et
al. 2015a)

Asymptomatic

Saliva

Post-craniotomy
chromic osteomyelitis
of the frontal bone
Child

Brain abscess (fatal)

Pus

(Petersen et al.
2007)
(De Vries, Arents
and Manson 2008)

Crohn’s disease

Intestinal biopsy

Child

Asymptomatic

Intestinal biopsy

Child
nd

Crohn’s disease
Ulcerative colitis

Feline

n/a

Oral disease

Faeces
Colonoscopic
biopsy
Saliva

Canine

n/a

n/a

Diarrhoeic faeces

Poultry

n/a

n/a

Retail meat

Bovine

n/a

n/a

Retail meat

Diabetes mellitus with
renal insufficiency
n/a

Query reactive arthritis

Associated increased
abundance of
oesophageal C.
concisus
No dental/oral disease

Wound
Faeces

Unpasteurised milk

(Zhang et al.
2009)
(Zhang et al.
2009)
(Man et al. 2010)
(Mukhopadhya et
al. 2011)
(Petersen et al.
2007)
(Chaban, Ngeleka
and Hill 2010)
(Lynch et al.
2011)
(Lynch et al.
2011)
(Serraino et al.
2013)
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Species/
subspecies

Campylobacter
corcagiensis
Campylobacter
cuniculorum

Campylobacter
curvus

Host/
Source

Immune status

Porcine

n/a

Campylobacter
infection
manifestation
n/a

Captive
lion-tailed
macaque
Cuniculine

n/a

Prairie dogs
(Cynomys
ludovicianu
s)
Human

Isolation source

Reference

n/a

Retail meat, caecal
contents and carcass
Faeces

(Scanlon et al.
2013)
(Koziel et al.
2014b)

n/a

n/a

Caecal contents

n/a

n/a

Caecum and liver

(Zanoni et al.
2009)
(Beisele et al.
2011)

n/a

Enteritis

Faeces

Stage IV ovarian
cancer with
chemotherapy,
radiation therapy and
tumour reduction
surgery
Lung cancer, postsurgery

Hepatic abscess

Abscess discharge

Pleural abscess

Abscess discharge

Hepatic abscess

Blood culture
(aspirate culture
negative)

Ulcerative colitis

Colonoscopic
biopsy
Pleural effusion

(Mukhopadhya et
al. 2011)
(Horio et al. 2017)

Faeces

Retail meat

(Chaban, Ngeleka
and Hill 2010)
(Lynch et al.
2011)
(Lynch et al.
2011)
(Scanlon et al.
2013)
(Kachler et al.
2000)
(Vandamme et al.
1989)
(Véron and
Chatelain 1973)
(Hood and Todd
1960)

History of smoking
and diverticulitis,
otherwise healthy
nd

Canine

12-year history or
bronchiectasis
n/a

Empyema

Bovine

n/a

Either asymptomatic
or enteritis
n/a

Porcine

n/a

n/a

Retail meat

Caecal contents
“Campylobacter
faecalis”

Campylobacter
fetus subsp.
fetus

Human

AIDS

nd

nd

Ovine

n/a

n/a

Faeces

Ewe

Aborting

Septic abortion

Human

Pregnant/aborted
foetus

Septic abortion

End-stage chronic
glomerulonephritis

Peritonitis without
diarrhoea and
subsequent
septicaemia 24 days
later, likely
associated with an
old arteriovenous
fistula
Groin abscess

Uterine
mucus/foetus brain
Placental tissue and
brain and isolated 6
months postabortion from the
cervix (faeces not
tested)
Peritoneal dialysate
fluid and blood
culture

Postsurgical
nd

nd
nd
n/a

nd

Cellulitis (ankle
abscess) with
diarrhoea
Sepsis

Pus

Encephalitis and
sepsis,
Enteritis

CSF and blood
culture
Faeces

Blood culture

(Lauwers et al.
1991; Lastovica et
al. 2000)
(Han, Tarrand and
Rice 2005)

(Han, Tarrand and
Rice 2005)
(Wetsch et al.
2006)

(Wens et al. 1985)

(Edmonds et al.
1985)*
(Edmonds et al.
1985)*
(Edmonds et al.
1985)*
(Edmonds et al.
1985)*
(Klein et al. 1986;
Lastovica et al.
2000; Bullman et
al. 2011)
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Species/
subspecies

Host/
Source

Immune status
Pregnant/neonate

Elderly

Prosthetic valve
endocarditis

Pregnant/neonate

Meningitis

Post-operative,
oesophago-cardial
adenocarcinoma and
metastasis to the brain
Immunocompetent

Brain abscess

Continuous
ambulatory peritoneal
dialysis
Pregnant with three
episodes of
spontaneous abortion
in the previous eight
years
Immunocompromised

Isolation source

Reference

Gastric aspirate and
faeces (neonate),
vagina and faeces
(mother)
Blood culture

(Simor et al.
1986)

CSF, faeces and
blood culture
(neonate),
endometrium, cervix
and vagina (mother)

Pus

(Caramelli et al.
1988; Farrugia,
Eykyn and Smyth
1994; Peetermans
et al. 2000;
Haruyama et al.
2011; Reid et al.
2016; Petridou,
Strakova and
Simpson 2018;
Lynch et al. 2019)
(Morooka et al.
1988)

(La Scola,
Chambourlier and
Bouillot 1998)

Bacteraemia,
endocarditis, and
pericardial effusion
without diarrhoea
Peritonitis with
subsequent
septicaemia
Bacteraemia
associated with
chorioamnionitis

Blood culture

Blood culture
(faeces not tested)

(Viejo et al. 2001)

Blood culture and
faeces

(Pacanowski et al.
2008)
(Wagenaar et al.
2014; Eke, Doub
and Chua 2021)

Dialysate

(Morrison et al.
1990)

(Wood et al.
1992)

Ovine

Aborted foetus

Bacteraemia with or
without diarrhoea
Mycotic aneurysms,
endocarditis,
vasculitis,
thrombophlebitis,
pericarditis, aortitis
Meningitis without
diarrhoea
Meningitis and
pyogenic
spondylodiscitis
Septic abortion

Bovine

Aborted foetus

Septic abortion

Vaginal mucus

n/a

n/a

Unpasteurised milk

Equine
(Equus
ferus
caballus)
Kangaroo
(Macropodi
dae),
Porcine

n/a

n/a

Faeces

n/a

nd

Small intestine

(Willoughby et al.
2005)

n/a

n/a

Retail meat

Human

Immunocompetent or
immunocompromised
males

Bacteraemia with or
without diarrhoea

Blood culture
(isolation from
faeces not
described)

(Scanlon et al.
2013)
(Tu et al. 2004;
Patrick et al.
2013; Fitzgerald
et al. 2014)

Vascular pathologies

Immunocompetent
Immunocompetent

Campylobacter
fetus subsp.
testudinum

Campylobacter
infection
manifestation
Septic premature
neonate

Aortic tissue or
blood culture

CSF
Blood culture and
CSF
Foetus brain

(Ishihara et al.
2018)
(Ikeda et al. 2019)

(Campero et al.
2005; Willoughby
et al. 2005;
Schulze et al.
2006)
(Campero et al.
2005; Willoughby
et al. 2005)
(Serraino et al.
2013)
(Willoughby et al.
2005)
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Species/
subspecies

Campylobacter
fetus subsp.
venerealis

Host/
Source

Florida box
turtle
(Terrapene
carolina
bauri),
Captive
western
hognose
snake
(Heterodon
nasicus)
Leopard
tortoise
(Stigmochel
ys pardalis
Bovine

Male

Campylobacter
infection
manifestation
Cellulitis

Male

Enteritis

Faeces

Male, liver cancer

Pleural fluid

Male, asthma

Pulmonary oedema
with bloody
diarrhoea
Haematoma

Male

Diarrhoea

Bile

n/a

Asymptomatic

Faeces

n/a

Asymptomatic

nd

(Fitzgerald et al.
2014)

n/a

Asymptomatic

Cloacal swab

(De Luca et al.
2020)

n/a

n/a

Vaginal mucus

(Florent 1959;
Willoughby et al.
2005; Schulze et
al. 2006)
(Campero et al.
2005; Willoughby
et al. 2005)
(Schulze et al.
2006)
(Willoughby et al.
2005)
(Holst et al. 1987;
Wagenaar et al.
2014)
(Ishihara et al.
2018)
(Willoughby et al.
2005)
(Piccirillo et al.
2016; De Luca et
al. 2020)
(De Luca et al.
2020)

Immune status

Isolation source

Reference

Blood culture

(Patrick et al.
2013)
(Patrick et al.
2013)
(Patrick et al.
2013)

Haematoma

(Aborted) foetus

Preputial washing
Prepuce
Human

Campylobacter
geochelonis

Campylobacter
gracilis

Western
Hermann’s
tortoise
Greek
tortoise (T.
graeca)
Human

nd

Bacterial vaginosis

Vaginal discharge

Immunocompetent

CSF

nd

Meningitis without
diarrhoea
Bacteraemia

n/a

n/a

Cloacal swab

n/a

n/a

Cloacal swab

nd

Periodontitis)

Oral cavity lesion

nd

Pleuropulmonary
infection
Intra-abdominal
abscess

nd

Brain abscess

Pus
Pus

Ruptured appendix

retropharyngealperitonsillar abscess
Actinomycotic
submandibular mass
Deep seated visceral
or head and neck
infection
Peritonitis

No dental/oral disease

Asymptomatic

Saliva

Biliary tree
obstruction or
appendiceal
perforation
Sinusitis source of
infection
nd
nd
nd

Blood culture

Pus

nd
Wound

nd

(Patrick et al.
2013)
(Patrick et al.
2013)
(Harvey and
Greenwood 1985;
Patrick et al.
2013)

(Tanner et al.
1981)
(Johnson et al.
1985)
(Johnson et al.
1985)

(Johnson et al.
1985)
(Johnson et al.
1985)
(Johnson et al.
1985)
(Johnson et al.
1985)
(Johnson et al.
1985)
(Petersen et al.
2007)
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Species/
subspecies

Campylobacter
helveticus

Campylobacter
hepaticus
Campylobacter
hominis

Campylobacter
hyointestinalis
subsp.
hyointestinalis

Child

Campylobacter
infection
manifestation
Crohn’s disease

Child
nd

Crohn’s disease
Ulcerative colitis

Postpartum

Brain abscess (fatal)

Faeces
Colonoscopic
biopsy
Pus

Canine

n/a

n/a

Diarrhoeic faeces

Feline

n/a

Asymptomatic or
diarrhoea

Faeces

Human

Infant

Diarrhoea

Faeces

Canine

n/a

Faeces

Bovine

n/a

Asymptomatic or
diarrhoea
n/a

Porcine

n/a

n/a

Faeces and carcass

Poultry

n/a

Spotty liver disease

Liver

Human

nd

Asymptomatic

Faeces

nd

Blood culture

Child

Fatal septicaemia
without diarrhoea
Crohn’s disease

Child

Asymptomatic

Intestinal biopsy

Child
nd

Crohn’s disease
Ulcerative colitis

Porcine

n/a

Human

n/a

Proliferative
enteritis
Enteritis

Faeces
Colonoscopic
biopsy
Intestinal tissue

Human

nd

Hamster
(Cricetinae
)
Bovine

Host/
Source

Immune status

Isolation source

Reference

Intestinal biopsy

(Zhang et al.
2009)
(Man et al. 2010)
(Mukhopadhya et
al. 2011)
(de Vries, Arents
and Manson 2008)
(Chaban, Ngeleka
and Hill 2010)
(Burnens,
Angéloz‐Wick
and Nicolet 1992;
Stanley et al.
1992)
(Platts-Mills et al.
2014)
(Chaban, Ngeleka
and Hill 2010)
(Lynch et al.
2011)
(Scanlon et al.
2013)
(Hao Van et al.
2016)
(Lawson et al.
2001)
(Linscott et al.
2005)
(Zhang et al.
2009)
(Zhang et al.
2009)
(Man et al. 2010)
(Mukhopadhya et
al. 2011)
(On et al. 1995)

Retail meat

Intestinal biopsy

Faeces

Blood culture

n/a

Fatal septicaemia
with diarrhoea
n/a

(Edmonds et al.
1987; Lastovica et
al. 2000; Bullman
et al. 2011; PlattsMills et al. 2014)
(Man 2011)

Intestinal tissue

(On et al. 1995)

n/a

n/a

Intestinal tissue
Faeces

(On et al. 1995)
(Oporto and
Hurtado 2011)
(Serraino et al.
2013)
(Oporto and
Hurtado 2011)
(Oporto and
Hurtado 2011;
Jay-Russell et al.
2012)
(On et al. 1995)
(Endtz et al. 1997)
(Bian et al. 2018)
(Bian et al. 2018)
(Gilbert et al.
2015)
(Gilbert et al.
2015)

Unpasteurised milk

Campylobacter
hyointestinalis
subsp. lawsonii
Campylobacter
iguaniorum

Ovine

n/a

n/a

Faeces

Porcine

n/a

n/a

Faeces

Porcine
Shellfish
Porcine
Bovine
Bearded
dragon
Green
iguana
(Iguana
iguana)
Alpaca
(Vicugna
pacos)

n/a
n/a
n/a
n/a
n/a

n/a
n/a
n/a
n/a
n/a

Stomach
nd
Faeces
Faeces
nd

n/a

n/a

nd

n/a

n/a

faeces

(Miller et al.
2016)
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Species/
subspecies

Campylobacter
insulaenigrae

Campylobacter
jejuni subsp.
doylei

Host/
Source
Hermann’s
tortoise (T.
hermanni)
Common
seal
Northern
elephant
seal
Antarctic
fur seals
(Arctoceph
alus
gazella)
South
American
sea lion
(Otaria
flavescens)
Harbour
porpoise
(Phocoena
phocoena)
Human

Human

Rock
pigeon
(Columba
livia)
Bovine
Ovine

n/a

Campylobacter
infection
manifestation
n/a

n/a

n/a

Rectal swabs

n/a

n/a

Faeces

n/a

n/a

Faeces?

(García-Peña et
al. 2010),

n/a

n/a

Faeces

(González et al.
2011)

n/a

n/a

Small intestine

(Foster et al.
2004)

End-stage renal failure
with dialysis and
autosomal dominant
polycystic kidney and
liver disease
n/a

Septicaemia with
associated enteritis

Blood culture
(aerobic), not
detected in faeces

(Chua et al. 2007)

Enteritis

Faeces

n/a

Enteritis

Faeces

nd
n/a

bacteraemia
n/a

blood culture
Faeces

(Inglis, Boras and
Houde 2011)
(Steele, Sangster
and Lanser 1985;
Steele and Owen
1988; Lastovica et
al. 2000)
(Morey 1996)
(Bellio et al.
2014)

n/a

n/a

Faeces

n/a

n/a

Faeces

Immune status

Isolation source

Reference

Cloacal swab

(De Luca et al.
2020)
(Foster et al.
2004)
(Stoddard et al.
2007)

Carcass

Campylobacter
jejuni subsp.
jejuni

(Karikari et al.
2017)
(Karikari et al.
2017)
(Karikari et al.
2017)
(Karikari et al.
2017)
(Pepersack et al.
1982; Wood et al.
1992)

Porcine

n/a

n/a

Faeces

Human

End-stage chronic
glomerulonephritis,
continuous ambulatory
peritoneal dialysis
Mother and daughter

Peritonitis with
associated diarrhoea

Dialysate and faeces

Faeces

(Chamovitz et al.
1983)

Chronic renal failure

C. jejuni-associated
haemolytic-uremic
syndrome
nd

n/a

Enteritis

Peritoneal dialysis
fluid
Faeces

Immunocompromised/
neonate

Bacteraemia with or
without diarrhoea

(Blaser et al.
1986)
(Blaser et al.
1986; Klein et al.
1986; Lastovica et
al. 2000; Bullman
et al. 2011)
(Blaser et al.
1986)

Neonate

Sepsis

Post radiation therapy

Thoracic wall
abscess
Acute cholecystitis

Immunocompetent

Blood culture, faecal
detection not
documented
Blood culture
nd
Gallbladder

(Blaser et al.
1986)
(Blaser et al.
1986)
(Blaser et al.
1986)
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Species/
subspecies

Host/
Source

Immune status
77 years, male

65 years
nd

Continuous
ambulatory peritoneal
dialysis
Bacterial
gastroenteritis

Isolation source

Reference

Urine

(Blaser et al.
1986)

Cyst fluid

(Blaser et al.
1986)
(Hughes and Rees
1997)

nd

Dialysate

(Wood et al.
1992)

Postinfectious
irritable bowel
syndrome
Postinfectious celiac
disease

nd

(Ruigómez,
García Rodríguez
and Panés 2007)
(Verdu et al.
2007)

nd

Child

Postinfectious
reactive arthritis
Crohn’s disease

Child

Asymptomatic

Intestinal biopsy

Child
nd

Crohn’s disease
Ulcerative colitis

Pregnant, aborting

Bacteraemia without
diarrhoea
Acute disseminated
encephalomyelitis
with associated
gastroenteritis
n/a

Faeces
Colonoscopic
biopsy
Blood culture

Six-year history of
postinfectious irritable
bowel syndrome (IBS)
is
nd

Caprine

Campylobacter
infection
manifestation
Urinary tract
infection without
diarrhoea
Ovarian cyst without
diarrhoea
Guillain-Barré
syndrome with
associated diarrhoea
Peritonitis (fatal)
without diarrhoea

Immunocompetent
with recent history of
Campylobacter
gastroenteritis
n/a

Diarrhoeic faeces

Intestinal biopsy

Serum IgA antiCampylobacter
jejuni
Faeces

Carcass
Macaroni
penguins
(Eudyptes
chrysoloph
us)
Gulls and
wild birds

n/a

n/a

Faeces

n/a

n/a

Faeces

Ovine

n/a

n/a

Gallbladder
Aborted foetus
Faeces
Carcass

Rhesus
macaques
Bovine

n/a
n/a

Asymptomatic or
chronic diarrhoea
n/a

Faeces
Aborted foetus
Bile
Unpasteurised milk
Faeces

Carcass
Ostrich

n/a

n/a

Cloacal swab

Pheasant

n/a

n/a

Cloacal swab

(Ternhag et al.
2008)
(Zhang et al.
2009)
(Zhang et al.
2009)
(Man et al. 2010)
(Mukhopadhya et
al. 2011)
(Skuhala et al.
2016)
(Marziali et al.
2017)

(Hutchinson et al.
1985; Karikari et
al. 2017)
(Karikari et al.
2017)
(Broman et al.
2000)

(Broman et al.
2002; Johansson
et al. 2018;
Gomez-Alvarez et
al. 2019)
(Ertaş et al. 2003)
(Campero et al.
2005)
(Karikari et al.
2017),
(Karikari et al.
2017)
(Sestak et al.
2003)
(Campero et al.
2005),
(Enokimoto et al.
2007)
(Serraino et al.
2013)
(Lynch et al.
2011; Scanlon et
al. 2013),
(Karikari et al.
2017)
(Cuomo et al.
2007)
(Dipineto et al.
2008)
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Species/
subspecies

Host/
Source

Immune status

Campylobacter
infection
manifestation
n/a

Isolation source

Reference

Rectal swab

(Dipineto et al.
2009)

Asymptomatic or
diarrhoea
n/a

Faeces

(Chaban, Ngeleka
and Hill 2010)
(Nonga and
Muhairwa 2010)

Red
squirrel
(Sciurus
vulgaris)
Canine

n/a

Domestic
duck
(Cairina
moschata)
Poultry

n/a

n/a

Asymptomatic or
diarrhoea

Retail meat and
faeces

Porcine,

n/a

n/a

Retail meat

n/a

Caecal contents

Faeces

Carcass

Campylobacter
lanienae

Campylobacter
lari subsp.
concheus

Campylobacter
lari subsp. lari

Rock
pigeon
Human

(Lynch et al.
2011; Bellio et al.
2014)
(Lynch et al.
2011)
(Jay-Russell et al.
2012; Scanlon et
al. 2013; Karikari
et al. 2017)
(Karikari et al.
2017)
(Bellio et al.
2014)
(Logan et al.
2000)
(Lévesque et al.
2016)
(Sasaki et al.
2003; Oporto and
Hurtado 2011;
Schweitzer et al.
2011; Jay-Russell
et al. 2012)
(Oporto and
Hurtado 2011)
(Oporto and
Hurtado 2011)
(Debruyne et al.
2009)
(Debruyne et al.
2009)
(Debruyne et al.
2009)

n/a

n/a

Carcass and faeces

Immunocompetent

Faeces

n/a

Asymptomatic
abattoir workers
Enteritis

Porcine

n/a

n/a

Faeces

Ovine

n/a

n/a

Faeces

Bovine

n/a

n/a

Faeces

Human

n/a

nd

faeces

nd

nd

Dialysate

Shellfish

n/a

n/a

nd

Gentoo
penguin
(Pygoscelis
papua) and
Chinstrap
penguin (P.
antarctica)
Canine

n/a

n/a

Cloacal swabs

(García-Peña et
al. 2017)

n/a

n/a

Faeces

(Bojanić et al.
2019)
(Leotta, Vigo and
Giacoboni 2006;
Debruyne et al.
2009; GomezAlvarez et al.
2019)
(Tauxe et al.
1985; Lastovica et
al. 2000; Martinot
et al. 2001;
Debruyne et al.
2009; Bullman et
al. 2011)
(Tauxe et al.
1985; Martinot et
al. 2001)
(Morris, Scully
and Garvey 1998)

Gull and
wild bird

Human

Faeces

Faeces

n/a

Enteritis

Faeces

Immunocompromised

Bacteraemia without
diarrhoea

Blood culture

nd

Pacemaker infection
and bacteraemia

Pacemaker pocket
aspirate (pus) and
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Species/
subspecies

Host/
Source

Immune status

81 years, male
Immunocompetent

Immunocompetent

Immunocompromised

Campylobacter
infection
manifestation

Prosthetic joint
infection
Septicaemia with a
history of diarrhoea
and penicillin three
weeks previously
Reactive arthritis
and diarrhoea

Isolation source
blood culture (not
detected in faeces
Aspirate
Blood culture (not
detected in faeces)

Faeces

Blood culture and
faeces
nd

(Werno et al.
2002)
(Söderström,
Schalén and
Walder 1991)
(Goudswaard,
Sabbe and te
Winkel 1995)
(Debruyne et al.
2009)
(Endtz et al. 1997)

Shellfish
(oysters
and
mussels)
Gentoo
penguin
and Adélie
penguin (P.
adeliae)
Equine

n/a

Bacteraemia with
associated diarrhoea
n/a

n/a

n/a

Cloacal swabs

(Leotta, Vigo and
Giacoboni 2006;
García-Peña et al.
2017)

n/a

n/a

Intestine

Poultry

n/a

n/a

Faeces

(Debruyne et al.
2009)
(Debruyne et al.
2009)
(Lynch et al.
2011)
(Debruyne et al.
2009)
(Chaban, Ngeleka
and Hill 2010)
(García-Peña et
al. 2010)
(Lynch et al.
2011)
(Oporto and
Hurtado 2011;
Karikari et al.
2017)
(Karikari et al.
2017)
(Scanlon et al.
2013; Karikari et
al. 2017)
(Karikari et al.
2017)

Retail meat
Wild birds

n/a

n/a

Faeces

Canine

n/a

Faeces

Antarctic
fur seals
Bovine

n/a

Asymptomatic or
diarrhoea
n/a

n/a

n/a

Retail meat

Faeces

Faeces

Carcass
Porcine

n/a

n/a

Caecal
contents/faeces

carcass

Campylobacter
lawrenceae
Campylobacter
mucosalis

Reference

Ovine

n/a

n/a

Faeces and carcass

Caprine

n/a

n/a

Faeces and carcass

Elephant
seal
Porcine

n/a

n/a

nd

n/a

Intestinal adenoma

Intestinal adenoma
mucous membrane

Adenomatosis

Spirochaetosis

Small intestine and
colonic mucosa
small intestine and
colonic mucosa
Caecal mucosa

n/a

Retail meat

Swine dysentery

(Karikari et al.
2017)
(Karikari et al.
2017)
(Karikari et al.
2017)
(Foley et al. 2004)
(Lawson and
Rowland 1974;
Rowland and
Lawson 1974)
(Lawson and
Rowland 1974)
(Lawson and
Rowland 1974)
(Lawson and
Rowland 1974)
(Lynch et al.
2011)
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Species/
subspecies

Host/
Source

Human

Campylobacter
ornithocola
Campylobacter
peloridis

Campylobacter
pinnipediorum
subsp.
caledonicus
Campylobacter
pinnipediorum
subsp.
pinnipediorum
Campylobacter
portucalensis
Campylobacter
rectus

Immune status

Campylobacter
infection
manifestation

Isolation source

Reference

Caecal contents

(Scanlon et al.
2013)
(Söderström,
Schalén and
Walder 1991)
(Friedman et al.
2004; Inglis,
Boras and Houde
2011)
(Chaban, Ngeleka
and Hill 2010)
(Lynch et al.
2011)
(Lynch et al.
2011)
(Cáceres et al.
2017)
(Debruyne et al.
2009)

Chronic lymphocytic
leukaemia postsplenectomy
n/a

Septicaemia without
diarrhoea

Blood culture

Enteritis

Faeces

Canine

n/a

Diarrhoea

Faeces

Poultry

n/a

n/a

Retail meat

Bovine

n/a

n/a

Retail meat

Wild bird

n/a

n/a

Faeces

Large
shellfish
(giant
mussel)
Human

n/a

n/a

nd

n/a

Enteritis

Faeces

nd

nd

Dialysis fluid

Wild birds

n/a

n/a

Faeces

Grey seal

n/a

Pulmonary abscess

nd

California
sea lion

n/a

Abscess

nd

(Gilbert et al.
2017)

Charolais
bull
Human

n/a

n/a

Preputial mucosa

(Silva et al. 2020)

nd

Gingivitis and
periodontitis
Actinomycotic chest
wall abscess
Enteritis

Oral cavity lesions

(Tanner et al.
1981)
(Spiegel and
Telford 1984)
(Lastovica et al.
2000)

Breast cellulitis

nd

Soft/skin tissue bite
infection
Oesophageal
adenocarcinoma/Bar
rett’s oesophagus
Asymptomatic

nd

(Goldstein 2001)

Biopsies

(Macfarlane et al.
2007; Kaakoush et
al. 2015a)
(Könönen et al.
2007; Cortelli et
al. 2008)
(De Vries, Arents
and Manson 2008)

nd
n/a
Large cell lymphoma
post chemotherapy
nd
Increased abundance
of C. rectus
Oral cavity
colonisation
History of chronic
otitis and
meningoradiculitis
Gastroesophageal
adenocarcinoma

Dorsal
intradural/vertebral
abscess
Palate soft tissue
abscess

Child

Aspirate
Faeces

Periodontal sulcus,
tongue, cheek
mucosa, and saliva
Pus

(Debruyne et al.
2009)
(Debruyne et al.
2009)
(Johansson et al.
2018)
(Gilbert et al.
2017)

Aspirate

(Mahlen and
Clarridge 2009)

Crohn’s disease

Intestinal biopsy

Child

Asymptomatic

Intestinal biopsy

nd

Severe periodontitis

Blood culture

nd

Fatal ruptured
mycotic intracranial
aneurysm with
subdural empyema
Right thigh
(anterior)
necrotizing soft

Blood culture and
subdural pus

(Zhang et al.
2009)
(Zhang et al.
2009)
(Castillo et al.
2011)
(Lam et al. 2011)

nd

Necrotic tissue
culture and pus

(Lam et al. 2011)
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Species/
subspecies

Host/
Source

Immune status

nd
Acute stroke patients

Campylobacter
showae

Campylobacter
sputorum subsp.
sputorum

Canine

n/a

Human

Cerebrovascular
accident and
hemiparesis
Child

Campylobacter
infection
manifestation
tissue infection
osteolytic lesion
with above knee
amputation
right empyema
thoracis
Cerebral microbleed
association
Asymptomatic or
diarrhoea
Infraorbital abscess

Isolation source

Reference

Pus

(Lam et al. 2011)

Positive serum
antibody titer
Faeces

(Shiga et al. 2020)

Aspirate

Crohn’s disease

Intestinal biopsy

Child
nd

Crohn’s disease
Ulcerative colitis

Canine

n/a

Human

nd

Asymptomatic or
diarrhoea
Gingivitis

Faeces
Colonoscopic
biopsy
Faeces

nd

Bronchitis

Sputum

nd

Pulmonary abscess

C. sputorum biovar
bubulus
nd
nd
n/a

Scrotal abscess

Transthoracic
aspirate
Aspirate

Pressure sore
Axillary abscess
Enteritis

Pus
Pus
Faeces

Knee abscess

Septicaemia
potentially
associated with a
knee abscess
n/a
n/a
n/a

Blood culture

Porcine
Ovine
Bovine

n/a
n/a
n/a

Gingival crevice

Intestine
Faeces
Semen
Retail meat
Faeces

Campylobacter
subantarcticus

“Campylobacter
troglodytis”

Canine

n/a

Faeces

n/a

Asymptomatic and
diarrhoea
n/a

Porcine
(feral)
Greyheaded
albatross
and blackbrowed
albatross
(Diomedea
melanophri
s
Gentoo
penguin
Wild bird

n/a

n/a

Faeces

n/a

n/a

Faeces

n/a

n/a

Faeces

Chinstrap
penguin
Wild
chimpanzee
(Pan
troglodytes
schweinfurt
hii),

n/a

n/a

Faeces

n/a

n/a

Faeces

Faeces

(Chaban, Ngeleka
and Hill 2010)
(De Vries, Arents
and Manson 2008)
(Zhang et al.
2009)
(Man et al. 2010)
(Mukhopadhya et
al. 2011)
(Chaban, Ngeleka
and Hill 2010)
(Véron and
Chatelain 1973;
Roop et al. 1986)
(Véron and
Chatelain 1973)
(Raffi et al. 1985)
(Raffi et al. 1985)
(On et al. 1998)
(On et al. 1998)
(Vandamme et al.
1989; Lastovica et
al. 2000)
(Foudraine et al.
1998)

(On et al. 1998)
(On et al. 1998)
(Petersen et al.
2007)
(Lynch et al.
2011)
(Oporto and
Hurtado 2011)
(Chaban, Ngeleka
and Hill 2010)
(Jay-Russell et al.
2012)
(Debruyne et al.
2010a)

(Debruyne et al.
2010a)
(Debruyne et al.
2010a; Johansson
et al. 2018)
(Johansson et al.
2018)
(Kaur et al. 2011)
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Species/
subspecies

Host/
Source

Campylobacter
upsaliensis

Human

Immune status
Infant (“C.
troglodytis” type II)

Canine

Isolation source

Reference

Faeces

(Platts-Mills et al.
2014)
(Sandstedt, Ursing
and Walder 1983;
Bojanić et al.
2019)
(Patton et al.
1989)

Asymptomatic or
diarrhoea

Faeces

83 years, male,
congestive heart
failure, renal
insufficiency and
obstructive lung
disease
nd

Bacteraemia

Blood culture

Breast abscess

Biopsy tissue culture

n/a

Enteritis

Faeces

Pregnant

Septic abortion

Infant

Asymptomatic

Blood culture and
fetoplacental
material
Faeces

n/a

Faeces

Bovine

Household cat of
aborting human
n/a

n/a

Retail meat

Human

nd

Subdural empyema

nd

nd

Perianal/perirectal
abscesses

Pus or vaginal
swabs

Amputated left thigh

Infected wound

Wound

nd

Aspiration
pneumonia

Infected wound

nd

Pulmonary abscess

Transtracheal
aspiration

nd

Pneumonitis
empyema

Pleural fluid

nd

Indwelling urinary
catheter urethral
discharge

Urethral swab

nd

Necrotising fasciitis

Pregnant

nd

Fluid aspirate and
tissue debriding
from the center of
the lesion
Amniotic fluid

nd

Infected face lesion

Wound

nd

Infected heel

Wound

nd

Clenched fist
injury/bite infection
Cavity (periapical,
root canal,

Wound

Human

Feline

Campylobacter
ureolyticus

Campylobacter
infection
manifestation
Enteritis

nd

nd

(Gaudreau and
Lamothe 1992)
(Lastovica et al.
2000; Bullman et
al. 2011)
(Gurgan and
Diker 1994)
(Platts-Mills et al.
2014)
(Gurgan and
Diker 1994)
(Lynch et al.
2011)
(Yoshikawa,
Chow and Guze
1975)
(Labbé, Sehoutens
and
Yourassowsky
1977; Duerden,
Bennet and
Faulkner 1982;
Johnson et al.
1985)
(Labbé, Sehoutens
and
Yourassowsky
1977)
(Labbé, Sehoutens
and
Yourassowsky
1977)
(Labbé, Sehoutens
and
Yourassowsky
1977)
(Labbé, Sehoutens
and
Yourassowsky
1977)
(Labbé, Sehoutens
and
Yourassowsky
1977)
(Giuliano et al.
1977)

(Jackson and
Goodman 1978)
(Jackson and
Goodman 1978)
(Jackson and
Goodman 1978)
(Goldstein et al.
1978)
(Duerden, Bennet
and Faulkner
1982)
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Species/
subspecies

Host/
Source

Immune status

Isolation source

Reference

Pustular lesion

(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)
(Duerden, Bennet
and Faulkner
1982)

nd

Infected sebaceous
cyst

nd

nd

Chronic otitis media

nd

nd

Chest wall abscess

nd

Peripheral vascular
disease/diabetic

Lower limb
gangrenous ulcer
lesion
Wound infection

Ulcer lesion

nd

Pilonidal abscess

nd

nd

Nail-bed infection

nd

nd

Axillary abscess

nd

nd

Breast abscess

nd

nd

Postpartum uterine
infection

urine

nd

Perineal and genital
necrotic cellulitis
and gangrene
(scrotal, penile or
vulval)
Bartholin’s abscess

nd

Bone infection
above the waist
Intra-abdominal
abscess
Brain abscess

Bone samples

Synovial fluid and
faeces

Child

Reactive arthritis
with associated
diarrhoea
Crohn’s disease

Child

Asymptomatic

Intestinal biopsy

n/a

Enteritis

Faeces

nd

Ulcerative colitis

nd

Necrotic foreskin 7
days after Pre-Pex
placement
Stomach pain

Colonoscopic
biopsy
Subpreputial swab

Post appendix and
large bowel surgery

nd

nd
nd
nd
nd

nd
nd
Equine

Campylobacter
infection
manifestation
submandibular)
abscesses
Acne conglobata

n/a

Papulopustular
rosacea
Acute endometritis

Wound

nd

Swab
Swab

Intestinal biopsy

Interproximal
gingival plaques
Nose and cheek
swab
Endometrial cells

(Duerden, Bennet
and Faulkner
1982)
(Johnson et al.
1985)
(Johnson et al.
1985)
(Johnson et al.
1985)
(Cox, Kempsell
and Gaston 2003)
(Zhang et al.
2009)
(Zhang et al.
2009)
(Bullman et al.
2011; Lucid et al.
2014; Miller et al.
2015)
(Mukhopadhya et
al. 2011)
(Liu et al. 2016)

(Basic et al. 2018)
(Rainer et al.
2019)
(Hariharan et al.
1994)
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Species/
subspecies

Host/
Source

Immune status

Bovine

n/a

Campylobacter
infection
manifestation
n/a

Isolation source

Reference

Retail meat

(Lynch et al.
2011)
(Koziel et al.
2012)
(Koziel et al.
2012)
(Koziel et al.
2014a)
(Koziel et al.
2014a)
(Koziel et al.
2014a)
(Debruyne et al.
2010b; Johansson
et al. 2018;
Gomez-Alvarez et
al. 2019)
(Kweon et al.
2015)

Faeces
Unpasteurised milk

Campylobacter
volucris

Campylobacter
vulpis

Porcine

n/a

n/a

Faeces

Feline

n/a

n/a

Faeces

Canine

n/a

n/a

Faeces

Gull and
wild bird

n/a

n/a

Faeces

Human

Polycythaemia vera
with splenomegaly
and alcoholic liver
cirrhosis
n/a

Bacteraemia

Blood culture

n/a

Cloaca

n/a

n/a

Caecal
contents

Gentoo
penguin
Wild red
foxes

(García-Peña et
al. 2017)
(Parisi et al. 2021)

* recorded as “atypical Campylobacter fetus subsp. fetus; n/a, not applicable; nd, not determined.

1.2

Campylobacteriosis

Campylobacter infection typically manifests as acute diarrhoeal illness and
enterocolitis; however, extraintestinal and systemic diseases are also associated with
members of the genus, with or without associated enteric disease (Table 1.2) (Adedayo
and Kirkpatrick 2008; Gallo et al. 2016).
Although C. fetus subsp. fetus is (Cff) regarded as the most common cause of
campylobacter bacteraemia (Dingle et al. 2010), Morey et al. (1996) reported 72 cases
of bacteraemia caused by Campylobacter spp. over a five-year period, in central
Australia, 85.2% of which were caused by C. jejuni subsp. doylei (Morey 1996).
Campylobacter spp. have unique growth requirements in vitro, internalised C. jejuni
may undergo significant physiological changes within the intracellular environment
(Jones et al. 1993; Watson and Galán 2008). This seems likely for C. jejuni
considering the low infective dose (Robinson 1981; Cawthraw et al. 1996).
1.2.1

Presentation of Campylobacter gastroenteritis

C. jejuni (as a model organism) colonises the lower intestinal tract, colonising the
intestinal crypts in the caecum and proximal colon. Most acute, symptomatic cases of
enteric campylobacteriosis present as one to five days of prodromal symptoms with
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fever, rigors and vomiting, followed by three to seven days of watery or bloody
diarrhoea with abdominal pain (Blaser et al. 1979; Dasti et al. 2010). Enteric
symptoms lasting three weeks have been noted and the illness may occasionally be
relapsing (Blaser et al. 1979; Karmali and Fleming 1979). The severity of illness varies
from mild disease to hospitalisations due to dehydration (Dasti et al. 2010). Although
C. jejuni is the most frequent cause of bacterial enteritis, other members of the genus
cause enteric infection, but are much less common (Table 1.2) (Bullman et al. 2011).
Successful colonisation and infection with thermophilic Campylobacter spp.,
critically depends on adhesion and invasion factors (Russell et al. 1993; KrauseGruszczynska et al. 2007a). Epithelial cell and colonic damage, and subsequent
diarrhoeal disease, are directly linked to the invasive nature C. jejuni (Karmali and
Fleming 1979; Russell et al. 1993).
1.2.2

Incidence and epidemiology of enteric campylobacteriosis

Cases of campylobacteriosis are typically sporadic in the developed world. It’s
estimated that approximately nine million cases of human campylobacteriosis occur
in the EU per annum with estimated total annual costs of 2.4 billion euro (European
Food Safety Authority 2011). Campylobacter is estimated to cause approximately 1.3
million infections per year in the US (Center for Disease Prevention and Control
2013). The true number of cases of illness is likely to be ten to 100 times higher, as
there is a considerable under-detection and under-reporting (due to gaps in the
notification systems, lack of symptoms, lack of hospitalisations) (European Food
Safety Authority 2011). Moreover, the relatively long incubation period preceding
Campylobacter infection challenges source attribution. The fastidious nature of
Campylobacter spp. and differing growth requirements of species members has
undoubtedly contributed to significant underreporting of campylobacteriosis cases and
fragmented epidemiological fingerprinting (Bowdre et al. 1976; Casey, Fitzgerald and
Lucey 2017).
Since 2011 the incidence campylobacteriosis cases has increased annually in Ireland,
reaching a peak of 3,030 reported cases in the Republic in 2018 (approximately eight
times the incidence of salmonellosis) (Health Protection Surveillance Centre 2019;
O’Connor et al. 2020), with a moderate decline 2019 and 2020 (Health Protection
Surveillance Centre 2020) (Figure 1.1a). Anomalously, lower numbers of all notifiable
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illnesses were reported in 2020 and almost 3,000 cases of campylobacteriosis have
already been reported in Ireland as of 28th of September 2021 (Dr Lisa O’Connor,
personal communication, 2021), likely to overtake peak incidence rate in 2018.
Although the population of Ireland is increasing, the crude incidence rates confirm a
sustained increase in Campylobacter infection per 100,000 population (Figure 1.1b)
Upwards of 90% of all human Campylobacter spp. infections (European Food Safety
Authority 2011) are reported to be caused by C. jejuni and C. coli; unsurprising
considering that detection methods are optimised for these species. This also indicates
that the true burden of campylobacteriosis is vastly underestimated. For instance, the
emerging species Campylobacter ureolyticus was detected in 24.4% of 340
Campylobacter-confirmed patient faecal samples in Cork University Hospital, using
a multiplex polymerase chain reaction (PCR) (Bullman et al. 2011). Later, C.
ureolyticus was detected in 41.8% of 191 culture-negative, Campylobacter DNApositive faecal samples from patients presenting with gastroenteritis, being the second
most prevalent Campylobacter species detected (Bullman et al. 2012). In the same
study, detected C. coli was detected in just 5.7% of these samples; challenging the
concept that C. coli is among the most dominant species causing intestinal disease in
Ireland (Bullman et al. 2012).
Diagnostic laboratories in the Republic of Ireland (ROI) have adopted molecular
methods to detect enteric pathogens – contributing to the increased notification rate
since circa. 2010 (Casey, Fitzgerald and Lucey 2017). However, this PCR assay
targets only C. jejuni and C. coli, and does not detect to the genus level, meaning that
other significant species are not included in the case numbers. Studies investigating
the current distribution of Campylobacter species contributing to gastroenteritis in
Ireland are warranted.
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A

B

Figure 1.1. (A) Number of reported campylobacteriosis cases in Ireland between 2004 and 2020
(Health Protection Surveillance Centre 2021). (B) Crude incidence rate (CIR) per 100,000 population,
Campylobacter infection in Ireland, 2004-2018 (Health Protection Surveillance Centre 2019).

The epidemiology of campylobacteriosis remains poorly understood. In contrast to
salmonella, campylobacter less able to multiply in the environment and is not
typically associated with direct person-person spread (Jones et al. 1993; Pebody, Ryan
and Wall 1997).
1.2.3

Seasonal pattern of enteric campylobacteriosis

Marked seasonal variation in the incidence of human Campylobacter infection has
been reported in northern and southern hemispheric countries, and highest reported
infection rates typically occur during summer months (Ministry of Food Agriculture
and Fisheries 2000; Nylen et al. 2002; Dasti et al. 2010). Seasonal changes in poultry
campylobacter-colonisation during warmer months is thought to be a significant
contributor to the observed seasonal pattern in humans (Ministry of Food Agriculture
and Fisheries 2000; Nylen et al. 2002; European Food Safety Authority 2011; Cody
et al. 2012). Epidemiological evidence has identified a significant overlap between C.
jejuni strains isolated from broilers and strains isolated from cases of human diarrhoeal
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campylobacteriosis (Habib et al. 2009). Other authors have not found a seasonal
variation in the carriage of Campylobacter spp. in broilers (Humphrey, Henley and
Lanning 1993; Evans and Sayers 2000), or peaks in broiler colonisation that appear
after the typical peak in cases of human infection (Kapperud et al. 1993; Kuhn et al.
2020b). Increased precipitation in the week before illness has been reported by some
to positively influence Campylobacter incidence (Kuhn et al. 2020a).
The seasonal variation may also reflect increased transmission related to water
activities or changes (Nylen et al. 2002; Jonsson et al. 2012), although the true
dynamics of the temporal distribution of human infections remains an open question
(Casey, Fitzgerald and Lucey 2017). Moreover, climate change may have local and
regional influence on Campylobacter spp. infection (Kuhn et al. 2020a). It may be
necessary to consider other nonpoultry sources as Campylobacter spp. reservoirs
(Nylen et al. 2002).
1.2.4

Sources of infection

Broilers are considered the most significant campylobacter-source (European Food
Safety Authority 2011), relative to human disease (Lawson et al. 2001).
Simultaneously, chicken meat production and consumption has increased dramatically
in the last 50 years (Figure 1.2) (De Haan et al. 2010; European Commission 2018a).
Poultry meat is a lean, white source of protein that is relatively low in cost compared
to other meats and is second after pig-meat as the most consumed meat in the EU
(European Commission 2018a). Chicken has also been adapted to many cuisines
worldwide. Moreover, the cost of rearing broilers is relatively economical once the
broiler house has been established. Poultry is normally reared under contract to
processors and poultry producers are not subject to the same price for product
fluctuations as other farmers (Department of Agriculture Food and the Marine 2016).
As of 2019, production of Irish poultry meat continues to increase (Central Statistics
Office 2020) and the number of poultry livestock in Ireland was over 11 million in
2016 (Central Statistics Office 2016). As the world population continues to increase,
the intensification of food production and farming is a natural consequence. EU
poultry alone is expected to increase by 3.8% between 2015-2025 (European
Commission 2018a).

25

Figure 1.2. Number of livestock animals slaughtered for meat in the world, 1961 – 2014. Graph
generated using census data provided by the United Nations Food and Agriculture Organisation (UN
FAO), 2017.

The consumption of contaminated chicken meat and cross-contamination from this
source is considered to be responsible for the majority (20-30%) of all sporadic human
cases of campylobacteriosis, while 50% to 80% may be attributed to the chicken
reservoir as a whole (European Food Safety Authority 2011; Khalid et al. 2020). Cross
contamination at the poultry processing plants during defeathering, evisceration and
carcass chilling results in a high proportion of campylobacter-contaminated poultry
carcasses and meat (European Food Safety Authority 2010a). Outbreaks are rare and
direct human infection might occur, but the effect is thought to be negligible (Pebody,
Ryan and Wall 1997; Lucey et al. 2000b; Ministry of Food Agriculture and Fisheries
2000). Other sources responsible for human infection include cattle, consumption of
beef and milk (particularly unpasteurised), wild birds and pets (Newell et al. 1985;
Kapperud et al. 1992; Altekruse et al. 1999; Allos 2001; Lévesque et al. 2008; Dasti
et al. 2010; Griekspoor et al. 2015; Hald et al. 2016).
C. jejuni and C. coli are found ubiquitously in nature, wild birds, reptiles and mammals
(Table 1.1 and 1.2) (Karmali and Fleming 1979; Ogden et al. 2009; Dasti et al. 2010;
Hald et al. 2016). C. jejuni has been detected in stool samples from asymptomatic
humans, although infrequently (Blaser et al. 1979; Iraola et al. 2017), while
Campylobacter concisus, Campylobacter gracilis, and Campylobacter hominis. are
colonisers of the human oral cavity (Table 1.2) (Allos et al. 2008). Sexual contact has
recently been reported as a risk factor for Campylobacter infection (Kuhn et al. 2021).
Interestingly, C. fetus has recently been established as a member of the intestinal
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microbiota of healthy individuals; serving as a potential reservoir for infection (Iraola
et al. 2017). This supports the theory of allopatric speciation, where host-associated
genetic signatures (related to adaption or drift) are epidemiologically significant
(Pascoe et al. 2017).
Water contaminated with faeces from birds and animals is also considered to be a
major natural reservoir (Newell et al. 1985; Jonsson et al. 2012) and has been linked
to outbreaks of Campylobacter infection (Pearson et al. 1993; Duke et al. 1996).
Farms could be a source of faecal bacterial run-off to the surroundings and to small
streams feeding into larger water systems (Jonsson et al. 2012), and Campylobacter
has been shown to survive in bovine faeces on pasture for up to 14 days (Gilpin et al.
2009) and can persist in temperate urban estuary water or its bed and bank sediment
for 14 and 21 days, respectively (Schang et al. 2016). Drinking water from a lake,
pond, stream of brook was associated with an increased risk of Campylobacter
infection in humans (Kapperud et al. 1992). Contamination of the drinking water
supply system in Norway caused a large outbreak of campylobacteriosis in 2019
(Hyllestad et al. 2020). C. jejuni in particular is rich in genetic diversity, suggesting
that sources for sporadic clinical infections are also likely to be diverse (Lévesque et
al. 2008).
1.2.5

Alternative paradigm of Campylobacter spp. epidemiology

Advances have been made, particularly in the last decade regarding infection control
measures in primary poultry production and during poultry processing, yet the burden
of campylobacter-associated gastroenteritis in humans remains a significant public
health threat (European Food Safety Authority 2011). In recent years, there has a
continued general upward trend of campylobacteriosis cases in Ireland (Figure 1.1a
and b) (Health Protection Surveillance Centre 2019). Yet a decrease in Campylobacter
prevalence in Irish broilers has been established in Ireland (Dr Helen Lynch, personal
communication, 2020). Taken together, there appears be a need to redefine the
paradigm that poultry is the major source of human infection throughout the year
(Casey, Fitzgerald and Lucey 2017). It is possible that endogenous persistence and
reactivation of Campylobacter spp. in the humans depends on a combination of strain
variation and host susceptibility, (Casey, Fitzgerald and Lucey 2017). Unless a
sustained decrease in the notification of human Campylobacter spp. gastroenteritis
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cases can be established, alternative reservoirs should be explored further. Intracellular
survival of Campylobacter and the potential impact of endogenous hormones are
discussed below.
1.2.5.1 Intracellular survival of Campylobacter
Internalised C. jejuni can survive intracellularly in intestinal and phagocytic cells,
often with cytotoxic effects (Konkel et al. 1992; Hickey, Majam and Guerry 2005).
Campylobacter DNA circulating in peripheral mononuclear cells in humans, detected
in 30% of health humans and 50% of patients with Guillain-Barré syndrome (GBS)
(van Rhijn et al. 2002) and by the age of 20 almost 95% of individuals have antibodies
against campylobacter (Ang et al. 2019). Wassenaar et al. (1997) revealed that 10%
of voluntary blood donors carried monocytes that were able to phagocytose but were
not able to kill either blood, stool or laboratory-adapted C. jejuni strains (Wassenaar
et al. 1997), indicating that Campylobacter may occasionally persist in monocytes.
Establishment and resurgence of human Campylobacter infection may result from
such reservoirs within the body (Casey, Fitzgerald and Lucey 2017).
Interestingly, C. fetus are internalised by bovine endometrium epithelial cells
(Campos-Múzquiz et al. 2019; Campos Muzquiz et al. 2021) but was not found to
replicate within them (Campos Muzquiz et al. 2021).
1.2.5.2. Biological hormones and Campylobacter infection
Perception of stress by the central nervous system results in the release of hormones
and neuroactive factors (neurochemicals and neuropeptides) that can affect immune
function (Freestone et al. 2008), but recent research has elucidated some of the effects
of these compounds (particularly catecholamines and glucocorticoids) on bacterial
populations. Catecholamine hormones (adrenaline (AD) and noradrenaline (NA))
have endocrinological roles and function also as neurotransmitters. In the intestinal
lumen, bacteria are exposed to catecholamine neurotransmitters released by
noradrenergic neurons of the enteric nervous system. Microbial endocrinology shows
that bacteria have evolved sensors specific for hormones, used to determine host
proximity – influencing the expression of genes used for colonisation (Freestone et al.
2008; Freestone 2013). Moreover, NA is not internalised by C. jejuni (Cogan et al.
2007). AD and NA have been shown to affect gene expression patterns relating to
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growth, iron uptake, motility and pathogenicity in C. jejuni (Xu et al. 2015; Truccollo,
Whyte and Bolton 2020).
1.2.5.2.1 Effect of eukaryotic hormones on bacterial growth rates and pathogenicity
Catecholamine and glucocorticoid neuroendocrine hormone changes can modulate
growth rates and pathogenicity of Campylobacter spp. (Cogan et al. 2007; Xu et al.
2015; Truccollo, Whyte and Bolton 2020). It’s also worth consideration that as
catecholamines can sequester iron, thus affecting the iron concentration in culture
media (Freestone et al. 2008). The full effect of biological hormones on
Campylobacter colonisation and infection remains largely unknown. NA is
synthesised by the adrenal glands and by adrenergic neurons of the enteric nervous
system that innervate the basolateral layer of the intestines (Hughes et al. 2009). NA
is released into the lumen of the intestine during conditions of stress or epithelial
degeneration and is abundant in the gut-associated lymphoid tissue (Sule et al. 2017).
In an Irish study involving five C. jejuni strains (clinical and broiler origin), AD and
NA increased growth rates in four of five strains and increased adhesion and invasion
of Caco-2 cells were observed in one and three of five strains, respectively (Truccollo,
Whyte and Bolton 2020). Xu et al. (2015) found that AD increased growth rates in C.
jejuni strain NCTC 11168, while Truccollo et al. (2020) observed the opposite effect
with the same strain (Xu et al. 2015; Truccollo, Whyte and Bolton 2020). Although
several consensus mutations exist within C. jejuni NCTC 11168 clones, widely used
among the Campylobacter research community, which may account for some
phenotypic or behavioural differences reported in the literature (Revez et al. 2012;
Butcher and Stintzi 2013).
1.2.5.2.1.1

Effect of catecholamines on bacterial iron homeostasis and aerobic

growth
The effects of catecholamines on bacterial growth promotion is thought to be an effect
of catecholamine-mediated iron uptake (Freestone et al. 2002, 2008). The catechol
moiety is known to remove ferric iron sequestered by host iron-binding proteins
lactoferrin and transferrin (Freestone et al. 2002).
It was determined in the early 1970s that NA and its precursors (dihydroxyphenyl
compounds) improved the aerotolerance of C. jejuni and the obligate microaerobe
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Spirillum volutans – a non-pathogenic freshwater species (Bowdre et al. 1976).
Development of bacterial iron binding systems promotes growth and aerobic survival
(Sarkodie et al. 2019). It was suggested that microaerobes are unable to synthesise
sufficient siderophores (iron-binding/chelating compounds) required for aerobic
growth (Bowdre et al. 1976), particularly in the intestinal mucosa where levels of free
iron are infinitesimal and are typically sequestered by host iron complexes (transferrin,
lactoferrin, haem and haemoglobin) (van Vilet et al. 2002; Andrews, Robinson and
Rodríguez-Quiñones 2003; Sarkodie et al. 2019). Thus, catecholamine ferric ironbinding properties and facilitation of bacterial ferric iron uptake contribute to the
improved aerotolerance and nutrient uptake in Campylobacter, observed in the
presence of NA (Bowdre et al. 1976; Sarkodie et al. 2019). The expression of
oxidative stress response factors is logical considering free iron in the extracellular
environment results in the production of oxygen radicals. Previously iron responsive
regulation of oxidative stress response genes has been demonstrated in C. jejuni (van
Vilet et al. 2002).
1.2.5.2.2 Human hormone seasonality
Animals show seasonal changes in hormones, considering seasonality governs
reproduction, pigmentation and migration, even in constant photoperiod or
temperature (Jacobs and Wingfield 2000; Tendler et al. 2021). A winter-spring peak
in effector hormones in humans was reported, while pituitary hormones affecting
reproduction (luteinising hormone (LH), metabolism (thyroid stimulating hormone
(TSH), stress (adrenocorticotropic hormone (ACTH)) and lactation (prolactin (PRL))
typically peak in summer months (Tendler et al. 2021).
The circannual rhythm and oscillations of hormone production is thought to be centred
in the pituitary stalk (MacGregor and Lincoln 2008) and photoperiod information is
relayed to the pars tuberalis from melatonin signals (Tendler et al. 2021). The effects
of seasonality on hormones increased with latitude, corresponding to a greater
photoperiod variation (Tendler et al. 2021). Increased dopamine function was linked
to the beneficial effects of light on mood in women with seasonal mood changes
(Cawley et al. 2013).
Tendler et al. (2021) postulate that gland masses grow due to trophic effects of
hormones, for example, the adrenal cell hypertrophy in response to cortisol secretion,
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generating a feedback circuit (Tendler et al. 2021). This cycle follows a seasonal
pattern, proportional to photoperiod, maximal on December 21 and minimal on June
21 (Tendler et al. 2021). Prolonged periods of stress or major depression may also
cause adrenal and pituitary gland enlargement (Rubin et al. 1995; Parker, Schatzberg
and Lyons 2003).
However, it is conceivable that environmental signals may contribute to the observed
circannual rhythm of hormones, which may impact host-bacteria interactions. Peak
incidence of campylobacter has been reported in females from 20-36 and in males
from birth until late teens (Gillespie et al. 2008), both associated with hormonal
changes (Fitzgerald et al. 2014). Further studies are warranted to investigate the
possibility of endogenous persistence and reactivation in humans.
1.2.6

Post-infectious sequelae

Although generally self-limiting, a number of significant post-infectious are
associated with Campylobacter infection (Moore et al. 2005) and major postinfectious manifestations are described below.
1.2.6.1 Guillain-Barré syndrome
Post infectious neuropathies associated with campylobacteriosis include GuillainBarré syndrome (GBS) and its variant Miller–Fisher syndrome (MFS) (Altekruse et
al. 1999; Yuki 2001). GBS is an acute inflammatory demyelinating polyneuropathy,
occurring in less than one thousand cases of campylobacteriosis (Nachamkin, Allos
and Ho 1998; Altekruse et al. 1999; Moran and Prendergast 2001; Yuki 2001). MFS
is a variant of GBS characterised by oculomotor weakness and ataxia (Godschalk et
al. 2007). C. jejuni is the most common antecedent infection in GBS (Nyati and Nyati
2013). However it’s likely that the true incidence of C. jejuni GBS is underestimated
using culture methods (Nachamkin, Allos and Ho 1998). Approximately 20% of GBS
patients are left with some disability, with mortality rates of 2–5% (Nachamkin, Allos
and Ho 1998; Altekruse et al. 1999). Outbreaks are rare, but have been reported
(Nachamkin, Allos and Ho 1998; Zhang et al. 2010, 2015). C. jejuni associated GBS
may also be more severe than GBS caused by other pathogens (Nachamkin, Allos and
Ho 1998; Nyati and Nyati 2013).
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1.2.6.1.1 Pathogenesis of Campylobacter jejuni Guillain-Barré syndrome
The pathogenesis of C. jejuni post-infectious neuropathies is associated with the
molecular mimicry of sialylated lipooligosaccharides (LOS) on the outer membrane
of C. jejuni and sugar moieties on peripheral (GBS-associated) or central (MFSassociated) gangliosides (membrane glycolipids) (Gilbert et al. 2002; Godschalk et al.
2007; Nielsen et al. 2010b). LOS are a low molecular weight form of
lipopolysaccharide (LPS) and function to preserve the integrity of the outer membrane
in some Gram negative bacteria. Gangliosides and sialylated glycosphingolipids and
are the most abundant nerve cell sialoglycans (Schnaar, Gerardy-Schahn and
Hildebrandt 2014). Anti-Campylobacter antibodies can cross-react with ganglioside
epitopes on neural tissues, which may result in autoimmune axonal degeneration and
dysfunction of the nodes of Ranvier (Nachamkin, Allos and Ho 1998; Godschalk et
al. 2004, 2007; Koga et al. 2006). The presence of sialylated LOS is also associated
with increased severity of enteric disease (Mortensen et al. 2009).
C. jejuni expressing LOS classes A, B and C are responsible for the majority of GBS
cases. LOS classes A, B and C are sialylated via sialyltransferases encoded by cstII
and cstIII (Elhadidy et al. 2018a). LOS class A has been identified as the most
significant risk factor for the development of GBS (Godschalk et al. 2004; Koga et al.
2006). Class A strains generally express cstII, encoding an enzyme with α-2,3sialyltransferase activity that transfers an α-2,3-sialic acid to both the inner and
terminal galactose residues of LOS, generating GM1-like and GD1a-like LOS mimics
(Koga et al. 2006). Both LOS classes A and B possess the cstII gene, but the cgtAII
gene (which encodes β-1,4-N-acetylgalactosaminyltransferase) is specific for class B
and can be used to distinguish between LOS classes A and B (Parker et al. 2005; Koga
et al. 2006).
Both LOS class A and B strains has been associated with MFS (Koga et al. 2006).
Mutations in cstII gene (Asn5l) can confer both α-2,3 and α-2,8-sialyltransferase
activity (Koga et al. 2006; Godschalk et al. 2007), enabling transfer of the disialyl
moiety to the outer core of LOS, thereby mimicking GQ1b (Gilbert et al. 2002;
Godschalk et al. 2004) and GT1a gangliosides (Koga et al. 2006). GQ1b is enriched
in the nerves that innervate the oculomotor muscles, explaining the association
between MFS and corresponding anti-GQ1b antibodies (Ang et al. 2002; Godschalk
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et al. 2004, 2007; Koga et al. 2006). Anti-GQ1b negative MFS cases have been
reported (Lee 2012). Other LOS mimics have been reported in C. jejuni MFS-causing
strains including GM3, GD2 and GD3-like structures (Moran and Prendergast 2001).
LOS class C strains are typically associated with GM1-like LOS but are less often
associated with the development of GBS (Koga et al. 2006). LOS class C expressing
C. jejuni isolates are frequently detected from poultry and humans (Habib et al. 2009).
The studies on C. jejuni-associated GBS are still inconclusive (Nyati and Nyati 2013).
Host immunogenetic factors (humoral and cellular immunity) appear to influence
disease outcome (Nachamkin et al. 2002; Koga et al. 2006; Amon et al. 2012; Nyati
and Nyati 2013). The equal distribution of the cstII gene in human, cattle and poultry
isolates indicates that microbial properties alone are insufficient to explain why only
a small minority of cases of C. jejuni enteritis trigger an autoimmune response (Koga
et al. 2006; Amon et al. 2012).
1.2.6.1.2 Lipooligosaccharide heterogeneity
The core region of LOS consists of inner and outer core domains and structural
variability is mainly limited to the outer core oligosaccharide portion (Moran and
Prendergast 2001). The addition of diverse carbohydrate moieties to the LOS Oantigen results in a range of LOS phenotypes among the C. jejuni population (Gilbert
et al. 2002; Koga et al. 2006; Godschalk et al. 2007; Neal-McKinney et al. 2018).
Genomic heterogeneity and structural diversity consequent to major (horizontal gene
transfer and frameshift mutations) and minor (deletions, insertions and missense
mutations) genetic variation may have resulted from selective pressure to evade
immune responses (Gilbert et al. 2002; Parker et al. 2008). Strains with the same LOS
biosynthesis genes can express diverse ganglioside mimics as a result of minor
mutations (Koga et al. 2006) or phase variation (Godschalk et al. 2007). Evidence of
homopolymeric G tracts (discussed below) and genetic rearrangement in LOS loci
have been described (Parkhill et al. 2000; Parker et al. 2005).
In some cases, nonsialylated LOS have also been linked to the development of GBS,
indicating that other mechanisms may play a role (Godschalk et al. 2007). However,
it is also possible that other evolutionary intermediates exist (Gilbert et al. 2002).
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1.2.6.2 Reiter’s syndrome (reactive arthritis)
Acute reactive arthritis is a spondyloarthropathies, characterised by sterile joint
inflammation within four weeks following an intestinal infection with Campylobacter
(or for example, Salmonella, Shigella, Yersinia and Escherichia) and may develop into
debilitating polyarthritis (Ponka, Martio and Kosunen 1981; Pope et al. 2007). RA is
estimated to occur in 1-5% and pathophysiology centres on molecular mimicry or
dysregulation of proinflammatory cytokines (Pope et al. 2007). The triggering
infection may be mild and overlooked as the inciting factor.
1.2.6.3 Inflammatory bowel disease
Campylobacter enteritis is now recognised as a risk factor for the development of
inflammatory bowel disease (IBD) (García Rodríguez, Ruigómez and Panés 2006), a
group of disorders that involve chronic inflammation of the digestive tract, including
Crohn’s disease and ulcerative colitis. The prevailing theory of pathogenesis of IBD
suggests that the intestinal immune system is inappropriately activated due to a
confluence of genetic and environmental factors, inducing inflammatory tissue
damage. Enteric pathogens may trigger an initial intestinal immune response and
trigger IBD (García Rodríguez, Ruigómez and Panés 2006). Mucosa-associated
bacteria are considered to be instigators in the development of both Crohn’s disease
and ulcerative colitis and leading bacterial candidates include, but are not limited to,
Escherichia coli, Helicobacter, Fusobacteria, Mycobacteria and Campylobacter spp.
(Kaakoush, Mitchell and Man 2014). However, authors have highlighted the lack of
information available on IBD linked to Campylobacter spp. (Keithlin et al. 2014) and
the ambiguity surrounding the proximal events of IBD pathogenesis (García
Rodríguez, Ruigómez and Panés 2006; Laing et al. 2018). Although, C. jejuni has
been significantly associated with Crohn’s disease and ulcerative colitis (Zhang et al.
2009; Man et al. 2010; Mukhopadhya et al. 2011), a report in 2003 warned that C.
jejuni enterocolitis may resemble acutely active stages of IBD, with similar clinical
pictures (Quondamcarlo et al. 2003).
Other members of the Campylobacter genus implicated in inflammatory bowel
diseases include, C. curvus, C. gracilis, C. hominis, C. rectus, C. showae, C.
ureolyticus (Zhang et al. 2009; Man et al. 2010; Mukhopadhya et al. 2011). C.
concisus has recently emerged as a putative cause of post-infectious IBD, defined by
34

adherence and invasion properties or toxin production in some strains (Man et al.
2010; Bradshaw et al. 2020). Moreover, C. concisus strains can stimulate high levels
of proinflammatory mediators interleukin (IL)-8 and tumour necrosis factor (TNF)-α
(Kaakoush et al. 2011; Kaakoush, Mitchell and Man 2014). Strains capable of
persisting in macrophages can induce high levels of IL-12 and strains surviving
intracellularly in host epithelial cells induce increased TNF-γ (Kaakoush, Mitchell and
Man 2014). Mukhopadhya et al. (2011) did not find a significant difference between
the prevalence of C. concisus in ulcerative colitis colonoscopic biopsies, compared
with normal controls (Mukhopadhya et al. 2011). However, IBD are multifactorial
diseases whose aetiology relies on a multitude of factors and the role of
Campylobacter spp. requires further explanation.

1.3

Campylobacter pathogenicity-associated factors

Campylobacter is a notoriously elusive pathogen, where significant knowledge gaps
exist in terms of pathogenesis and survival, particularly the molecular basis of such
virulence factors. Lack of a suitable animal model and complex nutritional
requirements have precluded Campylobacter comprehension to an extent
(Hendrixson, Akerley and DiRita 2001; Dasti et al. 2010). C. jejuni is the most often
used as a virulence model and the pathogenic potential of some species is unknown to
date (Table 1.2).
Campylobacter do not express a large variety of classical virulence factors. It appears
that host factors play a major role for pathogenesis of campylobacteriosis in man
(Dasti et al. 2010). Regulation of virulence gene expression ensures conservation of
resources by appropriately expressing relevant genes in response to specific
environmental signals (Rivera‐Amill et al. 2001).
1.3.1

Biofilm formation

Biofilms are defined as a community of microbial cells structured in a self-produced
polymeric matrix (a fabric of extracellular proteins, polysaccharides and nucleic
acids), adherent to biotic or abiotic surfaces and each other, or indeed at an interface
(solid-liquid, liquid-liquid or liquid-gas (Joshua et al. 2006; Teh, Lee and Dykes
2014). Biofilms are thought to provide protection against detrimental environmental
conditions, with concomitant reduced survival of planktonic counterparts under
ambient, or non-optimised conditions, as reported in an investigation of C. jejuni
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biofilms (Joshua et al. 2006). Biofilms may confer enhanced cell survival as a
consequence of slower growth rates and reduced perfusion of toxic substances through
the matrix (Kalmokoff et al. 2006). DNA is a common structural component of
biofilms, promoting horizontal gene transfer among counterparts (Brown et al. 2015).
Hydrophobic interactions, surface proteins, flagella and quorum sensing appear to play
a role in the development and maturation of campylobacter biofilms (Dykes,
Sampathkumar and Korber 2003; Kalmokoff et al. 2006; Asakura et al. 2007;
Svensson, Pryjma and Gaynor 2014).
Recently, it has been reported the acquisition of fluoroquinolone resistance increases
biofilm formation under aerobic conditions, associated with relaxation of DNA
supercoiling (Scanlan et al. 2017; Whelan et al. 2019). Relaxation of DNA
supercoiling was shown to regulate adhesion and invasion of C. jejuni strains (Scanlan
et al. 2017) and induced flagella-mediated protein secretion (Scanlan et al. 2017). Bae
et al. (2003) found that biofilm formation was associated with enhanced
fluoroquinolone resistance under microaerobic conditions (Bae and Jeon 2013).
1.3.2

Flagella

Motility is an important pathogenicity-associated factor that allows penetration and
colonisation of the mucin lining of the intestine, which is the primary habitat of
Campylobacter (most notably C. jejuni) in humans and animals. Thermophilic
Campylobacter feature a flagellum composed of O-linked glycosylated flagellin,
located at one or both poles (Dasti et al. 2010). The flagellar filament is comprised of
FlaA and FlaB (Konkel et al. 2004), where flaA, is essential for motility (Wassenaar,
Bleumink-Pluym and van der Zeijst 1991; Konkel et al. 2004). The flagellum is also
critical for attachment to and penetration of intestinal epithelial cells, with markedly
reduced levels of invasion associated with aflagellate mutants (Wassenaar, BleuminkPluym and van der Zeijst 1991). The flagellum and its components are crucial for the
initial interaction between C. jejuni and the host intestinal epithelial cells (Dasti et al.
2010). Konkel et al. (2004) demonstrated that the link between flagella and invasion
is a result of flagellar export of secretory proteins. Scanlan et al. (2017) also found
that relaxation of C. jejuni DNA supercoiling was accompanied by flagella-mediated
protein secretion corresponding to enhanced invasiveness (Scanlan et al. 2017).
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1.3.2.1 Regulation of flagellar biosynthesis
The control of flagellar biosynthesis has been linked to several regulators. Primordial
expression of C. jejuni flagellar genes is controlled by sigma(σ)-factor σ28 that triggers
a signaling cascade involving σ54 and a two-component regulatory system consisting
of the FlgS sensor kinase and the FlgR σ54-dependent response regulator (Hendrixson
2006). The σ28 sigma factor, encoded by fliA regulates the expression of flaA and other
minor flagellin genes. The σ54 sigma factor of the FlgSR system, encoded by rpoN, is
required for transcription of flaB and genes encoding the flagellar basal body, rod and
hook structures (Hendrixson, Akerley and DiRita 2001; Jagannathan, Constantinidou
and Penn 2001; Hendrixson 2006). Phosphorylation of FlgR by FlgS initiates the
activation of σ54-dependent middle and late phase flagellar genes (Hendrixson 2006).
Insertional inactivation of rpoN and flgR results in aflagellate C. jejuni mutants
(Jagannathan, Constantinidou and Penn 2001). C. jejuni mutants lacking fliA may still
produce truncated flagella assembled with FlaB and retain residual motility
(Hendrixson, Akerley and DiRita 2001; Jagannathan, Constantinidou and Penn 2001).
Moreover, flagellar components were found to be iron activated, suggesting a
regulatory coupling of iron homeostasis in C. jejuni and flagellar biosynthesis
(Butcher and Stintzi 2013).
1.3.2.2 Phase variable flagellar biosynthesis
Flagellum synthesis in C. jejuni is associated with phase variation (Wassenaar,
Bleumink-Pluym and van der Zeijst 1991). Phase variation and phenotypic modulation
is a response to environmental flux. Hendrixson et al. (2006) described the phase
variation of FlgR within the FlgSR regulation system involved in the transcription of
σ54-depenedent flagellar genes. Phase-variable production of a protein within a twopart system was described originally in Bordetella pertussis (Stibftz et al. 1989). The
addition or removal of a nucleotide within a conserved homopolymeric
adenine/thymine tract within flgR results in phase variation of FlgR, affecting
expression of σ54-dependent flagellar genes. The FlgSR phase variation system may
be unique to C. jejuni and contribute to successful host colonisation (Hendrixson
2006). However, this uncommon phenomenon may indicate that the aflagellate variant
may confer some sort of survivalist advantage, perhaps via shedding and subsequent
transmission of individual members of a bacterial population that unsuccessfully
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colonised the host (Hendrixson 2006). Field et al. (1986) found no correlation between
the virulence (mean lethal dose (LD-50) and number of CFU recovered from liver
embryos post-infection of motile versus nonmotile variants of a C. jejuni strain (1376)
in a chicken embryo model, although only one strain was assessed in the study.
1.3.3

Stress responses

Campylobacter must withstand untold suboptimal or damaging conditions in order to
survive in the environment and successfully colonise or cause disease. Strain to strain
variation in the repertoire and activation of genes involved in stress response
undoubtedly contributes to the varying survival and pathogenicity of campylobacters
(Thies et al. 1999). Although the full battery of stress-associated genes in
Campylobacter and preconditioning that affects their expression awaits full
elucidation, below are some key features that have been attributed to the survival and
concomitant success of Campylobacter as a pathogen. It is also recognised that there
is an overlap of genes expressed during exposure to different stress conditions, namely
heat, acid and oxidative shock (Reid et al. 2008).
1.3.3.1 Aerobic thermophilic Campylobacter spp.
C. jejuni appears to have the capacity to adapt to low oxygen environments within the
cell by changing its mode of respiration (Jones et al. 1993; Watson and Galán 2008),
and occasionally other Campylobacter species have been reported to grow aerobically
(Culligan et al. 2019). Interestingly, Jones et al. (1993) revealed that air-adapted
strains recovered from mouse gut contents retained their ability to grow in normal
atmospheric air. This was compounded by the enhanced survivability of aerobically
adapted C. jejuni strains at 37°C, and less pronounced at 42°C and 4°C (Jones et al.
1993).
1.3.3.2 Viable but nonculturable cells
During exposure to inhospitable conditions, some thermophilic Campylobacter spp.
can enter a viable but nonculturable state (VBNC), representing a notable survival
strategy (Rollins and Colwell 1986). Transition from spiral to coccoid morphology is
associated with C. jejuni viable but nonculturable cells (VBNC) (Rollins and Colwell
1986). VBNC may result from exposure of C. jejuni to acidic conditions (pH 4 for 2
hours) (Chaveerach et al. 2003) or in atmospheric air (Jones et al. 1993).

38

VBNC are capable of renewed metabolic activity, even after 60 days in static aqueous
media (Talibart et al. 2000). VBNC C. jejuni were successfully resuscitated after
passage through embryonated eggs (Chaveerach et al. 2003) and mice (Jones et al.
1993). Internalised C. jejuni may undergo significant physiological changes in the
intracellular environment (Watson and Galán 2008).
Bacteria that enter the VBNC state represent a major threat to food safety as they
remain undetected by standard food and water testing techniques (Casey, Fitzgerald
and Lucey 2017).
1.3.3.3 “Heat shock” proteins
Heat shock proteins (HSPs) are conserved and co-regulated stress response factors
(Konkel et al. 1998). HSPs proteins are expressed in response to misfolding proteins
upon exposure to suboptimal temperatures and general stress conditions (Reid et al.
2008). Transmission from environmental reservoirs, in vivo survival and successful
colonisation in the intestinal environment survival depends on the activation of stress
responses and HSPs (Brás et al. 1999). HSPs typically act as chaperones that mediate
protein folding, proteolysis of potentially deleterious misfolded proteins (Konkel et al.
1998) and protection or repair of DNA (Reid et al. 2008).
Survival in the gastric environment is integral to Campylobacter spp. pathogenesis. In
the absence of food, gastric pH in healthy individuals is about 2 (although this value
varies) and increases to between 6 and 7 upon ingestion of a meal (Dressman et al.
1990). The infective dose of enteric pathogens is related to their ability to withstand
acidic stress as well as exposure to reactive oxygen and nitrogen species, and the
infective dose of C. jejuni is low (Robinson 1981). Typical bacterial responses to acid
include prevention of H+ entry into the cell, extrusion of H+ from the cell, H+
consumption and repair of DNA and proteins, although yet to be elucidated in C. jejuni
(Reid et al. 2008). An in-vivo transcriptome study of acid-exposed C. jejuni strains
carried out in a neonatal piglet identified the up or downregulation of a myriad of
proteins upon acid exposure. The study identified a pausation in protein synthesis,
reflected by the downregulation of genes encoding ribosomal proteins. Upregulation
of heat shock genes in response to acid shock has been documented, including
chaperons and cochaperones (GroESL, DnaJK, GrpE and ClpB) (Wu et al. 1994; Reid
et al. 2008).
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Table 1.3. Representative bacterial factors involved in stress response in Campylobacter.
Stress
response
factor
GroESL-like
proteins

High
temperature
requirement
protein A
(HtrA)
Lon protease

DnaJ

RacR-RacS

KatA

ClpB

1.3.4

Remark
Upregulation of GroESL-like proteins has been described after temperature increase (37°C to 48°C),
exposure to alkaline pH conditions and in aerobically adapted C. jejuni (Wu et al. 1994; Takata et al. 1995;
Thies et al. 1999). In C. jejuni and other bacterial genera, GroES is thought to cooperate with GroEL to
prevent protein misfolding of partially denatured proteins (in an energy (ATP) dependent process) as well
as contributing to protein assembly (Takata et al. 1995; Thies et al. 1999). GroESL is constitutively
expressed and transcribed by the transcriptionally regulated bicistronic groE operon (Thies et al. 1999).
Increased levels of expression of a GroESL-like protein in Neisseria gonorrhoeae was identified under
low-oxygen conditions (Pannekoek, van Puiten and Dankert 1992). Hence, production of the GroESL-like
heat shock proteins promote survival of bacteria with specific oxygen requirements.
HtrA is a serine protease that can degrade and prevents aggregation of misfolded proteins in heat and
oxidative stress (Boehm et al. 2015). HtrA is required for growth at high temperatures (Boehm et al. 2015),
although htrA mutants were not sensitive to increased formation of oxygen radicals (Brøndsted et al. 2005).
ClpB and DnaK chaperones were upregulated in response to mutated HtrA (Brøndsted et al. 2005).
Heat-inducible ATP-dependent serine protease with ATPase activity. Two conserved ATP-binding
domains and a highly variable N-terminus. Upregulated in response to transition from 37°C to 48°C for 20
minutes (Thies, Hartung and Giegerich 1998).
DnaJ belongs to the Hsp-40 family of chaperones. The molecular chaperone mediates protein folding in
response to heat shock and proteolysis of unstable proteins. Upregulated in response to transition of C.
jejuni from 37°C to 43°C or 46°C for 10 minutes (Konkel et al. 1998).
RacR-RacS is two-component response regulator signal transduction system, that alters gene expression
in a temperature-dependent (and -independent) manner, associated with survival in the avian intestinal
tract (Brás et al. 1999).
Hydrogen-peroxide oxidoreductase believed to function in oxidative stress and macrophage killing.
Macrophage-dependent killing involves the generation of hydrogen peroxide (H2O2) and superoxide (Haas
and Goebel 1992). Concomitant upregulation of katA during acid stress in C. jejuni in response to FUR
(ferric uptake regulators) (Askoura et al. 2016).
Protease involved in heat stress response in cooperation with DnaK, DnaJ and GrpE. Protein binding
stimulates the ATPase activity, contributing to the unfolding of denatured protein aggregates. Exposure of
new hydrophobic binding sites on the surface of ClpB-bound aggregates contributes to the solubilization
and refolding of denatured protein aggregates by DnaK (Brøndsted et al. 2005).

Adhesion and invasion factors

The pathogenicity of Campylobacter is dependent on the ability to attach and invade
human epithelial intestinal cells (Krause-Gruszczynska et al. 2007a). Microtubuledependent invasion is considered a primary mechanism of colonic damage and
subsequent diarrhoeal disease caused by C. jejuni (Russell et al. 1993; KrauseGruszczynska et al. 2007b). Host cell invasion involves several key stages: bacterial
binding to specific host receptors, signaling to the host cell, and modification of
intracellular host signal transduction pathways, membrane and cytoskeletal
rearrangements and eventual internalisation of the bacteria (Watson and Galán 2008).
However, much of the molecular mechanisms involved in C. jejuni invasion are
widely unknown (Krause-Gruszczynska et al. 2007b). Marked variation in the degree
of in vitro attachment and invasion exists between clinical C. jejuni strains, and many
reports suggest that several factors determine invasiveness (Table 1.4) (Newell et al.
1985; Bacon et al. 2000; Louwen et al. 2008; Habib et al. 2009). Moreover, other
currently unknown proteins are likely involved in the invasiveness and pathogenesis
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of human campylobacteriosis (Dasti et al. 2010). Selected and representative
characterised Campylobacter adhesion and invasion factors are listed in Table 1.4.
Table 1.4. Representative bacterial factors involved in adhesion and invasion in Campylobacter jejuni.
Stress response
factor

Gene

Remark

Campylobacter
invasion antigen
B CiaB

ciaB

Surface exposed
JlpA lipoprotein

jlpA

Periplasmicbinding protein
PEB1

peb1A

PEB4

peb4

Widely distributed among the genus, the ciaB gene encodes a 73 kDa protein that is induced
by the presence of bile salt deoxycholate and is subsequently secreted into the cytoplasm of
eukaryotic cells important for Campylobacter spp. invasion (Konkel et al. 2004). Insertional
disruption of C. jejuni ciaB results in a non-invasive phenotype (Rivera‐Amill et al. 2001;
Ziprin et al. 2001). Habib et al. (2008) identified the ciaB gene in 100% of human (n=40) and
chicken meat (n=76) C. jejuni isolates, while Redondo et al. (2019) found that only 80% of
122 clinical Campylobacter spp. isolates harboured ciaB (Habib et al. 2008; Redondo, Carroll
and Mcnamara 2019). CiaB likely triggers a signaling pathway in susceptible host cells
(Rivera‐Amill et al. 2001). Campylobacter type III secretion system (injectisome) or signal
sequence responsible for CiaB secretion have not been identified (Rivera‐Amill et al. 2001).
Although orthologous type IV secretion system encoding genes were identified on a plasmid
(pVir) in C. jejuni in 2002 (homologous to bacterial conjugation machinery) (Bacon et al.
2002). It has been proposed that CiaB and other secreted proteins require a flagellar export
apparatus to enter the host, as the flagellar apparatus is the only C. jejuni type III export system
known to exist (Rivera‐Amill et al. 2001; Konkel et al. 2004; Dasti et al. 2010). Konkel et al.
(2004) demonstrated that mutations that affected flhB (involved in the export of flagellar
components) and flgB, flgC and flgE2 (nonfilamental structural components) resulted in the
loss of Cia protein export (Konkel et al. 2004).
The surface exposed JlpA lipoprotein is a major C. jejuni adhesion factor and interacts with
epithelial heat shock protein 90-α (HSP-90α), a molecular chaperone associated with a variety
of transcription factors and protein kinases (Jin et al. 2003). The jlpA gene encodes a 372 amino
acid lipoprotein that possesses a signal peptide at the N-terminus (Jin et al. 2004). JlpA binding
triggers activation of central innate immune proinflammatory mediators, NF-Κb (nuclear factor
kappa-light-chain-enhancer), coupled with p38 MAP (mitogen-activated protein) kinase (Jin et
al. 2003).
The PEB1 protein has homology to ATP-binding cassette transporters (Hickey et al. 1999).
Disruption of PEB1 in a mutant C. jejuni 81-176 strains has been linked to 50- to -100-fold
reduction in adherence to HeLa cells and significantly reduced rates of intestinal colonisation
in mouse challenge studies, compared to the wild-type strain (Pei et al. 1998). Similarly,
Hickey et al. (1999) found that peb1a mutated C. jejuni 81-176 invaded INT407 cells at 5.5%
the level of wild type stain and IL-8 production was reduced by 72% (Hickey et al. 1999). Role
may be limited to transport of amino acids, required for viability in the host (Flanagan et al.
2009),
The PEB4 protein is thought to act as a periplasmic chaperone, involved in the maturation and
export of proteins to the outer membrane (Kale et al. 2011). Mutants lacking PEB4 showed
reduced level of intestinal colonisation duration in mouse trial Biofilm formation was also
compromised in PEB4 mutants (Asakura et al. 2007).

1.3.4.1 Outer membrane fibronectin-binding protein CadF
CadF homologues have been described in several Campylobacter spp. Binding of C.
jejuni and C. coli (among other campylobacters) to host fibronectin (glycoprotein and
component of the extracellular matrix) is mediated by the integral outer membrane
fibronectin-binding protein (CadF) (Ziprin et al. 1999; Krause-Gruszczynska et al.
2007a). The cadF gene was detected in 99% of thermophilic human Campylobacter
isolates tested (n=122) collected over a 10-year period in an Irish study (Redondo,
Carroll and Mcnamara 2019) and in 100% of chicken meat (n=76) and human (n=40)
isolates in another European study (Habib et al. 2009). The role CadF in binding has
been demonstrated in vitro (Krause-Gruszczynska et al. 2007a) and in vivo (Ziprin et
al. 1999). The C. coli cadF gene differs from that of C. jejuni by a 39 bp insertion
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sequence and this difference is thought to contribute to the higher binding capacity of
CadF expressed by C. jejuni (Krause-Gruszczynska et al. 2007a).
1.3.4.1.1 CadF as a bifunctional protein
CadF is a bifunctional protein that also triggers small (~21 kDa) Rho GTPases in a
signal transduction pathway that ultimately leads to microtubule-dependent host cell
entry by C. jejuni via tyrosine phosphorylation of the focal adhesion protein paxillin
(Krause-Gruszczynska et al. 2007b). Members of the small Rho GTPase family are
guanine nucleotide-regulated switches, cycling between active (GTP-bound) and
inactive states (GDP-bound). GTPases transduce external stimuli to modulate and
induce a variety of eukaryotic host cell response. Although the molecular mechanisms
of downstream C. jejuni invasion pathways are not fully elucidated, Ras-related C3
botulinum toxin substrate 1 (Rac1) and cell division control protein 42 homolog
(Cdc42) trigger and regulate C. jejuni invasiveness. Krause-Gruszczynska, Rohde et
al. (2007) demonstrated using a cadF-negative mutant strain and human embryonic
intestinal epithelial cell (INT-407) model, that internalisation of C. jejuni is
accompanied by a time-dependent CadF activation of Rac1 and Cdc42 (KrauseGruszczynska et al. 2007b). However, CadF is not the sole factor involved in GTPase
activation and invasion (Krause-Gruszczynska et al. 2007b).
1.3.4.2 Fibronectin-like protein A FlpA
The conserved, surface-exposed fibronectin-like protein A, (FlpA) and CadF
constitute the major C. jejuni fibronectin binding proteins, facilitating adhesion and
invasion (Flanagan et al. 2009; Talukdar et al. 2020). The role of FlpA as a virulence
factor was first recognised by Flanagan et al. (2009) whereby flpA knockout mutants
showed reduced ability to colonise broiler chicks compared to the wild type strain.
Fibronectin-binding proteins CadF and FlpA are not redundant and both were found
to be necessary for the maximal binding of C. jejuni to host cell fibronectin, where the
defect in binding of C. jejuni ∆cadF ∆flpA double mutants to host cells could not be
restored by complementation with either CadF or FlpA alone (Talukdar et al. 2020).
Similar to multifunctional CadF, and in a cooperative manner, binding of FlpA to host
cell fibronectin triggers the activation of signaling pathways, including MAPK
(necessary for the internalisation of C. jejuni), and ultimately the delivery of Cia
effector proteins into the host cell cytosol (Talukdar et al. 2020).
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1.3.4.3 Campylobacter jejuni sialylated lipooligosaccharides
LOS also mediate adhesion and invasion (Louwen et al. 2008). Louwen et al. (2008)
demonstrated that strains expressing sialylated LOS classes (A, B and C) or GBSassociated strains invaded Caco-2 epithelial cell lines more frequently than strains
expressing nonsialylated LOS classes (D and E) or enteritis-associated strains
(Louwen et al. 2008). In the same study, significantly lower invasiveness, but not
adherence were observed in mutant strains with inactivated LOS sialyltransferase cstII
via knockout mutagenesis compared to their wild-type counterparts (Louwen et al.
2008). Numerous other studies have reported that C. jejuni strains expressing
sialylated LOS were more invasive to INT-407 cell lines (Habib et al. 2009) compared
to non-sialylated classes. However, many of the authors also acknowledge that some
C. jejuni isolates expressing sialylated LOS are poorly invasive, indicating that LOS
sialylation is not the single determinant of invasion (Louwen et al. 2008; Habib,
Uyttendaele and De Zutter 2011). However, it is noteworthy that strains sharing the
same LOS class may not necessarily express the same LOS structure as a consequence
of mutations that are not detectable using standard PCR (Parker et al. 2005; Louwen
et al. 2008). C. coli has a larger repertoire of sialyltransferases and is less likely to
generate ganglioside mimics (Culebro et al. 2018).
1.3.4.4 A model for Campylobacter jejuni invasion
The related organism, H. pylori colonises the apical surface of polarised epithelial
cells, eventually leading to the injection of signaling molecules at the basolateral
membrane that initiates infection. H. pylori secretes a serine protease (HtrA) that
cleaves occludin, claudin-8 and E-cadherin to create a cleft between tight junctions,
allowing paracellular transmigration (Figure 1.3 and 1.4). Subsequent needle-like pili
formation upon recognition of host integrin-B1 induces type IV secretion of signaling
molecule CagA at the basolateral site and induction of NF-κB and IFN-γ (Tegtmeyer
et al. 2017).
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Figure 1.3. The structure of the intestinal epithelium and mechanisms regulating intestinal barrier
integrity. Desmosomes are filaments linking protein plaques. Integral membrane proteins (occludin,
claudins, E-cadherin) in gap junctions (tight junctions and adherens junctions) extend into the
paracellular space. Zonula occludens are cytoskeletal linker proteins that interact with the cytoplasmic
peripheral membrane proteins to form cross-links with membrane cytoskeletal components (F-actin and
myosin). Intracellular signaling molecules tumour necrosing factor-α (TNF-α), interferon-γ (INF-γ) and
interleukins (ILs) regulate tight junction integrity (Chelakkot, Ghim and Ryu 2018).
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Figure 1.4. Helicobacter pylori epithelial cell tight junction disruption via secreted of HtrA, basolateral
type IV secretion of CagA at integrin sites and induction of intracellular signaling pathways (Tegtmeyer
et al. 2017).

A similar type of model has been proposed for C. jejuni, via the secretion of the high
temperature requirement protein A (HtrA) serine protease, that cleaves and
redistributes host protein occludin away from host cell tight junctions into the
cytoplasm (Figure 1.5) (Harrer et al. 2019). HtrA cleaves tight junction component
claudin-8 (Sharafutdinov et al. 2020) and cleaves E-cadherin, present in the adherens
junctions (Boehm et al. 2018). The absence of occludin does not inhibit tight junction
formation, as demonstrated in knockout mice, as other tight junction proteins
compensate for the defect (Saitou et al. 2000). However, increased permeability of the
host intestinal epithelium provides the bacterium temporary access to the fibronectin
receptors at the basal membrane, compounded by downstream effects on zonula
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occludens-1 proteins and apoptosis-inducing TNF-α and IFN-γ (Heimesaat et al. 2014;
Harrer et al. 2019).

Figure 1.5. Model for transmigration, adhesion and invasion of Campylobacter jejuni of intestinal
epithelial cells, depending on HtrA secretion and cleavage of occludin and E-cadherin, allowing access
to fibronectin-integrin complexes at the basolateral membrane (Harrer et al. 2019).

1.3.5

Surface-layer proteins

Campylobacter surface-layer proteins (SLPs) are large molecular weight proteins
encoded by the sap locus that form a proteinaceous capsule on the cell surface. SLPs
mediate resistance to complement C3b binding (Blaser et al. 1988; Tu, Dewhirst and
Blaser 2001), reported formally only among C. fetus and C. rectus. Recombination of
the sap homologues and resulting high frequency antigenic variation in the SLPs
contributes to persistent and systemic infections within the species (Tu, Gaudreau and
Blaser 2005). Variation of C. fetus SLP expression is mediated by inversion and
recombinational rearrangement of the sap promoter upstream of one of the multiple
sap homologue cassettes (Dworkin and Blaser 1996). As a guide, C. fetus strain 23D
harbours eight SLP homologues, located within a 54 kp sap island (Tu, Hui and Blaser
2004). Heterogeneity in the slp locus and assicuated antigenic variation in the
transcribed sap homologue has been reported to contribute to recurrent C. fetus
infection (Tu, Gaudreau and Blaser 2005).
1.3.6

Cytolethal distending toxin

Cytolethal distending toxin (CDT) is a heterotrimeric inhibitory cyclomodulin,
recognised as a major pathogenicity-associated factor of Campylobacter spp. and has
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been credited as the only toxin present in Campylobacter spp. (Dasti et al. 2010).
Although a zonula occludens toxin (Zot) was identified in C. concisus that shares
homology with Zots in Vibrio cholerae and Neisseria meningitidis, as well as putative
Campylobacter spp. toxins: invasin InvA, haemolysin TlyA and phospholipase PldA
(Kaakoush, Mitchell and Man 2014).
CDT belongs to the AB toxin family and is produced by several Gram negative
pathogenic bacteria with varied species-specific amino acid sequences (Heywood,
Henderson and Nair 2005; Dixon et al. 2015; Faïs et al. 2016). The heat-labile CDT
toxin was first described in E. coli in 1988, followed by identification in
Campylobacter spp. in the same year (Johnson and Lior 1988a, 1988b). CDTs from
different species have evolved partially overlapping yet distinct routes of intoxication
(Carette et al. 2011).C. jejuni CDT was originally shown to cause progressive cell
distention and cytotoxicity in mammalian cell lines: Caco-2, Chinese hamster ovary
(CHO), Vero, HeLa and HEp-2 (Johnson and Lior 1988a; Whitehouse et al. 1998).
An Irish genomic study found an inconsistent presentation of the cdtA, cdtB and cdtC
among 122 human thermophilic Campylobacter spp. from diarrhoeal stool samples,
indicating that other virulence factors contribute to the clinical presentation of enteric
campylobacteriosis (Redondo, Carroll and Mcnamara 2019).
1.3.6.1 Cytolethal distending toxin active subunit CdtB
The holotoxin (AB2) trimer consists of the active CdtB moiety and two binding
subunits, CdtA and CdtC (Pickett and Whitehouse 1999; Faïs et al. 2016). CDT is a
product of an operon containing cdtA, cdtB and cdtC (Heywood, Henderson and Nair
2005). The CdtB subunit is functionally and structurally homologous to mammalian
DNase I (Heywood, Henderson and Nair 2005; Faïs et al. 2016). The unique
mechanism of CDT cytotoxicity involves eukaryotic cell entry and breakage of
double-stranded DNA, initiating the cell’s own DNA damage-response mechanism
(Whitehouse et al. 1998; Heywood, Henderson and Nair 2005; Faïs et al. 2016).
Apoptosis or senescence (long-term cell cycle arrest) results from improper repair of
damaged DNA (Faïs et al. 2016). CDT induces cell cycle arrest at the G2/M boundary
(Whitehouse et al. 1998; Heywood, Henderson and Nair 2005).
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1.3.6.2 Cytolethal distending toxin carrier subunits, CdtA and CdtC
CdtA and CdtC serve as CdtB carriers to target host cell membranes (Figure 1.6). CdtA
and CdtC bind to cholesterol-rich domains a cholesterol-binding motif enabling
interaction with lipid rafts composed of cholesterol, phospholipids and sphingolipids
(Lai et al. 2016). Cholesterol is an essential ligand for C. jejuni CDT binding to the
cell membrane, following by host intoxication (Lai et al. 2016). Disruption of
cholesterol reduced CDT binding and toxin delivery which attenuated toxin-induced
cell cycle arrest (Lin et al. 2011). A 12 amino acid cholesterol recognition/interaction
amino acid consensus (CRAC)-like sequence (77LPFGYVQFTNPK88) was identified
in C. jejuni CdtC (Lin et al. 2011).The CRAC-like regions forms a hydrophobic
groove that facilitates cholesterol binding and localisation to the host cell membrane
(Lin et al. 2011; Lai et al. 2013). C. jejuni CdtA also possesses a conserved CRAClike motif (17LYACSSK23) with cholesterol binding affinity (Lin et al. 2011). Dixon
et al. (2015) reported that CdtA and CdtC can independently support CdtB mediated
toxicity in E. coli and Haemophilus ducreyi (Dixon et al. 2015). Although it was
reported that Aggregatibacter actinomycetemcomitans CDT toxicity was dependent
on the full holotoxin (Mise et al. 2005).

Figure 1.6. CdtA and CdtC bind to cholesterol-containing lipid rafts in the cell membrane, facilitating
CdtB cell entry via clathrin-coated pit endocytosis. Cytosolic translocation of CdtB followed by
retrograde trafficking from the Golgi apparatus to the endoplasmic reticulum may facilitate nuclear
entry where the toxic effects of CdtB are elicited (Lai et al. 2016).
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1.3.6.3 Cytolethal distending toxin immune modulation
In other bacteria CDT is known to induce altered pro-inflammatory cytokine
expression patterns, perpetuating infection by subverting host immune responses
(Johnson and Lior 1988a; Hickey et al. 2000; Ando-Suguimoto et al. 2014). CDTproducing C. jejuni have been shown to induce release of IL-8 from INT406 intestinal
epithelial cells (Hickey et al. 2000). CDT-producing A. actinomycetemcomitans has
also been demonstrated to inhibit macrophage phagocytosis allowing proliferation of
the periodontal pathogen (Ando-Suguimoto et al. 2014).
1.3.7

Type IV secretion systems

In Gram negative bacteria, type IV section systems (TIVSSs) are envelope-spanning
plexus components (Table 1.5 and Figure 1.7) that translocate proteins and nucleic
acid complexes between bacteria in a process related to bacterial conjugation (Cao and
Saier 2001). TIVSSs promote horizontal gene transfer between bacteria and
eukaryotes, and facilitate the induction of signal transduction pathways, inducing
cytokine expression and proinflammatory genes and cytoskeletal alteration,
contributing to invasion (Backert and Meyer 2006). TIVSS homologues have been
reported in C. jejuni, C. fetus and most recently in Campylobacter portucalensis sp.
nov. (van der Graaf-van Bloois et al. 2016b; Silva et al. 2020).
The pVir plasmid (~35 kbp), encoding orthologues of TIVSS proteins found in H.
pylori, was originally isolated from C. jejuni strain 81-176 (Bacon et al. 2000, 2002).
In C. jejuni strain 81-176 the pTet plasmid has been found to coexist with the pVir
plasmid (Bacon et al. 2000; Batchelor et al. 2004). The C. jejuni pTet plasmid and the
highly related C. coli version, pCC31, were also shown to harbour genes that encode
predicted proteins with homology to TIVSS proteins (Batchelor et al. 2004). However,
TIVSS homologues in pTet and pVir plasmids are functionally distinct (Batchelor et
al. 2004).
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Table 1.5. VirB protein homologues associated with type IV secretion systems. VirB protein
nomenclature relates to Agrobacterium tumefaciens and primarily characterised in the cag
pathogenicity island in Helicobacter pylori.
VirB
component

Gene

Remark

Reference

VirB1

virB1

(Gorkiewicz et al. 2010;
Backert et al. 2013)

VirB2

virB2

Lytic transglycolyase responsible for peptidoglycan degradation,
facilitating the assembly of the envelope-spanning secretion
apparatus found in type III and type IV secretion systems.
Major pilus component

VirB3

virb3

Major pilus/ATPase factor.

(Backert et al. 2013)

VirB4

virB4

ATPase - H. pylori inner membrane complex.

(Batchelor et al. 2004;
Backert et al. 2013)

VirB5

virb5

Minor pilus subunit

(Cao and Saier 2001)

VirB6

virB6

Inner membrane pore

(Cao and Saier 2001)

VirB7

virB7

Interacts with VirB9 and pilis

(Cao and Saier 2001)

VirB8

virB8

Inner membrane-periplasm-outer membrane pore complex

(Cao and Saier 2001)

VirB9

virB9

Inner membrane-periplasm-outer membrane pore complex

(Cao and Saier 2001)

VirB10

virB10

Inner membrane-periplasm-outer membrane pore complex

(Cao and Saier 2001)

VirB11

virb11

ATPase.

(Batchelor et al. 2004;
Backert et al. 2013)

VirD4

virD4

Transfer coupling protein ATPase.

(Batchelor et al. 2004;
Backert et al. 2013)

(Batchelor et al. 2004;
Backert et al. 2013)
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Figure 1.7. Assembled structure of VirB/VirD4 type IV secretion system, consisting of a protein
complex spanning the inner and outer membranes in Gram negative bacteria (Backert and Meyer 2006).

1.3.7.1 Clustered regularly interspaced short palindromic repeats
Clustered regularly interspaced short palindromic repeats (CRISPRs) present in
intergenic regions consist of two or more direct repeats of 21 bp or larger separated by
a unique spacer sequence of a similar size denotes a CRISPR (Fouts et al. 2005).
Strains can be differentiated based on the unique sequence, location within the genome
and relative abundance of repeats within the element (Fouts et al. 2005). In association
with Cas proteins, CRISPRs prevent invasion by mobile genetic elements to provide
adaptive immunity in bacteria (Makarova et al. 2011). The unique spacers are derived
from viral DNA from previous attacks that remain as hallmarks of infection
(Barrangou et al. 2007; Martynov, Severinov and Ispolatov 2017) and are used to
direct RNA interference-like cleavage of target DNA (Makarova et al. 2011) by Cas
proteins. The acquisition of new spacers to the CRISPR array occurs in systematic
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manner with the addition of new spacers always occurring at the 5’ end of an array,
with occasional sporadic loss of spacers (Barrangou et al. 2007). CRISPR-Cas systems
may contribute to the stabilisation of the Cff genome, where they are abundant (Ali et
al. 2012; Iraola et al. 2017; Nadin-Davis et al. 2021), but the functionality of CRISPRCas systems in C. fetus and among other Campylobacter spp. is unknown (Calleros et
al. 2017).
1.3.8

Campylobacter jejuni phase variation

Phase variation is a bacterial strategy used to reversibly respond to environmental
stimuli (van der Woude 2011), introducing subpopulations with higher fitness in
specific conditions (Cayrou et al. 2021). Several molecular mechanisms underlie
phase variation, including slipped strand mispairing, site-specific recombination, and
epigenetic regulation mediated by DNA methylation (van der Woude 2011). Slipped
strand mispairing of mother and daughter replicating DNA involves local denaturation
and mispairing of complementary bases at the site of an existing short tandem repeat
(Levinson and Gutman 1987).
Changes in the number of repeats can alter gene expression, interfering with critical
spacing thereby introducing frameshift mutations, acting as molecular on/off switches
(van der Woude 2011). Multiple Campylobacter spp. have been reported to harbour
intergenic or intragenic hypermutable homopolymeric G/C tracts and putative phase
variable genes (Fouts et al. 2005; O’Kane and Connerton 2017). Homopolymeric
tracts are associated with several loci in C. jejuni (Parkhill et al. 2000), often affecting
surface structures, including: flagella, capsular and LOS-associated genes, known to
be critical for adhesion and invasion (Cayrou et al. 2021). Phase variation of surface
layer proteins (SLPs) via recombination of sap homologues contributes to immune
evasion (Tu, Gaudreau and Blaser 2005).
1.3.9

Outer membrane vesicles

In the absence of a clear prototypical virulence-associated secretory system in
Campylobacter, outer membrane vesicles (OMVs) (spherical proteoliposomes) have
been proposed as a delivery mechanism (Elmi et al. 2012). Naturally produced
bacterial vesicles are discrete, closed outer membrane blebs; constitutively released
by Gram negative bacteria (Kuehn and Kesty 2005). CDT subunits (Lindmark et al.
2009) and seine proteases HtrA (Elmi et al. 2016) are contained within C. jejuni
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OMVs and are likely released from them. Bile concentrations influence OMV protein
content and facilitate colonisation (Taheri et al. 2018), where bile concentrations
reflective of the caecal environment enhance bacterial adhesion and invasion in
intestinal epithelial cells (Taheri et al. 2018). Taken together, OMVs enhance C. jejuni
invasion.

1.4

CAMPYLOBACTER IN BROILERS

Campylobacter spp. and particularly C. jejuni forms part of the normal microflora of
poultry, colonising caeca at the distal end of the gastrointestinal tract (GIT) and
proliferates in the extracellular space of the mucus filled intestinal crypts, escaping
mucosal clearance (Beery, Hugdahl and Doyle 1988). In poultry, temperatures of 41°C
promote continuous replication of Campylobacter spp. Once introduced into the
broiler house during commercial rearing, C. jejuni can spread rapidly (European Food
Safety Authority 2011).
1.4.1

Campylobacter as an enteric poultry pathogen?

Recent reports of intestinal inflammation, poor general gut health and profuse
diarrhoea in broilers may be consequent to C. jejuni infection in some breeds of
modern commercial broilers, challenging the paradigm that Campylobacter is merely
a poultry commensal (Humphrey et al. 2014). It has been a long held scientific belief
that Campylobacter spp. are commensal in chickens and cause contamination by
faecal spillage at slaughter (Humphrey 2006). Pododermatitis (hock burns) is an
indicator of poor flock health and is typically linked to high ammonia content in wet
litter (Bull et al. 2008). Broiler infection with C. jejuni and associated profuse
diarrhoea makes a direct contribution to the incidence of hock burns (Bull et al. 2008;
Williams et al. 2013; Humphrey et al. 2014).
1.4.1.1 Immune response in broilers challenged with Campylobacter jejuni
Innate and adaptive immune responses have been described in broilers exposed to C.
jejuni (Humphrey 2006; Humphrey et al. 2014). However, much evidence exists that
clinical signs of disease are uncommon in broilers inoculated with C. jejuni (Shanker,
Leet and Sorrellt 1988; Shaughnessy et al. 2009). Immune response to C. jejuni in
broilers is thought to be regulated by immune inflammatory mediators. Humphrey et
al. (2014) examined the effects of C. jejuni infection in four modern broiler breeds
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and found disease presentation in the faster-growing breeds was a consequence of
immune dysregulation. Fast-growing breeds in this study were characterised by the
absence of IL-10 (feedback regulator of immune responses (Wu et al. 2016))
expression, and a higher expression of proinflammatory signals such as CXCL
chemokines and IL-1β (Humphrey et al. 2014).
1.4.1.2 Effect of noradrenaline on the pathogenicity of Campylobacter jejuni in
broilers
NA has been shown to alter the pathogenic potential of C. jejuni and other bacterial
species (Lyte and Ernst 1992; Humphrey 2006; Cogan et al. 2007; Sule et al. 2017).
The role of AD enhancing the infectivity of Clostridium perfringens was reported in
1948 (Evans, Miles and Niven 1948). Cogan et al. (2007) reported increased in vitro
growth rates and motility of C. jejuni NCTC 11168 exposed to NA and enhanced
Caco-2 cell invasion and disruption of tight junctions. Breakdown of tight junctions
would likely release more NA into the intestinal lumen (Bansal et al. 2007). Numerous
reports exist of enhanced motility, attachment and biofilm formation in verotoxinproducing E. coli exposed to NA or AD (Bansal et al. 2007; Pasupuleti et al. 2014;
Yang et al. 2014).
1.4.1.3 Serotonin reduces in vitro colonisation
The distribution of neurochemicals in the gut is particularly important considering C.
jejuni has been reported to replicate predominantly in the intestinal mucosa in the
chicken gut (Van Deun et al. 2008). Stress can also stimulate the release of serotonin
in the gut (Lyte et al. 2020). In vivo studies are required to determine the effect of C.
jejuni growth in response to changes in serotonin concentrations, however serotonin
was found to downregulate essential colonisation factors and reduce adhesion to
HT29MTX-E12 colonic epithelial cell line (Lyte et al. 2021).
1.4.1.4 Stress-induced immune response in broilers and their implications on food
safety
Stress is thought to be a major contributory factor in the variable presentation of
disease in broilers (Humphrey 2006). Stress describes experiences that are perceived
as physiologically or psychologically challenging, with concomitant release of
hormones and neuroactive factors, notably adrenaline and noradrenaline. Many
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classes of animal immune cells are directly affected by catecholamines, where their
release is often associated with immune dysfunction or impairment and predispose to
infection, particular in broilers (Humphrey 2006; Freestone 2013).
1.4.1.4.1 Broiler welfare and sentience considerations
Poor financial returns from egg and poultry products have shaped the intensive nature
of poultry farming where livestock are exposed to acute and chronic stresses (Veissier
et al. 2008; Humphrey et al. 2014). EC directive 2007/43/EC lays down the minimum
requirements for the protection of chickens kept for meat production (European
Commission 2007). Major diseases with welfare implications for broilers include
dermatitis, ascites, skeletal problems and sudden death syndrome (European Food
Safety Authority 2010b; European Commission 2018a). Mandatory and voluntary
welfare indicators include mortality and pododermatitis, respectively (European
Commission 2018a). Partial depopulation (thinning), catching, transport of live birds
and prior feed deprivation have been identified as stressful events during chicken
production (Bull et al. 2008). Thinning and transport are also widely reported risk
factors responsible for the introduction of Campylobacter spp. to negative flocks or
increasing the strain diversity (Allen et al. 2008; Koolman, Whyte and Bolton 2014).
Heat stress and crating during transport have also been identified as physiological and
psychological stress events, creating acid-base and metabolism disturbances that also
negatively impacts meat quality (Akşit et al. 2006; Goel 2021). Taken together, a focus
on broiler welfare during rearing, transport and slaughter is an important consideration
to reduce the load of Campylobacter in live birds (Cogan et al. 2007).
1.4.1.4.2 Welfare interventions in the broiler production industry
The Brambell report (1965) influenced the welfare of animals kept under intensive
livestock husbandry systems, and farmer empathy and experience were emphasised as
critical to good animal care (Rogers Brambell 1965).
Maintaining appropriate litter has been credited with a reduction in coccidiosis and
necrotic enteritis (European Commission 2018a). Lower stocking densities are in
place in free range extensive and organic farming systems (Veissier et al. 2008).
Genetic selection of fast-growing birds has not come without a myriad of health and
fitness defects (immune response, skeletal integrity, heart and lung fitness, etc.) and
considering only a small number of broiler breeder companies produce genetic strains,
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they also have great influence on broiler welfare (European Commission 2018a). EC
regulation 2018/784 describes the approval of low atmospheric pressure stunning of
broilers before slaughter (European Commission 2018b). Although killing birds at a
younger age was proposed as a systematic welfare improvement measure during
broiler production by preventing ill health (European Commission 2018a) and
reducing Campylobacter spp. colonisation upon slaughter (European Food Safety
Authority 2011; European Commission 2018a), which in anthropomorphic terms
seems counterintuitive.
1.4.2

Campylobacter prevalence in broilers

A public health risk reduction of at least 50% is predicted if all broiler batches
complied with a critical limit of <1000 (103) CFU/g of broiler neck skin (European
Food Safety Authority 2011). Hence the European Commission (EC) recently
published regulation 2019/1495, amending EC No 2073/2005 – proposing process
hygiene criteria (PHC) for the poultry sector (European Commission 2005, 2017).
Within a moving window of 50 samples, no more than 15 can exceed the limit of 103
CFU/g (from 2020 to 2025) (European Commission 2017).
Ireland had the second highest prevalence of campylobacter-contaminated broiler
carcasses (98.3%) and a high rate of campylobacter-colonised broiler batches (83.1%)
in the 2008 European Food Safety Authority (EFSA) baseline study (European Food
Safety Authority 2010a). Compared to the European average of 75.8% campylobactercontaminated broiler carcasses and 71.2% campylobacter colonised broiler batches
and, ranging between 4.9–100% and 2.0–100%, respectively (European Food Safety
Authority 2010a). Updated data collected by the Department of Agriculture, Food and
the Marine in a year-long baseline prevalence survey (2017-2018) on campylobactercontamination and carriage rates in Irish broilers indicate that the burden of
Campylobacter species had reduced significantly within the last ten years (Dr Helen
Lynch, personal communication, 2020).
Biosecurity measures that successfully limited the levels of Salmonella in the poultry
industry were less effective in curbing Campylobacter spp. colonisation rates
(European Food Safety Authority 2011). Campylobacters are found more frequently
in livestock and in the environment, the infective dose (Cawthraw et al. 1996) and
colonisation threshold are lower than that of Salmonella in broilers (Humphrey 2006).
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1.4.2.1 Prevalence as a function of seasonality in broilers
A pronounced seasonal pattern in Campylobacter spp. carriage among poultry has
been documented during the warmer summer months in both hemispheres (Nylen et
al. 2002; Jorgensen et al. 2011; Cody et al. 2012; Hald et al. 2016; Ishihara et al.
2017), often corresponding to increased community incidences of human infection as
described above. Some authors, however, did not detect seasonal variation in broiler
carriage (Humphrey, Henley and Lanning 1993) and others found a negative
correlation between Campylobacter carriage rates in live broilers and maximum air
temperatures (Wallace et al. 1997). However, true seasonality in a 12-month interval
cannot be statistically verified (Wallace et al. 1997), and the cause of seasonality is
not fully understood (Hald et al. 2016). Moreover, an autumnal peak in the incidence
of broiler Campylobacter spp. colonisation was reported in Norway (data from 1990)
(Kapperud et al. 1993), while the incidence of Campylobacter gastroenteritis in
Nordic countries usually peaks in July and August (data from 2000-2015) (Kuhn et al.
2020b).
Direct temperature-dependent factors including elevated temperatures and high
humidity may contribute to increased bacterial growth and survival (Jorgensen et al.
2011; Ishihara et al. 2017). Indirect temperature-dependent factors that might be
influential mediators of seasonal variation include flies, migratory birds and rodents
(Wallace et al. 1997; Jorgensen et al. 2011). Hald et al. (2008) reported that flies
constitute a considerable risk for infection of broilers with Campylobacter spp. (Hald
et al. 2008). The Muscidae family of flies, particularly Musca domestica (the
housefly), are more prevalent during the summer period and have been identified as
significant Campylobacter spp. vectors, foraging on fresh faeces owing to their
synanthropic and omnivorous biology (Shane, Montrose and Harrington 1985; Hald
et al. 2008). Flies are more abundant during warmer months and may have more access
to broiler houses as ventilation increases within the house to compensate for increases
in air temperature (Jorgensen et al. 2011). Experimentally, houseflies can transmit C.
jejuni to day-old broiler chickens (Shane, Montrose and Harrington 1985). Housed
broilers may be exposed to increased ventilation and airflow through the broiler house
during summer months to compensate for the rise in temperature.
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1.4.2.2 Transmission to broiler from other animal sources
Campylobacter spp. are members of the intestinal microflora of many wild, domestic
and farm animals and can directly or indirectly contribute to the occurrence of
Campylobacter in broilers (Ogden et al. 2009; Sheppard et al. 2011). The presence of
other animals carrying Campylobacter spp. has been highlighted as a major
contributor to the emergence of Campylobacter-positive poultry flocks (Ellis-Iversen
et al. 2012). Sheppard et al. (2011) identified genetically similar or identical C. jejuni
strains present in other farm animals and broilers (Sheppard et al. 2011). Wild birds
are natural reservoirs of Campylobacter spp. and may contribute to the epidemiology
of campylobacters on farms (Hald et al. 2016). The non-random space use and
foraging ecology of birds may facilitate transmission in farm areas (Taff et al. 2016).
However, other authors found that Campylobacter spp. populations present in wild
birds different significantly from those isolated from chickens in nearby farms (Colles
et al. 2008; Sheppard et al. 2011).
1.4.2.3 Transmission to broilers and farm animals via contaminated water
Although Campylobacter spp. is not generally considered to proliferate outside the
animal host, survival and transmission of Campylobacter spp. in water has been
demonstrated (Shanker, Lee and Sorrell 1990). Release of Campylobacter spp. into
natural waters by animal hosts has been postulated to play a key role in the
maintenance and transmission of organisms in the environment (Pearson et al. 1993).
Campylobacter spp. may persist for months in water reservoirs, even at low
temperatures in a VBNC state (Rollins and Colwell 1986). Subsurface groundwater
provides a salutary environment for campylobacters outside the animal host, providing
a constant temperature and protection from desiccation and UV rays (Casey,
Fitzgerald and Lucey 2017).
A Norwegian study encompassing 18,488 broiler flocks from 623 different farms over
a 5-year period, indicated that heavy rainfall increased the probability of
Campylobacter colonisation in broilers, likely via transmission or survival in
persistent surface water reservoirs in the farm environment (Jonsson et al. 2012).
Agricultural run-off and dissemination of contaminated faeces by animal hosts into
streams may represent an important transmission vector between farms (Jonsson et al.
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2012). In another study, rainfall was found to influence Campylobacter prevalence in
broilers in association with temperature (Louis et al. 2005).

1.5

Thermophilic Campylobacter spp. antimicrobial resistance

Most cases of human enteric campylobacteriosis are self-limiting. Nevertheless,
severe, prolonged enteric illness or immunocompromisation may require antibiotic
therapy (Aarestrup and Engberg 2001; Allos 2001) and certainly in the case of
systemic Campylobacter spp. infections (McNulty 1987; Gallo et al. 2016). Reported
high rates of fluoroquinolone resistance in Campylobacter spp. has made macrolides
(typically azithromycin and erythromycin) the first line antibiotic class for the
treatment of human enteric campylobacteriosis (Karmali and Fleming 1979; Kuschner
et al. 1995; Aarestrup and Engberg 2001; Allos 2001; Luangtongkum et al. 2009;
Nielsen et al. 2016; Bolinger and Kathariou 2017; Casanovas-Moreno-Torres et al.
2020). Campylobacter bloodstream infections are routinely treated with intravenous
aminoglycosides (Aarestrup and Engberg 2001; Nielsen et al. 2010a).
Antimicrobial resistance (AMR) is internationally recognised as a major societal
challenge and novel antibiotic classes have not been brought to market in decades,
with the exception of teixobactin (macrocyclic depsipeptide natural product), that
targets Gram positive organisms (Gunjal et al. 2020). Gram negative bacterial
resistance is noteworthy as resistance has been observed in nearly all drugs considered
for treatment (Center for Disease Prevention and Control 2013). Overuse of
antimicrobials in humans and animals has driven AMR, fuelled by increased migration
and the uncontrolled and continuous contamination of fresh water supplies (Harbarth
et al. 2015).
1.5.1

Clinically relevant antimicrobials

The intensive use of antimicrobial agents for therapy, and infection prophylaxis in
poultry and other food animals selects for resistant strains with the potential to transfer
to humans (Aarestrup and Engberg 2001; Stapleton et al. 2010; Elhadidy et al. 2018b).
The antimicrobial agents used in food-producing animals in Europe are often the same,
or are members of the same class, as those used to treat human infection (European
Food Safety Authority and European Centre for Disease Prevention and Control
2018).
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Herein, critically important antimicrobial classes, including, (fluoro)quinolones,
macrolides and aminoglycosides and the highly important antimicrobial tetracycline
class (World Health Organisation 2018), relevant to Campylobacter spp. ecology, are
described.
1.5.1.1 Ciprofloxacin and fluoroquinolones
Fluoroquinolones are categorized as critically important drugs for human medicine
(World Health Organisation 2018). In the 1980s, fluoroquinolones were introduced as
effective agents against most major pathogens causing bacterial enteritis (Goodman et
al. 1990). However, the rapid emergence of resistance in Campylobacter has limited
its efficacy (Endtz et al. 1991; Wiström and Norrby 1995; Engberg et al. 2001).
Nalidixic acid is considered the predecessor of all members of the quinolone family,
while ciprofloxacin is a second-generation fluoroquinolone and differs from the older
analogues by the presence of a fluorine atom at position 6 of the quinolone nucleus
(Figure 1.8) (Wolfson and Hooper 1989). Second-generation fluoroquinolones,
including

ciprofloxacin,

norafloxacin

and

ofloxacin

are

active

against

Enterobacteriaceae, nonfermenters (including Pseudomonas aeruginosa) and some
staphylococci (Wolfson and Hooper 1989). The third-generation fluoroquinolone
moxifloxacin (MOX), patented in the early 1990s, has broader antibacterial spectra
than older fluoroquinolones and is active against Gram positive cocci and anaerobic
bacteria (Dalhoff, Petersen and Endermann 1996; Biedenbach et al. 1998; Van
Bambeke et al. 2005). Moreover, MOX has potent activity against fluoroquinoloneresistant Campylobacter spp. strains (Tankovic et al. 1999; Bachoual et al. 2001; Ruiz
et al. 2005).

Figure 1.8. Structure of nalidixic and newer fluoroquinolones norfloxacin and ciprofloxacin. Positions
of the fluorine ring are highlighted on the norfloxacin molecule. Figure adapted from Wolfson and
Hooper (1989).
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1.5.1.1.1 Fluoroquinolone mode of action
In Gram negative bacteria, DNA gyrase is the primary target of fluoroquinolones
(Payot et al. 2006). DNA gyrase is a heterotetrametric type IIA topoisomerase,
consisting of two polypeptide subunits (GyrA and GyrB, encoded by gyrA and gyrB,
respectively), catalysing ATP-dependent negative supercoiling of DNA to regulate
replication, repair and gene expression (Gellert et al. 1976; Drlica and Zhao 1997;
Klostermeier 2018). There are four functional domains in type II topoisomerases:
domain 1 (N-terminal of GyrB) is an ATPase, domain 2 (C-terminal of GyrB) is
responsible for subunit interactions, domain 3 (N-terminal of GyrA) controls the
breaking-re-joining function via protein-DNA bridges and domain 4 (C- terminal of
GyrA) can non-specifically bind to DNA.
The widespread detection of gyrA point mutations conferring fluoroquinolones
resistance

precludes

this

antimicrobial

for

empiric

treatment

of

enteric

campylobacteriosis (Luangtongkum et al. 2009; Bolinger and Kathariou 2017).
1.5.1.1.2 Use of fluoroquinolones in food-producing animals
The synthetic fluoroquinolone enrofloxacin is used to treat respiratory and alimentary
tract infections in poultry and has been demonstrated to promote fluoroquinoloneresistant Campylobacter spp. (Stapleton et al. 2010). Ciprofloxacin is the comparable
human drug in this class and a major metabolite of enrofloxacin. Despite the fact that
enrofloxacin has been banned in the US since 2005, enrofloxacin containing products
are still permitted and used in the poultry industry to treat infections in Ireland and
Europe (Endtz et al. 1991; European Medicines Agency 1998, 2014; US Food and
Drug Administration 2005; European Commission 2014; Giacomelli et al. 2014),
although it’s use is restricted (category B antimicrobial) in Europe, where use in foodproducing animals is only indicated if there are no antibiotics in categories C and D
(caution and prudence categories, respectively) that could be clinically effective
(European Medicines Agency 2013).
Statistically significant associations have been reported between fluoroquinolone
resistant Campylobacter strains and the use of fluoroquinolones in food-producing
animals (Endtz et al. 1991; Luo et al. 2003; Moore and Matsuda 2004; Taylor et al.
2016; European Food Safety Authority, European Centre for Disease Prevention and
Control and European Medicines Agency 2017). However, fluoroquinolone usage
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accounts for less than 1% of all veterinary antimicrobials in Ireland since 2009
(Beechinor 2009; Health Products Regulatory Authority. 2017; Department of
Agriculture Food and the Marine and Department of Health 2019). It is noteworthy
that veterinary antimicrobial usage (AMU) data is based on sales and does not include
a breakdown of usage by species (Department of Agriculture Food and the Marine and
Department of Health 2019).
1.5.1.2 Tetracyclines
Tetracyclines are broad spectrum agents, with activity against Gram positive and
Gram negative bacteria and are classed as highly important antimicrobials (World
Health Organisation 2018). Tetracycline has also been used to treat intracellular
chlamydiae, mycoplasmas, Plasmodium falciparum malaria and at subtherapeutic
concentrations for other non-infectious conditions (Roberts 2003). Tetracyclines were
discovered in the 1940s, followed by the emergence of bacterial resistance in the 1950s
(Akiba et al. 1960). Data suggests that tetracycline usage has decreased since, although
the global consumption of tetracycline per year is unknown (Roberts 2003).
Tetracyclines account for 10% of community AMU in Ireland in 2016, being the third
most commonly used antimicrobial (Department of Agriculture Food and the Marine
and Department of Health 2019). Tetracyclines are a relatively inexpensive class of
antimicrobials available and are attractive for use in developing countries (Roberts
2003). Tetracyclines are also used as alternative drugs to treat human enteric
campylobacteriosis (Ge et al. 2003).
1.5.1.2.1 Tetracycline mode of action
Tetracycline molecules comprise a linear fused tetracyclic nucleus (rings designated
A, B, C, and D) to which a variety of functional groups are attached. Tetracyclines are
translocated as positively charged cation-tetracycline complexes (via the Donnan
potential) through porin channels on the outer membrane of Gram negative bacteria,
leading to periplasmic accumulation. The dissociated and weakly lipophilic
tetracycline molecules can diffuse through the lipid bilayer of the inner cytoplasmic
membrane (Chopra and Roberts 2001). Once inside the cell, tetracycline molecules
can reversibly bind with the prokaryotic 30S ribosomal subunit (smaller subunit of the
70S ribosome) (Connell et al. 2003; Roberts 2003). Tetracyclines bind to the
aminoacyl-site (A-site) on the bacterial ribosome and inhibit bacterial protein
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synthesis during elongation by preventing the association of aminoacyl-tRNA with the
bacterial ribosome (Chopra and Roberts 2001; Roberts 2003; Wilson 2014;
Warburton, Amodeo and Roberts 2016).
1.5.1.2.2 Use of tetracyclines in food-producing animals
The use of tetracycline for growth promotion has been banned in Europe since the
early 1970s, in accordance with directive 70/524/EEC (Council of the European Union
1970). However, tetracyclines are used extensively in poultry production and animal
husbandry for the treatment of enteric, respiratory and dermal infections (Casewell et
al. 2003; Sarmah, Meyer and Boxall 2006; Carvalho and Santos 2016; GranadosChinchilla and Rodríguez 2017; Kuppusamy et al. 2018). Tetracycline is the most
commonly administered veterinary antibiotic in Ireland (Figure 1.9) (Health Products
Regulatory Authority. 2014, 2016; European Medicines Agency 2018a, 2020;
Department of Agriculture Food and the Marine and Department of Health 2019).
Orally administered oxytetracycline is excreted via the kidneys or biliary system,
largely unchanged, in poultry and among animals (Jjemba 2002; Kemper 2008; Chen
et al. 2017; Kuppusamy et al. 2018). Tetracyclines are polar and are highly adsorbed
in soil organic matter, which may serve as an antibiotic pollutant reservoir (Kemper
2008; Kuppusamy et al. 2018). Consequently, tetracyclines can frequently be detected
in soil and water, compounded by associated environmental persistence and
accumulation of bioactive tetracycline residues (Jjemba 2002; Fairchild et al. 2005;
Kemper 2008; Granados-Chinchilla and Rodríguez 2017; Grenni, Ancona and Barra
Caracciolo 2018; Kuppusamy et al. 2018). Although, the true extent of occurrence and
persistence of antibiotics in the environment is unknown (Kemper 2008; Carvalho and
Santos 2016; Department of Agriculture Food and the Marine and Department of
Health 2019).
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Figure 1.9. The total sales (mg/population corrected unit (PCU)) of veterinary antimicrobial agents, by
antimicrobial class in Ireland from 2010 to 2016 (European Medicines Agency 2018a).

1.5.1.2.3 Glycylcyclines
Glycylcyclines, including tigecycline are relatively new antimicrobials, discovered in
1993 and have a similar spectrum of activity to other tetracyclines but are also active
against bacteria with acquired tetracycline resistance genes (Petersen et al. 1999;
Chopra and Roberts 2001; Betriu et al. 2002; Chopra 2002; Roberts 2005; RodríguezAvial et al. 2006). Moreover, glycylcyclines retain activity to strains expressing
ribosomal protection proteins or efflux mechanisms (Chopra 2002). Like other
tetracyclines, the glycylcycline tigecycline inhibits bacterial protein synthesis at the
elongation stage by preventing tRNA binding to the small 30S ribosomal subunit
(Wilson 2014; Bender et al. 2018). Glycylcyclines exhibit higher binding affinity for
ribosomes compared to earlier tetracyclines (Bergeron et al. 1996). Tetracycline efflux
proteins may not recognise glycylcyclines or may not be a compatible transport system
for this analogue (Chopra 2002).
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Glycylcyclines are used as a last-resort antimicrobial in the treatment of vancomycinresistant enterococci (VRE), other multidrug-resistant Gram negative infections
(Center for Disease Prevention and Control 2013; Bender et al. 2018) and has the
potential to reinstate the therapeutic utility of tetracyclines to treat Campylobacter
infection

(Chopra

2002).

Correspondingly,

complete

Campylobacter

spp.

susceptibility to tigecycline has been frequently reported (Lehtopolku et al. 2010;
Wardak and Szych 2010; Bascuñana et al. 2011; Albert 2013). Although, a report from
Pakistan emerged in 2019 documenting a tigecycline-resistant C. jejuni isolate from
diarrhoeic human faeces (Noreen et al. 2019). The use of glycylcycline remains
restricted in animals in Europe (category A of antibiotics for use in animals) (European
Medicines Agency 2013).
1.5.1.3 Macrolides and erythromycin
Currently, macrolides (including erythromycin and azithromycin) are one of the few
remaining therapies for serious Campylobacter enteric infections owning to the high
level of (fluoro)quinolone and tetracycline resistance worldwide (Bolinger and
Kathariou 2017; Schiaffino, Platts-Mills and Kosek 2019). Macrolides are classed as
critically important antimicrobials (World Health Organisation 2018). In 2013 the
Centres for Disease Prevention and Control (CDC) listed fluoroquinolone- and
macrolide-resistant Campylobacter as one of the serious antibiotic resistant threats to
public health (Center for Disease Prevention and Control 2013). In Ireland, macrolides
constituted 18% of community AMU in Ireland in 2016, the second most commonly
used antimicrobial (Department of Agriculture Food and the Marine and Department
of Health 2019).
1.5.1.3.1 Macrolide mode of action
Macrolides are composed of a core macrolactone ring that can attach to several sugars
or side chains (Wilson 2014). Macrolides act by binding to the 50S ribosomal subunit
to interfere with protein synthesis by inhibiting translational elongation (Wilson
2014). Macrolides and other protein synthesis inhibitors establish an imbalance of
rRNA and ribosomal proteins, which subsequently interferes with the assembly of
ribosomal subunits (Siibak et al. 2009).
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1.5.1.3.2 Use of macrolides in food-producing animals
Sales data in Ireland indicated that macrolides and related drugs accounted for 6.9%
of all veterinary antibiotics sold in the country in 2016, broadly in line with figures
reported in the previous four years (Department of Agriculture Food and the Marine
and Department of Health 2019) and in the most recent (2020) European Surveillance
of Veterinary Antimicrobial Consumption (ESVAC) report (European Medicines
Agency 2020). Although the addition of macrolides to animal feed as growth
promoters has been banned in Europe since 1999 (Casewell et al. 2003), the macrolide
tylosin is still widely used as a therapeutic and prophylactic agent for broilers and food
animals (Gibreel and Taylor 2006; Lin et al. 2007; Persoons et al. 2012; European
Medicines Agency 2013).
1.5.1.4 Aminoglycosides
Aminoglycosides are potent, broad-spectrum antibiotics, particularly against members
of the Enterobacteriaceae family, multidrug-resistant Gram negative bacteria,
methicillin-resistant Staphylococcus aureus and Yersinia pestis (Krause et al. 2016).
Overall bacterial resistance rates to aminoglycosides among campylobacters are low
(Krause et al. 2016). Streptomycin was first isolated from Streptomyces griseus and
the antimicrobial properties were discovered in 1944 and several other members of the
aminoglycoside class were identified subsequently (Comroe 1978). Gentamicin was
isolated from Micromonospora purpurea (Weinstein et al. 1963).
Aminoglycosides are often used alone or in conjunction with β-lactam antibiotics to
treat serious invasive infections in humans, including but not limited to, bacteraemia,
meningitis, central nervous system infections, bacterial endocarditis (Krause et al.
2016; LeBras et al. 2016; van Duijkeren et al. 2019). Intravenous aminoglycosides are
used to treat Campylobacter bacteraemia and other systemic infections (Aarestrup and
Engberg 2001).
1.5.1.4.1 Aminoglycoside mode of action
Aminoglycosides consist of a core amino sugar structure connected via glycosidic
linkages to a dibasic aminocyclitol, typically 2-deoxystreptamine. Aminoglycosides
are classified by differences in the position, number and type of substituents on 2deoystreptamine. Streptomycin possesses a streptidine ring as the central
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aminocyclitol and gentamicin contains a 4,6-di-substituted deoxystreptamine ring
(Krause et al. 2016).
Generally, aminoglycosides bind with high affinity to regions of the A-site of the 30S
small ribosomal subunit (Kotra, Haddad and Mobashery 2000; Wilson 2014). Binding
causes a conformational change and interferes with recognition of cognate tRNA by
rRNA during translation, inhibiting elongation. Interactions also interfere with the
translocation of tRNA from the A-site to the peptidyl site (P-site) (Kotra, Haddad and
Mobashery 2000; Wilson 2014). The mechanism of binding and associated
downstream effects vary according to chemical structure (Krause et al. 2016). For
context, during bacterial protein synthesis, the 30S and 50S ribosomal subunits couple
to form the 70S ribosome. The initiator (aminoacetylated) tRNA and mRNA start
codon at this point are positioned at the ribosomal P-site. Elongation involves the
delivery of aminoacetlyated-tRNA to the ribosomal A-site and subsequently peptide
bond formation occurs between A- and P-site tRNAs (Wilson 2014).
1.5.1.4.2 Use of aminoglycosides in food-producing animals
Aminoglycosides are frequently used veterinary medicines. A recent One Health
report published in Ireland in 2019 indicated that aminoglycosides constituted 6.2%
of all veterinary antimicrobials sold in the country in 2016 (Department of Agriculture
Food and the Marine and Department of Health 2019). Correspondingly,
aminoglycosides constituted 6.2% of the total sale of antimicrobials in food-producing
animals in the EU, 2018 (European Medicines Agency 2020).
Aminoglycosides are administered to cattle, pigs, sheep, poultry, horses, goats, cats
and dogs for the treatment of septicaemia and digestive, respiratory and urinary
infections, via oral, parenteral or topical application. (European Medicines Agency
2017; van Duijkeren et al. 2019). Specifically, orally administered apramycin is used
to treat E. coli septicaemia and enteric infections in poultry (Afifi and Ramadan 1997;
European Medicines Agency 1999). Apramycin is poorly absorbed following oral
administration in broilers (Afifi and Ramadan 1997; European Medicines Agency
1999); unchanged apramycin residues are consistently higher in the kidneys after
intracrop, intramuscular and intravenous dosing (Afifi and Ramadan 1997). Outside
the EU gentamicin is administered in ovo to reduce Salmonella in day of hatch chicks
and as the delivery method for Marek’s disease vaccine (Bailey and Line 2001).
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1.5.2

Attempts to preserve the usefulness of clinically relevant antimicrobials

in the European Union
Several efforts have been made by EFSA, ECDC and the EU to address AMR in the
EU, including but not limited to the ban of antimicrobials as growth promoters, the
licensing of pharmaceutical products for food animals, delineation of maximum
residues in animal products, reporting veterinary antimicrobial sales data (to estimate
usage) and monitoring AMR in important zoonotic pathogens and commensals.
However, significant knowledge gaps exist within the EU, and certainly in many parts
of the world – where a risk of importing MDR strains remains. The EC and the WHO
have engaged to develop a global plan of action concerning AMR, and a trans-Atlantic
task force for AMR allows cooperation between the EU, Norway, USA and Canada.
A tiered system of antimicrobial prioritisation exists (World Health Organisation
2018) and the discontinued use of the highest priority critically important
antimicrobials and an overall reduction in AMU on dairy farms did not adversely
affect production, health or welfare in dairy cows (Turner et al. 2018). New
regulations offer some strategies to protect the clinical utility of antimicrobials (More
2020).
1.5.2.1 The ban of antimicrobials as growth promoters in animal agriculture
Antimicrobials at sub-therapeutic levels have been demonstrated to promote
production efficiency in animals (Moore and Evenson 1946). The growth promoter
effect of antibiotics was discovered in the 1940s, when improved growth was observed
in

animals

fed

dried

mycelia

of

Streptomyces

aureofaciens

containing

chlortetracycline residues (Castanon 2007). These improved animal growth rates are
associated with intestinal microbiota-antibiotic interactions with increased availability
of nutrients, enhanced nutrient digestibility, decreased toxic microbial metabolites and
a reduction in opportunistic pathogens and subclinical infections (Dibner and Richards
2005; Castanon 2007).
One of the first reports of resistance in food animals was made in 1951, after
experimental feeding of streptomycin in turkeys (Starr and Reynolds 1951). The
growth promotion properties of tetracycline were discovered in 1950s (Roberts 2003),
followed swiftly by the first reports of bacterial tetracycline-resistance (Akiba et al.
1960). Directive 70/524/EEC was published in December 1970 to establish common
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European regulations on feed additives (Council of the European Union 1970;
Castanon 2007).
The glycopeptide avoparcin was first prohibited in Denmark (May 20, 1995) and
Germany (January 19, 1996) due to the emergence of glycopeptide resistance in
human medicine. Avoparcin was banned as a feed additive in the EU in 1997 (directive
96/7/EC) (European Commission 1997a; Casewell et al. 2003; Castanon 2007),
followed by the ban on bacitracin, spiramycin, tylosin and virginiamycin in 1999 in
regulation 2821/98 (Council of the European Union 1998).
The ban on all antimicrobials as growth promoters in food animals in the EU came
into effect on January 1, 2006 according to regulation 1831/2003 (European
Parliament and Council of the European Union 2003; Castanon 2007), amending
directive 70/524/EEC (Council of the European Union 1970).
An increase in usage of veterinary therapeutic antimicrobials was observed after the
withdrawal of antimicrobial growth promoter, a directly attributable effect of an
increased incidence of infection (Casewell et al. 2003; Desmonts et al. 2004). Notably
the withdrawal of bacitracin has been associated with clostridial necrotic enteritis
(Casewell et al. 2003). The growth-promoter ban also reinforces improvements in
hygiene and biosecurity on-farm (Castanon 2007).
1.5.2.2 Mandatory reporting of antimicrobial resistance in Campylobacter spp. from
broilers in the European Union
Implementing decision 2013/652/EU details rules for monitoring and reporting of
AMR in zoonotic (concerning C. jejuni and C. coli) and commensal bacteria in animal
production and describes the mandatory biennial reporting of C. jejuni AMR in broiler
caecal samples in the EU since 2014 (European Commission 2013), using
recommended harmonised monitoring systems (European Centre for Disease
Prevention and Control. 2016).
Recently, EC implementing decision 2020/1729 (to cover period 2021 to 2027)
repealed decision 2013/652/EU, broadening the sampling of food-producing animals
and food (including imported food products), combinations of bacterial species and
testing strategies with the authorisation of whole-genome sequencing (WGS) for AMR
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monitoring requirements on a voluntary basis in each member state (European
Commission 2020a).
Antimicrobials relevant to Campylobacter in this panel include tetracycline,
erythromycin, gentamicin, ciprofloxacin, nalidixic acid and streptomycin (European
Food Safety Authority and European Centre for Disease Prevention and Control
2018). The inclusion of nalidixic acid (a quinolone) and streptomycin (an
aminoglycoside) provides supplementary information on the extent of resistance and
mechanisms of same to these antimicrobial classes (European Food Safety Authority
and European Centre for Disease Prevention and Control 2018).
Harmonised monitoring systems described by the ECDC were recommended to
participating European countries with a view to improve the quality and comparability
of AMR data collected (European Centre for Disease Prevention and Control. 2016).
Broth microdilution is recommended as the most appropriate testing method for
monitoring purposes, according to the International Standards Organisation (ISO)
20776:2006 standard for MIC determination and epidemiological cut-off (ECOFF)
values are defined by the European Committee on Antimicrobial Susceptibility
Testing (EUCAST). Clinical breakpoints are primarily used as interpretive criteria for
humans when reporting sensitive/intermediate/resistant, while ECOFFs are used for
animal and food isolates. The difference in interpretive criteria reflects the intentions
for testing. Antimicrobial susceptibility testing (AST) in humans is necessitated by
treatment of clinical disease, while the detection acquired resistance or changes in
resistance rates if the primary reason for AST in food and animal isolates (European
Centre for Disease Prevention and Control. 2016).
1.5.2.3 Reporting of antimicrobial sales data in the European Union in an attempt to
estimate antimicrobial usage
Companies marketing veterinary antimicrobials are required to submit annual returns
(on the quantities of antimicrobial preparations sold) to their national regulatory
authority (HPRA in Ireland), which is consolidated by ESVAC (Department of
Agriculture Food and the Marine and Department of Health 2019). Recent veterinary
AMU data was based solely on sales and did not include a breakdown of usage by
animal species. Currently, the information provided by companies on sales is selfdeclared and is not subject to independent verification or audit (Health Products
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Regulatory Authority. 2017; Department of Agriculture Food and the Marine and
Department of Health 2019).
Approximately two thirds of all animal AMU in Ireland is formulated as premixes or
oral remedies, presumed to be used as in-water or in-feed medication for the intensive
poultry and pig sectors (Department of Agriculture Food and the Marine and
Department of Health 2019). The 2020 ESVAC report revealed that overall sales of
veterinary antibiotics in European countries dropped by more than 34% between 2011
and 2018 (European Medicines Agency 2020). However, comprehensive surveillance
schemes are required to determine the actual usage of legally sold antimicrobials in
food animal production, and the EC has mandated that ESVAC develop an approach
for the estimating and reporting of AMU data for major food-producing animal species
(European Medicines Agency 2016a), and a concept paper on reporting has been
drafted (European Medicines Agency 2021). Stratification of AMU data per animal
species is to be incorporated in the template for future ESVAC sales data collection
(European Medicines Agency 2018b).
Ireland’s first joint report on AMU and AMR indicated that in 2016 Ireland was ranked
17th highest of 30 European countries for AMU in animals. In most EU countries,
reported antimicrobial use (AMU) (data based on pharmacy wholesale) is lower per
unit of biomass in food-producing animals than in humans. However, in Ireland, data
from 2014 estimates that human AMU per unit of biomass was approximately threefold higher than that of food-producing animals. (Department of Agriculture Food and
the Marine and Department of Health 2019). While Ireland ranked 9th highest of 25
European countries for antibacterial consumption in humans and 90% of AMU was in
the community (Department of Agriculture Food and the Marine and Department of
Health 2019).
1.5.2.4 Pharmaceuticals in the environment and future outlooks
Historically, the role of natural and farm environments in the emergence, selection and
dissemination of AMR has been neglected. Animal waste, untreated human sewage,
“night soil”, pharmaceutical manufacturing waste and use of antimicrobials as
pesticides on crops contribute to contamination of the natural environment,
particularly soil and water (EFSA Panel on Biological Hazards 2021) (Figure 1.10).
Residues of several pharmaceuticals can be found in surface and ground waters, soils
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and animal tissue (European Commission 2019), and direct transmission of resistant
bacteria from contaminated water to humans has been reported (Taylor et al. 2013).
The true stability of antimicrobials or their metabolic products or the prevalence and
survival of resistant bacteria in various environmental conditions (or combination of
conditions) remains an open question. Irrigation and fertilisers of faecal origin are
known to easily spread AMR in the farm environment (EFSA Panel on Biological
Hazards 2021). Regardless, continuous accumulation, transmission and positive
selection of resistant environmental bacteria contributes to the evolution of resistance
(European Commission 2019; EFSA Panel on Biological Hazards 2021). Commensal
bacteria may play a role in the preservation and dissemination of antibiotic resistance
in the gastrointestinal tract (Stanton and Humphrey 2003).

Figure 1.10. Environmental fate of tetracycline antibiotics and tetracycline-resistant bacteria. The
spread of tetracycline-resistant bacteria (dotted arrows), deposition and transmission of resistant
bacteria of bioactive tetracycline residues (solid arrows). Created with BioRender.com.

Efforts have been made in the last decade to begin to understand the scale and risk of
the environmental accumulation and transmission of AMR (Wellcome Trust 2018;
EFSA Panel on Biological Hazards 2021). Yet, there is no systematic surveillance for
AMR in the environment in Ireland or the EU (Department of Agriculture Food and
the Marine and Department of Health 2019), and the considerations involved are
extensive considering the global spatiotemporal coordination required to harmonise
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human and animal surveillance systems alone (Huijbers, Flach and Larsson 2019).
Moreover, many on-farm associated factors (rodents, wildlife, soil, air and dust)
thought to contribute to AMR are difficult to assess on a large scale, and runoff from
livestock is geography-dependent.
Annual EFSA reports (European Food Safety Authority 2021) are published on the
levels of veterinary medicinal product residues in live animals and animal products,
described in directives 96/23/EC, 97/747/EC and regulation EC 178/2002 (European
Commission 1996, 1997b, 2002). In 2019 the EC have adopted an approach to address
the growing concerns about accumulation of pharmaceuticals in the environment and
the devastating impact of pharmaceutical pollution on human, animal and
environmental health (European Commission 2019, 2020b, 2021) – a problem
predicted to worsen given the changes in the world’s climate (EFSA Panel on
Biological Hazards 2021). A reduction of 50% in antimicrobials sold for farmed
animals is targeted for 2030 in the Farm to Fork strategy in the European Green Deal
(European Commission 2020c). Culture-independent methodologies via large scale
metagenomics in complex microbial communities or in the environment may bridge
some the information gaps surrounding environmental AMR, and its relationship with
food animal production.
1.5.3

Prevalence of Campylobacter antimicrobial resistance in the EU and

Ireland
Data on Campylobacter AMR in Ireland is limited and is largely focused on C. jejuni
and C. coli, owing to their public health significance. There are significant gaps in data
on the AMR rates and molecular epidemiology in both human and animal Irish
Campylobacter isolates.
1.5.3.1 Prevalence of antimicrobial resistance in Campylobacter spp. from broilers
EU and Ireland
Data on Irish broiler Campylobacter spp. AMR are limited to the early 2000s (Lucey
et al. 2000b, 2002; Fallon et al. 2003; Corcoran et al. 2006a; McGill et al. 2006), but
have been supplemented by EFSA/European Centre for Disease Prevention and
Control (ECDC) AMR biennial reports on the AMR of a subset of C. jejuni isolated
from Irish broiler caecal samples, as described above. The majority of Campylobacter
73

spp. are intrinsically resistant to β-lactam antimicrobials, (including penams
(penicillin

derivatives)

and

cephams

(cephalosporins),

trimethoprim,

sulfamethoxazole, rifampicin and vancomycin (McNulty 1987; Wieczorek and Osek
2013).
1.5.3.1.1 Prevalence of fluoroquinolone and tetracycline resistance in Campylobacter
spp. from broilers in the EU and Ireland
Resistance to (fluoro)quinolones ranged from 14–28.9% in Irish broilers in the early
2000s (Lucey et al. 2000b, 2002; Fallon et al. 2003). Resistance to tetracycline (TET)
ranged from 19.4-24.4% during the same period (Lucey et al. 2000b, 2002; Fallon et
al. 2003). However, Corcoran et al. (2006) reported 42.2% and 34.4% resistance to
nalidixic acid (NAL) and TET, respectively in a sample of 32 Irish poultry
Campylobacter spp. isolates (data from 2002-2004). The EFSA/ECDC AMR
summary report in 2016 indicates that 24.7% and 25.3% of Irish broiler
Campylobacter spp. isolates tested were ciprofloxacin (CIP)- and TET-resistant,
respectively (European Food Safety Authority and European Centre for Disease
Prevention and Control 2018). Moreover, a statistically significant increase in
resistance to tetracycline among C. jejuni isolates from broilers in Ireland was
recorded between 2009 and 2021 (European Food Safety Authority and European
Centre for Disease Prevention and Control 2021), in line with observations made in a
recent report of AMR in Campylobacter isolates from caecal and neck skin samples
in Ireland (Lynch et al. 2020b).
Interestingly, between 1996 and 1998 in Ireland only 3.2% of poultry isolates tested
in a study by Lucey et al. (2000) were CIP-resistant. A distinct rise in resistance was
recorded among poultry and human isolates (28.9% and 30% respectively) collected
in 2000. Twenty years later, this level of resistance has remained stable and persistent
(European Food Safety Authority and European Centre for Disease Prevention and
Control 2018; Lynch et al. 2020b), despite their infrequent use in food animal
production. A study investigating Campylobacter AMR in Irish feedlot cattle and their
environment found that the environmental Campylobacter isolates were more resistant
to CIP and NAL (21.8% and 69%, respectively) than the animal isolates (8.5% and
28.5%, respectively) (Minihan et al. 2006).
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Typically, resistance to CIP and NAL are coinherited. However, many Irish studies
report discordant resistance rates between CIP and NAL, indicating that alternative
resistance mechanism exist among Irish Campylobacters, other than the archetypal
gyrA mutation resistance mechanism, described below (Fallon et al. 2003; Corcoran
et al. 2006a; McGill et al. 2006; Minihan et al. 2006).
The average resistance rates of Campylobacter broiler isolates reported in the EU in
2016 indicated that 50.7% of C. jejuni and 61.7% C. coli were TET-resistant and
66.9% of C. jejuni and 87.7% of C. coli isolates were CIP-resistant (European Food
Safety Authority and European Centre for Disease Prevention and Control 2018). In
some studies in Portugal and Spain, 90-100% of broiler Campylobacter strains tested
were TET-resistant (Torralbo et al. 2015; García-Sánchez et al. 2018). Near universal
resistance to (fluoro)quinolones has also been reported in Italy, Poland and Spain
(Giacomelli et al. 2014; García-Sánchez et al. 2018; Woźniak-Biel et al. 2018). In the
latest EFSA/ECDC summary report, generally high to extremely high levels of
tetracyclines and fluoroquinolones resistance were reported in Campylobacter spp.
from human and animal origin summary report (data from 2018/2019), particularly
among C. coli isolated from broilers (European Food Safety Authority and European
Centre for Disease Prevention and Control 2021).
1.5.3.1.2 Prevalence of macrolide resistance in Campylobacter from broilers in the
EU and Ireland
Thermophilic broiler Campylobacter spp. resistance to erythromycin ranged between
4.4–12.5 % around the turn of the century in Ireland (Lucey et al. 2000b, 2002; Fallon
et al. 2003; Corcoran et al. 2006a). In the 2018 EFSA/ECDC AMR summary report
indicated that all Irish Campylobacter spp. broiler isolates tested (n=174) were
erythromycin-sensitive and the overall European average broiler Campylobacter spp.
resistance to ERY was 1.3% (European Food Safety Authority and European Centre
for Disease Prevention and Control 2018). Resistance to ERY among C. jejuni and C.
coli from broilers in the EU in 2018/2019 was 1.3%, and 6.5%, respectively, although
resistance rates of C. coli from calves was reported at 23.3% (European Food Safety
Authority and European Centre for Disease Prevention and Control 2021).

75

1.5.3.1.3 Prevalence of aminoglycoside resistance Campylobacter spp. from broilers
in the EU and Ireland
Historically, the incidence of Campylobacter aminoglycoside resistance in Ireland has
been low, ranging from 1–8% among broiler isolates in the early 2000s (Lucey et al.
2000b, 2002; Fallon et al. 2003) and rates remain low to date ((European Food Safety
Authority and European Centre for Disease Prevention and Control 2018).
1.5.3.2 Prevalence of antimicrobial resistance in Campylobacter spp. from humans in
the EU and Ireland
Surveillance of human AMR in Ireland bears significant gaps in recent years (Table
1.6), as surveillance focuses on trends in invasive infections, while many infections,
including Campylobacter, are not currently subjected to national surveillance
(Department of Agriculture Food and the Marine and Department of Health 2019).
Only 17.9% of Campylobacter spp. isolates from humans were identified to species
level in 2016 (Department of Agriculture Food and the Marine and Department of
Health 2019). Moreover, due to the widespread adoption of culture independent
Campylobacter detection methods in Irish clinical laboratories (circa 2015), little is
known about the true antibiotic resistance rates currently due to difficulties in
obtaining Campylobacter cultures from humans (Redondo, Carroll and Mcnamara
2019). The most recent EFSA/ECDC AMR summary report did not find a statistically
significant increase in AMR among Campylobacter spp. isolates from humans in
Ireland between 2015-2019 (data from at least three years) (European Food Safety
Authority and European Centre for Disease Prevention and Control 2021).
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Table 1.6. Antimicrobial resistance rates of human Campylobacter spp. isolates collected in Ireland
between 1996 and 2004 (percentage of isolates resistant to clinically relevant antimicrobials tested).

Year of
isolation

No. of
isolates

Patients with
clinically
confirmed
gastroenteritis

1996-1998

Patients with
clinically
confirmed
gastroenteritis

Isolate origin

Species

TET

ERY

GEN

CIP

NAL

STR

Reference

36

Campylobacter
spp.

13.9

2.8

n/a

0

n/a

n/a

(Lucey et
al. 2000b)

2000

100

Campylobacter
spp.

31

2

n/a

34

n/a

n/a

(Lucey et
al. 2002)

Community and
in-patient

2001-2002

290

Campylobacter
jejuni

10

6.2

n/a

13

17

8.6

(McGill et
al. 2006)

Humans with
clinically
confirmed
gastroenteritis

2002-2004

34

Campylobacter
spp.

26.5

3

n/a

17.6

29.4

n/a

(Corcoran
et al.
2006a)

n/a: not applicable – antimicrobial not included in the study

In 2016, the levels of human C. jejuni ERY resistance was relatively low (2.1%) with
marked variation per country; Norway reported 11.6% C. jejuni ERY resistance and
Estonia and Portugal reported the highest rates of resistance (63.2% and 50%,
respectively). Resistance to GEN in human C. jejuni isolates in Europe in 2016 was
very low (0.4%), but higher in Italy (4.1%).
1.5.4

Thermophilic Campylobacter spp. antimicrobial resistance mechanisms

Resistance can be intrinsic or acquired through mutations, genetic rearrangements or
horizontal gene transfer of mobilisable resistance determinants. Coinheritance of
determinants genes on plasmids, transposons or integrons can confer multi-drug
resistance in a single evolutionary step (EFSA Panel on Biological Hazards 2021).
Although Campylobacter have conjugative and transformative capacity, often this is
influenced by the relatedness of the acquired DNA molecules to facilitate gene
expression. Still, resistance determinants emerge within the genus originating from
distantly related species.
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1.5.4.1 Campylobacter (fluoro)quinolone resistance mechanisms
Resistance to (fluoro)quinolones is largely mediated by chromosomal mutations in
DNA gyrase, typically conferred by the (A257T) Thr-86-Ile substitution in the
quinolone resistance-determining region (QRDR) of subunit A (gyrA) (Zirnstein et al.
1999) in Campylobacter spp. The QRDR is located near the Tyr-125 active site,
involved in DNA-protein bridge formation during DNA strand passage (Zirnstein et
al. 1999). The Thr-86-Ile mutation is associated with a fitness benefit and is stable in
the absence of selective pressure, consequently fluoroquinolone-resistant strains are
ecologically competitive and persistent even in the absence of antimicrobial selective
pressure (Luo et al. 2003, 2005). High level MOX-resistance has been associated with
double mutations in the gyrA (Bachoual et al. 2001; Ruiz et al. 2005).
1.5.4.2 Campylobacter tetracycline resistance mechanisms
Bacterial resistance to tetracycline can be conferred by ATP-dependent efflux,
enzymatic inactivation of tetracycline, or ribosomal protection (Roberts 2003, 2005;
Warburton, Amodeo and Roberts 2016). Exchange of tetracycline resistance genes
between unrelated bacterial genera has been demonstrated and the emergence of tet
genes in new bacterial genera is frequently reported (Roberts 2003, 2005). Acquisition
of tetracycline resistance determinants is often a consequence of transmissible genetic
elements (transposons, plasmids and integrons) (Roberts 2005). The presence of
multiple tet genes (coding for similar or different mechanisms) in Gram negative
isolates has also been documented (Roberts 2005).
1.5.4.2.1 Ribosomal protection proteins
Campylobacter tetracycline resistance is primarily mediated by a ribosomal protection
protein (RPP), encoded by tetO. TetO is capable of displacing tetracycline from its
primary binding site on the 30S ribosomal subunit (Connell et al. 2003; Gibreel et al.
2004; Wilson 2014), allowing the ribosome to return to its standard conformational
state for protein synthesis (Roberts 2005). Ribosomal conformation changes persist
after TetO has left the ribosome, preventing the rebinding of tetracycline (Connell et
al. 2003). Tetracycline RPPs are widely distributed among bacteria, and in 2005, it
was reported that the tetO existed in eleven bacterial genera, including four Gram
negative and seven Gram positive species (Roberts 2005; Thaker, Spanogiannopoulos
and Wright 2010). To date, 12 RPP tetracycline resistance genes have been reported
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(tetM, O, Q, S, T, W, 32, 36, 44, P, otrA and tet) (Warburton, Amodeo and Roberts
2016). The tet44 gene was identified originally in a Cff isolate in Switzerland, located
on a transferable pathogenicity island carrying a TIVSS unique to Cfv (Abril, Brodard
and Perreten 2010).
The tetM gene is considered the most prevalent RPP, due to its association with the
widely distributed Tn916/Tn1545 conjugative transposon family, (Giovanetti et al.
2003; Roberts 2003, 2005; Lancaster et al. 2004; Warburton, Amodeo and Roberts
2016). Conjugative transposons generally have a broad host range (Roberts 2005).
Other conjugative elements carrying ribosomal protection tet genes have been
identified, including the Tn1207.1-related transposon carrying tetO and mefA, where
the latter codes for a macrolide efflux pump (Giovanetti et al. 2003; Brenciani et al.
2005; Roberts 2005).
1.5.4.2.2 Plasmid-mediated tetracycline resistance
Self-transmissible or mobilisable plasmids promote bacterial plasticity and promote
the transfer of resistance determinants within or between taxa. Integration of plasmid
DNA into the chromosome through recombination or acquisition of chromosomal
genes via conjugative transposition (transposases) or integration (integrases) events
underpin the role of plasmids in genetic diversity (Ochman, Lawrence and Grolsman
2000).
Campylobacter tetO can be chromosomally located (Lee et al. 1994; Chopra and
Roberts 2001; Pratt and Korolik 2005; Roberts 2005; Friis et al. 2007; Kemper 2008;
Crespo et al. 2016) or plasmid-borne (Roberts 2005). The conserved acquisition
between members of different bacterial genera indicate that plasmid conjugation,
transposition or recombination events contribute to the dissemination and maintenance
of the tetO gene (Friis et al. 2007). Plasmids ranging from 3 to 208 kbp have been
documented in Campylobacter spp. (Lee et al. 1994; Friis et al. 2007) and are more
prevalent in tetracycline-resistant Campylobacter spp. strains (Marasini et al. 2018),
compared to tetracycline-sensitive strains (Gibreel et al. 2004). It has been postulated
the high proportion of tetracycline-resistant strains harbouring plasmids may reflect
the on-farm use of tetracyclines as well as other unknown selecting agents. In
Thailand, 91% (152/167) of Campylobacter spp. recovered from chicken meat
contained plasmid DNA compared to 44% of clinical isolates (Lee et al. 1994).
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The pTet plasmid is highly associated with the tetO carriage and may represent the
acquisition or divergence of tetO from its tetM homologue in Enterococcus (Friis et
al. 2007). The pTet plasmid (~45 kbp, but megaplasmids (>80 kbp) also exists within
this plasmid group (Lee et al. 1994; Marasini et al. 2018)) was originally identified
and characterised in C. jejuni strain 81-176 (Bacon et al. 2000; Batchelor et al. 2004).
Conjugative transfer of plasmids harbouring tetO has been demonstrated in vitro (Pratt
and Korolik 2005) and in vivo in chickens (Avrain, Vernozy-Rozand and Kempf
2004). Although, nonmobilisable tetO-containing plasmids have also been reported,
and barriers to conjugal transfer include plasmid host range, strain specificity and
restriction modification systems (Pratt and Korolik 2005). The mosaic pTet plasmid
harbours homologues of genes found in a variety of bacterial genera (Batchelor et al.
2004).
The analogous pCC31 plasmid was isolated from C. coli (Batchelor et al. 2004) and
is similar to the pTet plasmid, in terms of sequence content and gene organisation
(Batchelor et al. 2004). The high degree of relatedness, despite temporal and
geographic separation of the pTet/pCC31 plasmids suggests a conserved acquisition
and maintenance of genes within Campylobacter spp. (Batchelor et al. 2004; Friis et
al. 2007).
TIVSS homologues present in pTet/pCC31 may facilitate conjugal transfer of tetO
(Batchelor et al. 2004; Marasini et al. 2018). Mobile genetic elements often facilitate
the transfer of multiple AMR genes (Roberts 2003). The tetO gene has been
significantly

associated

with

aminoglycoside

and

streptomycin

resistance

determinants in Campylobacter (Nirdnoy, Mason and Guerry 2005; Abril, Brodard
and Perreten 2010; Marasini et al. 2018), accompanied in some cases by TIVSS genes
(Abril, Brodard and Perreten 2010; Escher et al. 2016; Marasini et al. 2018)/
Acquisition of tetracycline and streptomycin co-resistance is episodic through the
selection of mutations in ribosomal-related genes, which may be targets of both
antimicrobials (Blanco, Corona and Martinez 2019). In other bacterial genera, the tetO
gene has been linked with erythromycin resistance (Streptococcus pyogenes)
(Giovanetti et al. 2003). A linkage between tetM and ermB has also been established
in a variety Gram positive bacterial genera (Giovanetti et al. 2003).
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1.5.4.2.3 Mosaic tet resistance genes
Mosaic tet genes are widespread among Gram positive and Gram negative genera in
human and animal isolates (Patterson et al. 2007) and tet O/32/O has been detected
among thermophilic Campylobacter spp. (Warburton, Amodeo and Roberts 2016;
Lynch et al. 2020a).. Mosaic tetracycline resistance genes have been described,
derived from the interclass (double-crossover) recombination of two or more RPPencoding gene (predominantly tetO, W, 32 (Melville et al. 2001; Stanton, McDowall
and Rasmussen 2004; Patterson et al. 2007; Warburton, Amodeo and Roberts 2016)
and tetM, S (Novais et al. 2012)) to form a functional chimera (Warburton, Amodeo
and Roberts 2016). Stanton and Humphrey (2003) identified the first mosaic
tetracycline resistance RPP gene in Megasphera elsdenii, composed of a central tetW
region flanked by two tetO regions (Stanton and Humphrey 2003). However, the
progenitors of these mosaic genes are based only on the order in which they were
discovered, and the current classification system does not adequately reflect the
variable nature of tet RPPs (Novais et al. 2012; Warburton, Amodeo and Roberts
2016).
1.5.4.2.4 Tetracycline efflux genes
The tet efflux genes act to reduce the intracellular concentration of tetracycline and
protect the ribosome (Roberts 2003). In 2005, 23 tet efflux genes were identified
(Roberts 2005). While 21 tet efflux genes are associated with Gram negative bacteria,
tetB has the widest Gram negative host range, while tetK and tetL are found primarily
in Gram positive isolates (Roberts 2003).
1.5.4.3 Glycylcycline resistance mechanisms
Although glycylcyclines are not affected by classical tetracycline resistance
determinants, resistance to this class in Gram negative bacteria often results from the
overexpression of RND efflux pumps (Bender et al. 2018). Mutations in the SmeDEF
negative regulator smeT was found to confer tigecycline resistance Stenotrophomonas
maltophilia as well as cross resistance to other potential substrates; quinolones,
erythromycin and tetracycline (Blanco, Corona and Martinez 2019). Reduced
susceptibility to glycylcyclines was demonstrated to depend on tetracycline/substrate
recognition regions (transmembrane-spanning domain and the central interdomain
loop) of the tetA tetracycline efflux pump (Guay, Tuckman and Rothstein 1994;
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Tuckman, Petersen and Projan 2000). Typically, tetracycline efflux pumps share 12
transmembrane α-helices connected by cytoplasmic and periplasmic hydrophilic loop
regions, where the non-conserved cytoplasmic loop connecting α-helix 6 and 7 is
about twice the size of the other interdomain loops, and mutations here can alter the
configuration of the gated channel (Tuckman, Petersen and Projan 2000; Chopra and
Roberts 2001). Two veterinary Salmonella isolates with reduced susceptibility to early
glycylcyclines analogues were described and presented with identical mutations in the
largest interdomain loop of tetA (Tuckman, Petersen and Projan 2000). Interestingly,
the tetA variant genes described by Tuckman et al. (2000) were located
chromosomally in one strain and were plasmid-mediated in the other, which points to
a transposon-associated origin (Tuckman, Petersen and Projan 2000). Other authors
have described various spontaneous mutations upon mutational resistance to in Gram
negative Stenotrophomonas maltophilia upon exposure to tigecycline, although such
mutations could induce a fitness cost in the absence of antibiotic selective pressure
(Blanco, Corona and Martinez 2019).
Changes in ribosomal genesis has also been identified as a strategy for tigecycline
resistance (Beabout et al. 2015; Bender et al. 2018; Blanco, Corona and Martinez
2019). Mutations in the rpsJ gene that encodes the ribosomal S10 protein has been
identified as a key player mediating tigecycline resistance (Beabout et al. 2015). The
S10 protein and transcription factor is a component of the 30S ribosomal subunit.
Associated resistance-conferring mutations are localised to the tip of an extended loop
of the S10 protein which is in close proximity to the 16S rRNA tigecycline binding
site. Although S10 does not directly contact tigecycline, it does contact the 16S rRNA.
Altering the S10 loop likely affects the conformational dynamics of the 16S rRNA and
subsequently interferes with tigecycline ribosomal binding affinity. Mutations in this
protein were not associated with a concomitant fitness burden in E. faecalis S10
mutants, which suggest that this resistance determinant could be stable and persistent
within a bacterial population once established (Beabout et al. 2015). Nominal
tigecycline resistance mechanisms resistance in other bacterial genera include
mutations in LPS biosynthesis proteins (integral for membrane homeostasis) and
polyamine synthetic enzymes (involved in cell growth and survival via interaction
with nucleic acids and proteins and modulation of gene expression) (Blanco, Corona
and Martinez 2019).
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Campylobacter spp. are largely susceptible to tigecycline (a glycylcyclines); however,
resistance was reported in C. jejuni (Noreen et al. 2019). Recently, a novel tetL variant
was reported in tigecycline-resistant Campylobacter spp. isolated from poultry in
China (Yao et al. 2021).
1.5.4.4 Campylobacter macrolide resistance mechanisms
Macrolide resistance is commonly conferred by point mutations in the 23S rRNA,
mutations in ribosomal proteins L4 and L22 or the presence of the emerging ermB
gene. Resistance to macrolides is generally higher among C. coli compared with C.
jejuni, even though there are several mechanisms by which Campylobacter can
acquire resistance to these antimicrobial agents and despite the common use of
macrolides among poultry (Persoons et al. 2012; Bolinger and Kathariou 2017;
European Food Safety Authority and European Centre for Disease Prevention and
Control 2021). The lower occurrence and slower development of erythromycinresistant C. jejuni strains may be associated with a fitness burden carried by harbouring
macrolide resistance mechanisms, particularly chromosomally mediated 23s rRNA
mutations (Gibreel et al. 2005; Han et al. 2009; Hao et al. 2009; Ohno et al. 2016).
1.5.4.4.1 23S rRNA mutations conferring macrolide resistance
Point mutations at positions 2074 and 2075 (equivalent to 2058 and 2059 in E. coli,
respectively) in the 23S rRNA gene in combination with an active CmeABC efflux
pump remain the most prevalent genetic conferring macrolide resistance in
Campylobacter spp. (Luangtongkum et al. 2009; Bolinger and Kathariou 2017). The
occurrence of mutations in two out of there copies of Campylobacter spp. 23s rRNA
is sufficient to confer resistance (Gibreel et al. 2005; Ohno et al. 2016). Mutations
including A2074G (Vacher et al. 2003), A2075G (Gibreel et al. 2005), A2075C
(Vacher et al. 2003) and the rarely encountered A2074T (Ohno et al. 2016; Bolinger
and Kathariou 2017) have been reported, while A2058G remains the most common
mutation conferring resistance (Luangtongkum et al. 2009; Bolinger and Kathariou
2017).
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1.5.4.4.2 Mutations in ribosomal proteins associated with reduced susceptibility to
macrolides
Mutations in the rplD and rplV genes, encoding ribosomal proteins L4 and L22,
respectively result in reduced macrolide binding and are enhanced by mutations in the
CmeABC multidrug efflux pump (Cagliero et al. 2006). Mutations L4 and L22 are
associated with lower MICs but some mutations can be found in erythromycinsusceptible Campylobacter spp. isolates. (Bolton et al. 2013).
1.5.4.4.3 Ribosomal methylation encoded by ermB
ErmB dimethylates an adenine (equivalent of A2058 in E. coli) of bacterial 23S rRNA,
reducing the binding affinity of macrolides (Leclercq 2002). The first report of a
ribosomal methylase encoded by ermB in Campylobacter spp. emerged in 2014,
detected in a high-level erythromycin-resistant C. coli strain (ZTC113) of swine origin
(Campylobacter isolates were collected between November 2008 to June 2009) (Qin
et al. 2011, 2014). The ermB gene was found located on a chromosomal multidrugresistant genomic island (MDGRI) (Qin et al. 2014), likely originating from a Gram
positive species (Qin et al. 2014). Resistance mediated by ermB in Campylobacter
spp. was largely confined to China, which may reflect the extensive use of
antimicrobials in food-producing animals in China (Bolinger and Kathariou 2017).
Recently, reports have emerged from Europe documenting erythromycin-resistant C.
coli strains harbouring ermB: one broiler isolate in Spain (Florez-Cuadrado et al.
2016), one broiler isolate in Belgium (Elhadidy et al. 2019), two turkey isolates in
Spain (Florez-Cuadrado et al. 2017) and one clinical isolate in France (Jehanne et al.
2021).
A novel methyltransferase (ermN) conferring resistance to erythromycin was reported
inFrance (Jehanne et al. 2021), also unknowingly circulating in three French clinical
strains isolated in 2016 (Jehanne et al. 2021).
1.5.4.5 Campylobacter aminoglycoside resistance mechanisms
Historically, resistance to aminoglycosides is low among Campylobacter spp. but
resistance is emerging in food-producing animals in China and Asia (European Food
Safety Authority and European Centre for Disease Prevention and Control 2018).
Enzyme modification (Table 1.7) remains the most important aminoglycoside
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resistance mechanism and these genes are widely disseminated among Gram positive
and negative bacterial genera (Vanhoof, Hannecart-Pokorni and Content 1998).
Aminoglycoside acetyltransferases, nucleotidyltransferases (or adenylyltransferases)
and phosphotransferases are denoted by AAC/aac, ANT/ant (or AAD/aad) and
APH/aph, respectively (Table 1.7) (Shaw et al. 1993; Vanhoof, Hannecart-Pokorni
and Content 1998).
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Table 1.7. Aminoglycoside modifying enzyme types and aminoglycoside modification specificities
(Shaw et al. 1993).
Enzyme
modification

Enzyme
(protein designation)

Gene

Acetylation

Acetyltransferase (AAC)

aac

Adenylylation

Nucleotidyltransferase/
adenylyltransferase
(ANT/AAD)

ant/aad

Phosphorylation

Phosphotransferase (APH)

aph

Amino group
modification site
136’2’2”3”4’692”3’3”46-

Reporting of these heterogenous genes is confounded by two separate nomenclature
systems (Vanhoof, Hannecart-Pokorni and Content 1998). The system proposed by
Shaw et al. (1994) is as follows: the type of modification; the modification site; a
roman numeral to denote unique resistance profiles, and a letter to represent unique
protein sequences. For example, aac(6’)-In is the fourteenth gene (or unique protein
designation) encoding a 6’-N-acetyltransferase type I enzyme. The system proposed
by Novick et al. (1987) describes the type of modification; a letter to indicate the
modification site (AAC/aac modification sites A – 6’; B – 2’; and C – 3) and a Roman
numeral to denote a subdivision. For example, a 6’-N-acetyltransferase has been
reported as aacA or as aac(6’) according to the disparate nomenclature systems
(Novick et al. 1976; Shaw et al. 1993; Vanhoof, Hannecart-Pokorni and Content
1998). Nonetheless, variant aminoglycoside modifying enzymes are continually
emerging among Campylobacter spp. (Toth et al. 2013; Zhao et al. 2015; Fabre et al.
2018).
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Table 1.8. Representative aminoglycoside resistance determinants identified in Campylobacter spp.
Aminoglycoside
resistance
determinant
Aminoglycoside 3'phosphotransferase,
APH(3’)-I
Aminoglycoside 3’phosphotransferase
type III,
APH(3’)-III
Aminoglycoside 3’phosphotransferase
type VII, APH(3’)VII
(AphA-7)
Aminoglycoside 2’’phosphotransferase
type I,
APH(2’’)-If
Aminoglycoside 6nucleotidyltransferase
(adenylyltransferase)
type Ia,
ANT(6)-Ia
Aminoglycoside 6andenylyltransferase
type Ib,
ANT(6)-Ib
ANT(6)-Ie

Gene

Remark

aph(3’)-I

Alias: kanamycin resistance protein type I. Identified chromosomally adjacent to
IS15 in a ‘Campylobacter-like organism’, (widespread in Gram negatives) with
similar sequence identity to that carried by Tn903 in E. coli (Ouellette et al. 1987)
Identified on plasmids in clinical Campylobacter isolates (Gibreel, Sköld and Taylor
2004; Friis et al. 2007) and food/animal isolates (Gibreel, Sköld and Taylor 2004; Qin
et al. 2012).

AacA/AphD
Streptothricin
acetyltransferase.,
Sat
Streptothricin
acetyltransferase,
Sat4

aacA/aphD
sat

aph(3’)-III
(aphA-3)

aphA-7

Confers kanamycin resistance. Located on small plasmids (9.2 and 11.5 kbp in C.
jejuni isolated from retail meats (Tenover et al. 1992). Identified in C. coli isolated
from chickens (Qin et al. 2012).

aph(2’’)-If

Chromosomal or plasmid-borne and known to confer resistance to gentamicin (Qin et
al. 2012; Yao et al. 2017).

ant(6)-Ia

Confers streptomycin resistance. Associated with the aadE-sat4-aphA-3 gene cluster
(Qin et al. 2012). Identified in a transferable pathogenicity island in C. fetus subsp.
fetus (Abril, Brodard and Perreten 2010).

ant(6)-Ib

Confers streptomycin resistance (Hormeño et al. 2018).

ant(6)-Ie

Likely inherent to Campylobacter spp. and shares low homology with other ant(6)
genes (Olkkola et al. 2016; Hormeño et al. 2018).
Bifunctional enzyme conferring gentamicin resistance (Qin et al. 2012).
Identified in Campylobacter plasmids isolated from clinical, food (Gibreel, Sköld and
Taylor 2004) and swine isolates (Jacob et al. 1994).

sat4

Identified originally in C. coli from swine slurry (Jacob et al. 1994). Coexistence with
other aminoglycoside modifying enzymes chromosomally (Qin et al. 2012) or on
plasmids (Gibreel et al. 2005; Chen et al. 2013) has been reported in Campylobacter.

The aphA-3 gene is typically plasmid-borne (Gibreel, Sköld and Taylor 2004; Friis et
al. 2007) and Friis et al. (2007) identified the aphA-3 in C. jejuni as part of a
transposable element. Similarly, Gibreel, Sköld and Taylor (2004) identified insertion
sequence IS607 upstream of the aphA-3 gene on a conjugative plasmid (pCJG9) in C.
jejuni (Gibreel, Sköld and Taylor 2004). The aphA-3 gene has also detected as part of
a resistance cluster with sat and aadE in other conjugative plasmids (designated
pCJE8480) (Gibreel, Sköld and Taylor 2004; Qin et al. 2012) and an extended and
transferrable (via natural transformation) chromosomal genomic island (aphA-3-sat4aadE cluster, aacA/aphD, aac and aadE) was identified in C. coli isolates recovered
from broilers in China (Qin et al. 2012). An arsenal of aminoglycoside resistance
genes (kanamycin kinase, uridine phosphorylase, spectinomycin adenyl transferase,
hygromycin B-phosphorylase, pyrrolidone–carboxylase peptidase, aminoglycoside
adenylyltransferase and streptothricin acetyl transferase) were identified in C. coli
plasmid pCCDM183 (Marasini et al. 2018). Mutations in the 30S ribosomal protein
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S12 (rpsL gene) have also been identified as aminoglycoside resistance determinants
in C. coli (Olkkola et al. 2010).
1.5.4.6 CmeABC multidrug efflux pump
In Campylobacter spp. the tripartite multidrug efflux pump CmeABC is the
predominant multidrug efflux system, capable of extruding structurally diverse
antimicrobials (Yao et al. 2016). CmeABC efflux pump is essential for bile tolerance,
necessary for colonisation of the intestinal tract in chickens (Lin et al. 2003).
The pump is composed of an outer membrane channel protein (CmeC), an inner
membrane efflux transporter (CmeB) and a periplasmic fusion protein (CmeA) (Payot
et al. 2006; Gibreel, Wetsch and Taylor 2007). CmeB is a member of the resistancenodulation-division (RND) efflux transporter superfamily (Payot et al. 2006; Yao et
al. 2016). The cmeABC operon is transcriptionally repressed by the upstream cmeR
gene encoding a repressor CmeR, which binds to an inverted repeat in the cmeR-cmeA
intergenic region (Cagliero et al. 2007; Duarte et al. 2014). CmeR is a member of the
TetR family of regulators (TFRs), associated with antibiotic resistance and regulation
of genes encoding small-molecular exporters (Cuthbertson and Nodwell 2013)
Consequently, polymorphisms in the repressing site induce efflux pump
overexpression and enhanced resistance to antimicrobials and most notably,
macrolides (Cagliero et al. 2005; Bolinger and Kathariou 2017), fluroquinolones (Luo
et al. 2003; Piddock et al. 2003) and tetracyclines (Gibreel, Wetsch and Taylor 2007).

1.6

Campylobacter fetus

Although C. jejuni and C. coli are the subject of intense epidemiological, genomic and
transcriptomic analysis, the less well recognised C. fetus species is the archetypal
Campylobacter species and is a well-established economically important veterinary
pathogen. C. fetus has a broad host range among animals, humans (Wagenaar et al.
2014; Sahin et al. 2017) and reptiles (Fitzgerald et al. 2014). and can cause intestinal
and systemic disease in humans (Fitzgerald et al. 2014; Wagenaar et al. 2014).
1.6.1

Campylobacter fetus zoonosis

C. fetus (primarily Cff) has been frequently associated with zoonotic transmission
capable of causing intestinal illness and severe systemic infections in
immunocompromised and elderly humans (Morrison et al. 1990; Bullman et al. 2011;
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Bessède et al. 2014; Cypierre et al. 2014; Wagenaar et al. 2014; Escher et al. 2016;
Reid et al. 2016). Infection of immunocompetent patients has also been documented
(Nagy and Hla 2013; Mikals, Masel and Gleeson 2014; Chávez et al. 2017). This
species is the most commonly detected Campylobacter-causing bacteraemia, with a
high degree of mortality (Wagenaar et al. 2014). Cff has been well documented to
cause a spectrum of systemic illnesses in immunocompromised humans, including but
not limited to; septic abortions (Hood and Todd 1960), spondylodiscitis (Cunha et al.
2021), outbreaks of nosocomial neonatal meningitis (Morooka et al. 1988), peritonitis
(Wens et al. 1985), soft tissue infections (La Scola, Chambourlier and Bouillot 1998),
endocarditis (Morrison et al. 1990; Farrugia, Eykyn and Smyth 1994; Durovic et al.
2021), vascular pathologies (vasculitis, pericarditis, thrombophlebitis, mycotic
aneurysms, aortitis among others) (Morrison et al. 1990; Wagenaar et al. 2014; Nulens
et al. 2018; Eke, Doub and Chua 2021).
1.6.2

Campylobacter fetus subspecies

The C. fetus species currently comprises three subspecies, Cff, C. fetus subsp.
venerealis (Cfv) and C. fetus subsp. testudinum (Cft), each with distinct niche
preferences. Cff has a broad host range among farm animals and humans, inducing
abortion in sheep and cows. Cfv is predominantly associated with infectious infertility
in cattle, typically more host restricted than Cff (Vandamme and Ley 1991; Sahin et
al. 2017). Mammalian-associated Cff and Cfv are genetically distinct from the
reptilian-associated Cft (Tu, Dewhirst and Blaser 2001; Iraola et al. 2017).
1.6.2.1 Inconsistencies in Campylobacter fetus subspecies classification
The high degree of genetic relatedness between mammalian C. fetus isolates (Cff an
Cfv) challenges accurate subspecies identification (van der Graaf-van Bloois et al.
2014; Escher et al. 2016). Historically, Cff and Cfv are phenotypically differentiated
based on biochemical features and epidemiological data. Tolerance to 1% glycine
tolerance remains the gold standard for C. fetus subspecies differentiation, for which
Cff is glycine-tolerant (Schulze et al. 2006). However, glycine-tolerant Cfv strains
have been frequently reported (Hum et al. 1997; Vargas et al. 2003). Moreover, there
is no evidence that phenotypic markers (glycine tolerance, for example) are linked to
virulence of C. fetus subspecies.
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Cff and Cfv form a single species according to average nucleotide analysis and DNADNA hybridisation, and share >99.2% ANI (van der Graaf-van Bloois et al. 2014;
Iraola et al. 2017). Recent phylogenomic studies of the C. fetus species show that
mammalian C. fetus strains form two major clades, with significant host association
(Iraola et al. 2017). One lineage is almost exclusively associated with bovine host
(bovine lineage) and the other lineage are associated with human hosts among others
human lineage).
1.6.2.2. Campylobacter fetus subspecies evolution
C. fetus likely originated in man circa 10,500 years ago and the modern bovine lineage
was traced back to circa 2,500 years ago, coinciding with the domestication of cattle
and reverse transmission from bovines to humans was also proposed (Iraola et al.
2017).
The accessory genome content of bovine-associated C. fetus strains is generally larger
than that of human lineages (Iraola et al. 2017). The former was more frequently
associated horizontally acquired gene content (Kienesberger et al. 2014) via Cfvassociated chromosomal or plasmid-borne TIVSS genes (Gorkiewicz et al. 2010; van
der Graaf-van Bloois et al. 2014, 2016b; Escher et al. 2016; Iraola et al. 2017). TIVSSs
are not genotype specific, however. Moreover, the Cfv or bovine lineages possess ICE
elements – plasmid-like, self-transmissible mobile genetic elements, dependent on
phages or transposons for chromosomal insertion or excision using their own transfer
genes (tra genes, associated with conjugative transfer) (Kienesberger et al. 2014).
Conversely, within the smaller accessory genomes of human lineages or Cff restriction
modification systems, cas genes and CRISPR spacer loci were more abundant
(Kienesberger et al. 2014; Iraola et al. 2017). The stabilisation of horizontally acquired
elements in bovine lineages appears to have contributed to host adaptation, supporting
the theory that C. fetus strains “host-jumped” from humans to cattle (Iraola et al.
2017).
1.6.3

Campylobacter fetus as an intestinal pathobiont

Recently, C. fetus has emerged as an underappreciated human pathobiont (Iraola et al.
2017; Costa et al. 2019). Iraola et al. (2017) detected C. fetus in approximately 8% of
healthy faecal samples, while E. coli and C. jejuni were detectable in 7% and less than
0.5%, respectively (Iraola et al. 2017). C. fetus genotypes detected in the
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gastrointestinal microbiota of healthy individuals were predominantly represented by
strains from human lineages (77.9%), while 22.1% of strains belonged to the modern
bovine lineage. C. fetus appears to be a successful asymptomatic human coloniser,
irrespective of age, gender, ethnicity or geographical origin, likely capable of humanto-human transmission. (Iraola et al. 2017).

1.7

Conclusions

The burden of increasing incidence rates of campylobacteriosis remains an unresolved
public health challenge. Broilers are recognised as the predominant source of human
campylobacteriosis.

Ongoing

surveillance

of

epidemiological

trends

in

Campylobacter prevalence and distribution is essential to measure expected
compliance with EU PHC and the impact of biosecurity interventions, including
recently trialled “biosecurity cubes” (Greene et al. 2021). Alternative Campylobacter
sources, outside the poultry industry may need to be considered for the complete
elucidation of seasonal Campylobacter prevalence. The emerging pathogen C.
ureolyticus, for example, was detected in unpasteurised milk, and was not found to be
associated with a poultry source (Koziel et al. 2012) Increasing AMR is internationally
recognised as a major societal challenge and the intensive use of antimicrobials in
humans and animals selects for resistant strains. The maintenance of resistance genes
in bacterial populations is compounded by the emergence of novel, transferable AMR
determinants. The availability of genomic data provides new insights into
Campylobacter pathogenesis, evolution of the genus and origin of transferable factors,
particularly relevant to AMR. Significant gaps in the literature exist in relation to
Campylobacter survival, pathogenesis, evolution, intracellular behaviour and AMR
mechanisms, but advances in the availability of genomic sequence data continue to
bridge these gaps and may highlight areas for targeted therapeutics, biosecurity and
infection control measures. The genus is continually evolving, and novel species from
unexpected hosts are continually emerging. Despite the fastidious growth
requirements of Campylobacteraceae, their dominance in humans and animals is
intriguing.
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2.0 Chapter 2. Antimicrobial resistance of
Campylobacter isolates recovered from
broilers in the Republic of Ireland in 2017
and 2018: an update
A manuscript based on this chapter has been published in
British Poultry Science

Lynch, C.T., Lynch, H., Egan, J., Whyte, P., Bolton, D., Coffey, A., Lucey, B. Antimicrobial
resistance of Campylobacter isolates recovered from broilers in the Republic of Ireland in 2017 and
2018: An update. Br. Poult. Sci. 2020, 61:550–6, doi:10.1080/00071668.2020.1758300.

HL isolated and speciated Campylobacter spp. isolates.
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2.1

ABSTRACT

Campylobacteriosis is the leading cause of human bacterial gastroenteritis. Broilers
are considered the most significant source of human Campylobacter infection. In the
2008 European baseline survey Ireland had a high prevalence of campylobactercontaminated broiler carcasses (98.3%). Randomly selected Campylobacter isolates
(296 Campylobacter jejuni, 54 Campylobacter coli) recovered in 2017 and 2018, from
Irish broiler neck skin and caecal contents were tested for their resistance to
tetracycline,

erythromycin,

gentamicin,

ciprofloxacin,

nalidixic

acid

and

streptomycin. Overall, 45.1% of Campylobacter spp. isolates tested were resistant to
at least one antimicrobial. Tetracycline resistance (37.8%) was most prevalent in C.
jejuni, followed by ciprofloxacin/nalidixic acid resistance (28.7%). In C. coli,
resistance to ciprofloxacin/nalidixic acid (25.9%) was most prevalent followed by
resistance to tetracycline (13%). Gentamicin resistance was undetected and resistance
to streptomycin was low for C. jejuni (0.7%) and C. coli (3.7%). All C. jejuni isolates
examined were erythromycin-sensitive, while 9.3% of C. coli isolates were
erythromycin-resistant. Three multidrug-resistant C. coli isolates were recovered.
While antibiotic resistance rates are somewhat similar to figures reported nationally
over the past twenty years, the prevalence of tetracycline resistance in C. jejuni has
increased and the persistence of substantial ciprofloxacin resistance in the Irish broiler
reservoir is noteworthy, despite fluoroquinolones having been banned for growth
promotion in Europe since 2006.
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2.2

INTRODUCTION

Campylobacter is the most commonly reported foodborne bacterial pathogen causing
human gastroenteritis in the European Union (EU) and Ireland (European Food Safety
Authority 2011), of which Campylobacter jejuni and Campylobacter coli are the most
prevalent species within the genus reported in poultry (Moore et al. 2005; Sheppard
and Maiden 2015). Ireland had a high prevalence of campylobacter-contaminated
broiler carcasses (98.3%) and campylobacter-colonised broiler batches (83.1%) in the
2008 European Food Safety Authority (EFSA) baseline study (European Food Safety
Authority 2010a). Given that broilers are considered the most significant source of
human campylobacteriosis (European Food Safety Authority, European Centre for
Disease Prevention and Control and European Medicines Agency 2017), it is
important to monitor the Campylobacter antimicrobial resistance (AMR) rates among
broiler isolates. Monitoring and testing C. jejuni AMR in broiler caecal samples is
mandatory in the EU since 2014, as described by the European Commission (EC)
Decision 2013/652/EU, using recommended harmonised monitoring systems
(European Commission 2013; European Centre for Disease Prevention and Control.
2016). However, antimicrobial resistance data since the early 2000s regarding Irish
broiler Campylobacter isolates are limited (Lucey et al. 2002; Fallon et al. 2003;
Corcoran et al. 2006a; McGill et al. 2006).
Most cases of human campylobacteriosis are self-limiting. Nevertheless, severe,
prolonged enteric illness or immunocompromisation may require antibiotic therapy
(Aarestrup and Engberg 2001; Allos 2001). Reported high rates of fluoroquinolone
resistance in Campylobacter have made macrolides the first line antibiotic class for
the treatment of human campylobacteriosis (Aarestrup and Engberg 2001; Allos 2001;
Luangtongkum et al. 2009; Bolinger and Kathariou 2017; European Food Safety
Authority and European Centre for Disease Prevention and Control 2018).
Campylobacter bloodstream infections are routinely treated with intravenous
aminoglycosides (Aarestrup and Engberg 2001; Nielsen et al. 2010a).
The intensive use of antimicrobial agents for therapy and infection prophylaxis in
poultry and other food animals selects for resistant strains with the potential to
disseminate to humans (Aarestrup and Engberg 2001; Stapleton et al. 2010; Elhadidy
et al. 2018b; Department of Agriculture Food and the Marine and Department of
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Health 2019). Resistance may spread via horizontal gene transfer of mobile genetic
elements (Luangtongkum et al. 2009) or clonal dissemination of resistant strains
(Wimalarathna et al. 2013; Taylor et al. 2016). The use of antimicrobials as growth
promoters in food animal production has been banned in the EU since 2006, as
described by regulation 1831/2003 (European Parliament and Council of the European
Union 2003).
In the current study, Campylobacter isolates recovered from Irish broiler neck skin
and caecal contents were tested for their susceptibility to six clinically relevant
antimicrobials, namely tetracycline (TET), erythromycin (ERY), gentamicin (GEN),
ciprofloxacin (CIP), nalidixic acid (NAL) and streptomycin (STR), by minimum
inhibitory concentration (MIC) testing using broth microdilution according to
International Standards Organisation (ISO) 20776:2007 and EC Implementing
Decision 2013/652/EU (European Commission 2013; European Centre for Disease
Prevention and Control. 2016).
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2.3

METHODOLOGY

2.3.1

Bacterial isolates and growth conditions

A total of 350 Campylobacter isolates (296 C. jejuni and 54 C. coli) were randomly
selected for AMR testing. Campylobacter isolates were recovered from broiler neck
skin (n=266) and caecal contents (n=84), from intensively reared (n=267) and freerange broilers (n=83), collected between September 2017 and September 2018, from
the three major poultry processing plants in the Republic of Ireland. Isolates were
speciated using matrix-assisted laser desorption ionisation time-of-flight mass
spectrometry (MALDI-TOF MS) (Bruker, Billerica, MA, United States).
C. jejuni ATCC 33560 (DSM-4688) was used as a pan-susceptible control strain for
MIC broth microdilution testing in accordance with the European Commission
Decision 2013/652/EU. Bacterial isolates were maintained in defibrinated horse blood
(Oxoid, Basingstoke, England) with 30% glycerol (vol/vol) at –80°C. Isolates were
recovered from frozen stocks on blood free Campylobacter selectivity agar base
(Sigma-Aldrich, St Louis, MO, USA) and incubated for 24 hours at 42°C, under
microaerobic conditions.
2.3.2

Antimicrobial susceptibility testing

Susceptibility to TET, ERY, GEN, CIP, NAL and STR was assessed by MIC testing
using broth microdilution according to ISO 20776:2006 and EC Decision
2013/652/EU. (European Commission 2013; European Centre for Disease Prevention
and Control. 2016). Briefly, isolates were sub-cultured to Columbia blood agar (CBA)
(Fannin Ltd., Dublin, Ireland) and incubated for 20 ± 2 hours at 42°C under
microaerobic conditions. A 0.5 McFarland inoculum was prepared in 5 mL
demineralised water (Thermo Fisher Scientific, Waltham, MA, USA) and 100 µL was
transferred to 11 mL of Mueller Hinton broth with lysed horse blood (Thermo Fisher
Scientific). EUCAMP2 Sensititre plates (Thermo Fisher Scientific) were inoculated
with 100 µL of cell suspension per well and incubated for 20 ± 2 hours at 42°C, under
microaerobic conditions. Pre- and post-purity was assessed on CBA.
The MIC was reported as the lowest antimicrobial concentration completely inhibiting
visible bacterial growth. Antimicrobial resistance was determined by epidemiological
cut-off (ECOFF) values defined by the European Committee on Antimicrobial
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Susceptibility Testing (EUCAST) and recommended by EC Decision 2013/652/EU
(Table 2.1) (European Commission 2013).
Table 2.1. Antimicrobial resistance minimum inhibitory concentration epidemiological cut-off values
(R >), according to European Commission Decision 2013/652/EU.
Antimicrobial (abbreviation)
(range tested (µg/mL))
Tetracycline (TET)
(0.5-64)
Erythromycin (ERY)
(1-128)
Gentamicin (GEN)
(0.12-16)
Ciprofloxacin (CIP)
(0.12-16)
Nalidixic acid (NAL)
(1-64)
Streptomycin (STR)
(0.25-16)

Campylobacter jejuni
MIC (µg/mL) R >

Campylobacter coli
MIC (µg/mL) R >

1

2

4

8

2

2

0.5

0.5

16

16

4

4
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2.4

RESULTS

Overall, 158 of 350 (45.1%) Campylobacter spp. isolates tested were resistant to at
least one of the antimicrobials tested (Appendix A, Table A1) and resistance to TET
was most prevalent (34%), followed by CIP and NAL (28.3%). All CIP-resistant
isolates being co-resistant to NAL. GEN resistance was not detected and STR
resistance was low (0.7% of C. jejuni and 3.7% of C. coli isolates) (Table 2.2).
Resistance was higher in Campylobacter isolated from intensively reared broilers
(50.2%) compared to free-range broilers (28.9%).
Resistance to TET (37.8%) was most prevalent in C. jejuni, followed by resistance to
CIP/NAL (28.7%). Resistance to CIP/NAL (25.9%) was most prevalent in C. coli
followed by resistance to TET (13%). ERY resistance was detected in five (9.3%) C.
coli isolates only (Table 2.2).
Table 2.2. Antimicrobial resistance rates (number and percentage) of Campylobacter spp. isolates
recovered from Irish broilers in 2017 and 2018.
Antimicrobial
tested
TET
ERY
GEN
CIP
NAL
STR

Campylobacter spp.
(n=350)
119 (34%)
5 (1.4%)
0 (0%)
99 (28.3%)
99 (28.3%)
4 (1.1%)

Campylobacter jejuni
(n=296)
112 (37.8%)
0 (0%)
0 (0%)
85 (28.7%)
85 (28.7%)
2 (0.7%)

Campylobacter coli
(n=54)
7 (13%)
5 (9.3%)
0 (0%)
14 (25.9%)
14 (25.9%)
2 (3.7%)

Eight resistance types were observed. Pan-susceptibility was the most prevalent
Campylobacter spp. (54.9%) resistance type, followed by CIP-NAL-TET (19.3%) and
TET (17.9%) in C. jejuni and CIP/NAL (20.4%) and ERY-TET (7.4%) in C. coli
(Table 2.3). Three multidrug-resistant (MDR) C. coli isolates were recovered, while
MDR was not detected in any C. jejuni isolate tested (Table 2.3). Two of the MDR C.
coli were isolated from free-range farms.
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Table 2.3. Resistance types of Campylobacter spp. isolates recovered from Irish broilers in 2017 and
2018.
Resistance type
Pan-susceptible
CIP-NAL
CIP-NAL-TET
TET
STR-TET
CIP-NAL-STR-TET
CIP-ERY-NAL-TET
ERY-TET

Campylobacter spp.
192 (54.9%)
39 (11.1%)
57 (16.3%)
53 (15.1%)
2 (0.6%)
2 (0.6%)
1 (0.3%)
4 (1.1%)

Resistant isolates (%)
Campylobacter jejuni
156 (52.7%)
28 (9.5%)
57 (19.3%)
53 (17.9%)
2 (0.7%)
0 (0%)
0 (0%)
0 (0%)

Campylobacter coli
36 (66.7%)
11 (20.4%)
0 (0%)
0 (0%)
0 (0%)
2 (3.7%)
1 (1.9%)
4 (7.4%)
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DISCUSSION

This study reports the antimicrobial resistance prevalence of geographically and
temporally distinct, intensively reared and free-range broiler Campylobacter isolates
in Ireland. Resistance to therapeutically important antimicrobials in zoonotic bacteria
is a serious threat to public health and continues to compromise the efficacy of current
treatment options.
It was found that the proportion of TET-resistant thermophilic Campylobacter spp.
(Table 2.2) has risen (currently 34%) in comparison to reported resistance rates in
Ireland in the early 2000s, which ranged between 18.8-24.4% of broiler
Campylobacter spp. isolates (Lucey et al. 2000b, 2002; Fallon et al. 2003).
Furthermore, data submitted to the EU AMR Summary Report indicated that 25.3%
of Irish broiler Campylobacter isolates were TET-resistant in 2016 (European Food
Safety Authority and European Centre for Disease Prevention and Control 2018).
Although the TET resistance among the C. coli subset was 13%, resistance to TET
appears to have increased among C. jejuni isolated from broilers (37.8%) in Ireland
(Table 2.2). The use of tetracycline for growth promotion has been banned in Europe
since the early 1970s, in accordance with Directive 70/524/EEC (Council of the
European Union 1970). However, tetracyclines are extensively used in poultry
production and animal husbandry for the treatment of enteric, respiratory and dermal
infections (Casewell et al. 2003; Sarmah, Meyer and Boxall 2006; Carvalho and
Santos 2016; Granados-Chinchilla and Rodríguez 2017; Kuppusamy et al. 2018).
Tetracycline is the most commonly administered veterinary antibiotic in Ireland
(Health Products Regulatory Authority. 2014, 2016; Department of Agriculture Food
and the Marine and Department of Health 2019). Orally administered oxytetracycline
is excreted via the kidneys or biliary system, largely unchanged, in poultry and among
animals (Jjemba 2002; Kemper 2008; Chen et al. 2017; Kuppusamy et al. 2018).
Consequently, tetracyclines can frequently be detected in soil and water, compounded
by associated environmental persistence and accumulation of bioactive tetracycline
residues (Jjemba 2002; Fairchild et al. 2005; Kemper 2008; Granados-Chinchilla and
Rodríguez 2017; Grenni, Ancona and Barra Caracciolo 2018; Kuppusamy et al. 2018).
Tetracyclines are polar and are highly adsorbed in soil organic matter, which may
serve as an antibiotic pollutant reservoir (Kemper 2008; Kuppusamy et al. 2018).
Although, the true extent of occurrence and persistence of antibiotics in the
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environment is unknown (Kemper 2008; Carvalho and Santos 2016; Department of
Agriculture Food and the Marine and Department of Health 2019). Tetracycline
resistance is associated with the acquisition of conjugative plasmids harbouring the
ribosomal protection protein TetO (Gibreel et al. 2004; Kemper 2008; Crespo et al.
2016). The maintenance of tetracycline resistance may be mediated by some other
plasmid-encoded factor, conferring a survivalist advantage.
Despite a distinct rise in CIP resistance among broiler Campylobacter strains (3.1% to
28.9%) in Ireland between 1998 and 2000 (Lucey et al. 2000b, 2002), resistance has
since remained stable and persistent. The CIP resistance rate (28.3%) (Table 2.2)
reported here parallels data from Irish broiler Campylobacter isolates in the early
2000s, which ranged from 14–28.9% (Lucey et al. 2002; Fallon et al. 2003) and to a
reported resistance rate of 24.7% in Ireland, 2016 (European Food Safety Authority
and European Centre for Disease Prevention and Control 2018). Statistically
significant associations have been reported between fluoroquinolone resistant
Campylobacter strains and the use of fluoroquinolones in food-producing animals
(Endtz et al. 1991; Luo et al. 2003; Moore and Matsuda 2004; Taylor et al. 2016;
European Food Safety Authority, European Centre for Disease Prevention and Control
and European Medicines Agency 2017). The synthetic fluoroquinolone enrofloxacin,
used to treat respiratory and alimentary tract infections in poultry, has been
demonstrated to promote fluoroquinolone-resistant Campylobacter spp. (Endtz et al.
1991). Ciprofloxacin is the comparable human drug in this class and a major
metabolite of enrofloxacin. Despite the fact that enrofloxacin has been banned in the
US since 2005 (US Food and Drug Administration 2005), enrofloxacin containing
products are still permitted and used in the poultry industry to treat infection in Ireland
and Europe (European Medicines Agency 1998, 2014; European Commission 2014;
Giacomelli et al. 2014). The sustained level of CIP resistance in Ireland is marked
considering that fluoroquinolone usage has accounted for less than 1% of all veterinary
antimicrobials in Ireland since 2009 (Beechinor 2009; Health Products Regulatory
Authority. 2017; Department of Agriculture Food and the Marine and Department of
Health 2019). Resistance to (fluoro)quinolones is largely mediated by chromosomal
mutations in DNA gyrase subunit A (gyrA), typically conferred by the spontaneous
Thr-86-Ile substitution and clonal expansion of resistant lineages (Zirnstein et al.
1999; Lucey, O’Halloran and Fanning 2004; Bolton et al. 2013; Sproston,
101

Wimalarathna and Sheppard 2018). Fluoroquinolone-resistant Campylobacter spp. are
ecologically competitive and persistent even in the absence of antimicrobial selective
pressure (Zhang, Lin and Pereira 2003; Luo et al. 2005). Recently, it has been reported
that relaxation of DNA supercoiling associated with fluoroquinolone resistance
increases aerobic biofilm formation (Whelan et al. 2019), compounded by increased
epithelial cell invasion (Scanlan et al. 2017; Whelan et al. 2019), contributing to the
resilience of such strains. The persistence of fluoroquinolone-resistant Campylobacter
spp. circulating in Irish broilers supports the view that once acquired, resistance can
be maintained despite the limited use of the antimicrobial (Sproston, Wimalarathna
and Sheppard 2018).
Companies marketing veterinary antimicrobials are required to submit annual returns
(on the quantities of antimicrobial preparations sold) to their national regulatory
authority, which is consolidated by European Surveillance of Veterinary
Antimicrobial Consumption (ESVAC). Current veterinary antimicrobial usage data in
Ireland is based on sales and does not include a breakdown of usage by species or the
appropriateness of use. The information provided by companies is self-declared and
is not subject to independent verification or audit (Department of Agriculture Food
and the Marine and Department of Health 2019). ESVAC was mandated by the EC to
develop an approach for the collection and estimation of antimicrobial usage data for
major food-producing animal species in Europe (European Medicines Agency 2016a,
2016b).
Resistance rates of 46.9% and 56.2% to CIP and NAL respectively, and 34.4% to TET
have been reported previously among 32 Irish broiler isolates recovered in 2002-4
(Corcoran et al. 2006a). Moreover, 40.4% and 39.5% resistance to CIP and NAL
respectively, and 49.1% to tetracycline was reported from 36 Irish broiler isolates
submitted to the EFSA/ECDC AMR Summary Report in 2011 (European Food Safety
Authority and European Centre for Disease Prevention and Control. 2013). Although
the sample size is quite small (n=32 and n=36) (Corcoran et al. 2006a; European Food
Safety Authority and European Centre for Disease Prevention and Control. 2013) by
comparison with the 350 isolates analysed in this paper.
The CIP and TET resistance (Table 2.2) reported here also correlated to the results of
a UK-wide survey in retail poultry in 2001 and 2004–5, where the overall resistance
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rates of C. jejuni and C. coli isolates combined were 22.3% and 38% to CIP and TET,
respectively (Wimalarathna et al. 2013). In 2016 and 2017 in the UK, the proportion
chicken meat C. jejuni and C. coli isolates resistant to CIP was 41% and 52%,
respectively and 54% and 62% of C. jejuni and C. coli isolates were resistant to TET,
respectively (Public Health England 2018).
Overall antimicrobial resistance rates observed in this study were lower than the
European averages reported in the 2018 EU AMR Summary Report (data collected in
2016), where 66.9% of C. jejuni and 87.7% of C. coli isolates recovered from broilers
were CIP-resistant and 50.7% of C. jejuni and 61.7% of C. coli isolates were TETresistant (European Food Safety Authority and European Centre for Disease
Prevention and Control 2018). Ireland was ranked 17th in Europe in terms of
antimicrobial usage in 2016 (Department of Agriculture Food and the Marine and
Department of Health 2019). In some studies in Portugal and Spain, 90-100% of tested
Campylobacter strains isolated from broilers were TET-resistant (Torralbo et al. 2015;
García-Sánchez et al. 2018). Near universal resistance to (fluoro)quinolones has also
been reported in Italy, Poland and Spain (Giacomelli et al. 2014; García-Sánchez et
al. 2018; Woźniak-Biel et al. 2018).
Resistance to GEN was undetected and STR resistance remained low (Table 2.2),
comparable to the reported resistance rates in Ireland in 2016 (European Food Safety
Authority and European Centre for Disease Prevention and Control 2018). Although
GEN- and STR-resistant Campylobacter spp. strains are infrequently isolated across
Europe, resistance is emerging in China due to the extensive use of aminoglycoside
antibiotics to prevent and control bacterial disease in food animal production (Yao et
al. 2017; Elhadidy et al. 2018b; European Food Safety Authority and European Centre
for Disease Prevention and Control 2018).
Five C. coli isolates were identified as being ERY-resistant (9.3% of the C. coli
isolates), while all C. jejuni were ERY-susceptible. It is noteworthy that in 2016, all
Irish C. jejuni and C. coli broiler isolates (n=174) were ERY-susceptible (European
Food Safety Authority and European Centre for Disease Prevention and Control
2018). Resistance to ERY is generally higher among C. coli isolates compared with
C. jejuni (Giacomelli et al. 2014; Bolinger and Kathariou 2017; Casagrande Proietti
et al. 2018), even though there are several mechanisms by which Campylobacter can
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acquire resistance to these antimicrobial agents and despite the common use of
macrolides among poultry (Persoons et al. 2012; Bolinger and Kathariou 2017). The
lower occurrence and slower development of ERY-resistant C. jejuni strains may be
associated with a fitness burden carried by harbouring macrolide resistance
mechanisms, particularly chromosomally mediated 23s rRNA mutations (Gibreel et
al. 2005; Han et al. 2009; Hao et al. 2009; Luangtongkum et al. 2009, 2012; Ohno et
al. 2016). In contrast, 10.2% of Irish broiler C. jejuni isolates were resistant to ERY
in a study by Fallon et al. (2003). Although the addition of macrolides to animal feed
as growth promoters has been banned in Europe since 1999 (Casewell et al. 2003), the
macrolide tylosin is still used as a therapeutic and prophylactic agent for broilers and
food animals (Gibreel and Taylor 2006; Lin et al. 2007; Persoons et al. 2012).
The most frequently observed Campylobacter spp. resistance type was pansusceptibility (54.9%) (Table 2.3), similar to the most recent data of Irish broiler
Campylobacter isolates in the EU AMR Summary Report (European Food Safety
Authority and European Centre for Disease Prevention and Control 2018). Complete
susceptibility is also frequently reported in C. jejuni strains isolated from broilers in
Norway, Finland (87.6% and 85.5% respectively) (European Food Safety Authority
and European Centre for Disease Prevention and Control 2018) and Iceland (93.1%)
(Thorsteinsdottir et al. 2008).
Multidrug resistance (MDR) is defined as the resistance to three antimicrobial
substances, from any antimicrobial class (European Food Safety Authority and
European Centre for Disease Prevention and Control 2018). Three C. coli MDR
isolates (5.6% of C. coli isolates and 0.9% of the total Campylobacter subset) were
detected (Table 2.3), from geographically distinct regions. One MDR C. coli isolate
was co-resistant to CIP/NAL, ERY and TET – the antibiotics used to treat severe
human enteric campylobacteriosis. Resistance is typically more common in C. coli
compared to C. jejuni (Aarestrup and Engberg 2001; García-Sánchez et al. 2018),
compounded by a higher prevalence of C. coli MDR phenotypes (Torralbo et al.
2015). In this study, MDR was not observed among the 296 C. jejuni isolates tested.
However, a higher proportion of TET- and CIP/NAL-resistant C. jejuni (37.8% and
28.7% respectively) were observed compared with C. coli (13% and 25.9%
respectively). ERY-resistance was detected in five C. coli isolates only and there was
a higher proportion of STR-resistant C. coli (Table 2.2). However, the C. coli subset
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was small which is reflective of the typical dominance of C. jejuni colonisation in
broilers (Moore et al. 2005; Jorgensen et al. 2011).
In conclusion, this study provides an update of AMR among thermophilic Irish broiler
Campylobacter isolates. While the resistance rates are broadly comparable to figures
reported nationally over the past 20 years, TET resistance in C. jejuni has increased
among Irish broiler isolates. Although resistance to aminoglycosides was low, CIP
resistance has remained persistent in the Republic of Ireland since the early 2000s,
highlighting poultry as a reservoir of fluoroquinolone resistant populations, despite
reduced veterinary usage of the antimicrobial. Continued monitoring of poultry and
clinical Campylobacter spp. AMR trends is important in the effort to preserve the
useful life of antimicrobials.
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3.1

ABSTRACT

Campylobacteriosis is the leading cause of human bacterial gastroenteritis, very often
associated with poultry consumption. Thermophilic Campylobacter (Campylobacter
jejuni and Campylobacter coli) isolates (n=158) recovered from broiler neck skin and
caecal contents in Ireland over a one-year period, resistant to at least one of four
clinically relevant antimicrobial classes, were screened for resistance determinants.
All ciprofloxacin-resistant isolates (n=99) harboured the C257T nucleotide mutation
(conferring the Thr-86-Ile substitution) in conjunction with other synonymous and
nonsynonymous mutations, which may have epidemiological value. The A2075G
nucleotide mutation and amino acid substitutions in L4 and L22 were detected in all
erythromycin-resistant isolates (n=5). The tetO gene was detected in 100% (n=119) of
tetracycline-resistant isolates and three of which were found to harbour the mosaic
tetracycline resistance gene tetO/32/O. Two streptomycin-resistant C. jejuni isolates
(isolated from the same flock) harboured ant(6)-Ib, located in a multidrug resistance
genomic island, containing aminoglycoside, streptothricin (satA) and tetracycline
resistance genes (truncated tetO and mosaic tetO/32/O). The ant(6)-Ie gene was
identified in two streptomycin-resistant C. coli isolates. This study highlights the
widespread acquisition of antimicrobial resistance determinants among chickenassociated Campylobacter isolates, through horizontal gene transfer or clonal
expansion of resistant lineages. The stability of such resistance determinants is
compounded by the fluidity of mobile genetic element.
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3.2

INTRODUCTION

Campylobacter is the most commonly reported foodborne bacterial pathogen causing
human gastroenteritis in the European Union (EU) and Ireland, most often associated
with the broiler reservoir (European Food Safety Authority 2011). Ireland was found
to have a 98% prevalence of campylobacter-contaminated broiler carcasses in 2008
(European Food Safety Authority 2010a). Frequent isolation of antimicrobial-resistant
Campylobacter spp. of food animal origin continues to limit the spectrum of clinically
useful antimicrobials and is internationally recognised as a major societal challenge.
Veterinary antimicrobials used therapeutically and prophylactically are often the same
as, or belong to the same class as those used clinically (World Health Organisation
2018).
Macrolides, fluoroquinolones and aminoglycosides are classified as critically
important antimicrobials, while tetracycline is considered a highly important
antimicrobial (World Health Organisation 2018). Resistance to (fluoro)quinolones and
tetracyclines is highly prevalent in clinical and broiler-associated Campylobacter spp.
isolates, while resistance to erythromycin is typically low to moderate across Europe
(Duarte et al. 2014; European Food Safety Authority and European Centre for Disease
Prevention and Control 2018; European Food Safety Authority and European Centre
for Disease Prevention and Control. 2019). Macrolides are the first line antibiotic for
the treatment of enteric gastroenteritis, while fluoroquinolones and tetracyclines
remain as alternatives (Aarestrup and Engberg 2001; Alfredson and Korolik 2007;
Bolinger and Kathariou 2017). Systemic infections are routinely treated with
aminoglycosides (Aarestrup and Engberg 2001; Nielsen et al. 2010a) and resistance
to aminoglycosides is low in clinical and broiler isolates across Europe (European
Food Safety Authority and European Centre for Disease Prevention and Control
2018). Cross-resistance between aminoglycoside antimicrobials is incomplete and
although streptomycin is not used clinically to treat campylobacteriosis, resistance can
be used as an indicator for acquired aminoglycoside resistance genes.
In Gram negative bacteria, DNA gyrase is the primary target of fluoroquinolones
(Payot et al. 2006). DNA gyrase is a heterotetrameric type IIA topoisomerase,
consisting of two polypeptide subunits (GyrA and GyrB, encoded by gyrA and gyrB,
respectively), catalysing ATP-dependent negative supercoiling of DNA to regulate
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replication, repair and gene expression (Gellert et al. 1976; Drlica and Zhao 1997;
Klostermeier 2018). Resistance to (fluoro)quinolones among Campylobacter spp. is
largely mediated by chromosomal mutations in the quinolone resistance-determining
region (QRDR) of gyrA, typically conferred by the C257T nucleotide mutation (Thr86-Ile) (Zirnstein et al. 1999). The QRDR is located near the Tyr-125 active site,
involved in DNA-protein bridge formation during DNA strand passage (Zirnstein et
al. 1999).
Macrolides act by binding to the 50S bacterial ribosomal subunit and inhibit
translational elongation, and interfere with protein synthesis and subsequent ribosomal
subunit assembly (Siibak et al. 2009; Wilson 2014). Polymorphisms in the 23S
ribosomal RNA (rRNA), mutations in 50S ribosomal proteins L4 and L22 (encoded
by rplD and rplV, respectively) or the presence of the emerging ermB gene contribute
to macrolide resistance (Cagliero et al. 2006; Bolinger and Kathariou 2017). Βetahairpin extensions from 50S ribosomal proteins L4 and L22 are involved in the
regulation of nascent peptide exit from the large ribosomal subunit (Gong and
Yanofsky 2002; Zengel et al. 2003). Mutations in L4 and L22, combined with the
overexpression of antimicrobial efflux genes have been reported to contribute to highlevel macrolide resistance (Hao et al. 2013). The ribosomal methylase encoded by
ermB was reported recently for the first time in thermophilic Campylobacter spp.,
located on a chromosomal multidrug resistance genomic island (MDRGI) (likely
originating from a Gram positive species) in a high-level erythromycin-resistant
Campylobacter coli isolate (ZTC113) of swine origin in China (Qin et al. 2014;
Bolinger and Kathariou 2017). ErmB dimethylates adenine at position 2074 of the 23S
rRNA gene, reducing the binding affinity of macrolides (Leclercq 2002).
The intrinsic, chromosomally encoded resistance-nodulation-division (RND)
CmeABC (Campylobacter multidrug efflux) efflux pump in Campylobacter spp.
contributes to baseline resistance against structurally diverse antimicrobials (Gibreel,
Wetsch and Taylor 2007; Guo et al. 2010; Duarte et al. 2014; Yao et al. 2016). The
cmeABC operon encodes a tripartite multidrug efflux pump that consists of an outer
membrane channel protein (cmeC), an inner membrane efflux transporter (cmeB) and
a periplasmic fusion protein (cmeA) (Pumbwe and Piddock 2002). Repressor (cmeR)
binding to an inverted repeat (IR) (TGTAATAAATATTACA) in the intergenic region
between cmeR and cmeA transcriptionally represses the cmeABC operon (Cagliero et
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al. 2007; Pérez-Boto et al. 2010). Consequently, polymorphisms in the repressing site
induce efflux pump overexpression and enhanced resistance to antimicrobials, most
notably, erythromycin (Cagliero et al. 2005; Bolinger and Kathariou 2017).
Tetracycline resistance in Campylobacter spp. is largely conferred by a ribosomal
protection protein (RPP), TetO, capable of displacing tetracycline from its primary
binding site on the 30S ribosomal subunit (Connell et al. 2003; Wilson 2014).
Bacterial resistance to tetracycline is also associated with ATP-dependent efflux or
enzymatic inactivation of tetracycline (Roberts 2003, 2005; Warburton, Amodeo and
Roberts 2016). Campylobacter tetO can be located chromosomally but is often
plasmid-mediated (Connell et al. 2003; Gibreel et al. 2004; Pratt and Korolik 2005;
Roberts 2005; Friis et al. 2007). Tetracycline RPPs are widely distributed among
bacterial genera and it has been reported that the tetO gene exists in at least eleven
bacterial genera, including four Gram negative and seven Gram positive genera
(Roberts 2005). The conserved acquisition of tetO between members of different
bacterial genera indicates that conjugative plasmids, transposons, or recombination
events contribute to the dissemination and maintenance of the tetO gene (Friis et al.
2007).
Although tetO acquisition is the most prevalent genetic event conferring tetracycline
resistance among Campylobacter spp., mosaic tet genes (specifically tetO/32/O) have
also been reported within the genus (Warburton, Amodeo and Roberts 2016). Mosaic
tetracycline resistance genes are derived from the interclass (double-crossover)
recombination of two or more RPP-encoding gene (predominantly tetO, W, 32
(Melville et al. 2001; Stanton, McDowall and Rasmussen 2004; Patterson et al. 2007;
Warburton, Amodeo and Roberts 2016) and tetM, S (Novais et al. 2012) to form
functional chimera (Warburton, Amodeo and Roberts 2016). Mosaic tet genes are
widespread among Gram positive and Gram negative genera in human and animal
isolates (Patterson et al. 2007).
Aminoglycosides are broad spectrum antimicrobials and inhibit protein synthesis by
binding to 16S rRNA of the 30S ribosome (Kotra, Haddad and Mobashery 2000;
Krause et al. 2016). Campylobacter spp. resistance to aminoglycosides is mediated by
reduced antimicrobial binding affinity for target sites due to enzymatic modification,
via acetylation, phosphorylation or adenylation of amino or hydroxyl groups of the
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aminocyclitol nucleus or sugar moieties (Kotra, Haddad and Mobashery 2000;
Ramirez and Tolmasky 2010; Krause et al. 2016). Although there are two main
nomenclature systems used to identify aminoglycoside modifying enzymes (Novick
et al. 1976; Shaw et al. 1993; Vanhoof, Hannecart-Pokorni and Content 1998), we
followed the system proposed by Shaw et al. (1993), later extended to include an
expanded panel of aminoglycoside 6-nucleotidyltransferases (also known as
adenyltransferases) (Abril, Brodard and Perreten 2010; Hormeño et al. 2018). The
designation proposed by Shaw et al. (1993) is as follows: the type of modification
(nucleotidyltransferase/adenyltransferases (ANT)); the modification site (6’); a roman
numeral to denote unique resistance profiles (I), and a letter to represent unique protein
sequences (b) (Shaw et al. 1993). Genes for ANT enzymes are found on transposons,
plasmids or chromosome, often in associated with other resistance genes and very
often as part of the transposon-associated aminoglycoside-streptothricin resistance
gene cluster (ant(6)-I-sat4-aphA3), first isolated from Staphylococci (Werner,
Hildebrandt and Witte 2003; Nirdnoy, Mason and Guerry 2005). ANT(6)-I encoding
genes are widely distributed among clinical and animal streptomycin-resistant
thermophilic Campylobacter spp. isolates (Hormeño et al. 2018).
Despite the high prevalence of Campylobacter in broilers on the island of Ireland, in
the last twenty years, only a few reports of the molecular mechanisms contributing to
resistance exist for broiler (Lucey et al. 2000a, 2002; Moore et al. 2002; Oza et al.
2003; Corcoran et al. 2005; Bolton et al. 2013), clinical (Lucey et al. 2000a, 2002;
Moore et al. 2002; Corcoran et al. 2006b; Redondo, Carroll and Mcnamara 2019),
domestic animal (Acke et al. 2009) or ruminant (Lucey et al. 2000a; Minihan et al.
2006) isolates. We report the antimicrobial resistance determinants circulating among
158 resistant Campylobacter jejuni and Campylobacter coli isolates recovered from
Irish broiler neck skin and caecal samples over a one-year period (2017–2018).
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3.3

METHODOLOGY

3.3.1

Bacterial isolate culture conditions and susceptibility testing

A total of 350 thermophilic Campylobacter isolates (296 C. jejuni and 54 C. coli) were
recovered from free range and intensively reared broiler carcasses (neck skin and
caecal contents) using ISO 10272-2:2017 (European Food Safety Authority 2010a).
Isolates were collected between September 2017 and September 2018, from the three
largest poultry processing plants in the Republic of Ireland. The collection of isolates
was speciated using matrix-assisted laser desorption ionisation time-of-flight
(MALDI-TOF) mass spectrometry (MS) (Bruker, Billerica, MA, United States).
Isolates were previously tested (Lynch et al. 2020b) for their minimum inhibitory
concentration (MIC) to six clinically relevant antimicrobials, namely ciprofloxacin,
nalidixic acid, erythromycin, tetracycline, gentamicin, and streptomycin according to
ISO 20776:2006 and EC Decision 2013/652/EU (European Commission 2013;
European Centre for Disease Prevention and Control. 2016). Overall, 158 (140 C.
jejuni and 18 C. coli) isolates tested were resistant to at least one antimicrobial and
were subsequently tested for resistance determinants (Appendix A, Table A1).
3.3.2

DNA extraction

Briefly, isolates were recovered from −80°C on Columbia blood agar (CBA) (Fannin,
Dublin, Ireland) and incubated for 24h at 42°C, under microaerobic conditions (5%
O2, 10% CO2, 85% N2) and subcultured. DNA was extracted using the PureLink
Genomic DNA Mini Kit (Invitrogen, Carlsbad, CA, USA), according to
manufacturer’s instructions and DNA was standardised to 50–100 ng/μL.
3.3.3

Genotypic characterisation of antimicrobial resistance—PCR

amplification and sequencing
Primer sets, target genes and annealing temperatures are listed in Table 3.1. Primers
to detect mosaic tetracycline resistance genes (tetO/32/O and tetO/W/O) were
designed on SnapGene v. 2.3.2 software (from Insightful Science; available at
snapgene.com) and regions of primer complementarity were assessed on PrimerBLAST (Ye et al. 2012).
PCRs were performed with 2.5U of Amplitaq polymerase (Applied Biosystems, Foster
City, CA, USA), 1× PCR buffer I and 2.5 mM magnesium chloride (Applied
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Biosystems), 0.2 mM of each deoxyribonucleotide (Sigma-Aldrich, St Louis, MO,
USA), 0.2 pmol/μL of each primer, and 1 µL (1–2 ng/μL) of DNA. Reaction
conditions were denaturation at 94°C for 2 minutes, 35 cycles of denaturation at 94°C
for 30 seconds, annealing (Table 3.1) for 30 seconds and extension at 72°C for 1
minutes followed by a final extension at 72°C for 5 minutes. PCR products were
purified using the High Pure PCR Purification Kit (Sigma-Aldrich). Purified PCR
products were Sanger sequenced (forward and reverse reads) (Table 3.1) by Eurofins
Genomics (Eurofins Genomics, Ebersberg, Germany). Consensus sequences were
aligned and assembled on SeqMan Pro (Lasergene) (DNAStar, Madison, WI, USA).
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Table 3.1. Primer sequences and target genes used for the detection of antimicrobial resistance determinants in resistant thermophilic Campylobacter spp. isolates and sialylated
lipooligosaccharide (LOS) locus classes A, B and C in streptomycin-resistant Campylobacter jejuni isolates.
Primer

Type

Sequence (5’ - 3’)

GZgyrA5
ATT TTT AGC AAA GAT TCT GAT
A+S
GZgyrA6
CCA TAA ATT ATT CCA CCT GT
TetO-FW
ACG GAR AGT TTA TTG TAT ACC
A
TetO-RV
TGG CGT ATC TAT AAT GTT GAC
TetO/W/O-F
ATC CAG ACA GCA GTG ACA TC
A
TetO/W/O-R
ATG ATA GAC CGG AAA CAG GG
TetO/32/O-i-F
GAT ACA ATG AAT TTG GAG CG
A
TetO/32/O-i-R
AAT TGT CTT TTG CAC TCC C
TetO/32/O-ii-F
CGG GCA GGT TTT TAAG ATT G
A
TetO/32/O-ii-R
CTG TAT CAG CAA TCT CTG CG
F2-campy-23S
AAT TGA TGG GGT TAG CAT TAG C
A+S
R2-campy-23S
CAA CAA TGG CTC ATA TAC AAC TTG
L4C-F
TTA TCC CTC TTT TGT AAT AGA TTC TAA
A+S
L4C-R
ATG AGT AAA GTA GTT GTT TTA AAT GAT
L22C-F
TTA GCT TTC CTT TTT CAC TGT TGC TTT
A+S
L22C-R
ATG AGT AAA GCA TTA ATT AAA TTC ATA AG
erm(B)-F
GGG CAT TTA ACG ACG AAA CTG G
A
erm(B)-R
CTG TGG TAT GGC GGG TAA GT
CmecoliF3
AATGTTTTAGCCGATACT
A+S
CmecoliR4
AACACCGCTTACTTGAGG
cst-II-F
ATG AAA AAA GTT ATT ATT GCT GGA AAT G
A
cst-II-R
TTA TTT TCC TTT GAA ATA ATG CTT TAT
orf14c-F
CAA CTT TGC AAA ATG ATT TTA TCT ATC ATT
A
orf14c-R
ATG CAA ATA CAA CAA AAC AAT TC
A, amplification; A + S, amplification and sequencing

Target

Amplicon size (bp)

Annealing
(°C )

Reference

QRDR region of gyrA

673

50

(Zirnstein et al. 1999)

tetO

171

52

(Aminov, Garrigues-Jeanjean and
Mackie 2001)

tetO/W/O

489

50

This study

tetO/32/O type I

545

48

This study

tetO/32/Oi type II

365

50

This study

Domain V of 23S
rRNA

316

55

(Vacher et al. 2003)

rplD

614

48

(Corcoran et al. 2006b)

rplV

425

48

(Corcoran et al. 2006b)

ermB

421

52

(Wang et al. 2014)

cmeABC

428

45

(Pérez-Boto et al. 2010)

LOS locus class A/B

885/876

50

(Godschalk et al. 2007; GuyardNicodème et al. 2015)

LOS locus class C

995

50

(Guyard-Nicodème et al. 2015)
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Ciprofloxacin-resistant isolates (n=99) were screened for mutations in the QRDR of
the gyrA gene (Zirnstein et al. 1999). Products were purified and sequenced, as
described above. Consensus sequences were aligned to the gyrA of the reference C.
jejuni (GenBank accession number: L04566.1 and AL111168.1) and C. coli sequences
(GenBank accession number: AF092101.1 and NZ_UIGM01000003.1) on SnapGene
v. 2.3.2.
The primers used for the amplification and sequencing of domain V of 23S rRNA,
rplD and rplV (encoding L4 and L22 ribosomal proteins, respectively) and the
regulatory site of the cmeABC operon in five erythromycin-resistant C. coli isolates
are listed in Table 3.1. Partial multiple alignment to reference C. coli type strain NCTC
11366 (ATCC 33559) 23S rRNA (GenBank accession number: GQ167698.1), rplD
(GenBank accession number: DQ639752.1 and UIGM01000003.1), rplV (GenBank
accession number: UIGM01000003.1) and cmeABC operon (GenBank accession
number: FJ797670.1) sequences was performed on SnapGene v. 2.3.2. Isolates were
also screened for the presence of ermB, according to Wang et al. (2014).
Tetracycline-resistant isolates (n=119) were screened for the presence of tetO,
according to Aminov et al. (2001) and products were visualised on 2% agarose gel
electrophoresis. The tetO amplicon of a tetracycline-resistant C. jejuni isolate
(CITCj382-18) from this study was purified and sequenced (as described above) as a
positive control. Consensus sequences were aligned to the C. jejuni tetO gene
(GenBank accession number: M18896.2).
Primers were designed to target tetO/W/O (Table 3.1) based on alignments between
tetO (GenBank accession number: M18896.2) and mosaic tetO/W/O genes (GenBank
accession numbers: EF065524.1 and AY196921.1). Two tetO/32/O-targeting primers
(Table 3.1) were designed based on regions of homology between tetO (GenBank
accession number: M18896.2) and tetO/32/O type I genes with a longer central tet32
region (GenBank accession numbers: AJ295238.3 and JQ740052.1) and tetO/32/O
type II genes with a shorter central tet32 segment (GenBank accession numbers:
KY994102.1,

FP929050.1,

AIOQ01000025.1,

NZ_AUJS01000017.1

and

AABYPB010000033.1) (Warburton, Amodeo and Roberts 2016).
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Streptomycin-resistant isolates (n=4) were screened for sialylated LOS locus class
A/B and C (Table 3.1) by PCR, using C. jejuni 81-176 (ATCC BAA2151) and C.
jejuni NCTC 11168 (DSM 27585), respectively, as positive controls.
3.3.4

Moxifloxacin minimum inhibitory concentration testing

All (fluoro)quinolone-resistant isolates (n=99) were tested for moxifloxacin
susceptibility. Briefly, isolates were recovered from −80°C on CBA for 24h at 42°C
under microaerobic conditions and subcultured to CBA for 20 ± 2h at 42°C under
microaerobic conditions. In microtiter plates, 100 µL serial dilutions of moxifloxacin
(Sigma-Aldrich) were prepared in of Mueller Hinton broth with lysed horse blood
(Thermo Fisher Scientific, Waltham, MA, USA) ranging from 0.125–16 mg/L. A 0.5
McFarland inoculum was prepared in 5 mL demineralised water (Thermo Fisher
Scientific) and 100 µL was transferred to 11 mL of Mueller Hinton broth with lysed
horse blood (Thermo Fisher Scientific). Moxifloxacin serial dilutions were inoculated
with 100 µL of cell suspension and incubated for 20 ± 2h at 42°C under microaerobic
conditions.
3.3.5

Whole-genome sequencing and genomic analysis

The genomes of four streptomycin-resistant isolates (C. jejuni isolates CITCj625-18
and CITCj727-18 and C. coli isolates CITCc1631-18 and CITCc3448-18) were
sequenced. DNA was quantified in triplicate with the Quant-iT dsDNA Assay Kit
(Thermo Fisher Scientific). Genomic DNA libraries were prepared using the NexteraXT protocol (Illumina, San Diego, CA, USA), with changes including 2 ng of input
DNA and a minute PCR elongation time. DNA quantification and library preparation
were performed on a Hamilton Microlab STAR system. Pooled libraries were
quantified using the Kapa Biosystems library quantification kit on a Roche light cycler
96 qPCR machine. Libraries were sequenced on the Illumina HiSeq using a 250 bp
paired-end protocol. Reads were adapter trimmed using Trimmomatic 0.30 with a
sliding window quality cut-off of Q15 (Bolger, Lohse and Usadel 2014). De novo
assembly was performed using SPAdes v. 3.7 (Bankevich et al. 2012) and assembly
quality was assessed using QUAST (Gurevich et al. 2013).
Genomes were annotated using Prokka 1.14.3 (Seemann 2014). Similarity searches
were performed using the BLAST suit of programs (Altschul et al. 1990) and
InterProScan (Jones et al. 2014). Multi locus sequence typing (MLST) patterns was
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determined using PubMLST (Jolley, Bray and Maiden 2018). ANI was calculated
using EzBioCloud (Yoon et al. 2017b).
3.3.6

Data availability

This whole-genome project has been deposited at DDBJ/ENA/GenBank under the
accession number PRJNA612628. CITCj625-18, CITCj727-18, CITCc1631-18, and
CITCc3448-18 genomes can be accessed using SAMN14379027, SAMN14379028,
SAMN14379029 and SAMN14379030, respectively. The partial and complete gene
sequences deposited in GenBank are listed in Table 3.2. Erythromycin-resistant
isolates harboured identical ribosomal mutations and CITCc1303-18 partial sequences
were submitted. One representative gyrA GT was submitted for each type.
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Table 3.2. Accession numbers of partial sequences submitted to GenBank in this study.

Isolate

Gene

C. coli (CITCc1303-18)
C. coli (CITCc1303-18)
C. coli (CITCc1303-18)
C. jejuni (CITCj4193-17)
C. jejuni (CITCj999-18)
C. jejuni (CITCj193-18)
C. coli (CITCc3796-B-18)
C. coli (CITCc3636-B-17
C. coli (CITCc3521-18)
C. coli (CITCc3318-17)
C. coli (CITCc1631-18)
C. coli (CITCc3790-18)
C. coli (CITCc1303-18)
C. jejuni (CITCj625-18)
C. jejuni (CITcj727-18)
C. coli (CITCc3448-18)
C. jejuni (CITCj625-18)
C. jejuni (CITcj727-18)
C. coli (CITCc3448-18)
C. coli (CITCc1631-18)

23S ribosomal RNA, partial sequence
50S ribosomal protein L4 (rplD) gene, partial cds
50S ribosomal protein L22 (rplV) gene, partial cds
gyrA (GTJ-I), partial cds
gyrA (GTJ-II), partial cds
gyrA (GTJ-III), partial cds
gyrA (GTC-I), partial cds
gyrA (GTC-II), partial cds
gyrA (GTC-III), partial cds
gyrA (GTC-IV), partial cds
gyrA (GTC-V), partial cds
gyrA (GTC-VI), partial cds
gyrA (GTC-VII), partial cds
tetO/32/O type II, complete cds
tetO/32/O type II, complete cds
tetO/32/O type II, complete cds
ant(6)-Ib, complete cds
ant(6)-Ib, complete cds
ant(6)-Ie, complete cds
ant(6)-Ie, complete cds

GenBank
accession
number
MT155934
MT155935
MT155936
MT176407
MT176408
MT176409
MT176400
MT176401
MT176402
MT176403
MT176404
MT176405
MT176406
MT176410
MT176411
MT176412
MT176413
MT176414
MT176415
MT176416

Sequence
length (bp)
262
519
319
644
644
644
550
550
550
550
550
550
550
1920
1920
1920
867
867
900
550

118

3.4

RESULTS

3.4.1

Fluoroquinolone resistance

Isolates resistant to ciprofloxacin/nalidixic acid were screened for mutations in the
gyrA gene and 100% of isolates (n=99) harboured a C257T point mutation, which is
the dominant mutation conferring resistance among campylobacters. Resistant isolates
were grouped into C. jejuni gyrA and C. coli gyrA (arbitrarily named GTJs and GTCs,
respectively) sequence types based on the presence of synonymous and
nonsynonymous mutations present in the portion of the gyrA gene sequenced (Table
3.3). Ciprofloxacin-resistant C. jejuni isolates (n=85) were grouped into three GTJs
(GTJ-I, -II and -III). A large proportion (47.1%) carried the Thr-86-Ile substitution
exclusively (GTJ1). Synonymous mutations T72C, C243T, T357C, C360T, C471T,
T483C and C622T were exclusively associated with C. jejuni and were present in both
GTJ-II and GTJ-III. Nonsynonymous Ser-22-Gly (A64G) and Ala-206-Thr (G616A)
mutations were present in 35.3% and 17.7% of isolates of ciprofloxacin-resistant C.
jejuni isolates, respectively and were the basis of defining GTJ-II and GTJ-III,
respectively. Both GTJ-II and GTJ-III were associated with the Asn-203-Ser (A608G)
substitution. All CIP-resistant C. coli isolates tested (n=14) harboured one
nonsynonymous mutation only (Thr-86-Ile), but were grouped into seven GTCs based
on the presence of various synonymous mutations (Table 3.3).
No high-level moxifloxacin resistance was detected among the 99 (fluoro)quinoloneresistant isolates tested and MICs ranged from 0.5–8 mg/L.
Table 3.3. GyrA sequence types (GTs) and associated polymorphisms distributed among 85
ciprofloxacin-resistant Campylobacter jejuni isolates (GTJs) and 14 ciprofloxacin-resistant
Campylobacter coli isolates (GTCs). Polymorphisms causing an amino acid substitution
(nonsynonymous mutations) are highlighted in black.
GTJ

n= (%)

GTJ-I
GTJ-II
GTJ-III

40 (47.1)
30 (35.3)
15 (17.7)

GTC

n= (%)

GTC-I
GTC-II
GTC-III
GTC-IV
GTC-V
GTC-VI
GTC-VII

1 (7.1)
7 (50)
1 (7.1)
1 (7.1)
2 (14.3)
1 (7.1)
1 (7.1)

Nucleotide position (base indicated in brackets) of wild-type strain Campylobacter jejuni NCTC 11168 gyrA (GenBank accession
number: L04566.1 and AL111168.1)
64 (A)
72 (T)
243 (C)
257 (C)
357 (T)
360 (C)
471 (C)
483 (T)
608 (A)
616 (G)
622 (T)
.
.
.
T
.
.
.
.
.
.
.
G
C
T
T
C
T
T
C
G
.
T
.
C
T
T
C
T
T
C
G
A
T
Nucleotide position (base indicated in brackets) of wild-type strain Campylobacter coli NCTC 11366 gyrA (GenBank accession
number: AF092101.1 and NZ_UIGM01000003.1)
117 (T)
252 (C)
257 (C)
297 (C)
342 (T)
471 (T)
498 (G)
.
.
T
C
.
T
.
C
.
T
C
.
T
.
C
.
T
.
.
T
.
.
.
T
C
.
.
.
.
T
T
C
.
T
.
.
.
T
C
.
.
A
.
.
T
C
C
T
.
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3.4.2

Erythromycin resistance

Five erythromycin-resistant isolates were screened for mutations contributing to
erythromycin resistance. All five erythromycin-resistant isolates harboured the
A2075G mutation in the 23S rRNA gene. A T82C mutation (Ser-28-Pro substitution)
in the rplD gene was detected in the five isolates, and the partial sequences shared
100% homology with the rplD gene of erythromycin-sensitive C. coli isolates
(GenBank accession numbers: MH084640.1 and MH084639.1) (Wei and Kang 2018).
Identical mutations were also observed in the rplV sequence in all erythromycinresistant isolates: double point mutation at positions 308 and 309 (Ala-103-Val),
A325G (Thr-109-Ala), a double point mutation at positions 332 and 333 (Ala-111Glu), G340A (Ala-114-Thr) and C358A (Pro-120-Thr). Nonsynonymous mutations
(T282A, C294T, A306G, T321G) in rplV were also identified in all erythromycinresistant isolates. Partial rplV sequences in this study were homologous to a high-level
erythromycin-resistant clinical C. coli isolate rplV gene (GenBank accession number:
GU384982.1) (Pérez-Boto et al. 2010). Similarly, all five erythromycin-resistant
isolates harboured a 9 base pair deletion (positions 45–54) and an insertion at position
45 (G) in cmeR-cmeA intergenic region, upstream of the IR (positions 66-80),
homologous to sequences derived from erythromycin-resistant (GenBank accession
number: FJ797673.1) and erythromycin-sensitive (GenBank accession number:
FJ797671.1) strains (Guo et al. 2010). The ermB gene was not detected among the
erythromycin-resistant isolates tested.
3.4.3

Tetracycline resistance

A portion of the tetO gene was detected in 100% of tetracycline-resistant isolates
(n=119). Three isolates (CITCj625-18, CITCj727-18, and CITCc3448-18),
accounting for 2.5% of the tetracycline-resistant isolates, harboured the mosaic
tetO/32/O type II gene, confirmed by PCR/partial sequencing and genomic sequencing
(Figure 3.1b). Isolates CITCj625-18 and CITCj727-18 carried identical mosaic
tetracycline genes but differed from CITCCc3448-18 by Thr-118-Ile and Glu-176-Asp
substitutions and A684G and A789G point mutations. The mosaic tetracycline gene
detected among the Irish broilers isolates in this study was very similar to a
Streptococcus suis (GenBank accession number: KY994102.1) tetO/32/O gene (Table
3.4). Equally, the TetO/32/O sequences were >99.5% identical to Campylobacter spp.
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(GenBank

accession

numbers:

WP_052855148.1)

and

Clostridiales

(WP_117823345.1) TetO/32/O sequences.
Table 3.4. Percentage identity (percentage cover in brackets) of mosaic tetracycline resistance gene
(tetO/32/O) type II in three tetracycline-resistant Campylobacter spp. isolates detected in this study and
Streptococcus suis tetO/32/O gene (GenBank accession number: KY994102.1).
Species/strain
C. jejuni CITCj625-18
tetO/32/O
C. jejuni CITC727-18
tetO/32/O
C. coli CITCc-3448-18
tetO/32/O
KY994102.1 S. suis
tetO/32/O

3.4.4

C. jejuni
CITCj625-18
tetO/32/O

C. jejuni CITC72718 tetO/32/O

C. coli CITCc3448-18 tetO/32/O

KY994102.1 S. suis
tetO/32/O

100% (100%)

100% (100%)

99.78% (96%)

99.73% (96%)

100% (100%)

100% (100%)

99.78% (96%)

99.73% (96%)

99.78% (100%)

99.78% (100%)

100% (100%)

99.95% (100%)

99.73% (100%)

99.73% (100%)

99.95% (96%)

100% (100%)

Streptomycin resistance

C. jejuni isolates CITCj625-18 and CITCj727-18 were found to harbour multiple
resistance genes, including a truncated tetO (873 bp, truncated at the 3’ end), mosaic
tetO/32/O type II (1920 bp), aminoglycoside-6-nucleotidyltransferase (ant(6)-Ib)),
and streptothricin acetyltransferase (satA). These antimicrobial resistance genes were
located circumjacent to proteins involved in replication and recombination (Table 3.5,
Figure 3.1a). The MDRGI contained 10 open reading frames in a region of 35.9% GCcontent, compared to the average genomic GC-content of 30.5%. Genomic sequences
of C. jejuni isolates CITCj625-18 (first thin) (1,630,363 bp) and CITCj727-18 (final
thin, isolated a week later) (1,636,524 bp) were nearly identical with an average
nucleotide identity (ANI) of 99.99% and 30.5% GC-content, indicating that the
isolates had been circulating within and had been maintained by the flock. The pair
belonged to sequence type ST-45 clonal complex (ST-137) and harboured LOS locus
class C.
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Table 3.5. Description of Campylobacter jejuni strain CITCj625-18 (representative of strain CITCj72718) multidrug resistance genomic island.

Locus tag
HBF06_00624

HBF06_00625
HBF06_00627
HBF06_00628

HBF06_00629

HBF06_00630
HBF06_00631

HBF06_00632

HBF06_00633

HBF06_00634

Gene
annotation
Holliday junction ATPdependent DNA
helicase, RuvB
Histidine
phosphotransferase
Autotransporter
adhesion, CapC
Truncated tetracycline
resistance ribosomal
protection protein, TetO
Aminoglycoside 6nucleotidyltransferase,
ANT(6)-Ib
Replication protein,
RepB
DNA topoisomerase

InterProScan
protein
family or
domain
IPR004605

GenBank accession
number of closest
(% Identity
/% Coverage)
WP_002856258.1
100/100

IPR036641

MPA99107.1
100/90)
EAK6247206.1 99.16/94

IPR005546
IPR035650

AUA17601.1
99.59/82

IPR007530

WP_001255868.1
100/100

IPR002631

WP_052777339.1
100/100
WP_139898553.1
99.52/100

IPR000380

Streptothricin
acetyltransferase, SatA

IPR008125

EOO12820.1
96.86/100

Mosaic tetracycline
resistance ribosomal
protection protein,
TetO/32/O
Plasmid replication
protein

IPR035650

WP_052855148.1
100/100

None detected

EDP4862066.1
99.21/97

Predicted function
Holliday junction helicase
(strand exchange reactions in
homologous recombination)
Signal transduction
Protein secretion
Ribosomal protection protein
conferring tetracycline
resistance (TetO)
Adenylyltransferase activity
conferring resistance to
aminoglycosides
Plasmid replication protein
Topoisomerisation and single
stranded breakage during
transcription, DNA
replication and
recombination.
Acetylation of streptothricin
conferring resistance
Ribosomal protection protein
conferring tetracycline
resistance
Plasmid replication

Figure 3.1. (A) Schematic of Campylobacter jejuni isolate CITCj625-18 multidrug
resistance genomic island. (B) Schematic of the mosaic tetO/32/O type II gene detected in
CITCj625-18 and CITCj727-18. White bars are tetO and central, checked bar is tet32 (297
bp). Figure adapted from Warburton et al. (2016).

CITCc1631-18 and CITCc3448-18 belonged to ST-828 clonal complex (ST-6543 and
ST-1096, respectively) and harboured the ant(6)-Ie gene (900 bp), with almost
identical sequences (99.89% identity). ANT(6)-Ie in this study shared 99.66% amino
acid identity with each other, where CITCc3448-18 harboured a nonsynonymous
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G820A mutation (Val-274-Ile) and was identical to a C. coli ANT(6)-Ie protein
(GenBank: WP_052786298.1). CITCc1631-18 and CITCc3448-18 ANT(6)-Ie shared
between 29.7-36.1% identity to ANT(6)-Ia, ANT(6)-Ib, ANT(6)-Ic, and ANT(6)-Id
amino acid sequences (GenBank: AFJ97257.1, AFJ97264.1, AAR10415.1, and
WP_001258597.1, respectively) (Abril, Brodard and Perreten 2010; Olkkola et al.
2016; Hormeño et al. 2018).
Aminoglycoside 3-N-acetyltransferase (AAC(3)) (261 amino acids) was also detected
in both CITCj625-18 and CITCj727-18, 44.3% identical to a aminoglycoside 3-Nacetyltransferase (AAC(3)) variant (239 amino acids) in both CITCc1631-18 and
CITCc3448-18. However, these isolates were gentamicin-susceptible, although this
protein may confer resistance to other aminoglycoside antibiotics (Fabre et al. 2018).
The C. coli variant was identical to AAC(3) genes reported in Campylobacter spp.,
37.5% identical to AAC(3)-Ia described in Serratia marcescens (GenBank accession
number: Q7B9H0), and 19–32.25% similar to AAC(3) orthologous, including types
AAC(3)-Ib/Ic/Id/Ie/IIa/IIb/IIc/IId/IIe/IIf/IIIa/IIIb/IIIc/IVa/VIa/VIIIa/Ixa/Xa/XIa. The
AAC(3) variant in CITCj625-18 and CITCj727-18 was identical to Campylobacter
AAC(3) variants.
3.4.5

Overall distribution of antimicrobial resistance

The antimicrobial resistance rates of this pool of broiler-associated thermophilic
Campylobacter spp. isolates (resistant to at least one antimicrobial; n=158) have been
detailed previously (Lynch et al. 2020b), and are summarised below (Figure 3.2).
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Figure 3.2. Distribution of antimicrobial resistance among 158 thermophilic Campylobacter spp.
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3.5

DISCUSSION

This study reports the antimicrobial resistance determinants circulating among Irish
broiler-associated Campylobacter isolates, collected throughout the Republic of
Ireland, from the three largest poultry processors, over a one-year period (2017–2018).
The Thr-86-Ile mutation is the predominant genetic alteration conferring
(fluoro)quinolone resistance among Campylobacter spp. (Moore et al. 2005), and was
detected in all (fluoro)quinolone-resistant isolates (n=99) tested in the current study,
similar to reports published worldwide (Duarte et al. 2014; Sierra-Arguello et al. 2016;
Yang et al. 2017; Woźniak-Biel et al. 2018). Some studies have not detected the Thr86-Ile

mutation

universally

in

the

QRDR

of

(fluoro)quinolone-resistant

Campylobacter spp. isolates (Oza et al. 2003; Acke et al. 2009; Elhadidy et al. 2018b),
indicating that other factors are responsible for, or contribute to, (fluoro)quinolone
resistance.
Fluoroquinolone-resistant Campylobacter spp. are ecologically competitive and
persistent even in the absence of antimicrobial selective pressure (Zhang, Lin and
Pereira 2003; Luo et al. 2005; Whelan et al. 2019). Despite a distinct rise in
ciprofloxacin resistance among broiler Campylobacter isolates (3.1% to 28.9%) in
Ireland between 1998 and 2000 (Lucey et al. 2000b, 2002), in 2017–8 resistance to
ciprofloxacin remained stable (28.3%) (Lynch et al. 2020b). Clonal expansion of
resistant lineages has likely contributed to the persistence of ciprofloxacin resistance
in Ireland, considering that fluoroquinolones typically account for less than 1% of all
veterinary antimicrobials sold in Ireland (Health Products Regulatory Authority. 2014,
2017; Health Products Regulatory Authority 2018).
C. jejuni isolates harbouring multiple amino acid substitutions in the gyrA QRDR
(GTJ-II and GTJ-III) (Table 3.3) had ciprofloxacin MICs ranging from 8–16 mg/L,
except one GTJ-II isolate had an MIC of 4 mg/L, while isolates harbouring the Thr86-Ile mutation exclusively (GTJ-I) had MICs ranging from 4–16 mg/L. Similarly,
Ekkapobyotin et al. (2008) observed varying ciprofloxacin/nalidixic acid MICs in
isolates harbouring identical GyrA amino acid substitutions (Ekkapobyotin,
Padungtod and Chuanchuen 2008). Moreover, the Ser-22-Gly, Asn-203-Ser and Ala206-Thr mutations have been reported in fluoroquinolone-sensitive strains (Dionisi,
Luzzi and Carattoli 2004; Kinana et al. 2007; Ragimbeau et al. 2014). To confirm the
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apparent lack of involvement of these accessory gyrA mutations in the development
of fluoroquinolone resistance, the introduction of these mutations in fluoroquinolonesusceptible strains could be investigated. Authors have previously reported that double
mutations in gyrA (at amino acid positions 86 and 90) were necessary to produce high
level moxifloxacin resistance (Bachoual et al. 2001; Ruiz et al. 2005). Moxifloxacin
is a potent fluoroquinolone with activity against fluoroquinolone-resistant
campylobacters that harbour a single mutation in gyrA (Tankovic et al. 1999). In this
study, no high-level resistance to moxifloxacin was observed among the
(fluoro)quinolone-resistant isolates. These data indicate that these mutations outside
the gyrA QRDR have a negligible effect on (fluoro)quinolone resistance.
Variation in gyrA alleles within a population of Campylobacter isolates have been
identified as epidemiological markers and may serve as a supplementary approach to
classical epidemiological typing methods (Hakanen et al. 2002; Piddock et al. 2003;
Kinana et al. 2007; Ragimbeau et al. 2014). In our study, the GTs detected were
species specific, although Ragimbeau et al. (2014) reported the presence of a typical
C. coli gyrA type in 0.23% (n=1) of 430 C. jejuni isolates tested, and 1.4% (n=4) C.
coli isolates harboured a typical C. jejuni gyrA type. The amino acid substitutions
present in each of the three GTJ (Table 3.3) lineages have been associated with poultry
Campylobacter isolates previously (Ge et al. 2003; Oishi et al. 2015;
Thomrongsuwannakij,

Blackall

and

Chansiripornchai

2017).

Only

one

nonsynonymous mutation (Thr-86-Ile) was detected among the seven GTCs detected
(Table 3.3), similar to previous studies reporting a single nonsynonymous mutation
(Thr-86-Ile substitution) present in (fluoro)quinolone-resistant C. coli QRDR
sequences (Ge et al. 2003; Ragimbeau et al. 2014; Thomrongsuwannakij, Blackall and
Chansiripornchai 2017). It is likely that additional variants of Campylobacter spp.
gyrA alleles exist, and may reflect ecological evolution (Ragimbeau et al. 2014).
Identical mutations in the 23S rRNA, rplD, and rplV genes were detected in
erythromycin-resistant isolates (n=5), while MICs ranged from 128 mg/L to ≥ 128
mg/L. Three of these isolates were collected from the same flock in north-central
Ireland while one isolate was collected from a farm approximately 10 km away, the
following week. The fifth erythromycin-resistant isolate was recovered from a farm in
the mid-south-west of Ireland, two months previously, but all birds from these farms
were processed in the same processing plant.
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The A2075G point mutation in the 23S rRNA gene remains the most prevalent genetic
event conferring macrolide resistance (Luangtongkum et al. 2009; Bolinger and
Kathariou 2017) and was detected in all erythromycin-resistant isolates in this study.
The 23S rRNA A2074G and A2074C mutations were not detected. Mutations in the
rplV gene, encoding the 50S ribosomal protein L22 were detected in the C-terminal
region (amino acids 109–142) (Cagliero et al. 2006), including Thr-109-Ala, Ala-111Glu, Ala-114-Thr, and Pro-120-Thr. Nonsynonymous mutations (T282A and C294T)
were also observed in the region encoding the highly conserved β-hairpin loop at
amino acids 78–98 (Cagliero et al. 2006). Mutations in the RplD β-hairpin (spanning
amino acid positions 55–77 (Chittum and Champney 1994; Cagliero et al. 2006)) are
often associated with bacterial macrolide resistance, and such mutations were not
observed among the Irish erythromycin-resistant isolates tested in this study.
Moreover, polymorphisms were detected outside the cmeR regulatory IR. The effects
of mutations detected in this study in rplD, rplV, and the intergenic region of cmeRcmeA are unknown, but may enhance erythromycin mutation.
The ermB gene was not detected among the erythromycin-resistant isolates tested.
Resistance mediated by ermB in Campylobacter spp. is largely confined to China,
which may reflect the extensive use of antimicrobials in food producing animals in
China (Bolinger and Kathariou 2017). Three reports of genetically distinct ermBpositive C. coli isolates recovered from poultry exist in Europe (Florez-Cuadrado et
al. 2016, 2017; Elhadidy et al. 2019) and an ermB-positive isolate was detected for
the first time in the United States in a C. jejuni isolate of clinical origin (Chen et al.
2018a), while the ermB gene was recently detected in 18.3% of 240 thermophilic
Campylobacter spp. retail meat associated-isolates in South Africa (Igwaran and Okoh
2020). Mutations in C. jejuni 23S rRNA has been associated with a fitness cost and
reduced doubling times (Han et al. 2009; Luangtongkum et al. 2012; Zeitouni et al.
2012), although tolerance to low temperatures may facilitate persistence in the
environment and transmission of resistant strains through the food supply (Han et al.
2009).
All tetracycline-resistant isolates harboured a portion of the tetO gene, while three
isolates harboured the mosaic tetO/32/O type II gene were detected. Mosaic
tetracycline resistance genes in Campylobacter spp. are typically derived from tetO
and tet32 sequences in the type II conformation, with a shorter central tet32 segment
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(Warburton, Amodeo and Roberts 2016), although there are limited reports of these
resistance genes circulating among Campylobacter spp. The first mosaic tetracycline
RPP gene was detected in Megasphera elsdenii, composed of a central tetW region
flanked by two tetO regions (Stanton and Humphrey 2003). However, the progenitors
of these mosaic genes are based only on the order in which they were discovered, and
the current classification system does not adequately reflect the variable nature of
tetracycline RPPs (Novais et al. 2012; Warburton, Amodeo and Roberts 2016). The
tetO primers (Aminov, Garrigues-Jeanjean and Mackie 2001) used in this study
amplify a region at the beginning of the tetO gene and enable the detection of mosaic
tet genes with a central portion flanked by an initial tetO region until position 228. The
tetO/32/O type II gene reported here was associated exclusively with an MIC of 64
mg/L. However, 27 of 119 (22.7%) tetracycline-resistant Campylobacter spp. isolates
tested had MICs of 64 mg/L or ≥ 64 mg/L, indicating that other factors contribute to
enhanced tetracycline resistance. It should be noted that in this study, all three isolates
harbouring mosaic tetracycline genes were also co-resistant to streptomycin, enabling
co-selection and persistence of these antimicrobials. The burden of mosaic tetracycline
resistance genes within the genus should be considered as part of the approach to
elucidate developing and newly acquired antimicrobial resistance determinants within
the genus.
All streptomycin resistant (n=4) isolates had MICs of ≥ 16 mg/L. Streptomycinresistant C. jejuni isolates CITCj625-18 and CITCj727-18 (ST-137) harboured
sialylated LOS locus class C, which has been identified as a risk factor for postinfectious Guillain-Barré syndrome and increased severity of enteric disease
(Mortensen et al. 2009). CITCj625 and CITCj727-18 belonged to ST-137 – members
of the diverse C. jejuni ST-45 clonal complex (Dearlove et al. 2016; Llarena et al.
2016). ST-137 is frequently isolated from cases of enteric campylobacteriosis
(Dearlove et al. 2016) and broilers/avian (Mohan et al. 2013; Mäesaar et al. 2018;
Wei, Kang and Jang 2019), porcine (Dearlove et al. 2016), and bovine (Aksomaitiene
et al. 2019) hosts. The ST-137 genotype is widely dispersed and represents an
ecologically successful clone (Llarena et al. 2016). A study by Dearlove et al. (2016)
reported that ST-45 clonal complex was a generalist lineage capable of frequent
transmission between hosts.
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Genomic sequencing of tetracycline-/streptomycin-resistant C. jejuni isolates
(CITCj625-18 and CITCj727-18, isolated from the same flock, first and final thin)
revealed identical genes in a multidrug resistance genomic island (Table 3.5, Figure
3.1(A)). Both isolates harboured a truncated tetO gene and a mosaic tetO/32/O type II
gene, homologous that of Gram positive (GenBank accession number: KY994102.1)
and Campylobacter spp. isolates (GenBank accession number: WP_002823161.1).
The presence of multiple tet genes (coding for similar or different mechanisms) in
Gram negative isolates has also been documented (Roberts 2005). However, the
truncated form detected in this study (CITCj625-18 and CITCj727-18) is likely a
remnant of a region of insertion or recombination. Truncated tetO genes have also
been reported in C. coli MDGRI containing aadE (ant(6)-Ib) and ermB (Wang et al.
2014; Florez-Cuadrado et al. 2016). Aminoglycoside (ant(6)-Ib (867 bp)) and
streptothricin resistance (satA) genes were also located within the multidrug resistance
island (Figure 3.1(A)). Streptothricin acetyltransferase A (satA) is frequently reported
in Gram positive bacilli (Burckhardt and Escalante-Semerena 2019) and shares less
than 40% identity with the streptothricin acetyltransferase A (sat4) reported in
Campylobacter (Werner, Hildebrandt and Witte 2003; Qin et al. 2012; Wang et al.
2014). Plasmid replication proteins within the MDRGI suggest a plasmid as the
insertion vehicle of the resistance genes.
CITCc3448-18 belonged to ST-828 clonal complex (ST-1096). ST-1096 has been
isolated from a case of gastroenteritis in the United Kingdom (UK) in 2016
(https://pubmlst.org/) and has also been previously reported in C. coli of swine origin
in Spain, America, and Grenada (Wright et al. 2010; Amadi et al. 2017; Hormeño et
al. 2018). CITCc1631 was ST-6543 (ST-828 clonal complex), which has been
associated with clinical and chicken-associated isolates (Cody et al. 2013). There are
a total of fifteen depositions (all are UK-associated) of C. coli ST-6543 on the
PubMLST Campylobacter database at the time of writing (https://pubmlst.org/),
including eleven clinical isolates (faeces), two chicken-associated isolates, and two
isolates with no source allocation.
Both streptomycin-resistant C. coli isolates (CITCc1631-18 and CITCc3448-18)
harboured the emerging ant(6)-Ie gene (900 bp), found widely disseminated among
clinical and animal C. coli isolates (Olkkola et al. 2016; Hormeño et al. 2018). Unlike
other Campylobacter ant(6) genes, ant(6)-Ie appears to be inherent to C. coli and does
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not have a Gram positive ancestor (Olkkola et al. 2016). The ant(6)-Ie gene was
originally detected in a hypervariable genomic region, unaccompanied by other
resistance genes (Olkkola et al. 2016). Similarly, the CITCc1631-18 and CITCc344818 ant(6)-Ie genes were located chromosomally, and were not located near other
resistance determinants. Both streptomycin-resistant C. coli isolates were co-resistant
to ciprofloxacin/nalidixic acid (GTC-V) and tetracycline. C. coli isolate 1631-18
harboured tetO (1920 bp), while C. coli isolate CITCc3448-18 also harboured the
mosaic tetracycline resistance gene, tetO/32/O (1920 bp), highly homologous with that
detected in CITCj625-18 and CITCj727-18.
Although non-poultry sources contribute to campylobacteriosis incidence, poultry are
natural thermophilic Campylobacter spp. hosts. The broiler industry serves as a
reservoir for the dissemination of resistant campylobacters. The enrichment and
stability of Campylobacter spp. resistance determinants is compounded by their
natural competence and potential of recombination or acquisition of mobile genetic
elements. Taken together, the data collected in this study point to the widespread
dissemination of the dominant resistance determinants circulating among Irish
broilers, contributing to the development and perpetuation of resistance to clinically
relevant antimicrobials.
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4.0 Chapter 4. Investigation of molecular
mechanisms underlying tetracycline
resistance in thermophilic Campylobacter
spp. suggests that previous reports of tetAmediated resistance in these bacteria are
premature
A research letter based on this chapter has been published in
Gut Pathogens

Lynch, C., Hawkins, K., Lynch, H., Egan, J., Bolton, D., Coffey, A., Lucey, B. Investigation of
molecular mechanisms underlying tetracycline resistance in thermophilic Campylobacter spp.
suggests that previous reports of tet(A)-mediated resistance in these bacteria are premature. Gut
Pathog. 2019, 11:56, doi:10.1186/s13099-019-0338-1.

HL isolated and speciated Campylobacter spp. isolates.
KH assisted with PCR screening and sequence analysis.

131

4.1

ABSTRACT

The true prevalence of tetA, which codes for a tetracycline efflux pump, in
thermophilic Campylobacter spp. requires clarification after reports emerged in Iran
(2014) and Kenya (2016) reporting the detection of a novel tetA in Campylobacter.
During our investigation of antibiotic resistance mechanisms in a sample of Irish
thermophilic Campylobacter broiler isolates, it was determined that 100% of
tetracycline-resistant isolates (n=119) harboured tetO. Accessory tetracyclineresistance mechanisms were considered as tetracycline minimum inhibitory
concentrations ranged from 4 – ≥64 mg/L. Primers previously reported for the
detection of tetA in Campylobacter failed to produce an amplicon using a positive
control strain (Escherichia coli K12 SK1592 containing the pBR322 plasmid) and a
selection of Campylobacter isolates. Accordingly, we designed new tetA-targeting
primers on SnapGene v. 2.3.2 that successfully generated a 407 bp product from the
positive control strain only. Further in-silico analysis using BLASTn and SnapGene
v. 2.3.2 revealed that previously reported Campylobacter tetA sequences deposited on
GenBank shared 100% homology with Campylobacter tetO. We postulate that this
gave rise to the erroneous report of a high tetA prevalence among a pool of Kenyan
broiler Campylobacter isolates that were tested using primers designed based on these
apparent tetA sequences. In conclusion, further work would be required to determine
whether the homology between tetA potentially present in Campylobacter and known
tetA genes would be sufficient to allow amplification using the primers designed in
our study. Finally, the existence of tetA in thermophilic Campylobacter spp. remains
to be demonstrated.
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4.2

INTRODUCTION

The use of tetracycline for growth promotion has been banned in Europe since the
early 1970s, in accordance with directive 70/524/EEC (Council of the European Union
1970), however tetracyclines are used extensively in poultry production and animal
husbandry for the treatment of enteric, respiratory and dermal infections (Casewell et
al. 2003; Sarmah, Meyer and Boxall 2006; Carvalho and Santos 2016; GranadosChinchilla and Rodríguez 2017; Kuppusamy et al. 2018). Tetracycline is the most
commonly administered veterinary antibiotic in Ireland (Health Products Regulatory
Authority. 2014, 2016; European Medicines Agency 2018a, 2020; Department of
Agriculture Food and the Marine and Department of Health 2019). Resistance to
tetracyclines ranges from high to extremely high in Campylobacter from clinical,
food-producing animals and poultry meat across Europe (European Food Safety
Authority and European Centre for Disease Prevention and Control 2021) and
resistance among Campylobacter isolated from broilers in Ireland continues to
increase (Lynch et al. 2020b; European Food Safety Authority and European Centre
for Disease Prevention and Control 2021).
Campylobacter tetracycline resistance is primarily mediated by a ribosomal protection
protein (RPP), encoded by tetO. TetO is capable of displacing tetracycline from its
primary binding site on the 30S ribosomal subunit (Connell et al. 2003; Gibreel et al.
2004; Wilson 2014). Tetracycline RPPs are widely distributed among bacteria and are
often located on mobile genetic elements (Giovanetti et al. 2003; Roberts 2003, 2005;
Lancaster et al. 2004; Warburton, Amodeo and Roberts 2016). In other bacteria tet
efflux genes act to reduce the intracellular concentration of tetracycline thereby
protecting the ribosome (Roberts 2003).
We read with interest an article reporting the novel detection of tetA among
thermophilic Campylobacter spp. poultry isolates in Iran (Abdi-Hachesoo et al. 2014)
and the subsequent detection of tetA among a pool of Campylobacter spp. chicken
isolates in Kenya (Nguyen et al. 2016). It is a timely reminder of emerging antibiotic
resistance associated with the mobilisation of genes from other bacterial genera.
However, we seek clarification about the results published in the referenced articles
(Abdi-Hachesoo et al. 2014; Nguyen et al. 2016), and the true prevalence of tetA
among thermophilic Campylobacter spp.
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4.3

METHODOLOGY

4.3.1

Preliminary investigations surrounding tetracycline-resistant

Campylobacter
During the investigation of antibiotic resistance mechanisms among a sample of 350
Irish broiler Campylobacter spp. isolates (Appendix A, Table A1), we were especially
interested in tetracycline resistance genes, as phenotypic antimicrobial resistance to
tetracycline was most prevalent (34%), determined using broth microdilution,
minimum inhibitory concentration testing (Lynch et al. 2020b). Tetracycline-resistant
isolates were preliminarily screened for the presence of tetO, (Aminov, GarriguesJeanjean and Mackie, 2001) and it was determined that 100% of tetracycline-resistant
isolates harboured the tetO gene (Lynch et al. 2020a). However, accessory
tetracycline-resistance mechanisms were considered as minimum inhibitory
concentrations ranged from 4 – ≥64 mg/L. Moreover, the mobilisation of tetracyclineresistant determinants is associated with the presence of tet genes on plasmids (Chopra
and Roberts 2001). Hence, the tetA gene, which codes for an efflux protein and has
been reported to co-exist with tetO in Campylobacter, was considered as part of the
investigation (Abdi-Hachesoo et al. 2014; Nguyen et al. 2016).

4.3.2

tetA amplification strategies

We screened for the presence of tetA using primers described by (Abdi-Hachesoo et
al. 2014) (Table 4.1) and new tetA-targeting primers (Table 4.1) were also designed
on SnapGene v. 2.3.2, based on homologous regions of the tetA gene from the pBR322
plasmid (GenBank: J01749.1) and from Pseudomonas putida strain Fars110
(GenBank: JN937120.1) – the latter strain having been reported by Abdi-Hachesoo et
al. (2014) as a tetA positive control. In this study, Escherichia coli K12 SK1592
containing the pBR322 plasmid (DSM 3879), known to harbour tetA, was used as the
positive control strain.
DNA was extracted using PureLink™ Genomic DNA Mini Kit (Invitrogen, CA,
USA). Quality was assessed using the NanoDrop 1000 Spectrophotometer (Thermo
Fisher Scientific, Waltham, MA, USA) and visually assessed on 1% agarose gel
electrophoresis.
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PCR reaction mixtures (50 µL) contained 2.5U Amplitaq™ DNA polymerase
(Applied Biosystems, CA, USA), 1X buffer I (Applied Biosystems, CA, USA), 2.5
mM magnesium chloride, 0.2 mM of each dNTP (Sigma-Aldrich, MO, USA), 200 µM
forward and reverse primer (Table 4.1) and 1 µL of genomic DNA (100 ng/µL starting
concentration). The PCR cycling conditions were 95°C for 2 minutes, 35 cycles of
94°C for 30 seconds, annealing temperatures as described in Table 4.1 for 30 seconds,
72 °C for 1 minute and final extension at 72°C for 5 minutes. Amplified tetO and tetA
products were resolved by electrophoresis in a 2% and a 1.5% agarose gel,
respectively.
Table 4.1. Primers used for the detection of tetO and tetA.
Primer

Sequence (5’ – 3’)

TetO-FW

ACGGARAGTTTATTGTATACC

TetO-RV

TGGCGTATCTATAATGTTGAC

Tet(A)-F

GTGAAACCCAACATACCCC

Tet(A)-R

GAAGGCAAGCAGGATGTAG

Tet(A)-Camp-F

ATCGTGGCCGGCATCACCGG

Tet(A)-Camp-R

TCCTCGCCGAAAATGACCC

Amplicon size
(bp)

Annealing
temp. (°C)

Reference

171

52

(Aminov,
GarriguesJeanjean and
Mackie 2001)

888

50

(Maynard et al.
2003; AbdiHachesoo et al.
2014)

407

54

This study

In the Abdi-Hachesoo et al. (2014) publication, the original tetA primer (Tet(A)-F and
Tet(A)-R) reference is not listed in their bibliography, although these primers were
previously reported by Maynard et al. (2003) for the detection of tetA among Canadian
swine E. coli isolates (Maynard et al. 2003; Abdi-Hachesoo et al. 2014).
4.3.3

Analysis of previously reported Campylobacter tetA sequences

Similarity searches were performed using the BLAST suite of programs Basic Local
Alignment Search Tool (BLAST). Sequences were aligned and in silico analysis was
performed using SnapGene v. 2.3.2
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4.4

RESULTS

4.4.1

Amplification of tetA

The primers described by Abdi-Hachesooo et al. (2014) failed to produce an amplicon
in this study using the positive control strain containing the pBR322 plasmid. In
addition, a selection of tetracycline-resistant thermophilic Campylobacter spp. isolates
also failed to generate an amplicon. A 407 bp product was successfully amplified using
the new primers (Tet(A)-Camp-F and Tet(A)-Camp-R) (Table 4.1) using the E. coli
K12 positive control strain (Figure 4.1), while none of the tetracycline-resistant
thermophilic Campylobacter spp. isolates generated a product.

Figure 4.1. Agarose gel electrophoresis of tetA (407 bp) PCR products using primers designed in this
study. Escherichia coli K12 SK1592 containing the pBR322 plasmid (positive control) and a selection
of Campylobacter spp. isolates are shown. tetA was not detected among any Campylobacter spp. in this
study.

136

4.4.2

Sequence analysis

We scanned the C. coli and C. jejuni tetA GenBank sequences, Shiraz3 and Shiraz4
(GenBank accession numbers: JX891463.1 and JX891464.1, respectively) described
in the Abdi-Hachesoo et al. (2014) publication against all Campylobacteraceae (taxid:
72294) sequences using BLASTn. Multiple tetO sequences were returned with 100%
identity, including C. jejuni 81-176 (GenBank: NG_048260.1). Furthermore, our
alignment studies demonstrated absolute homology between tetO (GenBank:
M18896.2) and Shiraz3 and 4 tetA sequences (GenBank: JX891463.1 and
JX891464.1, respectively).
In 2016 a second study reporting a high prevalence of tetA among thermophilic
Campylobacter spp. isolated from extensively reared Kenyan broilers was published
by Nguyen and co-workers (Nguyen et al. 2016). In that study, the tetA primers
included the same primers as those used by Abdi-Hachesoo et al. (2014) but due to
anomalous product sizes, a second set of in-house tetA primers were designed by
Nguyen et al. (designated tet-A-1 and tet-A-2) (Nguyen et al. 2016). However, these
primers were designed by Nguyen et al. inadvertently based on the Shiraz 3 and 4
sequences (GenBank: JX891463.1 and JX891464.1, respectively) (Abdi-Hachesoo et
al. 2014), which we clarified above as tetO. To confirm this, we performed an in-silico
PCR using SnapGene v. 2.3.2 with the tet-A-1 and tet-A-2 primers (Nguyen et al.
2016) and Campylobacter tetO sequences (GenBank: M18896.2 and NG_048260.1).
A 486 bp product was predicted, which correlates to the amplicon length reported by
Nguyen et al. (2016). We believe that this reported high prevalence of tetA among this
subset (n=53) of thermophilic Campylobacter isolates is erroneous.
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4.5

DISCUSSION

The failure of the tetA primers listed by Abdi-Hachesoo et al. (2014) to produce an
amplicon with the same E. coli (DSM 3879 positive control strain), under less stringent
conditions, prompted further investigation within our study. We believe that it remains
to be determined whether tetA exists among thermophilic Campylobacter spp.
We have shown that sequences previously described as novel Campylobacter tetA
homologues (Abdi-Hachesoo et al. 2014) are identical to tetO. In a second study, these
sequences with erroneous designations prompted the design of primers in to detect
tetA, leading to the misconception that tetA was highly prevalent among
Campylobacter spp. isolated from rural chickens (Nguyen et al. 2016). We propose
that the true identity of the Shiraz 3 and 4 sequences are Campylobacter tetO
(standard). Our findings explain why clusters of tetA harbouring Campylobacter spp.
isolates have not been detected elsewhere or and have not been deposited in any
database, to our knowledge. However, recently Tang et al. (2020) reported
amplification of tetA in 6.5% of tetracycline-resistant Campylobacter isolates from
broilers in China, using the primers described by Abdi-Hashesoo (Tang et al. 2020).
However, control strains are not listed and the reverse tetA primer described in this
study (5’-TCCCACTGTTCCATATCGTCA-3’) (Tang et al. 2020) is not the same as
that described in the original publications (5’-GAAGGCAAGCAGGATGTAG-3’)
(Maynard et al. 2003; Abdi-Hachesoo et al. 2014) - instead this is the tetO reverse
primer.
Further study would be required to determine whether the homology between tetA
potentially present in Campylobacter and known tetA genes would be sufficient to
allow amplification using the primers designed in our study. Considering the
predominance of tetracyclines in veterinary medicine (European Medicines Agency
2018a; Health Products Regulatory Authority 2018), the accumulation of bioactive
tetracycline degradation products in the environment (Kemper 2008; Carvalho and
Santos 2016) and the concerning level of campylobacter tetracycline resistance
(European Food Safety Authority and European Centre for Disease Prevention and
Control 2021) - the investigation of alternative Campylobacter-associated tetracycline
resistance mechanisms is certainly worthwhile. However, we propose that the
presence of tetA in Campylobacter spp. remains an open question.
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5.0 Chapter 5. First reported detection of
biofilm formation by Campylobacter fetus
during investigation of a case of prosthetic
valve endocarditis
A manuscript based on this chapter has been published in the Journal of Clinical
Pathology

Lynch, C., O’Connor, J.A., O’Brien, D., Vaughan, C., Bolton, D., Coffey, A., Lucey, B. First reported
detection of biofilm formation by Campylobacter fetus during investigation of a case of prosthetic
valve endocarditis. J. Clin. Pathol. 2019, 72:554–7, doi:10.1136/jclinpath-2018-205677.

JOC isolated and speciated Campylobacter fetus CITCf01.
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5.1

ABSTRACT

Campylobacter fetus subsp fetus (Cff) can cause intestinal illness, particularly in
immunocompromised humans, with the potential to cause severe systemic infections.
Cff is a zoonotic pathogen with a broad host range among farm animals and humans,
inducing abortion in sheep and cows. The current paper describes a strain of Cff
isolated from a patient with prosthetic valve endocarditis in Mercy University
Hospital, Cork, Ireland, during 2017. Only six cases of C. fetus as a cause of prosthetic
valve endocarditis have been reported in the literature, with no reports of biofilm
formation within the species. The aetiological strain was speciated and subspeciated
by the VITEK 2 NH card and matrix- assisted laser desorption ionisation time-of-flight
mass spectrometry. Cff biofilm formation was analysed using a crystal violet staining
method. Campylobacter jejuni National Collection of Type Cultures (NCTC) 11168
was used as a positive control organism. Strains were incubated statically in Mueller
Hinton broth and Mueller Hinton broth supplemented with 0.025% sodium
deoxycholate for 3 and 7 days at 37°C, microaerobically. The Cff strain formed
stronger attached biofilms on polystyrene plates on day 3 (72 hours) than the C. jejuni
NCTC 11168 control strain but were weaker than the control strain on day 7 in Mueller
Hinton broth. Monoculture of this Cff isolate was found to exist in three defined forms
of biofilms (attached, air–liquid interface and floccules). This clinically significant Cff
isolate showed considerable biofilm-forming capability, which we suggest conferred
a survivalist advantage, contributing to the genesis of infective prosthetic valve
endocarditis.
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5.2

INTRODUCTION

Campylobacter fetus (subsp. fetus) (Cff) has a broad host range among farm animals
and humans (On 2001; Sahin et al. 2017). The bacterium is frequently associated with
zoonotic transmission causing a wide variety of clinical manifestations among
immunocompromised and elderly humans (Cypierre et al. 2014). Infection of
immunocompetent patients has also been documented (Nagy and Hla 2013; Mikals,
Masel and Gleeson 2014; Chávez et al. 2017).
Cff can cause intestinal illness (Bullman et al. 2011) with the potential to cause severe
systemic infections in humans (Morrison et al. 1990; Bessède et al. 2014; Wagenaar
et al. 2014; Reid et al. 2016). This species is the most commonly detected
Campylobacter causing bacteremia (Wagenaar et al. 2014) with a high degree of
mortality (Wagenaar et al. 2014; Reid et al. 2016). Cardiovascular pathologies may
also manifest consequent to its predilection for infecting the vascular endothelium
(Gazaigne et al. 2008; Haruyama et al. 2011). However, only six cases of Cff as a
cause of prosthetic valve endocarditis have been reported in the literature (Caramelli
et al. 1988; Farrugia, Eykyn and Smyth 1994; Peetermans et al. 2000; Haruyama et
al. 2011; Reid et al. 2016; Petridou, Strakova and Simpson 2018).
The C. fetus species comprises two prominent subspecies, Cff and C. fetus subsp.
venerealis (Cfv), with distinct niche preferences. The former has a broad host range
among farm animals and humans, inducing abortion in sheep and cows. The latter is a
sexually transmitted disease restricted to cattle (Vandamme and Ley 1991; Sahin et
al. 2017). The consumption of raw contaminated meat and occupational exposure to
infected animals are generally regarded as primary sources of sporadic human
infection (Wagenaar et al. 2014). However, data regarding transmission routes and
prevalence rates may be undermined by current isolation and culture techniques
(Wagenaar et al. 2014; Reid et al. 2016).
Biofilms are defined as a community of microbial cells structured in a self-produced
polymeric matrix (a fabric of extracellular proteins, polysaccharides and nucleic
acids), adherent to biotic or abiotic surfaces and each other, or indeed at an interface
(solid-liquid, liquid-liquid or liquid-gas) (Joshua et al. 2006; Teh, Lee and Dykes
2014). Biofilms are thought to provide protection against detrimental environmental
conditions, with concomitant reduced survival of planktonic counterparts under
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ambient, or non-optimised conditions, as reported in an investigation of
Campylobacter jejuni biofilms, including C. jejuni NCTC 11168 (Joshua et al. 2006).
Biofilms may confer enhanced cell survival as a consequence of slower growth rates
and reduced perfusion of toxic substances through the matrix (Kalmokoff et al. 2006).
Furthermore, biofilms are intrinsically resistant to common disinfectant and antibiotic
regimes, and also promote horizontal gene transfer of antibiotic resistance genes
among counterparts as DNA is a common structural component of biofilms (Asakura
et al. 2007; Teh, Lee and Dykes 2014; Brown et al. 2015; Kim et al. 2015).
Hydrophobic interactions, surface proteins, flagella and quorum sensing appear to play
a role in the development and maturation of Campylobacter biofilms (Dykes,
Sampathkumar and Korber 2003; Joshua et al. 2006; Kalmokoff et al. 2006; Asakura
et al. 2007; Bronowski, James and Winstanley 2014; Svensson, Pryjma and Gaynor
2014).
The current paper describes a strain of Cff isolated from a patient with prosthetic valve
endocarditis in the Mercy University Hospital (MUH), Cork, Ireland, during 2017.
Biofilm-forming capability may be an important mode of virulence for this organism
as has been shown previously for C. jejuni (Joshua et al. 2006; Svensson, Pryjma and
Gaynor 2014). No description of biofilm formation in C. fetus was found during a
literature search, including a paper by Gunther and Chen (2009) in which the type
strain (ATCC 15296) of Cff was tested and found not to be a reliable biofilm-former.
The investigation of biofilm-forming capabilities of the isolate in the current study
necessitated optimisation of a phenotypic method for biofilm detection that took the
growth requirements for the strain into consideration.
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5.3

METHODOLOGY

5.3.1

Bacterial isolates, and biofilm growth conditions

Isolate CITCf01 is a clinical strain obtained from the Mercy University Hospital, Cork,
Ireland in 2017, isolated from a monospecies prosthetic valve endocarditis infection.
C. jejuni NCTC 11168 was included as a control strain in the biofilm assay.
The Cff isolate was identified and subspeciated by the analytical profile index (API)
of the VITEK 2 system (bioMérieux, Marcy-l'Étoile, France) according to
manufacturer instructions. Briefly, a bacterial suspension adjusted to a McFarland
standard of 3 in 0.45% aqueous sodium chloride was used to inoculate a VITEK 2 NH
ID card, containing 64 wells with individual test substrates measuring various
metabolic activities. The card was applied to the automated VITEK 2 system and
incubated at 35.5°C for 6 hours, with colourimetic measurements every 15 minutes.
Test results were compacted by combining triplets of positive/negative binary results
into a VITEK 2 bionumber, using a computer-assisted algorithm of the VITEK 2
system. Result interpretation was performed automatically by database comparison.
Subspecies identification was confirmed by matrix-assisted laser desorption ionization
time-of-flight mass spectrometry MALDI-TOF MS (Bruker, Billerica, MA, United
States). The Cff isolate was also cultured on Mueller Hinton agar containing 0.5%, 1%
and 1.5% glycine and incubated for 48 hours at 37°C, under microaerobic conditions.
Strains were maintained at -80°C in defibrinated horse blood (Oxoid, Basingstoke,
England) with 30% (vol/vol) glycerol. Isolates were grown on Blood Free
Campylobacter Selectivity Agar Base (Sigma-Aldrich, St Louis, MO, USA) for 22 ±
2/46 ± 2 hours at 42°C under microaerobic conditions (N2, 85%; O2, 5 %; CO2, 10%).
Cultures were subsequently transferred to Mueller Hinton broth 2 (Sigma-Aldrich) for
24 hours at 42°C under microaerobic conditions. Two broths were assessed for their
effect on biofilm formation, namely Mueller Hinton broth 2 and Mueller Hinton broth
2 supplemented with sub-inhibitory concentrations of sodium deoxycholate (0.025 %)
(Sigma-Aldrich). Strains were grown to an OD600 of 0.05 (slow growing strain) and
diluted 1:2 in fresh broth (Mueller Hinton broth 2 and Mueller Hinton broth 2
supplemented with 0.025% sodium deoxycholate – final concentration) to a final
volume of 180 μL in a tissue culture microtiter 96 well plate (Sarstedt, Nümbrecht,
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Germany). Plates were incubated statically for three (72 hours) or seven days at 37°C
(to replicate in-vivo temperature conditions) under microaerobic conditions.
5.3.2

Optimisation of biofilm assay

To establish the most favourable conditions for biofilm propagation, the Cff strain was
tested with multiple broths and conditions, including shaking and static incubation, at
37°C and 42°C, under aerobic and microaerobic conditions. Biofilms were examined
at intervals of 1, 2, 3, 7, 14 and 21 days, to determine optimum incubation time for
biofilm formation.
5.3.3

Crystal violet staining method

Crystal violet staining was used to measure the extent of biofilm formation, as
previously described for C. jejuni and other bacteria (Reuter et al. 2010; Kelly et al.
2012), with some modifications. Briefly, wells were decanted and washed with 200
µL water and allowed to dry. Biofilms were stained with 200 µL 1% filtered crystal
violet (Sigma-Aldrich) for 30 minutes at room temperature. Wells were washed with
200 µL deionised water three times to remove unbound crystal violet and allowed to
dry. Crystal violet was solubilised with 200 µL 30% acetic acid and after 30 minutes,
the OD590 was determined on a SPECTRAmax™ 340 Microplate Reader (Molecular
Devices, San Jose, CA, USA). Three independent experiments were conducted, with
multiple replicates for each reading.
5.3.4

Pellicle formation

For growth of pellicles, 10 mL volume of Mueller Hinton broth 2 in borosilicate glass
tubes was inoculated with 20 colonies from a fresh 46 ± 2 hour culture grown on blood
free Campylobacter selectivity agar. Tubes were incubated statically for 21 days at
37°C under microaerobic conditions.
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5.4

RESULTS

5.4.1

Isolate identification

Cff identification was indicated both by the VITEK 2 biochemical profile (bionumber:
0210000522), and by MALDI-TOF MS. This Cff strain was capable of slow aerobic
growth and growth at 25°C, 37°C and 42°C and tolerant of 0.5%, 1% and 1.5%
glycine.
5.4.2

Establishment of conditions for estimating biofilm formation

From the results of a preliminary study (data not shown), 3 days and 7 days were
selected as optimum incubation intervals for biofilm formation. Strains did not form
appreciable biofilms under aerobic conditions nor under microaerobic conditions
when shaken at 50 – 150 rpm. Strongest biofilm formation reported in the current
study occurred when incubation was conducted statically at 37°C for 3 and 7 days,
under microaerobic conditions.
Mueller Hinton broth 2 alone (Reeser et al. 2007; Teh, Lee and Dykes 2016) and
supplemented with 0.025% sodium deoxycholate promoted biofilm formation, in
accordance with previous findings (Svensson, Pryjma and Gaynor 2014)
5.4.3

Biofilm formation assay

Cff CITCf01 produced stronger biofilms at 72 hours than the control strain C. jejuni
NCTC 11168 in both Mueller Hinton broth and Mueller Hinton broth supplemented
with 0.025% sodium deoxycholate (Figure 5.1) (p value: 0.004 and p value: 0.001,
respectively). However, after 7 days of incubation, Cff CITCf01 biofilms were less
extensive and weaker than the C. jejuni NCTC 11168 strain in Mueller Hinton broth
2 (p value: 0.004) (Figure 5.2), however there was no statistically significant
difference at day 7 in Mueller Hinton broth supplemented with 0.025% sodium
deoxycholate.

145

0.45

Absorbance at OD590

0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

Mueller-Hinton
Meuller
Hinton broth 2

Mueller-Hinton
+ 0.025%
sodium
deoxycholate
Meuller Hinton
+ 0.025%
sodium
deoxycholate

Figure 5.1. Biofilm formation (OD590) of Campylobacter jejuni NCTC 11168 (black) and
Campylobacter fetus subsp. fetus strain CITCf01 (white) after static incubation for 3 days (72 hours) at
37°C, under microaerobic conditions, followed by staining and quantification with crystal violet. Error
bars represent standard deviation.
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Figure 5.2. Biofilm formation (OD590) of Campylobacter jejuni NCTC 11168 (black) and
Campylobacter fetus subsp. fetus strain CITCf01 (white) after static incubation for 7 days at 37°C,
under microaerobic conditions, followed by staining and quantification with crystal violet. Error bars
represent standard deviation.

5.4.4

Air-liquid interface and floccule biofilm formation

Pellicle formation was observed in static incubation at 37°C microaerobically in
Mueller Hinton broth 2 in borosilicate glass tubes, at the air-liquid interface, within 48
hours and increasing in thickness over time (Figure 5.3). Unattached Cff floccule
formation was also observed after 48 hours of incubation in Mueller-Hinton broth 2
supplemented with 0.025% sodium deoxycholate, at 37°C and shaken at 100 rpm,
under microaerobic conditions (Figure 5.4).
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Figure 5.3. Campylobacter fetus subsp. fetus strain CITCf01 biofilm formation static incubation in
Mueller Hinton broth 2, for 21 days at 37°C, under microaerobic conditions. A dense, but fragile
pellicle, attached to the borosilicate glass tube was observed at the air liquid interface.

Figure 5.4. Campylobacter fetus subsp. fetus strain CITCf01 unattached floccule formation after 48
hours incubation in Mueller Hinton broth 2 supplemented with 0.025% sodium deoxycholate at 37°C
and shaken at 100 rpm, under microaerobic conditions. Floccules appear to have dissolved after an
additional 24 hours incubation.
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5.5

DISCUSSION

C. fetus is an emerging human pathogen and is the only notable Campylobacter
species, among 24 currently recognised species within the genus, capable of causing
a broad spectrum of systemic human infections, particularly among the
immunocompromised, elderly or pregnant (Nagy and Hla 2013; Wagenaar et al.
2014). Elucidation of the molecular mechanisms of biofilm formation in the genus of
Campylobacter is in its infancy, combined with a lack of specific data in relation to C.
fetus biofilm generation and its role in pathogenicity (Gunther IV and Chen 2009).
Hence, a semi-quantitative assay for the determination of biofilm forming propensity
of this C. fetus strain was developed. Having only a single Cff strain for this study was
a limitation. However, the clinical significance of the isolate suggests a need for
further studies of clinical strains of this species.
The VITEK 2 system and MALDI-TOF MS identified the etiologic strain as Cff.
However, discordance between molecular classification and MALDI-TOF MS spectra
has been reported within the C. fetus species and database expansion has been reported
to be required (Liu et al. 2017). Furthermore, this Cff strain was glycine tolerant and
capable of growth at 37°C and 42°C, features which distinguishes this species from
Cfv (Vandamme and Ley 1991; Vargas et al. 2003; Schulze et al. 2006).
The Cff strain formed stronger attached biofilms on polystyrene plates at day 3 (72
hours) (Figure 5.1) than the C. jejuni NCTC 11168 control strain (which has
previously been reported to be a biofilm producer) (Joshua et al. 2006; Kalmokoff et
al. 2006; Reuter et al. 2010; Brown et al. 2015; Turonova et al. 2015).
The less extensive Cff biofilm formation at day 7 in Mueller Hinton broth 2 suggests
a possible transition from sessile to planktonic growth during this time, which may
lead to the ability to colonise larger areas, thus leading to more persistent colonization
or infections. Biofilms are generally associated with enhanced survivability (Joshua et
al. 2006). Conversely, Dykes et al. (2003) demonstrated the reduced survivability of
C. jejuni biofilm grown cells when compared to planktonic grown cells, compounded
by a higher hydrophobicity of planktonic cells. Virulence among enteric pathogens is
critically dependent on bacterial hydrophobicity (Absolom 1988; Moser and Schröder
1997). Hence, transitioning from sessile to planktonic growth may be correlated with
increased pathogenicity, while biofilm formation or surface attachment may be
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essential for infection to occur (Dykes, Sampathkumar and Korber 2003), whether in
the gut or in the circulatory system. However in another study, a correlation between
sessile or planktonic Campylobacter and associated hydrophobicity was not
determined, which may indicate strain dependence within the genus (Nguyen, Turner
and Dykes 2011).
The strains in the study did not form attached biofilms when incubated in liquid
culture shaken at 50-150 rpm, similar to the results of a study carried out by Joshua et
al. (2006), when investigating biofilm formation in C. jejuni NCTC 11168. Moreover,
Rollins et al. (1986) described the logarithmic decline in recoverable C. jejuni from
stream water when incubated aerated with shaking compared to C. jejuni in a
stationary microcosm. Vigorous shaking may increase the oxygen levels in the culture
medium to unfavourable or lethal concentrations (Teh, Lee and Dykes 2014). The rate
of flow of transvalvular blood is 250 mL/sec (Blais et al. 2006) and it has been noted
previously that C. jejuni are unable to attach at flow rates as low as 300 mL/hr(Joshua
et al. 2006).
Moreover, biofilms formed successfully under microaerobic conditions, paralleled in
a study characterising biofilm formation in C. jejuni NCTC 11168 by Reeser et al.
(2007). Biofilms did not form effectively under aerobic conditions in-vitro (21%
oxygen and 0.04% carbon dioxide) in this study however the Cff isolate was capable
of slow growth aerobically. The Campylobacter genus is microaerophilic, requiring
lower levels of oxygen, generally at concentrations ranging from 2 – 10%, being also
capnophilic, requiring higher levels of carbon dioxide, generally at a concentration of
10%. The normal oxygen content of arterial and venous blood is around 20 and 10-15
volume per cent respectively, although notable variety has been reported in venous
blood. However, the oxygen content of arterial and venous blood in patients with
vascular pathologies and circulatory diseases can be as low as 3.5 and 1 volume
percent respectively (Harrop 1919). Contrastingly, a recent study by Reuter et al
(2010) described the increase in initial biofilm formation of C. jejuni NCTC 11168
under aerobic conditions, a finding mirrored by Asakura et al. (2007). Similarly,
Turonova et al (2015) determined that acclimation of C. jejuni NCTC 11168 and 81176 cells to oxygen enriched conditions led to significant enhancement of biofilm
formation during early attachment. However, all three of these studies investigated the
effects of aerobic biofilm growth on the same strain (C. jejuni NCTC 11168).
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Understanding persistence in aerobic environments is critical to the prevention of
human infection. In this case, however, an unknown initiator may have been involved
in the promotion of biofilm formation in-vivo.
Monoculture of this Cff isolate was found to exist in three defined forms of biofilms
when cultivated in Mueller Hinton broth 2 under appropriate conditions. Cff biofilms
were observed attached to polystyrene plastic of the microtiter plates and at the airliquid interface of a standing liquid culture in borosilicate glass tubes (Figure 5.3).
Floccules (unattached aggregates) were also observed in liquid culture of Mueller
Hinton broth 2 supplemented with 0.025% sodium deoxycholate shaken at 100 rpm
(Figure 5.4), a phenomenon described in a study by Joshua et al (2006) under similar
flow rates.
The prosthesis was a 23 mm perimount bovine pericardial bioprosthesis and a 30 mm
annuloplasty physio Edwards’ ring mitral valve, used for aortic valve replacement. It
is possible that this prosthesis facilitated biofilm growth by Cff, which is an area that
might benefit from a separate study. Furthermore, biofilm formation of human, animal
and environmental C. fetus and Cff strains should be characterised to demonstrate the
capacity for biofilm formation within the species and subspecies.
The global transcription response resulting in the generation of a biofilm may have
served as an environmental protection mechanism, initiating the development of the
prosthetic valve endocarditis. Cff resides in the gastrointestinal tract of cattle and
sheep and is likely shed in animal faeces - biofilm formation may also contribute to
survival in the environment, however further studies on the environmental persistence
of Cff are required. Conclusively, this clinically significant Cff isolate showed
considerable biofilm forming capability, which undoubtedly conferred a survivalist
advantage and contributed to the genesis of infective prosthetic valve endocarditis.
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6.0 Chapter 6. Genomic and phenotypic
analyses of two Campylobacter fetus isolates
from a patient with relapsed prosthetic
valve endocarditis
A manuscript based on this chapter has been submitted to Pathogens and Disease
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CRISPR spacer typing.
NW and CMcC assisted with phenotypic characterisation of C. fetus isolates.
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6.1

ABSTRACT

Campylobacter fetus can cause intestinal and systemic disease in humans and are well
established veterinary and economic pathogens. We report the complete genomic
sequences of two C. fetus subsp. fetus (Cff) isolates recovered in 2017 (CITCf01) and
2018 (CITCf02) from a case of recurrent prosthetic valve endocarditis. Both were
capable of growth aerobically. Their genomes were found to be highly conserved and
syntenic with 99.97% average nucleotide identity (ANI), while differences in their
respective sap loci defined the temporal separation of their genomes. Based on core
genome phylogeny and ANI of 83 human-associated Cff genomes, CITCf01 and
CITCf02 grouped in a clade of eleven sequence type (ST)3 Cff (including the Cff type
strain NCTC 10842T), originating from human or ovine hosts. CITCf01 and CITCf02
were marked for their lack of unique genomic features when compared to isolates
within the subspecies and the type strain in particular. We identified point mutations
in oxidative stress response genes, among others, that may contribute to aerobiosis.
We report a case of Cff causing relapsed prosthetic infectious endocarditis and we
highlight the sap island as a polymorphic site within the genetically stable ST3 lineage,
central to pathogenicity.
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6.2

INTRODUCTION

Campylobacter fetus is a well-established veterinary and economic pathogen capable
of causing intestinal and systemic disease in humans. Among the three currently
defined C. fetus subspecies, Campylobacter fetus subsp. venerealis (Cfv) is a bovineadapted clone causing bovine genital campylobacteriosis and infectious infertility in
cattle but is an infrequent cause of human infection (Wagenaar et al. 2014)
Campylobacter fetus subsp. testudinum (Cft) is largely reptile-associated (Fitzgerald
et al. 2014) though the type strain (Cft strain 03-427) was originally isolated from
human blood in 2003, while the subspecies was not defined until 2014 (Fitzgerald et
al. 2014).
The generalist lineage of Campylobacter fetus subsp. fetus (Cff) colonises the
intestinal and genital tract of ovine, bovine, avian and human hosts (Iraola et al. 2017)
and is associated with epizootic septic abortion in ruminants, predominantly sheep
(Sahin et al.). Cff is also a cause of intestinal illness in humans (Bullman et al. 2011)
but notably is the most frequent Campylobacter causing bacteraemia (Wagenaar et al.
2014). Cff has been well documented to cause a spectrum of systemic illnesses in
immunocompromised humans with a tropism for the vascular endothelium, especially
at sites of pre-existing damage (Morrison et al. 1990). Reported infections include but
are not limited to; septic abortion (Hood and Todd 1960), spondylodiscitis (Cunha et
al. 2021), outbreaks of nosocomial neonatal meningitis (Morooka et al. 1988), skin
and soft tissue infections (La Scola, Chambourlier and Bouillot 1998), peritonitis
(Wens et al. 1985), endocarditis (Durovic et al. 2021) and other vascular pathologies
(vasculitis, pericarditis, thrombophlebitis, mycotic aneurysms, aortitis among others)
(Morrison et al. 1990; Wagenaar et al. 2014; Nulens et al. 2018; Eke, Doub and Chua
2021). Persistent (Nakazawa et al. 2018), recurrent or relapsed (Tremblay, Gaudreau
and Lorange 2003; Tu, Gaudreau and Blaser 2005; Nishikubo et al. 2021) and
multifocal invasive C. fetus infections (Durovic et al. 2021) have also been reported.
In some instances, systemic C. fetus infections have been recorded in
immunocompetent individuals (Gazaigne et al. 2008) or were not preceded by
diarrhoeal illness (or Cff was not detected from faeces) (Eke, Doub and Chua 2021).
The source of infection is often linked to animal exposure (Wagenaar et al. 2014;
Nakazawa et al. 2018) or the consumption of contaminated meat products.
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Kiggins and Plastridge (1956) reported that atmospheric conditions of 5% oxygen and
10% carbon dioxide were optimal for C. fetus and growth in air is not a species trait
(Véron and Chatelain 1973). In nature, or during infection, Campylobacter spp. are
exposed to iron limiting conditions and oxidative stress. Aerotolerant Campylobacter
spp. have been described in the literature, with varying degrees of survival and growth
in air, typically Campylobacter jejuni isolated from retail meat or food animals (Oh,
McMullen and Jeon 2015; O’Kane and Connerton 2017; Kim et al. 2019) or humans
(Rodrigues et al. 2015). Reports of Cff aerobiosis are limited. Neill et al. (1985)
described rouge C. fetus strains that grew aerobically and failed to reduce nitrate and
due to the complexity and recent expansion of the genus, these isolates may belong to
a different species/subspecies category.
In this paper, we describe two Cff isolates (CITCf01 and CITCf02) recovered in 2017
and 2018, respectively from blood cultures of an Irish patient with recurrent prosthetic
valve endocarditis, that were marked for their ability to grow aerobically. Reports of
C. fetus causing prosthetic valve endocarditis are limited (Caramelli et al. 1988;
Farrugia, Eykyn and Smyth 1994; Peetermans et al. 2000; Haruyama et al. 2011; Reid
et al. 2016; Petridou, Strakova and Simpson 2018). In this study, our aim was to
investigate the phenotypic characteristics, antimicrobial resistance (AMR), genomic
composition and phylogeny of such isolates.
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6.3

METHODOLOGY

6.3.1

Bacterial isolates and growth conditions

Clinical Cff isolates CITCf01 and CITCf02 were obtained from an elderly male patient
(77 years upon first isolation) in the Mercy University Hospital, Cork, Ireland in a case
of recurrent prosthetic valve endocarditis, where CITCf01 was isolated from blood
cultures in 2017 and CITCf02 in November 2018.
The Cff isolates were recovered from aerobic and anaerobic blood culture bottles
(BacT/ALERT FA Plus and FN Plus) on the BacT/ALERT Virtuo continuous
monitoring blood culture system (bioMérieux, Marcy-l'Étoile, France). The Cff type
strain NCTC 10842T (hereafter referred to as NCTC 10842T) was obtained from the
German Collection of Microorganisms and Cell Cultures (DSMZ): DSM 5361.
Isolates were subsequently maintained at –80°C in defibrinated horse blood (Oxoid,
Basingstoke, England) with 30% (vol/vol) glycerol and recovered from frozen stocks
on Columbia blood agar (CBA) (Fannin, Dublin, Ireland), incubated for 22 ± 2/44 ± 4
hours at 37°C, under microaerobic conditions, and sub-cultured.
6.3.2

Identification and subspeciation

Cff isolates CITCf01 and CITCf02 were identified and subspeciated using the NH ID
card on the analytical profile index (API) of the VITEK 2 (bioMérieux, Marcy-l'Étoile,
France) according to manufacturer’s instructions, and as described previously (Lynch
et al. 2019). Species identification was performed in duplicate by matrix-assisted laser
desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS) on the
Bruker MALDI Microflex Biotyper instrument (Bruker Daltonics, Billerica, MA,
USA), as described previously (Koziel et al. 2014). Briefly, a single colony was
transferred to a position on a MALDI target polished steel plate (Bruker Daltonics).
Proteins were extracted by treatment with 1 µL of 70% formic acid. After air-drying,
samples were immediately overlaid with 1 µL of Bruker HCCA matrix solution (αcyano-4-hydroxycinnamic acid; 10 mg Bruker CHCA/mL) and allowed to air-dry
before MALDI-TOF MS analysis. Mass spectra were generated with a Microflex mass
spectrophotometer and assessed using the Biotyper Real Time Classification software
with flexControl software (version 3.4) (Bruker Daltonics).
6.3.3

Biochemical and phenotypic profiling
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To characterise isolates CITCf01 and CITCf02, classical phenotypic and biochemical
testing was performed as previously described (Sandstedt and Ursing 1991; On and
Holmes 1992; Ursing, Lior and Owen 1994; Cowan 2012), with appropriate control
organisms for each test. Briefly, growth at varying temperatures (room temperature
(18-21°C,) 25°C, 37°C and 42°C) or under aerobic, microaerobic and anaerobic
conditions was tested on CBA and observed at 24, 48 and 72 hours. Growth on Mueller
Hinton agar (Sigma-Aldrich, St Louis, MO, USA) at 37°C under aerobic conditions
was also assessed. All other testing, unless otherwise specified was conducted at 37°C,
under microaerobic conditions and examined at 24, 48 and 72 hours. Hippurate
production was determined using hippurate strip tests (Sigma-Aldrich) and indoxyl
acetate hydrolysis using 25 µg indoxyl acetate discs (Thermo Fischer Scientific,
Waltham, MA, USA), according to the manufacturer’s instructions. Nitrate reduction
was tested by inoculating 10 mL nitrate broth (9g/L), incubation at the appropriate
conditions for 48 hours and the addition of equal amounts sulfanilic acid (5 g/L in 30%
acetic acid) and α-naphtylamine solution (5 g/L in 5N acetic acid). Zinc was added to
the solution in the absence of a red colour development to confirm that nitrate was
present in the original medium. Triple sugar iron agar (Sigma-Aldrich) in 5 mL
aliquots (1 inch butt and 1.5-inch slant in borosilicate glass tubes) were inoculated
with stab cultures and incubated for seven days to identify slow H2S producers
(Ursing, Lior and Owen 1994), while urea slopes were stabbed with cultures and
incubated for up to six days (Christensen 1946). Glycine and NaCl tolerance were
assessed using Mueller Hinton agar (Sigma-Aldrich) spiked with varying
concentrations of glycine (1%, 1.5%, 2%, 2.5% and 3%) and NaCl (1.5%, 2% and
2.5%). Susceptibility to 30 µg cephalothin (Oxoid) and nalidixic acid (Oxoid) was
tested on CBA using an inoculum equivalent to a 0.5 McFarland standard.
6.3.4

Phenotypic antimicrobial resistance profiling

Isolates CITCf01 and CITCf02 were tested for resistance to five clinically relevant
antimicrobials namely, tetracycline (0.5-64 µg/mL), erythromycin (1-128 µg/mL),
ciprofloxacin (0.12-16 µg/mL), gentamicin (0.12-16 µg/mL), and streptomycin (0.2516 µg/mL) using broth microdilution minimum inhibitory concentration (MIC) testing
according to ISO 20776:2006. Briefly, isolates were sub-cultured to CBA and
incubated for 48 hours at 37°C under microaerobic conditions. A 0.5 McFarland
inoculum was prepared in 5 mL of demineralised water (Thermo Fisher Scientific)
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and 100 µL was transferred to 11 mL of Mueller Hinton broth with lysed horse blood
(Thermo Fisher Scientific). EUCAMP2 Sensititre plates (Thermo Fisher Scientific)
were inoculated with 100 µL of cell suspension per well and incubated for 48 hours at
37°C, under microaerobic conditions. Pre- and post-purity was assessed on CBA. The
MIC was reported as the lowest antimicrobial concentration completely inhibiting
visible bacterial growth.
6.3.5

Whole-genome sequencing

Whole-genome sequencing (WGS) of CITCf01 and CITCf02 was performed using
short-read Illumina and long-read Oxford Nanopore sequencing. For Illumina
sequencing, plate cultures of each isolate were harvested and resuspended in a tube
with cryopreservative™ (Microbank Pro-Lab Diagnostics UK, United Kingdom).
Twenty microlitres of the suspension was lysed with 120 µL of TE buffer containing
lysozyme (final concentration 0.1 mg/mL) and RNase A (ITW Reagents, Barcelona,
Spain) (final concentration 0.1 mg/mL), incubated for 25 minutes at 37°C. Proteinase
K (VWR Chemicals, Radnor, Pennsylvania, United States) (final concentration
0.1mg/mL) and SDS (Sigma-Aldrich, St Louis, MO, USA) (final concentration 0.5%
v/v) were added and incubated for 5 minutes at 65°C. Genomic DNA was purified
using an equal volume of SPRI beads and resuspended in EB buffer (Qiagen, Hilden,
Germany). DNA was quantified with the Quant-iT dsDNA HS kit (Thermo Fisher
Scientific) assay in an Eppendorf AF2200 plate reader (Eppendorf UK Ltd, United
Kingdom). Genomic DNA libraries were prepared using the Nextera XT Library Prep
Kit (Illumina, San Diego, USA) following the manufacturer’s protocol with the
following modifications: 2 ng of DNA were used as input, and PCR elongation time
was increased to 1 minute. DNA quantification and library preparation were carried
out on a Hamilton Microlab STAR automated liquid handling system (Hamilton
Bonaduz AG, Bonaduz, Switzerland). Pooled libraries were quantified using the Kapa
Biosystems Library Quantification Kit for Illumina on a Roche light cycler 96 qPCR
machine (Roche, Basel, Switzerland). Libraries were sequenced with the Illumina
HiSeq 2500 using a 250 bp paired-end protocol.
For Nanopore sequencing, broth cultures of each isolate were then pelleted and
resuspended in the tube with cryoperservative (Microbank, Pro-Lab Diagnostics UK).
Approximately 2x109 cells were used for high molecular weight (HMW) DNA
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extraction using Nanobind CCB Big DNA Kit (Circulomics, Baltimore, Maryland,
USA). DNA was quantified with the Qubit dsDNA HS assay in an Invitrogen Qubit
3.0 (Thermo Fisher Scientific). Long-read genomic DNA libraries were prepared with
Oxford Nanopore SQK-RBK004 kit with Native Barcoding EXP-NBD104/114
(Oxford Nanopore Technologies, United Kingdom) using 500 ng of HMW DNA.
Barcoded samples were pooled together into a single sequencing library and loaded in
a FLO-MIN106 (R.9.4) flow cell in a GridION (Oxford Nanopore Technologies).
Illumina reads were adapter trimmed using Trimmomatic 0.30 with a sliding window
quality cut-off of Q15 (Bolger, Lohse and Usadel 2014). Hybrid genome assembly
was performed using Unicycler v0.4.0 (Wick et al. 2017).
6.3.6

Bioinformatic analysis of CITCf01 and CITCf02 and comparison to the

Campylobacter fetus subsp. fetus type strain NCTC 10842T
Predicted open reading frames (ORFs) were annotated with Prokka 1.13.5 (Seemann
2014), using a reference annotation database derived from Cff (GenBank accession
numbers: CP008808.1, CP000487.1, LS483431.1), Cfv (GenBank accession number:
CM001228.1) and Cft (GenBank accession number: CP010953.1) genomes. AMR
genes were screened using the Resfinder database (Zankari et al. 2012) on ABRicate
(Seemann) and the Comprehensive Antibiotic Resistance Database (Jia et al. 2017;
Alcock et al. 2020).
Similarity searches were performed using the Basic Local Alignment Search Tool
(BLAST) suite of programs (Altschul et al. 1990). Selected predicted proteins were
analysed with InterProScan (Jones et al. 2014), EggNOG Mapper [v.2.0.1] (HuertaCepas et al. 2019), KEGG (Kanehisa 2019; Kanehisa et al. 2019; Yi et al. 2020), Pfam
(El-Gebali et al. 2019), HHPred (Zimmermann et al. 2018; Gabler et al. 2020) and
GhostKOALA (Kanehisa, Sato and Morishima 2016). Regulatory proteins were
predicted using P2RP (Barakat, Ortet and Whitworth 2013) and Rho–independent
transcription terminators using ARNold (Hofacker et al. 1994; Gautheret and Lambert
2001; Lesnik et al. 2001; Macke et al. 2001).
To assess the mobilome, prophage elements were detected using PHASTER (Zhou et
al. 2011; Arndt et al. 2016) and CRISPR (clustered regularly interspaced short
palindromic repeats) elements were identified using CRISPRCasFinder (Abby et al.
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2014; Pearson et al. 2015; Couvin et al. 2018). Plasmid prediction was performed
using PlasFlow (Krawczyk, Lipinski and Dziembowski 2018) and insertion sequences
using ISFinder (Siguier et al. 2006).
Genomic arrangements between CITCf01 and CITCf02 were viewed with Mauve
(Darling et al. 2004; Darling, Mau and Perna 2010), EasyFig (Sullivan, Petty and
Beatson 2011) and Artemis Comparison Tool (ACT) (Carver et al. 2005). Deduced
sap homologues were defined based on a 547 bp 5’ conserved region, where ORFs
lacking the shared 5’ start region or ORFs without the full conserved sequence were
regarded as truncated sap genes.
Clustering of gene orthologues in CITCf01 or CITCf02 and NCTC 10842T was
performed using ProteinOrtho Galaxy version 6.0.14+galaxy2.9.1 (Lechner et al.
2011) with the DIAMOND (Buchfink, Xie and Huson 2014) alignment algorithm.
Core and accessory gene counts were determined with 95% minimal sequence
similarity, 80% minimal coverage and 60% minimal percent identity (Bisanz et al.
2020). Genome map was generated using CGView (Stothard and Wishart 2005).
Single nucleotide polymorphism (SNP) and small insertion and deletion (indel) calling
was performed with Snippy (Galaxy version 4.5.0) (Seeman 2015) using default
parameters, mapping the paired-end reads of CITCf01 to NCTC 10842T as the
reference genome, or paired-end reads of CITCf02 to CITCf01 as the reference
genome. Nonsynonymous SNPs were called using Mummer and default parameters
(Galaxy version 4.0.0beta2+galaxy1) (Marçais et al. 2018).
6.3.7

Campylobacter fetus subsp. fetus phylogeny and pangenome analysis

Additional complete and draft Cff genomes (n=81) were retrieved from NCBI and
included 73 human-associated C. fetus genomes collected in a metagenomics study by
Iraola et al. (2017). Isolate attributes are detailed in Appendix B, Table B1. Pairedend reads were assembled using SPAdes v.3.11.1 and quality checked using fastqc.
Pairwise average nucleotide identity (ANI) was calculated using FastANI (Jain et al.
2018) and the Cff ANI heatmap was created using Pheatmap v1.0.12 (Kolde 2012).
Core and accessory genomes of the 83 (total) Cff genomes were analysed using Roary
[v. 3.12.0] (Page et al. 2015). Coding sequences (CDS) with at least 95% identity were
considered as part of the core genome for the analysis, and core is defined as a gene
present in at least 99% of samples (van der Graaf-Van Bloois et al. 2014; Iraola et al.
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2017). Alignment of concatenated core genes was performed by Roary and
FASTTREE [v. 2.1.10] (Price, Dehal and Arkin 2010) was used to construct the
maximum-likelihood phylogenetic tree. The phylogenetic tree was visualised using
iTOL v5 (Letunic and Bork 2016). Multi locus sequence types (MLST) profiles were
interrogated using the PubMLST Campylobacter database (Jolley, Bray and Maiden
2018). Bayesian-clustering was also performed on Roary concatenated core genes
(Cheng et al. 2013). CRISPR (clustered regularly interspaced short palindromic
repeats) spacer typing was used to differentiate the ST3 Cff isolates. CRISPR spacer
sequences were extracted with MinCED [v.0.4.2] (Bland et al. 2007) and redundant
sequences were removed using BLASTn (-task BLASTn-short). The R package
heatmaply was used for hierarchical clustering of shared spacer sequences and
visualisation (Galili et al. 2018).
6.3.8

Data availability

Genomes for both Cff isolates CITCf01 and CITCf02 were deposited in GenBank
under the following accession numbers CP072664 and CP072665.
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6.4

RESULTS

6.4.1

Isolation and identification

We report the isolation, phenotypic behaviour and genomic attributes of two Cff
isolates recovered from an elderly male patient in a case of recurrent prosthetic valve
endocarditis. Cff isolates CITCf01 and CITCf02 were isolated from blood culture
bottles in 2017 and 2018. Although stool samples were not taken on these occasions,
Campylobacter was not detected in a stool sample taken in April 2017. A reliable
identification (MALDI score > 2.000) of Cff subspecies membership was made for
the sister isolates CITCf01 and CITCf02, corresponding to their VITEK profile
(bionumber: 0210000522).
6.4.2

Phenotypic and biochemical characteristics of CITCf01 and CITCf02

Cff isolates CITCf01 and CITCf02 behaved as typical Cff (Table 6.1), despite their
unusual ability to grow under aerobic conditions on CBA, not observed for NCTC
10842T, as confirmed in this study. Faint growth of isolates CITCf01 and CITCf02
appeared after 24 hours incubation and by 48-72 hours, colonies were coarser and
smaller than their counterparts grown under microaerobic conditions. Aerobic cultures
of CITCf01 and CITCf02 rarely grew beyond the third quadrant of the CBA plate after
72 hours of incubation. The isolates also grew aerobically on Mueller-Hinton agar,
although weaker than on CBA.
Both clinical Cff isolates CITCf01 and CITCf02 were sensitive to tetracycline,
erythromycin, ciprofloxacin, gentamicin and streptomycin (Table 2). CITCf01 and
CITCf02 were resistant to nalidixic acid (30 µg) and susceptible to cephalothin (30
µg) – where resistance to nalidixic acid is a C. fetus specific trait (Gazaigne et al. 2008;
Cowan 2012). Resistance to antimicrobials is typically lower within the species
compared to C. jejuni and Campylobacter coli (Pacanowski et al. 2008). Third
generation cephalosporins, fluoroquinolones and macrolides are not indicated as
empirical treatment of C. fetus bacteraemia or invasive infections due to increasing
rates of resistance (Gazaigne et al. 2008; Lee et al. 2011; Mosca, Del Gaudio and
Miragliotta 2017; Nulens et al. 2018), multidrug resistance (Anstead et al. 2001) or
post-treatment ciprofloxacin resistance (Meier et al. 1998; Nishikubo et al. 2021). A
carbapenem or amoxicillin–clavulanate in monotherapy, or in combination with
gentamicin, is the current practice as first-line therapy, although an in vitro imipenem161

resistant C. fetus has been reported (Nulens et al. 2018). Notably, a gentamicinresistant C. fetus isolate was recovered from retail pork in Ireland over ten years ago
(Scanlon et al. 2013). Correct early antimicrobial therapy improves patient outcomes
(Morrison et al. 1990), but despite increasing rates of AMR within the genus relatively
little is known about the true rates of resistance among C. fetus isolates, accounting
for geography and host (Kwon et al. 1994; Tremblay, Gaudreau and Lorange 2003).
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Table 6.1. Phenotypic characteristics of Campylobacter fetus subsp. fetus (Cff) isolates CITCf01 and
CITCf02 compared to C. fetus subspecies - Cff, Campylobacter fetus subsp. venerealis (Cfv) and
Campylobacter fetus subsp. testudinum (Cft), where the latter has been reported previously to grow
aerobically. Data for reference taxa were defined based on previously reported species/subspecies
descriptions (Véron and Chatelain 1973; Fitzgerald et al. 2014; Gilbert et al. 2017).
Cff CITCf01 Cff CITCf02
Cff
Oxidase
+
+
+
Catalase
+
+
+
Urease
Nitrate reduction
+
+
+
Hippurate hydrolysis
Indoxyl acetate hydrolysis
H2S production
α-haemolysis
Growth in/at/on
18-22°C (microaerobic)
+
+
v
25°C (microaerobic)
+
+
+
37°C (microaerobic)
+
+
+
42°C (microaerobic)
+
+
v
37°C (anaerobic)
+
+
v
37°C (aerobic)
+
+
CCDA
+
+
+
Glycine 1%
+
+
+
MacConkey agar
+
+
v
Nutrient agar
+
+
+
Resistance to
Nalidixic acid (30 µg)
+
+
+
Cephalothin (30 µg)
+, 90–100%; v, 11–89%; -, 0-10% of strains positive; nd, not determined

Cfv
+
v
v
v

Cft
+
+
+
-

v
+
+
v
+
v
v
+

+
+
+
v
+
v
+
+
v
nd

v
-

+
nd

Table 6.2. Minimum inhibitory concentrations (MIC) and antimicrobial resistance of Campylobacter
fetus subsp. fetus (Cff) isolates CITCf01 and CITCf02.

Cff isolate CITCf01

Cff isolate CITCf02

MIC (µg/mL)

MIC (µg/mL)

Tetracycline

≤ 0.5 (S)

1 (S)

Erythromycin

≤ 1 (S)

≤ 1 (S)

Ciprofloxacin

0.5 (S)

0.25 (S)

Gentamicin

0.5 (S)

0.5 (S)

Streptomycin

2 (S)

2 (S)

Antimicrobial

S, sensitive; R, resistant
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6.4.3

Genomic features of Cff isolates and comparative analysis

Genome assembly was performed using short- and long-reads to obtain high-quality
complete genome sequences for Cff sister isolates CIT01 (recovered in 2017) and
CIT02 (recovered in 2018) with 334x and 688x coverage, respectively. The salient
properties (genome size, % GC-content, CDS and tRNA number) of their genomes
were found not to be appreciably different from the type strain NCTC 10842T (Table
3 and Appendix B, Figure B1), or that reported for the species in general (Oliveira et
al. 2016; Hou et al. 2018; Miller and Yee 2019). No obvious antimicrobial resistance
determinants were predicted on the genomes of CITCf01 and CITCf02. No plasmids
were identified, while three prophage elements (5.8 kbp, 9.6 kbp and 5.6 kbp in size)
were predicted.
CITCf01 and CITCf02 harbour three cytolethal distending toxin (CDT) homologues
(cdtABC), identical to those present in NCTC 10842T, with the exception of a double
substitution in the third CITCf01 and CITCf02 CdtB homologue (J5248_00930 and
J5249_00926), not found in other Cff strains. CDT is a heterotrimeric inhibitory
cyclomodulin,

recognised

as

a

major

pathogenicity-associated

factor

of

Campylobacter spp. (Dasti et al. 2010). In other bacteria CDT is known to induce
altered pro-inflammatory cytokine expression patterns, perpetuating infection by
subverting host immune responses (Johnson and Lior 1988; Hickey et al. 2000; AndoSuguimoto et al. 2014). The CdtB subunit is functionally and structurally homologous
to mammalian DNase I (Heywood, Henderson and Nair 2005) and induces apoptosis
or senescence of host cells due to improper repair of damaged DNA (Whitehouse et
al. 1998; Heywood, Henderson and Nair 2005). Whether or not the mutation in
CdtB_3 enhances virulence properties is unknown.
Table 3. Genomic attributes of Campylobacter fetus subsp. fetus isolates CITCf01 and CITCf02 and
type strain NCTC 10842T.
Campylobacter fetus
subsp. fetus isolate
CITCf01

Campylobacter fetus
subsp. fetus isolate
CITCf02

Campylobacter
fetus
subsp. fetus type strain
NCTC
10842T
(presence/absence)

Genome size (bp)

1,781,331

1,769,856

1,763,253

GC-content (%)

33.3

33.3

33.3

Protein coding sequences (# of ORFs)

1,734

1,733

1,730

tRNAs

44

44

44

rRNA

9

9

9
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The position of Cff isolates CITCf01 and CITCf02 within the major human C. fetus
lineage was determined by comparison to 81 non-redundant genomes of Cff obtained
from public repositories (details of genomes can be found in Supplementary
information 1, Table S1). There are two major C. fetus lineages (bovine- and humanassociated), described previously (Iraola et al. 2017; Abdel-Glil et al. 2020) and the
majority of selected genomes in this study represent Cff isolated from human sources
and the four nonhuman isolates belong to the ‘human C. fetus’ evolutionary lineage
(Abdel-Glil et al. 2020). An average nucleotide identity (ANI) of >99.2% was found
to be shared among all genomes showing that the isolates reported in this study are
highly conserved at the nucleotide level (Figure 6.1), consistent with previous reports
(van der Graaf-van Bloois et al. 2014; Escher et al., 2016).
Multi-locus sequencing typing (MLST) is a common methodology for C. fetus
subtyping, with at least 73 reported STs on PubMLST to date. Phylogenetic placement
utilising shared genes (core genes) was conducted with CITCf01 and CITCf02 among
the representative 81 Cff genomes - comprised of eight defined sequence types (STs).
Isolates CITCf01, CITCf02 along with NCTC 10842T could be seen to cluster with
nine Cff isolates with an >99.9% ANI (Figure 6.1, Figure 6.2), where the genomes of
CITCf01 and CITCf01 share 99.97% ANI. Isolates in this ST3 cluster (n=11) are from
the United Kingdom (UK), France and Canada, with nine in total being isolated from
humans and two from ovine hosts. MLST clustering of Cff genomes corresponded
with core genome phylogeny (Figure 6.2), similar to findings in other studies (van der
Graaf-van Bloois et al. 2014; Iraola et al. 2017; Abdel-Glil et al. 2020). BAPS
identified seven clusters among the Cff genomes and was consistent with the observed
phylogenetic clusters. ST3 represents a generalist lineage where isolates have been
recovered from human, ovine, bovine, equine and simian hosts (Van Bergen et al.
2005; Escher et al. 2016; van der Graaf-van Bloois et al. 2016; Emele et al. 2019).
ST3 has been reported as one of the most frequently isolated STs from humans, sheep
and cattle in the UK (Duncan et al. 2014). ST4 is dominant among bovid-associated
C. fetus, but members of both major lineages (human and bovine) belong to this ST
(Iraola et al. 2017; Abdel-Glil et al. 2020).
Pangenome analysis was performed to investigate the genetic diversity of CITCf01
and CITCf02 within the context of the subspecies, among the above mentioned 81 Cff
genomes. These genomes were predicted to contain a median of 1,756 ORFs (range
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1,738-1,941) that could be placed into a total pangenome of 2,899 orthologous groups
(OGs). The core genome was found to be comprised of 1,447 genes (approximately
83% of each genome), an accessory genome with a median of 279 ORFs (range 261464) and unique genes per strain with a median of 2 ORFs (range 0-73). The genomes
of Cff isolates CITCf01 and CITCf02 were particularly marked for the lack of novel
genetic elements when compared to other members of the human C. fetus lineage. The
genes associated with CITCf01 and CITCf02 being comprised of those identified as
core genes of Cff, with an accessory genome of 270 or 280 ORFs
Further typing based on CRISPR arrays was performed to understand the origin and
divergence of CITCf01 and CITCf01 among nine closely related Cff genomes.
CRISPR-Cas systems direct RNA interference-like cleavage of foreign DNA (phage,
plasmids, etc.) and form part of the bacterial adaptive immune system (Soto-Perez et
al. 2019). These systems function by storing sequences of foreign DNA from past
exposures as spacers that form part of CRISPR arrays. The acquisition of new spacers
to the CRISPR array occurs systematically, with the addition of new spacers at the 5’
end of an array, with occasional sporadic loss of spacers (Barrangou et al. 2007).
However, the functionality of CRISPR-Cas systems in C. fetus has yet to be
demonstrated (Calleros et al. 2017), but may contribute to the stabilisation of the
subspecies (Ali et al. 2012). Based on the concept that these arrays undergo
expansion/deletion of spacer elements; it is possible to determine the divergence of
closely related strains. Cff isolates CITCf01 and CITCf02 harbour two CRISPR arrays
(arbitrarily named CRISPR array-I and CRISPR array-II, in order of appearance on
the genome). These arrays are composed of an identical 30 bp direct repeat sequence
(GTTTGCTAATGACAATGTTTGTGTTGAAAC) and 8 and 26 spacers (9 and 27
repeat units), respectively, with similar arrays found among the other Cff isolates. The
genomes of the eleven strains possess a median of 41 spacers (range 20 to 62)
comprising of 72 unique spacers. Hierarchically clustering of the presence/absence of
unique spacers among genomes shows that Cff isolates with different origins will tend
to differ with the spacer content of their CRISPR arrays (Calleros et al. 2017).
Additionally, analysis shows that isolates CITCf01 and CITCf02 share similar
CRISPR spacers, supporting the notion that they are the same isolate, obtained at
different time points (Appendix B, Figure B2). Alignment of their CRISPR arrays also
verifies this observation with arrays sharing the same arrangement of their spacers.
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Furthermore, spacer content of CITCf01 and CITCf02 was most similar to genomes
of ERS672259 and ERS672260, both isolated in France from human sources.
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Figure 6.1. Average nucleotide identity of 83 Campylobacter fetus subsp. fetus (Cff) genomes, illustrated with details relating to isolation source and country of origin. The
open black box indicates a cluster (n=11) containing Cff isolates CITCf01 and CITCf02 and the Cff type strain NCTC 10842T.
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(GenBank

accession

number:

LS483431.1).
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Figure 6.2. Maximum-likelihood phylogenomic tree based on core genome alignment of 83
Campylobacter fetus subsp. fetus (Cff) isolates. C. fetus subsp. testudinum (Cft) type strain 03-427T
(GenBank accession number: CP006833.1) was used as the outgroup. Branches are labelled with
sequence accession numbers and isolate details are listed in Table S1. The vertical colour strip shows
BAPS clusters. Branch labels are shaded with corresponding multi-locus sequence type (ST). Bootstrap
values (0-1) based on 500 repetitions and are shown beside branches. Cff isolates CITCf01, CITCf02
and type strain NCTC 10842T are labelled on the tree and cluster with ST3 Cff genomes, highlighted in
an open black box
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6.4.4

Genetic factors potentially contributing to aerobic growth

We took advantage of the high degree of genetic relatedness between Cff isolates
CITCf01, CITCf02 and the subspecies type strain NCTC 10842T to determine any
changes at a genetic level that may account for their differential survival in air.
Considering the lack of large insertions or deletions, major gene rearrangements or the
acquisition of novel genes, we believe subtle differences in regulation of genes
involved in oxidative stress may be responsible. A total of 155 and 170 SNPs and
indels were detected on the genomes of CITCf01 and CITCf02, respectively when
compared to NCTC 10842T. Nonsynonymous mutations were detected in a subset of
60 ORFs (outside of the sap island) and KEGG functional categories were assigned to
76.67% of sequences which were predominantly associated with signal transduction,
genetic regulation, cellular processes, carbohydrate and amino acid metabolism
(Supplementary information 2, Figure S4).
A high proportion of these nonsynonymous mutations were located in a 50 kbp region
containing various oxidative stress response genes. We detected an interrupted 4Fe4S ferredoxin gene (corresponding to fdxB) within this region (Figure 6.3) in both
isolates and fdxB was recently reported to be upregulated upon exposure to bile in C.
jejuni (Kreuder et al. 2017). Ferredoxins function as electron carriers in a wide variety
of a biological reactions (Bruschi and Guerlesquin 1988) and iron-sulphur clusters
have functions relating to electron transfer, gene regulation, environmental sensing
and substrate activation (Frazzon, Fick and Dean 2002). A putative iron-inducible
2[4Fe-4S] ferredoxin fdxA gene was also identified within this region; previously
described as a central player in the aerotolerance of C. jejuni. A mutated homeostatic
response regulator transcription factor (hsrA) and HAMP domain-containing histidine
kinase genes are located directly upstream of a truncated ferredoxin gene (fdxB). HsrA
is known to mediate oxidative stress response as part of a two-component signaling
system in H. pylori (Olekhnovich et al. 2014; Flint, Stintzi and Saraiva 2016) and C.
jejuni (Garénaux et al. 2008). Garénaux et al. (2008) reported the upregulation of a
HsrA homologue in C. jejuni in response to oxidative stress.
Guanosine-5'-triphosphate,3'-diphosphate pyrophosphatase gppA is located directly
downstream of fdxB and GppA catalyses the conversion of guanosine pentaphosphate
(pppGpp) to guanosine tetraphosphate (ppGpp), where the latter is an alarmone
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regulating bacterial cellular activities in response to oxidative, amino acid or stringent
stress response (Keasling, Bertsch and Kornberg 1993; Kumar et al. 2016; Ronneau
and Hallez 2019). Another putative GppA with higher homology to SpoT (known to
maintain (p)ppGpp levels in C. jejuni) is located elsewhere on the genomes of
CITCf01 and CITCf02 (J5248_01174 and J5249_01171). Alkyl hydroperoxide
reductase C (ahpC), peroxide response transcriptional regulator (perR) and a further
downstream iron ABC transporter operon are also located within this region (Figure
6.3), previously reported as important oxidative stress response factors that contribute
to aerotolerance in C. jejuni (Baillon et al. 1999; Palyada, Threadgill and Stintzi 2004;
Handley et al. 2015; Rodrigues et al. 2016).
Point mutations were detected in multiple transcription factors genes throughout the
genomes of CITCf01 and CITCf02 (Supplementary information 1, Table S2). A sole
LysR-type regulator was shown to have a profound effect on the global stress response
and energy metabolism in C. jejuni (Dufour et al. 2013). Of note, a C115T transition
mutation (Pro-39-Ser) was detected in one copy of an encoded Rrf2 family
transcriptional regulator gene and homologues described in Escherichia coli regulate
the transcription of several operons and genes involved in the biogenesis of Fe-S
clusters and Fe-S-containing proteins (Yeo et al. 2006). A T236C transition mutation
(Val-79-Ala) was detected in a TetR/AcrR family transcriptional regulator gene
(corresponding to the DNA-binding homeobox (InterPro accession number:
IPR009057)) (Kisker et al. 1995; Mannervik 1999), located downstream of an iron
uptake ABC transporter complex and cytochrome c oxidase accessory protein gene
(ccoG) and upstream of an iron-inducible, apo-Fur-repressed hydrogenase (Flint,
Stintzi and Saraiva 2016), which may play a role in iron scavenging and oxidative
stress response (Rodrigues et al. 2016; Liu et al. 2018).
Much of the data surrounding stress response in Campylobacter surrounds C. jejuni
(Takata et al. 1995; Park 2002; Rodrigues et al. 2016; Teren et al. 2019; Song et al.
2020) Transcriptome studies in C. jejuni point to a complex approach to stress and
aerobic response in Campylobacter (Rodrigues et al. 2016; Kreuder et al. 2017). The
overlap between oxidative stress response and general stress response (Birk et al.
2012; Varsaki et al. 2015) is thought to be attributed to altered metabolism during
stress and disturbed electron transport systems leading to the generation of reactive
oxygen species, thus oxidative stress responses promote homeostasis (Kim et al.
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2015). Although we have identified some differences in genetic content between Cff
isolates CITCf01, CITCf02 and NCTC 10842T, gene expression studies are necessary
to determine factors contributing to aerobic growth in Cff. Certainly, other Cff isolates
should be tested for their ability to grow aerobically (given 72 hours growth at 37°C
to observe slow growth) to assess if this is more common than originally thought, as
this has implications for the survival and evolution of the subspecies.
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Figure 6.3. Genomic island of Campylobacter fetus subsp. fetus isolate CITCf01 (mirrored in isolate CITCf02) harbouring a high abundance of genes putatively associated
with oxidative stress response. Open reading frames harbouring point mutations resulting in amino acid substitutions are highlighted in green. The truncated genes are
highlighted in purple.
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The sap island differentiates CITCf01 and CITCf02
The genomes of CITCf01 and CITCf02 are highly conserved and syntenic, where a
total of 18 SNPs and indels were detected between them. However, the isolates were
readily distinguished by their respective sapB genomic islands. This gene cluster is
associated with the proteinaceous S-layer on the outer surface of the bacterial cell,
composed of a monolayer of regularly spaced and self-assembling paracrystalline Slayer proteins (SLPs) (Sleytr and Messner 1983; Koval 1988) and is common to just
two Campylobacter species, namely C. fetus and Campylobacter rectus. Sap
homologues, promoter, transcriptional terminators sequences and SLP secretion
systems are located in the invertible sap island (Tu, Hui and Blaser 2004) and the sap
homologue located directly downstream of the sap promoter is transcribed, while all
other sap homologues are transcriptionally silent (Tu, Gaudreau and Blaser 2005). The
conserved 5’ sapA region mediates recombination and inversion among multiple
homologues, resulting in phase variation (Fagan and Fairweather 2014). C. fetus
serotypes A and B correspond to SapA and SapB homologues; differentiated by their
respective 183 N-terminal amino acid residues (Dworkin, Tummuru and Blaser 1995).
The sap island present in CITCf01 spans 75 kbp and contains eleven full (2415 to
3882 bp) and two truncated sapB homologues. While the CITCf02 sap island is
considerably shorter (60 kbp) with seven sapB homologues and eight partials, likely
reflecting recombination remnants (Figure 6.4). A putative Shine-Dalgarno sequence
(AGGAG) (Tu, Gaudreau and Blaser 2005) precedes (-10 bp) CITCf01 and CITCf02
sapB homologues but is not present upstream of the partial sapB homologues in
CITCf01. GDP-mannose 4,6-dehydratase (wcbK) (J5248_00491 and J5249_00488)
has been exclusively associated with Cff SapB strains (Kienesberger et al. 2014) and
was found to be located at the 3’ end of the sap loci in isolates CITCf01 and CITCf02
(Figure 6.4). Genetic rearrangements of the sap island promote long term colonisation
of the host (Tu, Gaudreau and Blaser 2005).
sapDEF encodes a type I secretion system that has been recognised as the constitutive
transporter required for SLP secretion to the cell surface (Thompson et al. 1998;
Thompson 2002). We identified sapDEF homologues on the genome of CITCf01, but
these genes are absent in CITCf02 and NCTC 10842T. Similarly, sapDEF homologues
were detected in 95.3% (n=81) of Cff isolates examined in this study, while the
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predicted MlaFEDB-like transporter apparatus, also located within the sap island, was
detected in all Cff genomes examined. The Gram negative MlaFEDB complex is
known to function as an intermembrane phospholipid trafficking system, preventing
their accumulation in the outer membrane (Malinverni and Silhavy 2009; Chi et al.
2020). Considering the absence of sapDEF on the genome of CITCf02, it’s likely
another transport system facilitates or compensates for the transport of SLPs to the cell
surface. Recently, the presence of sapDEF and the absence of known sap homologues
was reported in a putative novel species “Candidatus Campylobacter infans”;
phylogenetically related to C. fetus (Bian et al. 2020).
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Figure 6.4. Genomic arrangement of Campylobacter fetus subsp. fetus isolates CITCf01 and CITCf02 chromosomal sap islands, created using Mauve.
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6.5

DISCUSSION

We report the isolation, phenotypic behaviour and genomic attributes of two Cff
isolates recovered from an elderly male patient in a case of recurrent prosthetic valve
endocarditis. C. fetus bloodstream infections are typically seen in elderly (often male)
or immunocompromised populations (Gazaigne et al. 2008; Pacanowski et al. 2008;
Cypierre et al. 2014; Wagenaar et al. 2014; Patrick et al. 2018).
The complete picture of the adaptive strategies employed by Cff isolates CITCf01 and
CITCf02 to grow under an ambient gaseous atmosphere remain unclear, but it appears
that subtle genetic changes are responsible. The ability to grow in air should remain
an important consideration in the transmission of Cff in the environment - clinically
or agriculturally. The unexpected ability of isolates in this study to grow under aerobic
conditions may have promoted survival in the open environment or the successful
establishment of infection in vivo. Aerotolerance and hyper-aerotolerance have been
associated with increased resistance to oxidative stress (peroxide and superoxide) in
C. jejuni and C. coli strains (Oh, McMullen and Jeon 2015; O’Kane and Connerton
2017). Despite the frequent exposure of obligate microaerobic Campylobacter spp. to
oxidative stress in the environment or during colonisation and infection, the adaptive
strategies used to survive and even grow in atmospheric oxygen remain poorly
understood (Kumar et al. 2016). Campylobacters lack many classical stress response
mechanisms, contributing to their growth under narrow temperature ranges and
general inability to grow under aerobic conditions (Kumar et al. 2016). However, a
consideration of the high level of conservation of CITCf01 and CITCf02 to other
isolates of Cff in relation to their genomic composition (nucleotide homology, shared
genes, etc.) shows that they are not atypical isolates of this subspecies. Therefore,
unless this phenotype is a result of SNPs or indels among shared genes associated with
signal transduction, genetic regulation, cellular processes, carbohydrate and amino
acid metabolism identified well with the Cff isolates of this study.
C. fetus evades antibody-mediated death via high frequency antigenic variation of the
S-layer by recombination of sap homologues (Thompson 2002). Our findings
highlight this feature of the polymorphic sap island to facilitate recurrent systemic Cff
infection, observed as a hotspot for inversion, rearrangment and deletions of genes.
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We also show conservation among ST3 Cff strains, pointing to a stable lineage with
CITCf01 and CITCf02 belonging to this ST. Limited source attribution of sporadic
cases exists, but food animals are often suspected (Costa et al. 2020), despite the
infrequent isolation of Cff from food (Scanlon et al. 2013; Wagenaar et al. 2014),
where the latter may be a consequence of insufficient detection systems. Undercooked
meat was implicated as the likely cause of C. fetus bacteraemia and meningitis in a
33-year-old woman on maintenance therapy for acute lymphoblastic leukaemia,
suggesting that neutropenic diet should be considered (Nakatani et al. 2021). As an
alternative view to that of Nakatani et al. (2021), C. fetus can establish as a member
of the intestinal microbiota of healthy individuals (Iraola et al. 2017), with the human
gut serving as a natural reservoir. It is difficult to make this assumption about this case,
as stool samples were not taken on the patient when CITCf01 and CITCf02 were
isolated and Campylobacter spp. was not detected from a subsequent stool sample
taken in the intervening period and several blood cultures from the patient yielded no
growth in late 2018, 2019 and 2020. Pertinent to the current paper, the multiplex PCR
assay used to detect enteric pathogens in a large number of Irish diagnostic laboratories
targets C. jejuni and C. coli and not the Campylobacter genus. It is possible that the
human gut acted as a reservoir for this bacterium before causing relapsed infective
prosthetic valve endocarditis. Long-term endogenous persistence or intracellular
survival of Campylobacter spp. in the human host may not be surprising (Casey et al.
2017), considering this tendency among other curved or spiral bacterial genera.
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7.0 Chapter 7. Campylobacter majalis sp. nov.
and Campylobacter suis sp. nov., novel
Campylobacter species isolated from
porcine gastrointestinal mucosa
A manuscript based on this chapter has been submitted to the International Journal
of Systemic and Evolutionary Microbiology
Lynch, C.T., Peeters, C., Walsh, N., McCarthy, C., Coffey, A. Lucey B., Vandamme, P. (2021)
Campylobacter majalis sp. nov. and Campylobacter suis sp. nov., novel Campylobacter species
isolated from porcine gastrointestinal mucosa. Int. J. Syst. (in submission)

PV and CP provided novel Campylobacter spp. strains and provided whole genome
sequencing.
CP performed phylogenomic analysis.
NW and CMcC assisted with phenotypic characterisation of Campylobacter spp.
strains and molecular laboratory work.
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7.1

ABSTRACT

Strains LMG 7974T and LMG 8286T represent single, novel Campylobacter lineages
with Campylobacter pinnipediorum and Campylobacter mucosalis as nearest
phylogenomic neighbours, respectively. Average nucleotide identity and digital DNADNA hybridization analyses of LMG 7974T, LMG 8286T and Campylobacter type
strains confirmed that these strains represent novel Campylobacter species.
Anomalous biochemical characteristics and low MALDI-TOF mass spectrometry log
scores supported their designation as novel Campylobacter species. We therefore
propose to classify strain LMG 7974T as the type strain of the novel species
Campylobacter majalis sp. nov. and strain LMG 8286T as the type strain of the novel
species Campylobacter suis sp. nov.
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7.2

INTRODUCTION

The genus Campylobacter belong to the Epsilonproteobacteria class, also
encompassing curved and spirilloid genera Wolinella spp. and Helicobacter spp.
Members of the Campylobacter genus are most frequently isolated from the
gastrointestinal tract of birds, animals, reptiles and man (Lawson et al. 2001; Moore
et al. 2005; Dingle et al. 2010; Fitzgerald et al. 2014). Campylobacter spp. are
important economic veterinary pathogens and a frequent cause of intestinal and
systemic disease in humans (Moore et al. 2005; Wagenaar et al. 2014; Kaakoush et
al. 2015b), sometimes associated with post-infectious sequalae (Altekruse et al. 1999;
García Rodríguez, Ruigómez and Panés 2006; Casey, Fitzgerald and Lucey 2017).
The Campylobacter genus comprises 47 species/subspecies (in October 2021) of
which Campylobacter jejuni and Campylobacter coli are reported to be the most
dominant species causing human gastroenteritis. Other species within the genus exist
in distinct ecologies in separate niches (On 2001), with some single host specialists
and other dominant multi-host generalist species.
There is a high prevalence of campylobacter-colonisation in pigs, predominantly C.
coli (Man 2011; Kaakoush et al. 2015b), which contributes to cases of foodborne
gastroenteritis in humans (Sheppard and Maiden 2015; European Food Safety
Authority and European Centre for Disease Prevention and Control. 2019) and
evolution of the genus (Sheppard and Maiden 2015) where multiple Campylobacter
spp. may co-inhabit the same environment (Terefe et al. 2020). Moreover, livestock
represents a significant reservoir for the horizontal transmission of campylobacters to
humans (Terefe et al. 2020). Although much of what is known about the genus relates
to species with clinical or agricultural relevance (Sheppard and Maiden 2015), novel
Campylobacter spp. are increasingly being isolated from wild animals, reptiles and
environmental and marine sources (Debruyne et al. 2009; Kaur et al. 2011; Fitzgerald
et al. 2014; Piccirillo et al. 2016; Boukerb et al. 2019; Bryant et al. 2020).
Furthermore, some species have been confirmed as human intestinal commensals
(Lawson et al. 2001; Zhang et al. 2009; Iraola et al. 2017).
In the present study, a polyphasic taxonomic approach was taken to characterise and
define two strains isolated in the 1980s from porcine gastrointestinal mucosa,
originally classified as Campylobacter mucosalis and Campylobacter hyointestinalis.
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C. mucosalis was first isolated from the lesions of porcine intestinal adenomatosis and
since from the gastrointestinal mucosa of pigs with porcine necrotic enteritis, regional
ileitis, proliferative haemorrhagic enteropathy (Roop et al. 1985), adenomatosis and
swine dysentery (Lawson and Rowland 1974). C. mucosalis is an infrequent cause of
human disease but has been reported as the putative cause (molecular confirmation
was not performed) of septicaemia in a 77-year-old male with chronic lymphocytic
leukaemia (Söderström, Schalén and Walder 1991). C. mucosalis was also isolated
from diarrhoeic faeces (Friedman et al. 2004; Inglis, Boras and Houde 2011), canine
faeces (Chaban, Ngeleka and Hill 2010), bovine and poultry retail meat (Lynch et al.
2011).
We describe novel catalase and oxidase negative Campylobacter isolates from pigs
and formally classify them as novel Campylobacter species, Campylobacter majalis
sp. nov., with LMG 7974T as the type strain and Campylobacter suis sp. nov., with
LMG 8286T as the type strain.
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7.3

ISOLATION AND ECOLOGY

Strain LMG 7974T was isolated from intestine of a pig in the United Kingdom (UK)
and was deposited as CCUG 20705T in 1987 in the Culture Collection of the
University of Gothenburg (Gothenburg, Sweden) as C. mucosalis, although
biochemically aberrant. Strain LMG 8286T was isolated from porcine gastric mucosa
in Germany (Kasper and Dickgiesser 1984) in the 1980s and was deposited in National
Collection of Type Cultures (London, UK) as NCTC 11879T, and was tentatively
identified as C. hyointestinalis (Costas, Owen and Jackman 1987).
For the present study, strains LMG 7974T and LMG 8286T were obtained from the
BCCM/LMG Bacteria Collection (http://www.belspo.be/bccm/) and were routinely
cultivated on Columbia blood agar (CBA) (Fannin Ltd, Dublin, Ireland) and incubated
under microaerobic conditions at 37°C for 48 hours.

7.4

PHYLOGENY

Based on partial 16S rRNA amplification (Koziel et al. 2014) and alignment with
Campylobacter type strains, LMG 7974T and LMG 8286T clustered with C. mucosalis
strain ATCC 43264T on a Neighbour-Joining dendrogram using the Tamura-3
parameter on MEGA-X (Kumar et al. 2018) (data not shown). However, the
taxonomic resolution of the 16S rRNA gene sequence to discriminate closely related
Campylobacter spp. is limited (Gorkiewicz et al. 2003) and leads to misclassification
(Gorkiewicz et al. 2003; Muralidharan et al. 2016). Moreover, the method is
insensitive to evolutionary changes in the rest of the genome (Barco et al. 2020).
The whole-genome sequencing protocol for LMG 7974T and LMG 8286T is described
as follows. Genomic DNA of strains LMG 7974T and LMG 8286T was extracted using
the Maxwell® 16 tissue DNA purification kit and a Maxwell® 16 Instrument
(Promega, Madison, WI USA). The resulting DNA extract was treated with RNase (2
mg/mL, 5 µL per 100 µL of extract) and incubated at 37°C for 1 hour. DNA purity
and

integrity

were

assessed

on

a

1.0%

agarose

gel

and

measured

spectrophotometrically at 234, 260, and 280 nm. DNA quantification was performed
using a Quantus fluorimeter and the QuantiFluor ONE dsDNA System (Promega).
Genomes were sequenced at the Oxford Genomics Centre (University of Oxford,
Oxford, United Kingdom) using the Illumina HiSeq6000 (PE150) platform. Quality
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reports were created with FastQC v. 0.11.8. Prior to assembly, reads were trimmed
(Phred score >Q30) and filtered (length >50 bp) with fastp 0.20.0 (Chen et al. 2018b).
with correction option enabled. Assembly was performed with Shovill v. 1.1.0
(https://github.com/tseemann/shovill), with SPAdes genome assembler 3.14.0 at its
core and read error correction disabled. Contigs shorter than 500 bp were removed
from the final assembly. Quality of the final assembly was verified with The Quality
Assessment Tool for Genome Analysis (QUAST) which generates summary statistics
such as the number of contigs, N50, L50 and the G+C content (Gurevich et al. 2013).
Raw reads were mapped against the assemblies using BWA-MEM (Li and Durbin
2009). Mapped reads were subjected to a quality control using Qualimap (GarcíaAlcalde et al. 2012; Okonechnikov, Conesa and García-Alcalde 2016) to determine
the coverage and error rate. Finally, the assemblies were checked for completeness
and contamination using CheckM v. 1.1.2 (Parks et al. 2015). Annotation was
performed using Prokka 1.14.5 (Seemann 2014). The annotated genome assemblies
were submitted into the European Nucleotide Archive (ENA) and are publicly
available under PRJEB41439.
To improve resolution of the phylogeny inferred from partial 16S rRNA sequences,
the full 16S rRNA gene sequences were extracted from the genome sequences of
strains

LMG

7974T

and

(https://github.com/tseemann/barrnap)

LMG
and

were

8286T
compared

using
with

barnnap
those

of

Campylobacter type strains using the EzBioCloud server (Yoon et al. 2017a). The 16S
rRNA sequences of strains LMG 7974T and LMG 8286T showed 97.84% and 98.74%
identity, respectively, to C. mucosalis ATCC 43264T and that of LMG 7974T showed
96.28% identity to both C. pinnipediorum subspecies.
The genomes of strains LMG 7974T and LMG 8286T were submitted to the Type
(Strain) Genome Server (TYGS) (Meier-Kolthoff et al. 2021) to identify the nearest
phylogenomic neighbours and to calculate the degree of relatedness towards the
nearest neighbour species. Digital DNA-DNA hybridization (dDDH) values and
confidence intervals were calculated using the recommended settings of the GGDC
2.1 (Meier-Kolthoff et al. 2014). The average nucleotide identity (ANI) values were
calculated using the OrthoANIu algorithm (Yoon et al. 2017b). As shown in Table 7.1
and Appendix C, Table C2, the orthoANIu and dDDH values between strains LMG
7974T and LMG 8286T and type strains of established Campylobacter species were
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well below the species delineation threshold of 70% dDDH (Goris et al. 2007) and 9596% orthoANIu (Richter and Rosselló-Móra 2009; Meier-Kolthoff et al. 2013).
The whole-genome sequences of Campylobacter type strains were downloaded from
the GenBank database (Appendix C, Table C1) and a total of 40 Campylobacter
sequences were used in the phylogenomic and pangenomic analysis of LMG 7974T
and LMG 8286T. A phylogenomic tree based on the analysis of 107 single-copy core
genes was constructed using bcgTree (Ankenbrand and Keller 2016) with Arcobacter
anaerophilus DSM 24363T as outgroup. The tree topology was statistically analysed
using 1000 bootstrapping replications. Visualization and annotation of the tree were
performed using iTOL (Letunic and Bork 2016). In this phylogenomic tree, strains
LMG 7974T and LMG 8286T clustered with C. pinnipediorum and C. mucosalis,
respectively, and their positions were supported by very high bootstrap values (Figure
7.1).
Table 7.1. OrthoANIu and digital DNA-DNA hybridization (dDDH) values (in %) of strains LMG
7974T and LMG 8286T towards their nearest phylogenetic neighbours.

Strain
Campylobacter majalis sp.
nov. LMG 7974T
Campylobacter suis sp. nov.
LMG 8286T
Campylobacter mucosalis
ATCC 43264T
Campylobacter
pinnipediorum subsp.
caledonicus RM18021T
Campylobacter
pinnipediorum subsp.
pinnipediorum RM17260T

OrthoANIu (%)
LMG 7974T
LMG 8286T

dDDH (%)
LMG 7974T
LMG 8286T

100

73.0

100

20.4

73.0

100

20.4

100

72.4

73.7

20.8

18.0

72.5

71.8

18.4

17.9

72.2

71.6

17.9

19.3

188

189

Figure 7.1. Maximum-likelihood bcgTree tree based on 107 core genes showing the phylogenetic relationships of strains LMG 7974T and LMG 8276T with respect to the type
strains of established Campylobacter species. Arcobacter anaerophilus DSM 24363T was used as an outgroup. The sequence accession numbers are given between parentheses.
Bootstrap percentages (1000 replicates) are shown next to the branch points. Bar, 0.01 changes per nucleotide position.
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The annotated assemblies (in GFF3 format) of strains LMG 7974T, LMG 8286T and
established Campylobacter type strains were analysed using Roary (Page et al. 2015)
to construct a pangenome. Coding sequences with at least 35% identity were
considered as part of the core genome (van der Graaf-van Bloois et al. 2014; Iraola
et al. 2017) to allow clustering of divergent gene sequences and where core was
defined as a gene present in at least 99% of samples (Page et al. 2015; Iraola et al.
2017). The resulting pangenome of Campylobacter type strains contained 12,953
orthologous gene clusters. A total of 494 core genes (Appendix C, Table C3), and
643 soft core genes (i.e. occurring in at least 95% of the genomes) were conserved
across the Campylobacter genus.
A total of 246 and 144 singleton genes were identified in LMG 7974T and LMG 8286T,
respectively, predicted to be involved in metabolism (carbohydrate, amino acid,
energy), cell signaling, response regulation (LMG 7974T) and metabolism
(carbohydrate, amino acid, cofactors, lipid, and energy), cell signaling and response
regulation (LMG 8286T), with large proportions of genes encoding hypothetical
proteins.

7.5

GENOME FEATURES

Strains LMG 7974T and LMG 8286T have genomes of 1,941,929 bp and 1,707,359 bp
in length with a %GC-content of 33.8% and 37.2%, respectively. The %GC-content
of Campylobacter genomes generally ranges between 25-46% (Bloomfield et al.
2020). Table 7.2 summarises the general genome features of strains LMG 7974T, LMG
8286T and their nearest phylogenetic neighbours for comparison.
Selected predicted protein sets were further analysed with InterProScan (Jones et al.
2014), EggNOG Mapper Galaxy version 2.0.1 (Huerta-Cepas et al. 2019), KEGG
(Kanehisa 2019; Kanehisa et al. 2019; Yi et al. 2020), Pfam (El-Gebali et al. 2019)
and HHPred (Zimmermann et al. 2018; Gabler et al. 2020). Similarity searches were
performed using the BLAST suite of programs (Altschul et al. 1990). Regulatory
proteins were predicted using P2RP (Barakat, Ortet and Whitworth, 2013).
To assess the mobilome, prophage elements were detected using PHASTER (Arndt et
al. 2016) and plasmids were predicted using PlasmidFinder 2.1 (Carattoli et al. 2014)
using thresholds of 95% minimum identity and 60% minimum coverage. CRISPR-
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Cas elements were identified using CRISPRCasFinder (Abby et al. 2014; Pearson et
al. 2015; Couvin et al. 2018) and insertion sequences were predicted using ISFinder
(Siguier et al. 2006). Plasmids were not detected in either case. Strain LMG 7974T
was found to harbour one CRISPR array, with one spacer (repeat consensus:
TATTGTAACGAGCGAAGCGAAGTT). Both C. pinnipediorum and C. mucosalis
type strains were found to harbour CRISPR arrays, each with only one spacer, while
strain LMG 8286T did not harbour CRISPR-Cas genetic components. In each case,
Cas proteins were not detected (Table 7.2), indicating the CRISPR arrays are inactive
or were misannotated as a consequence of repetitive sequences mimicking CRISPRs
(Shmakov et al. 2020).
Strain LMG 8286T harbours a predicted intact 22.4 kbp prophage region (35% GCcontent) with 29 proteins. An additional prophage integrase gene (intA) was found
elsewhere on the genome (LMG8286_01801). Strain LMG 7974T harbours a predicted
80% complete 20.1 kbp prophage region (33.7% GC-content), with 38 proteins and an
incomplete 9.4 kbp downstream prophage region with 20 additional proteins. An
integrase gene (LMG7974_01684) is located downstream. The prophage region
described here constituted a significant proportion of the divergent genes present in
strain LMG 7974T, when compared to other Campylobacter spp. Horizontal gene
transfer can incorporate large portions of foreign DNA in a single genetic event,
promoting genomic diversification within the genus (Sheppard and Maiden 2015).
Multiple insertion sequences (n=13) (Table 7.2) and putative transposase ISCco3
(LMG7974_01244), ISCagr1 (LMG7974_01954) genes were identified on the
genome of strain LMG 7974T. Strain LMG 8286T also harbours an IS1595 family
transposase ISRhba1 (LMG8286_01242) not detected among other Campylobacter
spp., with the exception of homologues (less than 90% identity) present in single nontype Campylobacter showae and Campylobacter concisus strains.
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Table 7.2. General genome features of Campylobacter majalis sp. nov. LMG 7974T and Campylobacter
suis sp. nov. LMG 8286T.

Campylobacter
suis LMG 8286T

Campylobacter
mucosalis ATCC
23544T

Campylobacter
magalis LMG
7974T

Accession number
Genome size
%GC-content
Protein coding sequences
(# of ORFs)

GCA_905120475
1.7 Mb
37.2

GCF_013372205.1
1.77 Mb
36.6

GCA_905120465
1.94 Mb
33.8

Campylobacter
pinnipediorum
subsp.
pinnipediorum
RM17260T
GCF_002021925.1
1.74 Mb
30.4

1,787

1,764

1,912

1,701

1,703

tRNAs

40

43

39

45

45

ND

ISFtu7, ISFtu3
(IS1595 family)

ISCamsp1,
ISCagr1, ISFtu7,
ISFtu3, ISIse1
(IS1595 family)

ISCcl1
(IS256 family)

ND

1

ND

1

2

1

ND
ND
23

1
ND
21

1
ND
26

2
ND
22

1
ND
22

21

15

16

13

13

ND

2 copies

ND

ND

ND

Insertion sequences
Prophage region (>80%
intact)
CRISPR array
Cas proteins
Transcription factors
Response regulators (twocomponent system)
Cytolethal distending toxin
(cdtABC) genes

Campylobacter
pinnipediorum
subsp. caledonicus
RM18021T
GCF_002022005.1
1.76 Mb
31.0

ND, not detected

Antimicrobial resistance genes were screened using the Resfinder database (Zankari
et al. 2012) and Abricate (Seeman) and using the Comprehensive Antibiotic
Resistance Database (Jia et al. 2017; Alcock et al. 2020). No resistance genes relative
to clinically relevant antimicrobials were identified, corresponding to their phenotypic
antimicrobial resistance profiles (see below), and as expected for that decade where
the general prevalence of antimicrobial resistance was lower among food producing
animals worldwide. Resistance nodulation division (RND) multidrug efflux pump
homologues were identified, although these are constitutive within the genus (Lin,
Overbye Michel and Zhang 2002). Sequences with homology to the cmeABC operon
were detected, known to contribute to bile resistance and a broad range of
antimicrobial agents in Campylobacter spp. (Lin, Overbye Michel and Zhang 2002;
Lin et al. 2003). Mutations in such multidrug efflux pumps enhance resistance to
clinically relevant antimicrobials including fluoroquinolones, tetracyclines and
macrolides (Cagliero et al. 2005, 2007; Lehri et al. 2015). MacAB homologues were
present on the genomes of both strains LMG 7974T and LMG 8286T, although the
LMG 8286T MacB sequence (LMG8286_00543) was distinct from those of other
members of the genus. Measurable resistance to erythromycin was not detected in
either case. Macrolide-specific efflux proteins MacAB are frequently detected among
Campylobacter spp. and overexpression confers resistance to macrolides in E. coli
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(Kobayashi, Nishino and Yamaguchi 2001). A unique aminoglycoside N(3')acetyltransferase gene (LMG7974_01463) was detected on the genome of strain LMG
7974T that shared less than 50% identity with C. pinnipediorum homologous.
Factors known to contribute to pathogenicity within the genus were screened using
VFDB (Chen et al. 2005; Liu et al. 2019). Campylobacter adherence and invasion
homologues

including

porA

(LMG7974_00131

and

LMG8286_

00535/LMG8286_00469/LMG8286_01678), cadF (Krause-Gruszczynska et al.
2007a) (LMG8286_00125 and LMG7974_00730) and ciaB (Rivera‐Amill et al. 2001)
(LMG7974_00343 and LMG8286_01544) were detected on the genomes of both
strains LMG 7974T and LMG 8286T. A unique omptin family outer membrane
protease (325 amino acids) was identified on the genome of strain LMG 7974T
(LMG7974_00033), with approximately 43% identity to homologues (closest match)
identified in Escherichia coli and other clinically important Enterobacteriaceae.
Omptins are differentially associated with enterobacterial virulence, and it’s thought
that omptin evolution is dependent on the lifestyle of the host (Kukkonen and
Korhonen 2004). Strain LMG 7974T harbours genes encoding a putative filamentous
bacteriohemerythrin-like protein (LMG7974_01392) and transferrin-binding protein
(LMG7974_01338), each with less than 65% identity with all other Campylobacter
spp. homologues deposited in the National Centre for Biotechnology Information
(NCBI) database.
Stress response genes located on the genomes of strains LMG 7974T and LMG 8286T
include chaperone proteins htpG (LMG7974_01524 and LMG8286_00730), htpX
(LMG8286_00378,
LMG8286_00467),

LMG8286_01336),
dnaJ

dnaK

(LMG7974_00047

and

(LMG7974_01065
LMG8286_00443

and
and

LMG8286_01335), clpB1 (LMG7974_01805 andLMG8286_00737), cochaperone
DjlA (LMG7974_01867 and LMG8286_00393), heat shock proteins grpE
(LMG7974_01067 and LMG8286_00466), hspR (LMG8286_00442) and the heatinducible transcription repressor hrcA (LMG7974_01068 and LMG8286_00465).
Additionally,

various

thiol

peroxidase

(tpx)

(LMG7974_01860

and

LMG8286_00635) and peroxiredoxin (bcp) (LMG8286_00978) genes were detected
and are known to contribute to oxidative stress and aerotolerance (Atack et al. 2008).
The catalase gene (katA) was detected in strain LMG 8286, although this strain was
phenotypically catalase negative.
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Of note, singleton genes present on the genome of strain LMG 8286T involve
polysaccharide biosynthesis and transport genes (LMG8286_00919-00920), where an
O-antigen polysaccharide polymerase Wzy family homologue (LMG8286_00919)
was detected that is unique to the genus.

7.6

PHYSIOLOGY AND CHEMOTAXONOMY

The Gram stain of LMG 7974T and LMG 8286T indicated slender, curved Gram
negative bacilli, typical of campylobacter. The colonial morphologies of both strains
were similar and appeared as small (1 mm), greyish, circular, punctiform colonies with
entire margins. Isolates were maintained in defibrinated horse blood with 30%
(vol/vol) glycerol at -80°C and were routinely cultured on CBA at 37°C for 48 hours.
Biochemical and phenotypic tests were performed in triplicate as previously described
(Sandstedt and Ursing 1991; On and Holmes 1992; Ursing, Lior and Owen 1994;
Cowan 2012) with appropriate positive and negative control organisms (Cowan 2012).
Growth at varying temperatures and atmospheric conditions was tested on CBA and
observed at 24, 48 and 72 hours. All other testing, unless otherwise specified was
conducted at 37°C, under microaerobic conditions, observed at 24, 48 and 72 hours.
Hippurate production was determined using hippurate strip tests (Sigma-Aldrich, St
Louis, MO, USA) and indoxyl acetate hydrolysis using 25 µg indoxyl acetate discs
(Thermo Fischer Scientific, Waltham, MA, USA), according to the manufacturer’s
instructions. Nitrate reduction was tested by inoculating 10 mL nitrate broth (9g/L),
incubating for the appropriate conditions for 48 hours and adding equal amounts
sulfanilic acid (5 g/L in 30% acetic acid) and α-naphtylamine solution (5 g/L in 5N
acetic acid) (Sigma-Aldrich). Zinc was added to the solution in the absence of a red
colour development to confirm if nitrate was present in the original medium. Triple
sugar iron agar (Sigma-Aldrich) in 5 mL aliquots (1 inch butt and 1.5 inch slant in
borosilicate glass tubes) were inoculated with stab cultures and incubated for seven
days to identify slow H2S producers (Ursing, Lior and Owen 1994), while urea slopes
were stabbed with cultures and incubated for up to six days (Christensen 1946).
Glycine and NaCl tolerance were assessed using Mueller Hinton agar (Sigma-Aldrich)
spiked with varying concentrations of glycine (1%, 1.5%, 2%, 2.5% and 3%) and NaCl
(1.5%, 2% and 2.5%). Susceptibility to 30 µg cephalothin (Oxoid, Basingstoke,
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England) and 30 µg nalidixic acid (Oxoid) was tested on CBA using an inoculum
equivalent to a 0.5 McFarland standard.
Strains LMG 7974T and LMG 8286T were notably biochemically inert, and both were
catalase and oxidase negative (Table 7.3). The phenotypic and biochemical profiles
were distinctive and were not identical to the typical profile of any other member of
the genus (Table 7.3). To the best of our knowledge, Campylobacter gracilis and
Campylobacter ornithocola are the only other Campylobacter species consistently
reported as oxidase negative. C. mucosalis has a broadly similar set of biochemical
characteristics, but C. mucosalis is oxidase positive and is capable of growth on
nutrient agar and on media containing 2% NaCl. Unlike the majority of other members
of the genus, LMG 8286T failed to reduce nitrate (Table 7.3). The type strains of both
novel species did not produce urease, failed to reduce nitrate and did not hydrolyse
indoxyl acetate; they grew on charcoal cefoperazone deoxycholate agar (CCDA) and
did not grow on media containing 1% glycine, 2% NaCl, 0.4% 2,3,5-triphenyl
tetrazolium chloride (TTC) or on MacConkey or nutrient agar (Table 7.3).
Both strains were capable of growth microaerobically and anaerobically at 37˚C on
CBA. Notably, weak aerobic growth of strain LMG 8286T on CBA was noted after 72
hours under routine culture conditions.
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Table 7.3. Biochemical and phenotypic characteristics distinguishing Campylobacter majalis sp. nov. and Campylobacter suis sp. nov. from other taxa of the Campylobacter
genus
1. C. majalis sp. nov.; C. suis sp. nov.; 3. C. armoricus; 4. C. aviculae; 5. C. avium; 6. C. blaseri; 7. C. canadensis; 8. C. coli; 9. C. concisus; 10. C. corcagiensis; 11. C. cuniculorum; 12. C. curvus; 13. C. estrildidarum;
14. C. fetus subsp. fetus 15. C. fetus subsp. testudinum; 16. C. fetus subsp. venerealis; 17. C. geochelonis; 18. C. gracilis; 19. C. helveticus; 20. C. hepaticus; 21. C. hominis 22. C. hyointestinalis subsp. hyointestinalis;
23. C. hyointestinalis subsp. lawsonii; 24. C. iguaniorum; 25. C. insulaenigrae; 26. C. jejuni subsp. doylei; 27. C. jejuni subsp. jejuni; 28. C. lanienae; 29. C. lari subsp. concheus; 30. C. lari subsp. lari; 31. C. mucosalis;
32. C. novaezeelandiae; 33. C. ornithocola; 34. C. peloridis; 35. C. pinnipediorum subsp. caledonicus; 36. C. pinnipediorum subsp. pinnipediorum; 37. C. portucalensis; 38. C. rectus; 39. C. showae; 40. C. sputorum;
41. C. subantarcticus; 42. C. taeniopygiae; 43. “C. troglodytis”; 44. C. upsaliensis; 45. C. ureolyticus; 46. C. volucris, 47. C. vulpis
Data for reference taxa were adapted from previously reported species/subspecies descriptions (Steele and Owen 1988; On et al. 1995; Logan et al. 2000; Lawson et al. 2001; Foster et al. 2004; Inglis et al. 2007;
Debruyne et al. 2009, 2010a; Rossi et al. 2009; Kaur et al. 2011; Fitzgerald et al. 2014; Koziel et al. 2014b; Gilbert et al. 2015; Hao Van et al. 2016; Piccirillo et al. 2016; Cáceres et al. 2017; Boukerb et al. 2019; Bryant
et al. 2020; Silva et al. 2020).#
Oxidase
Catalase
Urease
Nitrate reduction
Hippurate hydrolysis
Indoxyl acetate
hydrolysis
H2S production
α-haemolysis
Growth at/in/on
18-22°C
(microaerobic)
25°C (microaerobic)
37°C (microaerobic)
42°C (microaerobic)
37°C (anaerobic)
37°C (aerobic)
CCDA
Glycine 1%
MacConkey agar
TTC (0.04%)
NaCl (2%)
Nutrient agar
Resistance to
Nalidixic acid (30
µg)
Cephalothin (30 µg)

% GC-content

1
-

2
-

3
+
+
+
-

4
+
v
+

5
+
w
+
+

6
+
+
+
+
-

7
+
v
v
v
-

8
+
+
+
-

9
v
v
-

10
+
+
+
v
-

11
+
+
+
-

12
+
+
v

13
v
v
v

14
+
+
+
-

15
+
+
+
-

16
+
v
v
-

17
+
+
+
+

18
v
v
-

19
+
+
-

20
+
+
v
v

21
+
-

22
+
+
+
-

23
+
+
+
-

24
+
+
+
-

25
+
+
+
-

26
+
v
+

27
+
+
+
+

28
+
+
+
-

29
+
+
+
nd

30
+
+
+
-

31
+
v
-

32
+
+
+
-

33
+
+
v
-

-

-

+

-

+

+
-

+

-

-

-

nd

nd

nd

+
+
+
+
+
v
+

+
+
+
+
v
v
+
+

+
+
+
nd
+
w
+
+

+
+
+
nd
+
nd
nd
nd
nd

+
+
nd
+
+
nd
nd
v
+

v

v

nd

v

-

-

nd

v

-

-

-

-

-

-

+

+

-

+

-

v

+

v

-

-

-

-

-

v

+

+

-

-

-

-

-

+

+

-

+
-

-

nd
-

v
-

-

+
-

v
-

v

v

+
-

+

v
v

v
-

-

-

v

-

-

+

-

-

+
v

+
v

+
+

nd

+

+

+

nd
nd

-

-

-

nd

-

nd

-

-

nd

-

v

+

v

-

-

-

nd

nd

-

+

nd

-

-

nd

nd

+
+
+
+
-

+
+
+
w
+
-

nd
+
+
+
nd
+
nd
v
nd

nd
+
+
nd
nd
nd
v
nd
nd
nd
nd

+
+
nd
-

+
+
+
+
w
+
nd
nd
nd

+
+
+
+
v
+
nd
nd
-

+
+
+
v
v
nd
+

+
v
+
v
v
v
v

nd
+
+
+
nd
+
+
w

+
v
v
nd
+

v
v
+
v
+
v
+
v
+

nd
+
+
nd
nd
nd
v
nd
nd
nd
nd

+
+
v
v
+
+
v
nd
+

+
+
v
+
v
+
+
v
nd
nd
nd

+
+
v
+
v
v
nd
+

+
+
+
+
+
+
nd

v
+
v
+
v
v
+

+
+
+
v
nd
v

+
+
nd
+
+
nd

+
v
+
nd
+
nd
+
nd

v
+
+
+
+
v
v
+

+
+
+
+
v
v
+

+
+
+
+
+
nd
nd
nd
nd

+
nd
+
nd
nd
nd

+
+
v
v
+

+
+
+
+
+
+

+
+
+
nd
+
nd
nd

+
+
nd
+
v
+
+
+

+

+

-

-

-

-

v

-

v

+

v

+

-

+

+

v

+

v

-

v

v

+

+

+

+

-

-

+

-

-

+

+

+

+

-

-

+

-

-

v

-

+

-

nd

-

-

-

-

-

-

v

-

-

+

-

+

+

+

+

-

33
.8

37
.2

29

N
D

31

37
41

32

45
46

29

33
–
35

33

33
34

33
.6

44
46

28

32
33

35
36

31
33

31

30
31

30

29
30

36
38

28

nd

30

35

nd

32

nd

34

v

36

28
a

36

+

25

30

34
+
+
nd
nd
nd

35
+
+
+
+
-

nd
nd

29

36
+
+
+
-

37
+
-

38
+
v
+
-

39
v
+
+
-

-

-

-

+

+
+

+
+

-

+

-

-

nd

+
+
+
v
nd
nd
nd
nd

+
+
+
nd
nd
nd
nd

+
+
w
nd
v
nd

30

31

nd

40
+
v*
v*
v
-

41
+
+
nd
+
-

42
+
+
v
+

v

-

-

-

v
+

+
+

+

-

-

-

-

-

v
+
+
v
v

v
v
+
+
v
+
+
v

+
+
+
v
+
v
+
+

+
+
+
nd
v
v
nd
+
-

nd

43
+
+
v
v
v

44
+
+
-

45
+
v
+
+
-

46
+
+
nd
+
-

47
+
+
-

+

v

-

+

nd
nd

+

v

nd

+

nd

-

nd

-

nd

nd
+
+
nd
nd
nd
nd
nd
nd
nd

+
+
nd
nd
nd
+
nd
v
v
nd

+
+
+
+
nd
+

+
v
+
nd
+
v
+
+

+
+
+
nd
w
-

+
+
+
+
nd
nd
nd
-

v

-

v

+

v

+

-

-

+

nd

-

-

-

-

+

v

v

-

+

-

28

45
46

44
46

29
33

29

34
38

32
36

28
30

29

34
.6

30

w, weakly positive; +, 90–100%; (v), 11–89% of strains positive; -, 0-10%; nd, not determined
a
NZ_CP007770.1 and NZ_LR134471.1
*
Test results differ between C. sputorum biovars sputorum (catalase and urease negative), paraureolyticus (catalase negative, urease positive) and faecalis (catalase positive, urease negative)

197

Resistance to five clinically relevant antimicrobials (erythromycin, tetracycline,
gentamicin, ciprofloxacin and streptomycin) was assessed using broth microdilution
minimum inhibitory concentration testing according to ISO 20776:2006 using
guidelines set out by EUCAST, originally described for Campylobacter jejuni and
Campylobacter coli (European Centre for Disease Prevention and Control. 2016).
Both strains LMG 7974T and LMG 8286T were susceptible to the five antimicrobials
tested.
Species identification was performed in duplicate by matrix-assisted laser
desorption/ionisation time-of-flight mass spectrometry (MALDI-TOF MS) on the
Bruker MALDI Microflex Biotyper instrument (Bruker Daltonics, Billerica, MA,
USA). Briefly, a single colony was transferred to a position on a MALDI target
polished steel plate (Bruker Daltonics). Proteins were extracted by treatment with 1
µL of 70% formic acid. After air-drying, samples were immediately overlaid with 1
µL of Bruker α-cyano-4-hydroxycinnamic acid (HCCA) matrix solution (10 mg
Bruker HCCA/mL) and allowed to air-dry before MALDI-TOF MS analysis. Mass
spectra were generated with a Microflex mass spectrophotometer and assessed using
the Biotyper Real Time Classification software with flexControl software (version
3.4) (Bruker Daltonics). A logarithmic score between 0 and 3 was assigned to each
spectrum describing the extent of peak matching. A score of 0 to 1.699 defines a
situation with no reliable identification; a score between 1.700 and 1.999 defines
probable genus identification; a score between 2.000 and 2.299 defines a secure genus
identification and probable species identification; a score between 2.300 and 3.000
define highly probable species identification (Koziel et al. 2014b). No reliable
identification was obtained for the novel strains, with average MALDI score values of
1.225 and 1.300 for strains LMG 7974T and LMG 8286T, respectively.

7.7

CONCLUSION

In conclusion, the present study demonstrated that strains LMG 7974T and LMG 8286T
represent novel Campylobacter species that can be distinguished using genomic,
phenotypic and chemotaxonomic characteristics from nearest neighbour species. Of
note, the strains were on the same clade as C. mucosalis (largely associated with pigs)
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and C. pinnipediorum (associated with marine animals), indicating the strong host
associations of these species. Strain LMG 8286T was also marked for its ability to
grow weakly under aerobic conditions.
We therefore propose to classify these strains in the novel species Campylobacter
majalis sp. nov. with LMG 7974T as the type strain and in the novel species
Campylobacter suis sp. nov. with LMG 828T as the type strain.

7.8

PROTOLOGUE

7.8.1

Description of Campylobacter majalis sp. nov.

Campylobacter majalis (ma.ja’lis. L. gen. masc. n. majalis of a pig).

Cells are Gram negative curved bacilli. Greyish, slightly raised colonies with entire
margins on CBA at 37°C under microaerobic conditions for 48 hours. Catalase,
oxidase and urease negative. H2S producing. Not capable of nitrate reduction. No
hydrolysis of hippurate and indoxyl acetate. Capable of growth at 37°C and 42°C
under microaerobic conditions for 48 hours, but not at room temperature or at 25°C
under the same conditions. Capable of anaerobic growth, but unable to grow
aerobically.
The type strain is LMG 7974T (=CCUG 20705T) and was isolated from porcine
intestinal mucosa in the UK in the 1980s. The 16S rRNA gene and whole-genome
sequence

of

strain

LMG

7974T

are

publicly

available

through

the

DDBJ/ENA/GenBank accession numbers LR989048 and CAJHOF000000000,
respectively. The GC content is 33.8%.
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7.8.2

Description of Campylobacter suis sp. nov.

Campylobacter suis (su’is. L. gen. masc./fem. n. suis of a pig).

Cells are Gram negative curved bacilli. Greyish, slightly raised colonies with entire
margins on CBA at 37°C under microaerobic conditions for 48 hours. Catalase,
oxidase and urease negative. Does not produce H2S. Not capable of nitrate reduction.
No hydrolysis of hippurate and indoxyl acetate. Capable of growth at 37°C and 42°C
under microaerobic conditions for 48 hours, but not at room temperature or at 25°C
under the same conditions. Capable of anaerobic growth and weak aerobic growth.
The type strain is LMG 8286T (=NCTC 11879T) and was isolated from porcine gastric
mucosa in Germany in the 1980s. The 16S rRNA gene and whole-genome sequences
of strain 8286T are publicly available through the DDBJ/ENA/GenBank accession
numbers LR989049 and CAJHOE000000000, respectively. The GC content is 37.2%.
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THESIS SUMMARY
Campylobacter spp. are well-established human and veterinary pathogens and remain
the leading cause of human bacterial gastroenteritis and the most frequently reported
zoonosis in the European Union (EU) and Ireland. Soft tissue, systemic and recurrent
infections in immunocompromised and immunocompetent individuals have been
recorded for several species in the genus and post-infectious sequalae are a significant
complication of enteric Campylobacter jejuni disease.
Campylobacter spp. were formally recognised in 1906, isolated from aborting ewes,
but the role of campylobacters as an enteric pathogen remained undiscovered until the
early 1970s – primarily due to their fastidious nature and specific growth requirements.
Campylobacteraceae exist in the environment and have a broad host range spanning
from terrestrial and marine mammalian, avian and reptilian hosts. C. jejuni and
Campylobacter coli are considered the leading cause enteric campylobacteriosis, and
the most frequently isolated from broilers. However, detection methods are optimised
for these species, and detection of viable but non-culturable Campylobacter spp. DNA
indicated that Campylobacter ureolyticus is the second most common campylobacter
causing gastroenteritis in Ireland. Other members of the genus contribute to the disease
burden – but are not currently included in the number of campylobacteriosis cases in
Ireland per annum.
Although the epidemiology of campylobacteriosis remains poorly understood, broilers
are considered the most significant campylobacter-source and chicken meat
production and consumption has simultaneously increased throughout the world in
recent decades. Ireland had the second highest prevalence of campylobactercontaminated broiler carcasses (98.3%) and a high rate of campylobacter-colonised
broiler batches (83.1%) in the 2008 European Food Safety Authority (EFSA) baseline
study, compared to the European average of 75.8% campylobacter-contaminated
broiler carcasses and 71.2% campylobacter-colonised broiler batches (ranges 4.9–
100% and 2.0–100%, respectively). Updated data collected by the Department of
Agriculture, Food and the Marine (DAFM) in a year-long baseline prevalence survey
(2017-2018) on campylobacter-contamination and carriage rates in Irish broilers (in
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collaboration with the work carried out in Munster Technological University (MTU))
indicate that the burden of Campylobacter had reduced significantly among Irish
broilers, but new process hygiene criteria still pose challenges for the poultry industry.
Advances have been made, particularly in the last decade, to improve infection control
measures in primary poultry production and during processing; still the burden of
campylobacteriosis remains a significant public health threat.
Coinciding with the introduction of molecular methods to detect enteric pathogens in
medical laboratories in Ireland, the incidence campylobacteriosis cases has increased
annually since 2011 and peaked in 2018, and despite a moderate decrease in case
notification in 2019 and 2020, a record number of campylobacteriosis cases for the
year 2021 is likely to be reported (circa. 3,000 cases reported as of September 28,
2021). As clinical laboratories in Ireland detect only target species C. jejuni and C.
coli and considering milder cases are often not reported, the true prevalence of
campylobacteriosis is likely to be considerably higher. For comparison, the number of
campylobacteriosis cases reported in Ireland in 2018 was 3,030 – approximately eight
times the incidence of salmonellosis. Campylobacter is not typically transmitted from
person-to-person and unlike Salmonella, Campylobacter cannot multiply on food at
room temperature and is poorly able to survive in the ambient atmosphere, indicating
other sources should be considered.
The Campylobacter genus comprises 47 species/subspecies (in October 2021),
existing in distinct ecologies in separate niches, with some single host specialists and
other dominant multi-host generalist species. Recent expansion of the genus continues
in unsuspecting hosts, despite the challenges in the successful isolation of
campylobacters from environmental samples. Nonetheless, the epidemiological
fingerprinting of the genus is fragmented, and novel species or evolutionary
intermediates are yet to be discovered.
Antimicrobial resistance (AMR) is internationally recognised as a major societal
challenge and novel antimicrobials for Gram negative bacteria have not been brought
to market in decades. The spread of AMR is fuelled by the growth of human and
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animal populations, intensification of animal production, uncontrolled contamination
of fresh water supplies, climate change, increasing international travel and trade.
As part of the Food Institutional Research Measure (FIRM) funded project (15/F/641)
in collaboration with Backweston (DAFM), Teagasc Ashtown and University College
Dublin (UCD), a representative selection of Campylobacter isolates were chosen
randomly from the 2017-2018 baseline prevalence study (carried out in Backweston)
and were tested for their resistance to six clinically relevant antimicrobials (Chapter
2). Campylobacter isolates (n=350) in the AMR prevalence study included 296 C.
jejuni and 54 C. coli, recovered from broiler neck skin (n=266) and caecal samples
(n=84), from intensively reared (n=267) and free-range broilers (n=83) from the three
major poultry processing plants in the Republic of Ireland. Susceptibility to
tetracycline, erythromycin, gentamicin, ciprofloxacin, nalidixic acid and streptomycin
was assessed by minimum inhibitory concentration testing using broth microdilution
in accordance with ISO 20776:2006 and European Commission Decision
2015/652/EU. Overall, 45.1% of Campylobacter spp. isolates tested were resistant to
at least one antimicrobial and resistance rates were broadly comparable to figures
reported nationally over past twenty years, but before the turn of the decade the
reported resistance rates were markedly lower in Ireland. Resistance to gentamicin
was undetected in this study and resistance to erythromycin remained low - found only
in a subset of five C. coli isolates, comparable to previously reported Irish and
European data. Fluoroquinolone resistance remains stable and persistent in
Campylobacter spp. from broilers in Ireland. In our study, increased resistance to
tetracycline among C. jejuni isolates was observed (Chapter 2), in line with the latest
(2021) European Food Safety Authority (EFSA) and European Centre for Disease
Prevention and Control (ECDC) annual AMR summary report, where an increase in
tetracycline resistance was recorded for C. jejuni isolates in Ireland from 2009 to 2021.
Tetracycline remains the most frequently used veterinary antimicrobial in Ireland and
the third most administered antimicrobial in the community (community use
represents upwards of 90% of all human antimicrobial use in Ireland). Orally
administered tetracyclines are excreted via the kidneys and biliary system largely
unchanged and are frequently found detected in soil and water - compounding the
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environmental persistence of bioactive residues. We also identified three multidrug
resistant (MDR) isolates and one of these was resistant to ciprofloxacin, erythromycin
and tetracycline – the antibiotics used to treat severe enteric campylobacteriosis. The
work described in this chapter (Chapter 2) was published in British Poultry Science
in 2020.
All resistant Campylobacter isolates detected in Chapter 2 were assessed for genetic
mechanisms contributing to resistance using a combination of molecular detection
methods including polymerase chain reaction (PCR) screening, Sanger sequencing
and whole-genome sequencing (WGS) (Chapter 3). Previously described resistance
mechanisms were detected and confirmed in all resistant Campylobacter isolates. We
describe the detection of mosaic tetracycline resistance genes in three tetracyclineresistant isolates, using a PCR assay developed in this study and confirmed by WGS.
Aminoglycoside modifying enzymes were located on the genomes of the four
streptomycin-resistant isolates. We highlight the potential for spread via clonal
expansion or horizontal transfer of mobile genetic elements. The antimicrobial
resistance determinants circulating among Irish broilers described here (Chapter 3)
was published in Antibiotics (MDPI) in 2020.
During the investigation of tetracycline resistance, where a portion of the tetO gene
was detected in all tetracycline-resistant isolates, we were especially interested in
accessory tetracycline resistance mechanisms (Chapter 4) as phenotypic
antimicrobial resistance to tetracycline was most prevalent (34%) but minimum
inhibitory concentrations ranged from 4 to ≥64 mg/L. The novel detection of tetA
among thermophilic Campylobacter spp. poultry isolates in Iran was reported in 2014,
and the subsequent detection of apparent tetA among a pool of Campylobacter spp.
isolates from chickens in Kenya emerged two years later (2016). In this study we tested
primers originally described in the Iranian publication and they failed to yield a
product using the positive control strain Escherichia coli strain K12 SK1592 with the
pBR322 plasmid. We designed new primers to detect tetA potentially circulating
among Campylobacter spp. (confirmed using E. coli positive control strain), and we
did not detect tetA among tetracycline-resistant Campylobacter isolates collected in
this study. We then confirmed that C. jejuni and C. coli sequences erroneously
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described as tetA in the original publication shared absolute homology with tetO, and
we postulate that this led to the development of apparent tetA-targeting primers in the
Kenyan study. Instead, the primers that were designed were actually targeting a
different region of tetO, and 90-100% prevalence of tetA among Campylobacter
isolates from domestic chickens in Kenya was erroneously reported. Thus, we believe
that reports of tetA within the genus are premature and a research letter based on this
work was published in Gut Pathogens in 2019.
Campylobacter fetus is the most common campylobacter causing bacteraemia and
represents an important veterinary pathogen, causing infectious infertility in cattle and
infectious abortion in ewes. A C. fetus isolate (CITCf01) was recovered from a case
of prosthetic valve endocarditis in an elderly male in the Mercy University Hospital
(MUH), Cork, Ireland in 2017. This strain was subspeciated using matrix-assisted
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) and
C. fetus subsp. fetus (Cff) membership was confirmed by growth at 42° and the goldstandard glycine tolerance test. A genome announcement of the draft genomic
sequence of CITCf01 was published in Microbiology Resource Announcements in
2019 (Appendix D). This Cff isolate was marked for its unique ability to grow in
ambient air at 37°C. We developed a modified crystal violet staining biofilm assay for
Cff and published the first report of biofilm formation within the species in the Journal
of Clinical Pathology in 2019 (Chapter 5). CITCf01 formed stronger attached
biofilms on polystyrene plates on day 3 (72 hours) than the C. jejuni NCTC 11168
control strain, and undoubtedly contributed to the establishment of infection in vivo
on an abiotic surface.
The patient was re-admitted to MUH in 2018 with recurrent prosthetic valve
endocarditis, where a Cff isolate (CITCf02) was recovered from blood culture bottles.
We report the complete genomic sequences of the sister isolates CITCf01 and
CITCf02, both capable of aerobic growth (Chapter 6). Their genomes were found to
be highly conserved and syntenic and differences in their respective sap loci defined
the temporal separation of their genomes. Based on core genome phylogeny and ANI
of 83 Cff genomes, CITCf01 and CITCf02 grouped in a clade of eleven sequence type
(ST)3 Cff (including the Cff type strain NCTC 10842T), originating from human or
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ovine hosts. CITCf01 and CITCf02 were marked for their lack of unique genomic
features when compared to isolates within the subspecies and the Cff type strain in
particular. We identified point mutations in oxidative stress response genes, among
others, that may contribute to aerobiosis. We report a case of Cff causing relapsed
prosthetic infectious endocarditis and we highlight the sap island as a polymorphic
site within the genetically stable ST3 lineage. The work in this chapter (Chapter 6)
has been submitted for publication in Pathogens and Disease.
We describe catalase and oxidase negative Campylobacter species, isolated from pigs
and formally classify them as novel Campylobacter species, Campylobacter majalis
sp. nov. with LMG 7974T as the type strain and Campylobacter suis sp. nov. with LMG
8286T as the type strain (Chapter 7). Average nucleotide identity and digital DNADNA hybridization analyses of LMG 7974T, LMG 8286T and Campylobacter type
strains confirmed that these strains represent novel Campylobacter species.
Anomalous biochemical characteristics and low MALDI-TOF mass spectrometry log
scores supported their designation as novel Campylobacter species. This chapter is
formatted for submission to the International Journal of Systematic and Evolutionary
Microbiology.
This thesis presents a comprehensive AMR prevalence study to update current data on
Campylobacter spp. isolates from Irish broilers, the most significant Campylobacter
source in developed countries. The genetic factors contributing to persistence,
dissemination and emergence of antimicrobial resistance circulating in the poultry
industry in Ireland is described. We report the sixth and seventh instance of prosthetic
valve endocarditis caused by C. fetus and the first recurrent case. We describe the first
report of biofilm formation within the species and document aerobic growth of sister
Cff isolates, having important implications for survival and virulence of the pathogen.
Genomic analysis of these isolates reveal genetic elements that may contribute to
aerobic growth and persistent infection. C. majalis sp. nov. and C. suis sp. nov. are
formally classified as novel Campylobacter species using a polyphasic approach in an
attempt to bridge the gaps in the evolution of the genus.
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Appendix A
Table A1. Campylobacter spp. isolate used in Chapter II, III and IV, source information, minimum inhibitory concentration (mg/L) and phenotypic susceptibility to six clinically
relevant antimicrobials.

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

3228

1

Claremorris

Conventional

Final

32

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

3233

1

Claremorris

Conventional

Final

32

Caeca

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

3237

1

Templeglantine

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3240

1

Monaghan

Conventional

Final

32

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

3245

1

Monaghan

Conventional

Final

32

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3308

2

Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3309-B

2

Monaghan

Conventional

Final

39

Caeca

C. coli

≤1

S

8

R

≤ 0.5

S

0.25

S

64

R

2

S

3315

2

Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

≤ 0.12

S

4

S

0.5

S

3318

2

Monaghan

Free Range

First

56

Neck Skin

C. coli

≤1

S

4

R

≤ 0.5

S

0.5

S

64

R

2

S

3320

2

Monaghan

Free Range

First

56

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

3328

1

Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3339

1

Monaghan

Conventional

First

34

Caeca

C. jejuni

≤1

S

4

R

16

R

0.5

S

64

R

1

S

3344

1

Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

1

S

3347

2

Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

4

R

16

R

0.25

S

32

R

≤ 0.25

S

3353

2

Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

3363

2

Monaghan

Free Range

First

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3600

1

Broadford, Limerick

Free Range

Final

57

Neck Skin

C. jejuni

≤1

S

16

R

64

R

0.25

S

64

R

1

S

3601

1

Broadford, Limerick

Free Range

Final

57

Neck Skin

C. jejuni

≤1

S

16

R

64

R

0.25

S

64

R

1

S

3602

1

Broadford, Limerick

Free Range

Final

57

Neck Skin

C. jejuni

≤1

S

16

R

64

R

0.25

S

64

R

1

S

3603

1

Broadford, Limerick

Free Range

Final

57

Neck Skin

C. jejuni

≤1

S

16

R

32

R

0.25

S

64

R

1

S
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Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

3604

1

Broadford, Limerick

Free Range

Final

57

Neck Skin

C. jejuni

≤1

S

16

R

32

R

0.25

S

64

R

1

S

3605

1

Broadford, Limerick

Free Range

Final

57

Caeca

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

2

S

3622-A

2

Scotstown, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3622-B

2

Scotstown, Monaghan

Conventional

Final

40

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3627

2

Cootehill, Cavan

Conventional

Final

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3636-A

2

Ballybay, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

8

R

64

R

0.5

S

64

R

1

S

3636-B

2

Ballybay, Monaghan

Conventional

First

34

Neck Skin

C. coli

≤1

S

4

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3675

1

Limerick

Free Range

First

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3678

1

Limerick

Free Range

First

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

3679

1

Limerick

Free Range

First

56

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

8

S

1

S

3736

2

Limerick

Free Range

Final

Not
specified

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3740

2

Newbliss, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

≤ 0.12

S

8

S

0.5

S

3747

2

Cavan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

3753

1

Clones, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3754

1

Clones, Monaghan

Conventional

First

33

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3756

3

Waterford

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

16

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3757

3

Waterford

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

16

R

≤ 0.5

S

1

S

≥ 64

R

2

S

3758

3

Waterford

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3759

3

Waterford

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

16

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3760

3

Waterford

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3761

3

Waterford

Conventional

Final

33

Caeca

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3767

3

Limerick

Conventional

First

31

Caeca

C. jejuni

≤1

S

≤ 0.12

S

4

R

0.5

S

2

S

4

S

3785

2

Tydavnet, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

3786

2

Tydavnet, Monaghan

Conventional

Final

41

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

276

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

4091

1

Emyvale, Monaghan

Conventional

Final

42

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.25

S

4

S

1

S

4095

1

Emyvale, Monaghan

Conventional

Final

42

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.25

S

4

S

1

S

4102

1

Tybavnet, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

0.25

S

64

R

0.25

S

8

S

1

S

4103

1

Tybavnet, Monaghan

Conventional

First

32

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≥ 64

R

0.25

S

8

S

1

S

4109

2

Ardagh, Limerick

Free Range

First

57

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4114

2

Scotstown, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4115

2

Scotstown, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4131

1

Newcastlewest,
Limerick

Free Range

First

58

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

4134

1

Ballintubber, Limerick

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4189

2

Redhills, Cavan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

1

S

4193

2

Castleblaney, Monaghan

Conventional

Final

38

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

1

S

4274

1

Monaghan

Conventional

Final

34

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≥ 64

R

≤ 0.12

S

8

S

1

S

4284

2

Silverstream, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

4291

3

Shannonvale

Conventional

Final

38

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

4295

2

Cappoquin, Waterford

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

4304

3

Clonakilty, Cork

Conventional

First

32

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4309

3

Timoleague

Conventional

Final

34

Neck Skin

C. jejuni

≤1

S

16

R

≤ 0.5

S

1

S

≥ 64

R

2

S

4412

2

Newbliss, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

0.5

S

≥ 64

R

0.25

S

8

S

1

S

4456

2

Emyvale, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

4

R

32

R

0.5

S

≥ 64

R

1

S

4480

2

Newbliss, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4486

2

Cootehill, Cavan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4492

1

Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

8

R

4

R

0.5

S

≥ 64

R

2

S

4506

1

Glasslough, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4520

2

Inniskeen, Monaghan

Free range

First

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S
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Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

4536

1

Smithboro, Monaghan

Conventional

Final

37

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

4546

1

Monaghan

Conventional

First

33

Caeca

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

4607

2

Ballybay, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

4610-A

2

Kingscourt, Cavan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4610-B

2

Kingscourt, Cavan

Conventional

First

35

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

4618-A

2

Navan, Meath

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4618-B

2

Navan, Meath

Free range

Final

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4762

2

Carrickmacross,
Monaghan

Free range

Final

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4767

2

Ballinode, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4845

2

Clones, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4856

2

Dundalk, Louth

Conventional

First

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4859

2

Drum, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

Conventional

First

32

Neck Skin

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

Free range

First

56

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

Free range

First

56

Neck Skin

C. coli

≤1

S

0.25

S

≤ 0.5

S

0.5

S

8

S

2

S

Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick

4878-A

1

4878-B

1

4884-A

1

4884-B

1

4927

3

Rathcormac, Cork

Conventional

Final

34

Caeca

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

4980

3

Reenascrenna, Cork

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

5007

2

Newbliss, Monaghan

Conventional

Final

38

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

5018

1

Newcastlewest,
Limerick

Free range

First

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

5026

1

Ballagh, Limerick

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

1

S

5047

2

Croagh, Limerick

Free range

First

56

Neck Skin

C. jejuni

≤1

S

4

R

32

R

0.5

S

≥ 64

R

1

S

5062

2

Ballinode, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

4

R

32

R

0.5

S

≥ 64

R

1

S

5071

1

Mayo

Conventional

First

32

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

4

S

278

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

5076-A

1

Clones, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

4

R

32

R

0.25

S

≥ 64

R

1

S

5076-B

1

Clones, Monaghan

Conventional

Final

39

Neck Skin

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

5155

2

Emyvale, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

5171

2

Emyvale, Monaghan

Conventional

First

35

Caeca

C. jejuni

≤1

S

8

R

4

R

0.5

S

64

R

2

S

5174

2

Newbliss, Monaghan

Conventional

Final

38

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

1

S

5192

3

Ballymore, Cork

Conventional

Final

34

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

5244-A

1

Broadford, Limerick

Conventional

Final

39

Caeca

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

5244-B

1

Broadford, Limerick

Conventional

Final

39

Caeca

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

5281

2

Emyvale, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

5293

2

Castleblaney, Monaghan

Conventional

First

34

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

4

S

5302

2

Newcastlewest,
Limerick

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

14-18

2

Baileborough, Cavan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

48-18

1

Scotstown, Monaghan

Conventional

Final

38

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

61-A-18

1

Ballagh, Limerick

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

61-B-18

1

Ballagh, Limerick

Conventional

Final

40

Neck Skin

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

70-18

2

Virginia, Cavan

Free range

First

56

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

75-18

2

Clones, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

8

R

32

R

1

S

≥ 64

R

2

S

89-18

2

Newbliss, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

95-18

2

Clones, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

102-18

2

Inniskeen, Monaghan

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

110-18

2

Clontibret, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

122-18

2

Newcastlewest,
Limerick

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

146-18

1

Bruree, Limerick

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

8

R

8

R

1

S

≥ 64

R

2

S

186-18

1

Newcastlewest,
Limerick

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

2

S

1

S

279

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

2

Ballybay, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

4

R

0.5

S

≥ 64

R

2

S

203-18

2

Carrickmacross,
Monaghan

Free range

Final

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

209-18

2

Ballybay, Monaghan

Conventional

First

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Free range

Final

57

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Free range

Final

57

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

193-18

Newcastlewest,
Limerick
Newcastlewest,
Limerick

264-18

1

265-18

1

302-18

3

Ballynor, Cork

Conventional

Final

35

Neck Skin

C. jejuni

≤1

S

0.25

S

≤ 0.5

S

1

S

8

S

2

S

304-18

3

Reenascrenna, Cork

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

354-18

2

Newbliss, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

8

R

4

R

0.25

S

≥ 64

R

1

S

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

Newcastlewest,
Limerick
Newcastlewest,
Limerick

382-118

2

495-18

2

Free range

First

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

496-18

2

Ballinode, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

505-18

1

Clontribret, Monaghan

Conventional

Final

38

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

511-18

1

Castlemahon, Limerick

Free range

First

57

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

518-18

1

Smithboro, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

551-18

2

Carrickmacross,
Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

1

S

553-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

s

4

S

1

S

558-18

2

Cootehill, Cavan

Conventional

Final

39

Caeca

C. jejuni

≤1

S

4

R

32

R

0.25

S

≥ 64

R

1

S

570-18

2

Emyvale, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

625-18

1

Emyvale, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.5

S

4

S

≥ 16

R

635-18

1

Drum, Monaghan

Conventional

Final

34

Caeca

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

1

S

636-18

2

Cootehill, Cavan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

650-18

2

Cootehill, Cavan

Conventional

First

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

651-18

2

Newcastlewest,
Limerick

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

727-18

1

Emyvale, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.5

S

4

S

≥ 16

R

280

Isolate

Factory

Location
Newcastlewest,
Limerick
Newcastlewest,
Limerick

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.5

S

4

S

2

S

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Production
type

Thin
Status

Age
(days)

Sample

Free range

First

57

Neck Skin

Free range

First

57

Species

733-A-18

1

733-B-18

1

938-18

3

Kinsale, Cork

Conventional

Final

36

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

939-18

3

Kinsale, Cork

Conventional

Final

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

949-18

3

Ballingarry, Limerick

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

980-18

3

Knockduff, Cork

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.25

S

4

S

1

S

988-18

2

Carrickmacross,
Monaghan

Conventional

Final

41

Caeca

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

990-18

2

Scotstown, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

999-18

2

Clones, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

16

R

0.5

S

≥ 64

R

2

S

1000-18

2

Clones, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1023-18

1

Newcastlewest,
Limerick

Free range

First

57

Caeca

C. jejuni

≤1

S

8

R

16

R

0.5

S

64

R

2

S

1030-18

1

Scotstown, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

1260-18

2

Ardagh, Limerick

Free range

Final

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

1261-18

2

Ardagh, Limerick

Free range

Final

56

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

8

R

0.5

S

≥ 64

R

2

S

Conventional

Final

33

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

Dunraymond,
Monaghan
Newcastlewest,
Limerick

1262-18

2

1277-18

1

1280-18

1

Feohanash, Limerick

Free range

Final

57

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

1290-A-18

1

Lissamiska, Mayo

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.5

S

4

S

2

S

1290-B-18

1

Lissamiska, Mayo

Conventional

Final

40

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

1291-B-18

1

Lissamiska, Mayo

Conventional

Final

40

Caeca

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

1303-18

1

Ashford, Limerick

Free range

First

56

Caeca

C. coli

≥ 128

R

8

R

32

R

0.5

S

64

R

2

S

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

Conventional

Final

41

Caeca

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

1

S

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1337-18

2

1338-18

2

1349-18

3

Dunraymond,
Monaghan
Dunraymond,
Monaghan
Mallow, Cork

281

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

1358-A-18

3

Clonakilty, Cork

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

1358-B-18

3

Clonakilty, Cork

Conventional

Final

40

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1436-18

2

Newbliss, Monaghan

Conventional

First

36

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1442-18

2

Bailieborough, Cavan

Free range

First

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1446-18

2

Bailieborough, Cavan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1466-A-18

2

Virginia, Cavan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1466-B-18

2

Virginia, Cavan

Free range

First

56

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1631-18

2

Ballybay, Monaghan

Free range

First

56

Neck Skin

C. coli

≤1

S

16

R

64

R

1

S

≥ 64

R

≥ 16

R

1636-18

2

Emyvale, Monaghan

Conventional

First

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

1640-18

2

Emyvale, Monaghan

Conventional

First

36

Caeca

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

1645-18

2

Tydavnet, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

16

R

16

R

0.5

S

≥ 64

R

2

S

1646-18

2

Tydavnet, Monaghan

Conventional

Final

41

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

1785-A-18

1

Castlemahon, Limerick

Free range

First

57

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1785-B-18

1

Castlemahon, Limerick

Free range

First

57

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

1

S

1790-18

1

Castlemahon, Limerick

Free range

First

57

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

1795-18

1

Ardagh, Limerick

Conventional

Final

37

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

1846-18

1

Glaslough, Monaghan

Conventional

Final

38

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1852-18

2

Newbliss, Monaghan

Conventional

Final

41

Caeca

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

1854-18

2

Newbliss, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

1863-18

2

Carrickroe, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1973-18

2

Newcastlewest,
Limerick

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

1980-18

2

Glaslough, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

1984-18

2

Glaslough, Monaghan

Conventional

Final

41

Caeca

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

1996-18

1

Broadford, Limerick

Free range

First

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

282

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

2001-18

1

Bruree, Limerick

Conventional

Final

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2011-18

2

Newbliss, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

2039-18

3

Clonakilty, Cork

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2055-18

3

Carraigtwohill, Cork

Conventional

Final

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2056-18

3

Carraigtwohill, Cork

Conventional

Final

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2060-18

3

Carraigtwohill, Cork

Conventional

Final

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

2

S

1

S

Conventional

Final

41

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

Threemilehouse,
Monaghan
Threemilehouse,
Monaghan

2325-18

2

2326-18

2

2351-18

1

Newbliss, Monaghan

Conventional

First

32

Neck Skin

C. coli

≥ 128

R

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2354-18

1

Newbliss, Monaghan

Conventional

First

32

Neck Skin

C. coli

128

R

≤ 0.12

S

16

R

0.5

S

4

S

2

S

2356-18

1

Newbliss, Monaghan

Conventional

First

32

Caeca

C. coli

≥ 128

R

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2359-18

1

Broadford, Limerick

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2375-18

2

Cootehill, Cavan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

≤ 0.12

S

4

S

1

S

2376-18

2

Cootehill, Cavan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

2378-18

2

Cootehill, Cavan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

2379-18

2

Cootehill, Cavan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

2435-18

2

Cootehill, Cavan

Conventional

Final

39

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2436-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2437-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2438-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2440-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2442-18

2

Cootehill, Cavan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2444-18

2

Cootehill, Cavan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2502-18

2

Emyvale, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

283

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

2503-18

2

Emyvale, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

2505-18

2

Emyvale, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2506-18

2

Emyvale, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

2507-18

2

Cootehill, Cavan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.25

S

4

S

1

S

Free range

Final

57

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

Conventional

First

33

Caeca

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

1

S

≥ 64

R

2

S

Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick

2531-18

1

2537-18

1

2538-18

1

2540-18

1

2542-18

1

2548-18

1

Clones, Monaghan

Conventional

Final

43

Neck Skin

C. coli

128

R

≤ 0.12

S

32

R

0.25

S

4

S

1

S

2630-18

2

Tydavnet, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2631-18

2

Tydavnet, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2633-18

2

Tydavnet, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2636-18

2

Scotstown, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

2639-18

1

Scotstown, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.25

S

2

S

1

S

2740-A-18

2

Cootehill, Cavan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

≤ 0.12

S

4

S

1

S

2740-B-18

2

Cootehill, Cavan

Conventional

Final

41

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2741-A-18

2

Cootehill, Cavan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2741-B-18

2

Cootehill, Cavan

Conventional

final

41

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2746-18

2

Inniskeen, Dundalk

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2747-18

2

Inniskeen, Dundalk

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2748-18

2

Inniskeen, Dundalk

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2750-18

2

Inniskeen, Dundalk

Conventional

First

34

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2837-18

1

Newcastlewest,
Limerick

Free range

Final

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

284

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Free range

Final

56

Neck Skin

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Species

2841-18

1

Newcastlewest,
Limerick

2844-A-18

1

Castleblaney, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2844-B-18

1

Castleblaney, Monaghan

Conventional

First

33

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2848-A-18

1

Castleblaney, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

2

S

2848-B-18

1

Castleblaney, Monaghan

Conventional

First

33

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2849-18

3

Clonakilty, Cork

Conventional

Final

33

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

2850-18

3

Clonakilty, Cork

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2852-18

3

Clonakilty, Cork

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

64

R

2

S

2854-18

3

Clonakilty, Cork

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

16

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

2885-18

3

Clonakilty, Cork

Conventional

Final

36

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

2887-18

3

Clonakilty, Cork

Conventional

Final

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2888-18

3

Clonakilty, Cork

Conventional

Final

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2947-B-18

1

Feolanagh, Limerick

Free range

First

57

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

2949-18

1

Feolanagh, Limerick

Free range

First

57

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

2950-18

1

Feolanagh, Limerick

Free range

First

57

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

2952-18

1

Scotstown, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

2953-18

1

Scotstown, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

2955-18

1

Scotstown, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

2956-18

1

Scotstown, Monaghan

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

≤ 0.12

S

2

S

0.5

S

2959-18

1

Tullyard, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

2969-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.5

S

4

S

2

S

2970-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.5

S

4

S

2

S

2971-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

1

S

4

S

2

S

2972-18

2

Cootehill, Cavan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≥ 64

R

1

S

4

S

2

S

285

Isolate

2973-18

Factory

2

Location

Cootehill, Cavan
Carrickmacross,
Monaghan
Carrickmacross,
Monaghan

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

C. jejuni

≤1

S

≤ 0.12

S

64

R

1

S

4

S

2

S

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.25

S

4

S

1

S

Production
type

Thin
Status

Age
(days)

Sample

Conventional

Final

39

Neck Skin

Conventional

Final

40

Species

2976-18

2

2979-18

2

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.5

S

4

S

2

S

3059-18

2

Rockcorry, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

3062-18

2

Rockcorry, Monaghan

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3064-A-18

2

Newbliss, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

3064-B-18

2

Newbliss, Monaghan

Conventional

First

34

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

3106-18

1

Broadford, Limerick

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3179-18

2

Ballybay, Monaghan

Free range

Final

57

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3266-18

2

Cappoquin, Waterford

Conventional

Final

39

Neck Skin

C. jejuni

≤1

S

8

R

4

R

0.5

S

≥ 64

R

2

S

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.5

S

4

S

2

S

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.5

S

4

S

2

S

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.5

S

4

S

2

S

Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick
Newcastlewest,
Limerick

3272-18

1

3273-18

1

3353-18

2

3393-18

2

3394-18

2

3396-18

2

3408-18

1

Mallous, Cork

Free range

First

57

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3413-A-18

1

Ballagh, Limerick

Conventional

Final

43

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3413-B-18

1

Ballagh, Limerick

Conventional

Final

43

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3415-18

1

Ballagh, Limerick

Conventional

Final

43

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3448-18

3

Cappagh, Waterford

Conventional

First

32

Caeca

C. coli

≤1

S

8

R

64

R

0.5

S

≥ 64

R

16

R

3449-18

3

Cappagh, Waterford

Conventional

First

32

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3476-18

2

Smithboro, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

0.5

S

≥ 64

R

0.5

S

8

S

2

S

3478-18

2

Smithboro, Monaghan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

0.25

S

≥ 64

R

0.25

S

8

S

1

S

286

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

3479-18

2

Ballybay, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

0.25

S

≤ 0.5

S

0.5

S

4

S

2

S

3480-18

2

Ballybay, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

3485-18

2

Emyvale, Monaghan

Conventional

First

33

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3486-18

2

Emyvale, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3487-18

2

Emyvale, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

3488-18

2

Emyvale, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

3489-18

2

Emyvale, Monaghan

Conventional

First

33

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

3517-18

2

Greenfield, Cavan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3518-18

2

Greenfield, Cavan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3519-18

2

Greenfield, Cavan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

1

S

4

S

2

S

3521-18

2

Cootehill, Cavan

Conventional

Final

40

Caeca

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3574-18

1

Newcastlewest,
Limerick

Free range

First

57

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

≥ 64

R

2

S

3577-18

1

Clones, Monaghan

Conventional

Final

33

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.25

S

≥ 64

R

1

S

3611-A-18

2

Cootehill, Cavan

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

16

R

≥ 64

R

0.5

S

≥ 64

R

2

S

3611-B-18

2

Cootehill, Cavan

Conventional

First

34

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3614-18

2

Scotstown, Monaghan

Free range

First

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≥ 64

R

0.5

S

8

S

2

S

3616-18

2

Scotstown, Monaghan

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3642-18

2

Castleblaney, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3643-18

2

Castleblaney, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

3660-18

2

Tydavnet, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3661-18

2

Tydavnet, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3672-18

2

Scotstown, Monaghan

Free range

Final

57

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3677-18

2

Scotstown, Monaghan

Free range

Final

57

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3738-18

2

Inniskeen, Dundalk

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

8

R

32

R

0.5

S

≥ 64

R

2

S

287

Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

3768-18

2

Emyvale, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.5

S

64

R

2

S

3769-A-18

2

Castleblaney, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

3769-B-18

2

Castleblaney, Monaghan

Conventional

Final

40

Neck Skin

C. coli

≤1

S

8

R

≤ 0.5

S

0.5

S

64

R

2

S

3795-18

3

Dungarven, Waterford

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.25

S

64

R

1

S

Conventional

Final

35

Neck Skin

C. jejuni

≤1

S

16

R

≤ 0.5

S

0.5

S

64

R

2

S

Conventional

Final

35

Neck Skin

C. coli

≤1

S

16

R

≤ 0.5

S

0.5

S

64

R

2

S

Newcastlewest,
Limerick
Newcastlewest,
Limerick

3786-18

3

3790-18

3

3796-18

3

Dungarven, Waterford

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

8

R

≤ 0.5

S

0.25

S

64

R

1

S

3800-18

2

Poles, Cavan

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

3801-18

2

Poles, Cavan

Free range

Final

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

2

S

3805-18

1

Feohanagh, Limerick

Free range

First

56

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3804-18

2

Poles, Cavan

Free range

Final

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

1

S

3819-18

2

Carrickroe, Monaghan

Conventional

First

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.25

S

4

S

0.5

S

3821-18

2

Carrickroe, Monaghan

Conventional

First

36

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.25

S

4

S

1

S

3845-18

2

Rockcorry, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3850-18

2

Rockcorry, Monaghan

Conventional

First

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

3911-18

1

Feohanagh, Limerick

Conventional

First

33

Caeca

C. jejuni

≤1

S

≤ 0.12

S

32

R

≤ 0.12

S

2

S

0.5

S

3953-18

2

Glaslough, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

16

R

8

R

0.5

S

≥ 64

R

2

S

3965-18

2

Glaslough, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4053-A-18

1

Newbliss, Monaghan

Conventional

Final

41

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

64

R

0.5

S

8

R

1

S

4053-B-18

1

Newbliss, Monaghan

Conventional

Final

41

Neck Skin

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

2

S

2

S

4055-18

1

Newbliss, Monaghan

Conventional

Final

41

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4056-18

1

Derry, Monaghan

Conventional

Final

37

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

4367-18

2

Ballybay, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4376-18

2

Emyvale, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S
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Isolate

Factory

Location

Production
type

Thin
Status

Age
(days)

Sample

Species

Erythromycin

Ciprofloxacin

Tetracycline

Gentamicin

Nalidixic acid

Streptomycin

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

MIC
(mg/L)

Result

4471-18

2

Emyvale, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

8

R

64

R

0.5

S

≥ 64

R

1

S

4472-18

2

Tydavnet, Monaghan

Conventional

First

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

32

R

0.5

S

4

S

1

S

4475-18

2

Tydavnet, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.25

S

4

S

1

S

4481-18

3

Dungarven, Waterford

Conventional

First

32

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4489-18

3

Newcastlewest,
Limerick

Conventional

Final

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4490-18

3

Castlemahon, Limerick

Conventional

First

34

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4491-18

3

Castlemahon, Limerick

Conventional

First

34

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

4496-18

2

Tydavnet, Monaghan

Conventional

Final

40

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

4

S

2

S

4508-18

2

Newcastlewest,
Limerick

Free range

Final

56

Caeca

C. jejuni

≤1

S

≤ 0.12

S

16

R

0.25

S

4

S

0.5

S

4535-18

2

Ballinode, Monaghan

Conventional

First

35

Caeca

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

4537-18

2

Ballinode, Monaghan

Conventional

First

35

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

8

S

2

S

4546-18

2

Carrickroe, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

16

R

≤ 0.12

S

4

S

≤ 0.25

S

4554-A-18

1

Ahawilk, Limerick

Free range

First

56

Caeca

C. jejuni

≤1

S

16

R

≥ 64

R

0.5

S

≥ 64

R

1

S

4554-B-18

1

Ahawilk, Limerick

Free range

First

56

Caeca

C. coli

≤1

S

≤ 0.12

S

≤ 0.5

S

0.5

S

16

S

1

S

4555-18

1

Ahawilk, Limerick

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

4557-18

1

Ahawilk, Limerick

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

4559-18

1

Ahawilk, Limerick

Free range

First

56

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S

4576-18

2

Carrickroe, Monaghan

Conventional

Final

40

Neck Skin

C. jejuni

≤1

S

≤ 0.12

S

≤ 0.5

S

0.25

S

4

S

1

S
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Appendix B
Table B1. Details of Campylobacter fetus subsp. fetus genomes used for comparison study.
Isolate

Accession no.
(GenBank or SRA)

Isolation source

Country of isolation

Year of
isolation

CITCf01

CP072664

Human

Ireland

2017

CITCf02

CP072665

Human

Ireland

2019

82-40

CP000487.1

Human

US

nd

04/554

CP008808.1

Bovine

Argentina

nd

GTC _08732

ERS672218

Human

Japan

1979

GTC _11236

ERS672220

Human

Japan

NA

96-48

ERS672224

Human

Japan

1993

01-187

ERS672226

Human

Japan

2001

2004/103h

ERS672233

Human

France

2004

2004/199h

ERS672234

Human

France

2004

2004/359h

ERS672235

Human

France

2004

2004/362h

ERS672236

Human

France

2004

2004/526h

ERS672237

Human

France

2004

2004/598h

ERS672238

Human

France

2004

2004/605h

ERS672239

Human

France

2004

2004/637h

ERS672240

Human

France

2004

2006/222h

ERS672241

Human

France

2006

2006/367h

ERS672242

Human

France

2006

2006/479h

ERS672243

Human

France

2006

2006/588h

ERS672244

Human

France

2006

2006/621h

ERS672245

Human

France

2006

2006/649h

ERS672246

Human

France

2006

2008/170h

ERS672247

Human

France

2008

2008/568h

ERS672248

Human

France

2008

2008/604h

ERS672249

Human

France

2008

2008/691h

ERS672250

Human

France

2008

2008/755h

ERS672251

Human

France

2008

2008/898h

ERS672252

Human

France

2008

2010/41h

ERS672253

Human

France

2010

2010/524h

ERS672254

Human

France

2010

2010/1094h

ERS672255

Human

France

2010

2010/1119h

ERS672256

Human

France

2010

2010/1180h

ERS672257

Human

France

2010

2012/60h

ERS672258

Human

France

2012

2012/185h

ERS672259

Human

France

2012

2012/286h

ERS672260

Human

France

2012

2012/331h

ERS672261

Human

France

2012

2012/879h

ERS672263

Human

France

2012

2012/1045h

ERS672264

Human

France

2012

2014/52h

ERS672265

Human

France

2014

2014/602h

ERS672266

Human

France

2014

2014/790h

ERS672267

Human

France

2014

2014/947h

ERS672269

Human

France

2014

2014/1097h

ERS672270

Human

France

2014

2007/123h

ERS672271

Human

France

2007

290

2009/56h

ERS672272

Human

France

2009

CF156

ERS672273

Human

Turkey

2013

001A-0374

ERS686652

Human

Canada

2005

001A-0648

ERS686653

Human

Canada

2007

ID111063

ERS739225

Human

Canada

2011

ID117228

ERS739226

Human

Canada

2012

ID129038

ERS739227

Human

Canada

2013

ID131159

ERS739228

Human

Canada

2014

ID134381

ERS739229

Human

Canada

2014

ID136207

ERS739230

Human

Canada

2014

ID136551

ERS739231

Human

Canada

2014

ID136656

ERS739232

Human

Canada

2014

ID136706

ERS739233

Human

Canada

2014

ID132939

ERS739234

Human

Canada

2014

2975

ERS739256

Human

Taiwan

2002

923

ERS739257

Human

Taiwan

2003

7035

ERS739258

Human

Taiwan

2004

My5726

ERS739259

Human

Taiwan

2006

1592

ERS739260

Human

Taiwan

2006

1830

ERS739261

Human

Taiwan

2008

8468

ERS739262

Human

Taiwan

2009

0003304-2

ERS739263

Human

Taiwan

2009

2115

ERS739264

Human

Taiwan

2010

2819

ERS739265

Human

Taiwan

2010

5871

ERS739266

Human

Taiwan

2010

1666

ERS739267

Human

Taiwan

2011

9502

ERS739270

Human

Taiwan

2011

8031708

ERS739272

Human

Taiwan

2012

8025552

ERS739273

Human

Taiwan

2013

3069482

ERS739274

Human

Taiwan

2014

82-40

GCA_000015085.1

Human

US

2006

H1-UY

GCA_001399955.1

Human

Uruguay

2013

BT 10/98

GCF_001699575.1

Ovine

UK

1999

HC1

GCF_003426005.1

Human

Uruguay

2016

HC2

GCF_003426015.1

Human

Uruguay

2016

D0052

GCF_008014295.1

Human

US

nd

CCUG 6823 AT

GCF_008693125.1

Ovine

UK

nd

NCTC 10842T

LS483431.1

Ovine

nd

1972

nd, not determined
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Table B2. Campylobacter fetus subsp. fetus (Cff) isolates CITCf01 and CITCf02 genomic attributes
versus the presence (1) or absence (0) in the Cff type strain NCTC 10842T.
Cff isolate
CITCf01

Cff isolate
CITCf02

Cff type strain
NCTC10842T

DNA starvation protection protein Dps

J5248_00080

J5249_00080

1

Chaperonin GroEL

J5248_00682

J5249_00677

1

DnaJ-class molecular chaperone CbpA

J5248_00745

J5249_00740

1

Chaperone protein ClpB

J5248_00918

J5249_00914

1

Chaperone protein HtpG

J5248_00932

J5249_00928

1

Lon protease

J5248_01024

J5249_01020

1

Chaperone protein DnaK

J5248_01052

J5249_01048

1

Heat shock protein GrpE

J5248_01053

J5249_01049

1

Transcriptional regulator of DnaK operon, HrcA

J5248_01054

J5249_01050

1

Chaperone protein DnaJ

J5248_01096

J5249_01092

1

Flagellar hook protein FlgE_1

J5248_00008

J5249_00008

1

Flagellar basal body P-ring protein FlgI

J5248_00096

J5249_00096

1

Flagellar biosynthesis anti-sigma factor FlgM

J5248_00098

J5249_00098

1

Flagellar protein FlgN

J5248_00099

J5249_00099

1

Flagellar hook-associated protein FlgK

J5248_00100

J5249_00100

1

Flagellar hook-basal body protein

J5248_00517

J5249_00514

1

Flagellar basal-body rod protein FlgG

J5248_00519*

J5249_00515

1

Flagellar basal body rod protein FlgC

J5248_00686

J5249_00681

1

Flagellar basal body rod protein FlgB

J5248_00687

J5249_00682

1

Flagellar basal body L-ring protein FlgH

J5248_00792

J5249_00787

1

Flagellar hook protein FlgE_2

J5248_01695

J5249_01693

1*

Flagellar protein FlaG

J5248_00093

J5249_00093

1

Flagellin

J5248_00514

J5249_00511

1

Flagellin B FlaB

J5248_01569

J5249_01567

1*

Flagellar biosynthesis protein FlhB

J5248_00339

J5249_00339

1

Flagellar basal body rod modification protein

J5248_00009

J5249_00009

1

Flagellar hook-length control protein FliK_1

J5248_00010

J5249_00010

1

Flagellar biosynthesis protein FlhA

J5248_01058

J5249_01054

1*

Flagellar biosynthesis protein FlhF

J5248_01445

J5249_01444

1

FlhB-like flagellar biosynthesis protein

J5248_01143

J5249_01140

1

Flagellar motor stator protein MotA

J5248_00224

J5249_00224

1

Flagellar motor stator protein MotB

J5248_00225

J5249_00225

1

Flagellar hook protein

J5248_00664

J5249_00659

1

Flagellar export chaperone FliS

J5248_00091

J5249_00091

1

Flagellar filament capping protein FliD

J5248_00092

J5249_00092

1

Flagellar biosynthesis protein FliQ

J5248_00199

J5249_00199

1

Flagellar assembly protein FliH

J5248_00261

J5249_00261

1*

Flagellar motor switch protein FliG

J5248_00262

J5249_00262

1

flagellar basal body M-ring protein FliF

J5248_00263

J5249_00263

1

Flagellar motor switch protein FliN

J5248_00352

J5249_00352

1

FliJ family protein

J5248_00367

J5249_00367

1

Flagellar hook-basal body complex protein FliE

J5248_00685

J5249_00680

1

Flagellar type III secretion system pore protein FliP

J5248_00734

J5249_00729

1

Flagellar basal body-associated protein FliL

J5248_00898

J5249_00894

1

Flagellar assembly protein FliW

J5248_01032

J5249_01028

1

Flagellar hook-length control protein FliK_2

J5248_01142

J5249_01139

1

Flagellar type III secretion system protein FliR

J5248_01377

J5249_01376

1

RNA polymerase sigma factor FliA

J5248_01448

J5249_01447

1

Flagellar motor switch protein FliM

J5248_01449

J5249_01448

1

Genomic attribute
Protein chaperones

Motility
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Flagellar motor switch protein FliY

J5248_01450

J5249_01449

1

Flagellar protein export ATPase FliI

J5248_01622

J5249_01620

1

Superoxide dismutase SodB

J5248_00031

J5249_00031

1

S-ribosylhomocysteine lyase LuxS

J5248_00112

J5249_00112

1

Cytochrome c oxidase accessory protein CcoG

J5248_00122

J5249_00122

1

Ppx/GppA family phosphatase

J5248_00241

J5249_00241

1

Alkyl hydroperoxide reductase subunit C AhpC

J5248_00248

J5249_00248

1

Thioredoxin reductase TrxB

J5248_00291

J5249_00291

1

Thioredoxin-dependent thiol peroxidase Bcp

J5248_00306

J5249_00306

1

Catalase KatA
Guanosine-5'-triphosphate,3'-diphosphate
pyrophosphatase
Peptide methionine sulfoxide reductase MsrA/MsrB

J5248_01022

J5249_01018

1

J5248_01174

J5249_01171

1

J5248_01239

J5249_01238

1

Iron receptor CfrA
ATP-dependent Clp endopeptidase proteolytic subunit
ClpP
Thiol peroxidase Tpx

J5248_01499

J5249_01499

1

J5248_01619

J5249_01617

1

J5248_01704

J5249_01702

1

J5248_00121

J5249_00121

1*

J5248_00141

J5249_00141

1

J5248_00214

J5249_00214

1

J5248_00259

J5249_00259

1

J5248_00300

J5249_00300

1

J5248_01055

J5249_01051

1

J5248_01364

J5249_01363

1

J5248_00359

J5249_00359

1

J5248_00698

J5249_00693

1

J5248_01372

J5249_01371

1

J5248_00425

J5249_00425

1

J5248_00776

J5249_00771

1

J5248_00746

J5249_00741

1

J5248_00895

J5249_00891

1*

J5248_01059

J5249_01055

1

IclR family transcriptional regulator

J5248_01026

J5249_01022

1

Ferric uptake regulation protein Fur

J5248_01105

J5249_01101

1

J5248_01169

J5249_01166

1

J5248_01243

J5249_01242

1

J5248_01244

J5249_01243

1

HlxR transcriptional regulator

J5248_01186

J5249_01183

1

MarR family transcriptional regulator

J5248_01497

J5249_01497

1

ArsR family transcriptional regulator

J5248_01654

J5249_01652

1

Fur family transcriptional regulator

J5248_01661

J5249_01659

1

J5248_00238

J5249_00238

1

J5248_00428

J5249_00428

1

J5248_00448

J5249_00448

1

J5248_00533

J5249_00529

1

J5248_00742

J5249_00737

1

J5248_00820

J5249_00815

1

J5248_01098

J5249_01094

1

J5248_01199

J5249_01196

1

Sensor histidine kinase

J5248_00139

1

PAS domain-containing sensor histidine kinase

J5248_00372

Sensor histidine kinase

J5248_01228

J5249_00139
J5249_00372*/J5
249_00372
J5249_01227

Oxidative stress response proteins

Transcriptional regulators
TetR/AcrR family transcriptional regulator
Unclassified response regulator transcription factor
Peroxide-responsive transcriptional repressor PerR
Xre family transcriptional regulator

LysR family transcriptional regulator

Crp/Fnr family transcriptional regulator
Helix-turn-helix transcriptional regulator
Rrf2 family transcriptional regulator

AraC family transcriptional regulator

Histidine kinases

HAMP domain-containing histidine kinases

1
1
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Hybrid sensor histidine kinase/response regulator CheA

J5248_00328

J5249_00328

1

J5248_00140

J5249_00140

1

J5248_00405

J5249_00406

1

J5248_01229

J5249_01228

1

Response regulators

CheY family response regulator

J5248_01291

J5249_01290

1

Homeostatic response regulator transcription factor HsrA

J5248_00237

J5249_00237

1*

Chemotaxis protein CheV

J5248_00327

J5249_00327

1

Transcriptional regulatory protein WalR-like

J5248_00429

J5249_00429

1*

Response regulator PleD

J5248_01155

J5249_01152

1

J5248_00373

J5249_00374

1

J5248_00449

J5249_00449

1

J5248_00534

J5249_00530

1

J5248_00743

J5249_00738

1

J5248_00819

J5249_00814

1

J5248_01097

J5249_01093

1

Transcriptional regulatory protein OmpR

*, point mutation or frameshift mutation

294

Figure B1. BlastP analysis of predicted coding sequences (CDS) predicted in Campylobacter fetus
subsp. fetus (Cff) type strain NCTC 10842T and their identity to those present in isolates CITCf01 and
CITCf02 (red blocks), visualised using CGView. The outer ring represents the genome of NCTC
10842T and blue arrows shows forward and reverse strand coding sequences. The red rings represent
regions of sequence similarity detected by BLAST comparisons conducted between CDS translations
from the reference genome NCTC 10842T and CITCf01 and CITCf02. The inner rings are the GC
content relative to the mean GC content of the genome and GC skew (innermost) is illustrated where
green represents positive skew and purple a negative skew.
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Figure B2. Heat map showing the presence/absence of spacers (red is present and blue is absent) in
the CRISPR array in the highly related cluster of Campylobacter fetus subsp. fetus genomes,
including CITCf01, CITCf02 and type strain NCTC 10842T.
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09120: Genetic information processing
7

09182 : Protein families - genetic information processing
09193: Protein families - signaling and cellular processes

16

09130: Environmental information processing

5

09140: Cellular processes
09101: Carbohydrate metabolism
7
1
1

09102: Energy metabolism
09105: Amino acid metabolism
09106: Metabolism of other amino acids

3

09108: Metabolism of cofactors and vitamins

1

6

2

09103: Lipid metabolism
3
4

4

09160: Human diseases
Unclassified

Figure B3. KEGG functional annotation of 60 predicted open reading frames harbouring
nonsynonymous mutations in Campylobacter fetus subsp. fetus (Cff) isolates CITCf01 using the Cff
type strain NCTC 10842T homologues as reference.
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Appendix C
Table C1. Type Campylobacter species (or subspecies) RefSeq assembly accession numbers used in
the pangenomic and phylogenomic analysis of Campylobacter majalis sp. nov. and Campylobacter suis
sp. nov.

Campylobacter armoricus strain CCUG 73571T

RefSeq assembly accession
number
GCF_013372105.1

“Campylobacter aviculae” strain MIT17-670T

GCF_005406215.1

Campylobacter avium strain LMG 24591T

GCF_002238335.1

Campylobacter blaseri strain LMG 30333T

GCF_013201895.1

Campylobacter canadensis strain LMG 24001T

GCF_013177655.1

Campylobacter species

T

Campylobacter coli strain LMG 6440

GCF_003590975.1

Campylobacter concisus strain ATCC 33237T

GCF_001298465.1

Campylobacter corcagiensis strain LMG 27932T

GCF_013201645.1

Campylobacter cuniculorum DSM 23162T

GCF_002104335.1

Campylobacter curvus DSM 6644T

GCF_000376325.1

“Campylobacter estrildidarum” strain MIT17-664T

GCF_005406205.1

Campylobacter fetus subsp. fetus strain NCTC 10842T

GCF_900475935.1

Campylobacter geochelonis strain LMG 29375T

GCF_013201685.1

Campylobacter gracilis strain ATCC 33236

T

GCF_001190745.1

Campylobacter helveticus strain ATCC 51209T

GCF_002080395.1

Campylobacter hepaticus strain HV10T

GCF_001687475.2

Campylobacter hominis strain NCTC 13146T

GCF_900446395.1

Campylobacter hyointestinalis strain ATCC 35217T

GCF_900116585.1

Campylobacter iguaniorum strain 1485ET

GCF_000736415.1

Campylobacter insulaenigrae strain NCTC 12927T

GCF_000816185.1

Campylobacter jejuni strain NCTC 11351T

GCF_001457695.1

Campylobacter lanienae strain NCTC 13004T
Campylobacter lari subsp. lari strain LMG 8846

GCF_002139935.1
T

GCF_013372185.1

Campylobacter mucosalis strain ATCC 43264T

GCF_013372205.1

“Campylobacter novaezeelandiae” strain B423bT

GCF_004323845.1

Campylobacter ornithocola strain LMG 29815T

GCF_013201605.1

Campylobacter peloridis strain LMG 23910T

GCF_000816785.1

Campylobacter pinnipediorum subsp. pinnipediorum strain RM17260T

GCF_002021925.1

Campylobacter pinnipediorum subsp. caledonicus strain RM18021T

GCF_002022005.1

Campylobacter portucalensis strain FMV-PI01T

GCF_009690845.1

Campylobacter rectus strain ATCC 33238T

GCF_004803795.1

Campylobacter showae strain ATCC 51146

T

GCF_004803815.1

Campylobacter sputorum biovar sputorum strain LMG 7795T

GCF_008245005.1

Campylobacter subantarcticus LMG 24377T

GCF_000816305.1

“Campylobacter taeniopygiae” strain MIT10-5678T

GCF_005406225.1

“Campylobacter troglodytis” strain MIT 05-9149AT

GCF_006864425.1

Campylobacter upsaliensis strain NCTC 11541T

GCF_900637395.1

Campylobacter ureolyticus strain LMG 6451T

GCF_013372225.1

Campylobacter volucris strain LMG 24380T

GCF_008245045.1

Campylobacter vulpis strain 251/13T

GCF_002738305.1
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Table C2. Average nucleotide identity (ANI) and digital DNA-DNA hybridisation (dDDH) values (%)
based on Campylobacter majalis sp. nov. strain LMG 7974T and Campylobacter suis sp. nov. strain
LMG 8286T compared to other Campylobacter taxa. Colours represent green (identical) to red (least
similar) for both orthoANIu and dDDH independently.
orthoANIu (%)
LMG
LMG
7974T
8286T
100.0
73.0

Campylobacter species
Campylobacter majalis sp. nov. LMG 7974T

dDDH (%)
LMG
LMG
7974T
8286T
100
20.4

Campylobacter suis sp. nov. LMG 8286T

73.0

100.0

20.4

100

Campylobacter armoricus CCUG 73571T

68.6

67.8

20.3

20.9

Campylobacter aviculae MIT 17-670T

68.5

68.1

17.5

20.3

67.5

67.5

20.5

20.1

Campylobacter avium LMG 24591

T

68.8

68.6

21.3

19.4

Campylobacter canadensis LMG 24001T

68.4

67.4

23.1

24.7

Campylobacter coli LMG 6440T

68.2

67.8

18.9

20.3

71.0

72.1

18.9

18.9

Campylobacter corcagiensis LMG 27932

T

68.9

68.3

19.4

17.7

Campylobacter cuniculorum LMG 24588

T

Campylobacter blaseri LMG 30333

T

Campylobacter concisus ATCC 33237

T

68.2

67.5

20

21.7

Campylobacter curvus DSM 6644T

70.0

71.3

19.2

17.8

Campylobacter estrildidarum MIT 17-664T

68.8

68.3

21.1

20.2

68.6

69.1

21.4

20.2

69.5

69.6

19.9

18.2

68.6

68.7

20.6

19.7

Campylobacter fetus subsp. fetus NCTC 10842
Campylobacter geochelonis LMG 29375
Campylobacter gracilis ATCC 33236

T

T

T

68.1

67.2

21.7

22.1

Campylobacter hepaticus HV10T

69.2

68.0

21.1

23.7

Campylobacter hominis NCTC 13146T

68.9

68.3

23.6

21.7

68.7

69.2

20.5

19.4

69.1

69.2

20.3

19.2

Campylobacter helveticus ATCC 51209

T

T

Campylobacter hyointestinalis subsp. hyointestinalis ATCC 35217
T

Campylobacter iguaniorum 1485E

68.7

67.7

21.4

21.7

Campylobacter jejuni subsp. jejuni NCTC 11351T

68.6

68.0

22.9

20.4

Campylobacter lanienae NCTC 13004T

68.8

68.6

22.8

22.2

68.9

68.4

22.4

21.8

72.4

73.7

20.8

18

Campylobacter insulaenigrae NCTC 12927

Campylobacter lari subsp. lari LMG 8846
Campylobacter mucosalis ATCC 43264

T

T

T

68.9

68.0

19.4

19.9

Campylobacter ornithocola LMG 29815T

68.6

68.0

20.4

22.6

Campylobacter peloridis LMG 23910T

68.8

68.4

20.4

22.2

72.5

71.8

18.4

17.9

72.2

71.6

17.9

19.3

69.1

68.2

18.4

17.8

Campylobacter novaezeelandiae B423b

T

Campylobacter pinnipediorum subsp. caledonicus RM18021

T

Campylobacter pinnipediorum subsp. pinnipediorum RM17260
Campylobacter portucalensis FMV-PI01

T

T

69.6

70.0

22.9

20.1

Campylobacter showae ATCC 51146T

69.8

70.1

21.4

19.4

Campylobacter sputorum LMG 7795T

69.3

68.8

19.5

19

68.7

67.7

22.1

21.6

68.8

68.1

19.9

20

"Campylobacter troglodytis" MIT 05-9149A

67.5

67.2

30.1

27

Campylobacter upsaliensis NCTC 11541T

68.0

67.5

21.1

21.3

Campylobacter ureolyticus LMG 6451T

68.9

68.3

19.1

18.4

69.3
67.9

68.3
67.3

21.9
19

19.4
17.9

Campylobacter rectus ATCC 33238

T

Campylobacter subantarcticus LMG 24377

T

Campylobacter taeniopygiae MIT 10-5678T
T

Campylobacter volucris LMG 24380
Campylobacter vulpis 251/13T

T
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Table C3. Annotation of Campylobacter genus core genes based on Roary pangenome analysis (35%
minimum identity) including Campylobacter majalis sp. nov. and Campylobacter suis sp. nov.
Campylobacter
majalis
LMG7974
locus tag
LMG7974_01371
LMG7974_00480
LMG7974_01489
LMG7974_00965
LMG7974_00470
LMG7974_00102
LMG7974_01556
LMG7974_00770
LMG7974_01355
LMG7974_01282
LMG7974_00112
LMG7974_00376
LMG7974_01503
LMG7974_01219
LMG7974_00902
LMG7974_01129
LMG7974_00820
LMG7974_01421
LMG7974_01431
LMG7974_01881
LMG7974_00505
LMG7974_01153
LMG7974_00809
LMG7974_00807
LMG7974_01716
LMG7974_00492
LMG7974_00482
LMG7974_00481
LMG7974_00479
LMG7974_00478
LMG7974_00477
LMG7974_00466
LMG7974_00464
LMG7974_00768
LMG7974_00772
LMG7974_00773
LMG7974_00777
LMG7974_00709
LMG7974_00716
LMG7974_01769
LMG7974_01545
LMG7974_01847
LMG7974_00994
LMG7974_00995
LMG7974_00367
LMG7974_01851
LMG7974_00618
LMG7974_00553
LMG7974_01511
LMG7974_01758
LMG7974_01754
LMG7974_00513
LMG7974_00693
LMG7974_01332
LMG7974_00141
LMG7974_00053
LMG7974_00277
LMG7974_00276
LMG7974_00259
LMG7974_00254
LMG7974_00264
LMG7974_00263
LMG7974_00202
LMG7974_00201
LMG7974_00199
LMG7974_00609
LMG7974_01738
LMG7974_00554
LMG7974_00547
LMG7974_00719
LMG7974_01493
LMG7974_01490
LMG7974_00903
LMG7974_01484
LMG7974_00037

Campylobacter
suis
LMG8286
locus tag
LMG8286_00228
LMG8286_00202
LMG8286_01401
LMG8286_01056
LMG8286_00192
LMG8286_00684
LMG8286_00478
LMG8286_00214
LMG8286_00934
LMG8286_01462
LMG8286_01670
LMG8286_00847
LMG8286_00339
LMG8286_01470
LMG8286_00061
LMG8286_01079
LMG8286_01049
LMG8286_01134
LMG8286_01143
LMG8286_01164
LMG8286_01052
LMG8286_01090
LMG8286_01792
LMG8286_01794
LMG8286_00069
LMG8286_00086
LMG8286_00204
LMG8286_00203
LMG8286_00201
LMG8286_00200
LMG8286_00199
LMG8286_00188
LMG8286_00186
LMG8286_00212
LMG8286_00216
LMG8286_00217
LMG8286_00221
LMG8286_01284
LMG8286_01291
LMG8286_01647
LMG8286_00926
LMG8286_00881
LMG8286_01062
LMG8286_01061
LMG8286_00843
LMG8286_01278
LMG8286_00655
LMG8286_00805
LMG8286_00251
LMG8286_01641
LMG8286_01637
LMG8286_00582
LMG8286_01368
LMG8286_00440
LMG8286_01263
LMG8286_00780
LMG8286_00389
LMG8286_00388
LMG8286_00491
LMG8286_00488
LMG8286_00379
LMG8286_00378
LMG8286_00421
LMG8286_00420
LMG8286_00418
LMG8286_00640
LMG8286_00541
LMG8286_00509
LMG8286_00958
LMG8286_01391
LMG8286_01397
LMG8286_01400
LMG8286_00062
LMG8286_01406
LMG8286_01565

Gene

Annotation

ftsE
soj
fur
fabF
exbD_1
msbA
cbf2
group_156
mepM
cdsA
recR
group_1670
resA_2
accB
dxs
group_1702
recJ
rsmA
group_1719
coaE
murE
group_1731
mqnD
murB
gerN
group_1735
fmt
birA
parB
atpG_1
atpF
cpoB
fabD
bamA
tsaB
thrB
rimP
folK
fas6
ispDF
algC
rimO
mraY
gpmI
group_1758
lgt
group_1763
truD
tpiA
glmS
gpt
yaaA
rpoBC_2
secA
trpS
era
group_1780
yidC
pepD
cmoB
prmC
htpX
hemL
group_1787
lepB
aspC
tgt
glyS
copA_2
pyk
group_1794
group_1795
perR
aroE
lptD

Cell division ATP-binding protein FtsE
Sporulation initiation inhibitor protein Soj
Ferric uptake regulation protein
3-oxoacyl-[acyl-carrier-protein] synthase 2
Biopolymer transport protein ExbD
Lipid A export ATP-binding/permease protein MsbA
Putative peptidyl-prolyl cis-trans isomerase Cbf2
hypothetical protein
Murein DD-endopeptidase MepM
hypothetical protein
Recombination protein RecR
hypothetical protein
Thiol-disulfide oxidoreductase ResA
Biotin carboxyl carrier protein of acetyl-CoA carboxylase
1-deoxy-D-xylulose-5-phosphate synthase
hypothetical protein
Single-stranded-DNA-specific exonuclease RecJ
Ribosomal RNA small subunit methyltransferase A
putative RNA pseudouridine synthase
Dephospho-CoA kinase
UDP-N-acetylmuramoyl-L-alanyl-D-glutamate--2,6-diaminopimelate ligase
putative protein
1,4-dihydroxy-6-naphtoate synthase
UDP-N-acetylenolpyruvoylglucosamine reductase
Na(+)/H(+)-K(+) antiporter GerN
hypothetical protein
Methionyl-tRNA formyltransferase
Bifunctional ligase/repressor BirA
putative chromosome-partitioning protein ParB
ATP synthase subunit b'
ATP synthase subunit b
Cell division coordinator CpoB
Malonyl CoA-acyl carrier protein transacylase
Outer membrane protein assembly factor BamA
hypothetical protein
Homoserine kinase
Ribosome maturation factor RimP
hypothetical protein
hypothetical protein
Bifunctional enzyme IspD/IspF
Phosphomannomutase/phosphoglucomutase
Ribosomal protein S12 methylthiotransferase RimO
Phospho-N-acetylmuramoyl-pentapeptide-transferase
2,3-bisphosphoglycerate-independent phosphoglycerate mutase
hypothetical protein
Phosphatidylglycerol--prolipoprotein diacylglyceryl transferase
hypothetical protein
tRNA pseudouridine synthase D
Triosephosphate isomerase
Glutamine--fructose-6-phosphate aminotransferase [isomerizing]
Xanthine phosphoribosyltransferase
hypothetical protein
Bifunctional DNA-directed RNA polymerase subunit beta-beta'
Protein translocase subunit SecA
Tryptophan--tRNA ligase
GTPase Era
hypothetical protein
Membrane protein insertase YidC
Cytosol non-specific dipeptidase
tRNA U34 carboxymethyltransferase
Release factor glutamine methyltransferase
Protease HtpX
Glutamate-1-semialdehyde 2,1-aminomutase
hypothetical protein
Signal peptidase I
Aspartate aminotransferase
Queuine tRNA-ribosyltransferase
Glycine--tRNA ligase beta subunit
putative copper-importing P-type ATPase A
Pyruvate kinase
hypothetical protein
hypothetical protein
hypothetical protein
Shikimate dehydrogenase (NADP(+))
LPS-assembly protein LptD
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Campylobacter
majalis
LMG7974
locus tag
LMG7974_01375
LMG7974_01372
LMG7974_01369
LMG7974_01365
LMG7974_01363
LMG7974_00104
LMG7974_00101
LMG7974_00097
LMG7974_00094
LMG7974_00628
LMG7974_00334
LMG7974_00091
LMG7974_00088
LMG7974_00081
LMG7974_01732
LMG7974_01730
LMG7974_00187
LMG7974_00004
LMG7974_00598
LMG7974_00604

Campylobacter
suis
LMG8286
locus tag
LMG8286_00224
LMG8286_00227
LMG8286_00230
LMG8286_00234
LMG8286_00236
LMG8286_00682
LMG8286_00685
LMG8286_00689
LMG8286_00692
LMG8286_00694
LMG8286_00266
LMG8286_00742
LMG8286_00745
LMG8286_00715
LMG8286_00551
LMG8286_00553
LMG8286_00287
LMG8286_00274
LMG8286_00673
LMG8286_00668

LMG7974_00576

LMG8286_00702

murG

LMG7974_00541
LMG7974_01528
LMG7974_01529
LMG7974_01100
LMG7974_00281
LMG7974_01386
LMG7974_01108
LMG7974_01109
LMG7974_01111
LMG7974_01114
LMG7974_01093
LMG7974_01553
LMG7974_01557
LMG7974_00074
LMG7974_00072
LMG7974_01155
LMG7974_00311
LMG7974_00312
LMG7974_00315
LMG7974_00786
LMG7974_01172
LMG7974_01410
LMG7974_01409
LMG7974_01408
LMG7974_01407
LMG7974_00545
LMG7974_01072
LMG7974_01078
LMG7974_01079
LMG7974_01080
LMG7974_01085
LMG7974_00559
LMG7974_01788
LMG7974_00009
LMG7974_00751
LMG7974_00749
LMG7974_00746
LMG7974_00745
LMG7974_01743
LMG7974_01499
LMG7974_01053
LMG7974_01507
LMG7974_00662
LMG7974_00664
LMG7974_00665
LMG7974_01331
LMG7974_01482
LMG7974_00423
LMG7974_00429
LMG7974_00640
LMG7974_00638
LMG7974_00297
LMG7974_00440
LMG7974_00781
LMG7974_00783
LMG7974_00767
LMG7974_00896
LMG7974_00895
LMG7974_00891
LMG7974_01441

LMG8286_00701
LMG8286_00773
LMG8286_00774
LMG8286_00455
LMG8286_00644
LMG8286_01271
LMG8286_00486
LMG8286_00485
LMG8286_00483
LMG8286_00481
LMG8286_00468
LMG8286_00475
LMG8286_00479
LMG8286_00762
LMG8286_00764
LMG8286_00838
LMG8286_00837
LMG8286_00836
LMG8286_00833
LMG8286_00408
LMG8286_00801
LMG8286_00524
LMG8286_00525
LMG8286_00526
LMG8286_00527
LMG8286_00759
LMG8286_00332
LMG8286_00326
LMG8286_00325
LMG8286_00324
LMG8286_00319
LMG8286_00504
LMG8286_00862
LMG8286_00893
LMG8286_00901
LMG8286_00903
LMG8286_00906
LMG8286_00907
LMG8286_00912
LMG8286_00335
LMG8286_00724
LMG8286_00343
LMG8286_01337
LMG8286_01339
LMG8286_01340
LMG8286_00441
LMG8286_01318
LMG8286_01385
LMG8286_01378
LMG8286_00822
LMG8286_00820
LMG8286_00950
LMG8286_00155
LMG8286_00177
LMG8286_00175
LMG8286_00211
LMG8286_00055
LMG8286_00054
LMG8286_00051
LMG8286_00046

yggS
tsaE
group_1822
hemA
mltG
yajL
gloC
nadE
lpxK
kdsB
dsbD
ompA
nth_2
yfiC
lapB_1
yqgF
dprA
group_1857
rnr
bamD
trmA
truA
group_1862
pppA
uppS
aroH
trmD
waaA
smc
group_1869
rlhA
group_1871
dinG
priA
folC
group_1878
secF
secD
pepF1
truB
resA_3
ftsI
group_1888
rsmG
ribA
lolC
pyrE_1
murC
ileS
rsmH
ppiD
aroA
group_1906
group_1907
plsX
polA
lysA
group_1911
tal
lpxH

Gene

Annotation

rluD
trmB
smc_2
tyrS
group_1803
group_1804
cysS
ddl
murF
ackA
rlpA
queA
hemW
folP
aroB
mtaB
mltC
ybeY
murA
tmk

Ribosomal large subunit pseudouridine synthase D
tRNA (guanine-N(7)-)-methyltransferase
hypothetical protein
Tyrosine--tRNA ligase
hypothetical protein
putative zinc protease
Cysteine--tRNA ligase
D-alanine--D-alanine ligase
UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase
Acetate kinase
Endolytic peptidoglycan transglycosylase RlpA
S-adenosylmethionine:tRNA ribosyltransferase-isomerase
Heme chaperone HemW
Bifunctional dihydropteroate synthase/dihydropteroate reductase
3-dehydroquinate synthase
Threonylcarbamoyladenosine tRNA methylthiotransferase MtaB
Membrane-bound lytic murein transglycosylase C
Endoribonuclease YbeY
UDP-N-acetylglucosamine 1-carboxyvinyltransferase
Thymidylate kinase
UDP-N-acetylglucosamine--N-acetylmuramyl-(pentapeptide) pyrophosphorylundecaprenol N-acetylglucosamine transferase
Pyridoxal phosphate homeostasis protein
hypothetical protein
putative protein
Glutamyl-tRNA reductase
Endolytic murein transglycosylase
Protein/nucleic acid deglycase 3
putative protein
NH(3)-dependent NAD(+) synthetase
Tetraacyldisaccharide 4'-kinase
3-deoxy-manno-octulosonate cytidylyltransferase
Thiol:disulfide interchange protein DsbD
Peptidoglycan-associated lipoprotein
Endonuclease III
tRNA1(Val) (adenine(37)-N6)-methyltransferase
hypothetical protein
Putative pre-16S rRNA nuclease
hypothetical protein
hypothetical protein
Ribonuclease R
Outer membrane protein assembly factor BamD
tRNA/tmRNA (uracil-C(5))-methyltransferase
tRNA pseudouridine synthase A
hypothetical protein
Prepilin peptidase PppA
Isoprenyl transferase
Phospho-2-dehydro-3-deoxyheptonate aldolase
tRNA (guanine-N(1)-)-methyltransferase
3-deoxy-D-manno-octulosonic acid transferase
Chromosome partition protein Smc
GTP cyclohydrolase 1 type 2
hypothetical protein
hypothetical protein
3'-5' exonuclease DinG
primosomal protein N'
Dihydrofolate synthase/folylpolyglutamate synthase
hypothetical protein
Protein translocase subunit SecF
Protein translocase subunit SecD
Oligoendopeptidase F, plasmid
tRNA pseudouridine synthase B
Thiol-disulfide oxidoreductase ResA
Peptidoglycan D,D-transpeptidase FtsI
hypothetical protein
Ribosomal RNA small subunit methyltransferase G
GTP cyclohydrolase-2
Lipoprotein-releasing system transmembrane protein LolC
Orotate phosphoribosyltransferase
UDP-N-acetylmuramate--L-alanine ligase
Isoleucine--tRNA ligase
Ribosomal RNA small subunit methyltransferase H
hypothetical protein
3-phosphoshikimate 1-carboxyvinyltransferase
dITP/XTP pyrophosphatase
hypothetical protein
Phosphate acyltransferase
DNA polymerase I
Diaminopimelate decarboxylase
hypothetical protein
Transaldolase
UDP-2,3-diacylglucosamine hydrolase
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Campylobacter
majalis
LMG7974
locus tag
LMG7974_01149
LMG7974_01262
LMG7974_01238
LMG7974_00923
LMG7974_00927
LMG7974_00488
LMG7974_00487
LMG7974_00829
LMG7974_01889
LMG7974_00816
LMG7974_00819
LMG7974_01139
LMG7974_01283
LMG7974_01280
LMG7974_01126
LMG7974_00978
LMG7974_00985
LMG7974_00986
LMG7974_01142
LMG7974_01144
LMG7974_01420
LMG7974_00860
LMG7974_01235
LMG7974_00441
LMG7974_00941
LMG7974_01101
LMG7974_01137
LMG7974_00378
LMG7974_00489
LMG7974_00493
LMG7974_00476
LMG7974_00474
LMG7974_00472
LMG7974_00468
LMG7974_00465
LMG7974_01708
LMG7974_01709
LMG7974_01713
LMG7974_00717
LMG7974_00992
LMG7974_01094
LMG7974_00370
LMG7974_00413
LMG7974_00394
LMG7974_00617
LMG7974_01321
LMG7974_01753
LMG7974_01333
LMG7974_00145
LMG7974_00148
LMG7974_01037
LMG7974_00203
LMG7974_00200
LMG7974_00026
LMG7974_01496
LMG7974_01492
LMG7974_00234
LMG7974_00038
LMG7974_00035
LMG7974_01376
LMG7974_01077
LMG7974_01370
LMG7974_01367
LMG7974_00542
LMG7974_01091
LMG7974_00100
LMG7974_00098
LMG7974_00095
LMG7974_00627
LMG7974_00538
LMG7974_00176
LMG7974_00339
LMG7974_00338
LMG7974_00336
LMG7974_00335
LMG7974_00330
LMG7974_00329
LMG7974_00327
LMG7974_00326
LMG7974_00090
LMG7974_00089
LMG7974_00085

Campylobacter
suis
LMG8286
locus tag
LMG8286_01017
LMG8286_01024
LMG8286_01436
LMG8286_01435
LMG8286_01431
LMG8286_01425
LMG8286_01424
LMG8286_00992
LMG8286_01013
LMG8286_01033
LMG8286_01030
LMG8286_01156
LMG8286_01461
LMG8286_01464
LMG8286_01580
LMG8286_00032
LMG8286_00025
LMG8286_00024
LMG8286_01181
LMG8286_01178
LMG8286_01133
LMG8286_01593
LMG8286_01161
LMG8286_00156
LMG8286_01041
LMG8286_00454
LMG8286_01126
LMG8286_00072
LMG8286_00089
LMG8286_00085
LMG8286_00198
LMG8286_00196
LMG8286_00194
LMG8286_00190
LMG8286_00187
LMG8286_00167
LMG8286_00166
LMG8286_00162
LMG8286_01292
LMG8286_01064
LMG8286_00462
LMG8286_00840
LMG8286_00108
LMG8286_00121
LMG8286_00656
LMG8286_01547
LMG8286_01636
LMG8286_00439
LMG8286_01258
LMG8286_01256
LMG8286_01530
LMG8286_00422
LMG8286_00419
LMG8286_00295
LMG8286_01394
LMG8286_01398
LMG8286_01330
LMG8286_01566
LMG8286_01563
LMG8286_00223
LMG8286_00327
LMG8286_00229
LMG8286_00232
LMG8286_00700
LMG8286_00679
LMG8286_00686
LMG8286_00688
LMG8286_00691
LMG8286_00695
LMG8286_00572
LMG8286_00259
LMG8286_00261
LMG8286_00262
LMG8286_00264
LMG8286_00265
LMG8286_00270
LMG8286_00271
LMG8286_00272
LMG8286_00273
LMG8286_00743
LMG8286_00744
LMG8286_00711

Gene

Annotation

group_1914
lpxA
queH
trxB
hom
rsmE
group_1920
group_1921
group_1922
def
tig
pcm
dxr
rqcH
group_1928
hpr
mdtE
bepE
ruvC
dnaN
rnj
mntB_1
rnhB
yajR
group_1944
ispB
ung
bioB
gppA_1
plsY
atpD_1
atpG_2
atpC
tolB
slyD
group_1956
dusB
accD
mnmA_1
murD
acpS
nusA
group_1990
rexB
rsmD
group_1998
group_2000
lolA
kdsA
nusB
prmA
group_2013
folD
ruvB_1
coaX
gatC
uvrC
group_2022
pnp
mrdB
rluD_2
group_2026
rpoZ
mmpA
pgsA
murJ
ruvA
menH
plsX_1
valS
adk
nadK
recN
ycfH
mltD
lptA
engB
group_2042
mrdA
tatC
tatB
rppH

hypothetical protein
Acyl-[acyl-carrier-protein]--UDP-N-acetylglucosamine O-acyltransferase
Epoxyqueuosine reductase QueH
Thioredoxin reductase
Homoserine dehydrogenase
Ribosomal RNA small subunit methyltransferase E
hypothetical protein
hypothetical protein
hypothetical protein
Peptide deformylase
Trigger factor
Protein-L-isoaspartate O-methyltransferase
1-deoxy-D-xylulose 5-phosphate reductoisomerase
hypothetical protein
hypothetical protein
Putative 2-hydroxyacid dehydrogenase
Multidrug resistance protein MdtE
Efflux pump membrane transporter BepE
Crossover junction endodeoxyribonuclease RuvC
Beta sliding clamp
Ribonuclease J
Manganese transport system membrane protein MntB
Ribonuclease HII
Inner membrane transport protein YajR
Nucleoid-associated protein
Octaprenyl diphosphate synthase
Uracil-DNA glycosylase
Biotin synthase
Guanosine-5'-triphosphate,3'-diphosphate pyrophosphatase
Glycerol-3-phosphate acyltransferase
ATP synthase subunit delta
ATP synthase gamma chain
ATP synthase epsilon chain
Tol-Pal system protein TolB
hypothetical protein
hypothetical protein
tRNA-dihydrouridine synthase B
Acetyl-coenzyme A carboxylase carboxyl transferase subunit beta
tRNA-specific 2-thiouridylase MnmA
UDP-N-acetylmuramoylalanine--D-glutamate ligase
Holo-[acyl-carrier-protein] synthase
Transcription termination/antitermination protein NusA
hypothetical protein
hypothetical protein
Ribosomal RNA small subunit methyltransferase D
hypothetical protein
hypothetical protein
Outer-membrane lipoprotein carrier protein
2-dehydro-3-deoxyphosphooctonate aldolase
Transcription antitermination protein NusB
Ribosomal protein L11 methyltransferase
hypothetical protein
Bifunctional protein FolD protein
Holliday junction ATP-dependent DNA helicase RuvB
Type III pantothenate kinase
Glutamyl-tRNA(Gln) amidotransferase subunit C
UvrABC system protein C
hypothetical protein
Polyribonucleotide nucleotidyltransferase
Peptidoglycan glycosyltransferase MrdB
hypothetical protein
hypothetical protein
DNA-directed RNA polymerase subunit omega
Metalloprotease MmpA
CDP-diacylglycerol--glycerol-3-phosphate 3-phosphatidyltransferase
Lipid II flippase MurJ
Holliday junction ATP-dependent DNA helicase RuvA
2-succinyl-6-hydroxy-2,4-cyclohexadiene-1-carboxylate synthase
hypothetical protein
Valine--tRNA ligase
Adenylate kinase
NAD kinase
DNA repair protein RecN
putative metal-dependent hydrolase YcfH
hypothetical protein
Lipopolysaccharide export system protein LptA
putative GTP-binding protein EngB
hypothetical protein
Peptidoglycan D,D-transpeptidase MrdA
Sec-independent protein translocase protein TatC
Sec-independent protein translocase protein TatB
RNA pyrophosphohydrolase
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Campylobacter
majalis
LMG7974
locus tag
LMG7974_00083
LMG7974_00082
LMG7974_00080
LMG7974_00079
LMG7974_00193
LMG7974_00197
LMG7974_01733
LMG7974_00184
LMG7974_00183
LMG7974_00605
LMG7974_00050
LMG7974_00623
LMG7974_00529
LMG7974_00531
LMG7974_01554
LMG7974_01061
LMG7974_01063
LMG7974_01405
LMG7974_01404
LMG7974_01073
LMG7974_01054
LMG7974_01088
LMG7974_01787
LMG7974_01547
LMG7974_00748
LMG7974_00458
LMG7974_00455
LMG7974_01694
LMG7974_01696
LMG7974_01700
LMG7974_01689
LMG7974_00040
LMG7974_00666
LMG7974_00669
LMG7974_00434
LMG7974_00430
LMG7974_00641
LMG7974_00299
LMG7974_00298
LMG7974_00296
LMG7974_00294
LMG7974_01046
LMG7974_01048
LMG7974_01852
LMG7974_00780
LMG7974_00784
LMG7974_00841
LMG7974_00905
LMG7974_00894
LMG7974_01438
LMG7974_01878
LMG7974_00930
LMG7974_00931
LMG7974_00932
LMG7974_01022
LMG7974_00119
LMG7974_01025
LMG7974_01026
LMG7974_01029
LMG7974_01286
LMG7974_01695
LMG7974_01145
LMG7974_01426
LMG7974_01436
LMG7974_01896
LMG7974_01003
LMG7974_00935
LMG7974_00389
LMG7974_00463
LMG7974_01712
LMG7974_00771
LMG7974_00964
LMG7974_00369
LMG7974_00368
LMG7974_00022
LMG7974_01513
LMG7974_00359
LMG7974_00577
LMG7974_00557
LMG7974_01488
LMG7974_01487
LMG7974_01366

Campylobacter
suis
LMG8286
locus tag
LMG8286_00713
LMG8286_00714
LMG8286_00716
LMG8286_00717
LMG8286_00412
LMG8286_00416
LMG8286_00550
LMG8286_00284
LMG8286_00283
LMG8286_00642
LMG8286_00777
LMG8286_00748
LMG8286_00361
LMG8286_00359
LMG8286_00476
LMG8286_00431
LMG8286_00429
LMG8286_00529
LMG8286_00530
LMG8286_00331
LMG8286_00723
LMG8286_00316
LMG8286_00863
LMG8286_00928
LMG8286_00904
LMG8286_00348
LMG8286_00351
LMG8286_01446
LMG8286_01448
LMG8286_01453
LMG8286_01441
LMG8286_01568
LMG8286_01341
LMG8286_01344
LMG8286_01383
LMG8286_01379
LMG8286_00823
LMG8286_00944
LMG8286_00949
LMG8286_00951
LMG8286_00953
LMG8286_00666
LMG8286_00664
LMG8286_01716
LMG8286_00178
LMG8286_00174
LMG8286_00065
LMG8286_00064
LMG8286_00053
LMG8286_00044
LMG8286_00039
LMG8286_01429
LMG8286_01428
LMG8286_01427
LMG8286_01015
LMG8286_00975
LMG8286_01083
LMG8286_01085
LMG8286_01087
LMG8286_01458
LMG8286_01447
LMG8286_01177
LMG8286_01138
LMG8286_01145
LMG8286_01597
LMG8286_01100
LMG8286_01046
LMG8286_00078
LMG8286_00185
LMG8286_00163
LMG8286_00215
LMG8286_01055
LMG8286_00841
LMG8286_00842
LMG8286_00157
LMG8286_00249
LMG8286_01326
LMG8286_00703
LMG8286_00506
LMG8286_01402
LMG8286_01403
LMG8286_00233

Gene

Annotation

group_2047
group_2048
ligA_1
tlyA
pepA
ywlF
group_2053
fbp
group_2060
hisS
rplI
lpxD
nadE_2
aguA
group_2067
group_2071
iscR
coaBC
glmU
rimM
ftsY
glnA
rpe
groS
leuS
alaS
pbpF
argS
gmk
tsf
psbV
group_2093
hemB
hemN
nit1
gatA
ftsL
rpsA
ispH
pheT
group_2106
gpsA
atpB
rarA
ndk
fabH
xseA
menG
pth
lpxB
surE
rodZ
rlmB
rsmI
iscS
aroC
secG
frr
group_2148
tsaD
tatA
gyrB
rlmN
nrdA
exoA
rplR
rpoA
topA
pfs
rlmH
lpxC
accA
group_2197
miaB
nspC
gapA
hemE
ftsW
trmL
lysU
glyA
relA

hypothetical protein
hypothetical protein
DNA ligase
16S/23S rRNA (cytidine-2'-O)-methyltransferase TlyA
Cytosol aminopeptidase
Putative sugar phosphate isomerase YwlF
hypothetical protein
Fructose-1,6-bisphosphatase class 1
hypothetical protein
Histidine--tRNA ligase
50S ribosomal protein L9
UDP-3-O-acylglucosamine N-acyltransferase
N-carbamoyl-D-amino acid hydrolase
Agmatine deiminase
hypothetical protein
3',5'-cyclic-nucleotide phosphodiesterase
HTH-type transcriptional regulator IscR
Coenzyme A biosynthesis bifunctional protein CoaBC
Bifunctional protein GlmU
Ribosome maturation factor RimM
Signal recognition particle receptor FtsY
Glutamine synthetase
Ribulose-phosphate 3-epimerase
10 kDa chaperonin
Leucine--tRNA ligase
Alanine--tRNA ligase
Penicillin-binding protein 1F
Arginine--tRNA ligase
Guanylate kinase
Elongation factor Ts
hypothetical protein
hypothetical protein
Delta-aminolevulinic acid dehydratase
Oxygen-independent coproporphyrinogen III oxidase
hypothetical protein
Glutamyl-tRNA(Gln) amidotransferase subunit A
hypothetical protein
30S ribosomal protein S1
4-hydroxy-3-methylbut-2-enyl diphosphate reductase
Phenylalanine--tRNA ligase beta subunit
putative HIT-like protein
Glycerol-3-phosphate dehydrogenase [NAD(P)+]
ATP synthase subunit a
putative AAA domain-containing protein
Nucleoside diphosphate kinase
3-oxoacyl-[acyl-carrier-protein] synthase 3
Exodeoxyribonuclease 7 large subunit
Demethylmenaquinone methyltransferase
Peptidyl-tRNA hydrolase
Lipid-A-disaccharide synthase
5'-nucleotidase SurE
hypothetical protein
23S rRNA (guanosine-2'-O-)-methyltransferase RlmB
Ribosomal RNA small subunit methyltransferase I
Cysteine desulfurase IscS
Chorismate synthase
hypothetical protein
Ribosome-recycling factor
hypothetical protein
tRNA N6-adenosine threonylcarbamoyltransferase
Sec-independent protein translocase protein TatA
DNA gyrase subunit B
putative dual-specificity RNA methyltransferase RlmN
Ribonucleoside-diphosphate reductase 1 subunit alpha
Exodeoxyribonuclease
50S ribosomal protein L18
DNA-directed RNA polymerase subunit alpha
DNA topoisomerase 1
Aminodeoxyfutalosine nucleosidase
Ribosomal RNA large subunit methyltransferase H
UDP-3-O-acyl-N-acetylglucosamine deacetylase
Acetyl-coenzyme A carboxylase carboxyl transferase subunit alpha
hypothetical protein
tRNA-2-methylthio-N(6)-dimethylallyladenosine synthase
Carboxynorspermidine/carboxyspermidine decarboxylase
Glyceraldehyde-3-phosphate dehydrogenase 1
Uroporphyrinogen decarboxylase
putative peptidoglycan glycosyltransferase FtsW
tRNA (cytidine(34)-2'-O)-methyltransferase
Lysine--tRNA ligase, heat inducible
Serine hydroxymethyltransferase
GTP pyrophosphokinase
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Campylobacter
majalis
LMG7974
locus tag
LMG7974_01364
LMG7974_00332
LMG7974_00078
LMG7974_01524
LMG7974_01804
LMG7974_00182
LMG7974_00603
LMG7974_01096
LMG7974_01099
LMG7974_01390
LMG7974_01555
LMG7974_01745
LMG7974_01790
LMG7974_00508
LMG7974_00365
LMG7974_00295
LMG7974_01476
LMG7974_01474
LMG7974_01047
LMG7974_01052
LMG7974_00308
LMG7974_00843
LMG7974_00732
LMG7974_00897
LMG7974_01265
LMG7974_01261
LMG7974_01241
LMG7974_00906
LMG7974_00815
LMG7974_01254
LMG7974_01128
LMG7974_01023
LMG7974_01143
LMG7974_00821
LMG7974_00876
LMG7974_01001
LMG7974_00968
LMG7974_00491
LMG7974_00462
LMG7974_01772
LMG7974_00357
LMG7974_00416
LMG7974_00436
LMG7974_00147
LMG7974_00105
LMG7974_00096
LMG7974_00177
LMG7974_00084
LMG7974_01349
LMG7974_00076
LMG7974_00070
LMG7974_01067
LMG7974_00560
LMG7974_01502
LMG7974_00431
LMG7974_00014
LMG7974_01056
LMG7974_01256
LMG7974_01148
LMG7974_00873
LMG7974_01300
LMG7974_00707
LMG7974_00442
LMG7974_00689
LMG7974_00692
LMG7974_01368
LMG7974_00106
LMG7974_00174
LMG7974_00188
LMG7974_01074
LMG7974_01076
LMG7974_01081
LMG7974_01690
LMG7974_00307
LMG7974_00310
LMG7974_00118
LMG7974_01874
LMG7974_00828
LMG7974_01418
LMG7974_01014
LMG7974_01004
LMG7974_01704

Campylobacter
suis
LMG8286
locus tag
LMG8286_00235
LMG8286_00268
LMG8286_00718
LMG8286_00730
LMG8286_00736
LMG8286_00282
LMG8286_00669
LMG8286_00459
LMG8286_00456
LMG8286_01266
LMG8286_00477
LMG8286_00910
LMG8286_01536
LMG8286_00170
LMG8286_01319
LMG8286_00952
LMG8286_01660
LMG8286_01662
LMG8286_00665
LMG8286_00725
LMG8286_00938
LMG8286_01074
LMG8286_00066
LMG8286_00056
LMG8286_01021
LMG8286_01025
LMG8286_00978
LMG8286_00988
LMG8286_01034
LMG8286_01029
LMG8286_01080
LMG8286_01081
LMG8286_01180
LMG8286_01048
LMG8286_01148
LMG8286_01098
LMG8286_01096
LMG8286_00087
LMG8286_00184
LMG8286_01650
LMG8286_00239
LMG8286_00105
LMG8286_01554
LMG8286_01257
LMG8286_00681
LMG8286_00690
LMG8286_00260
LMG8286_00712
LMG8286_00704
LMG8286_00760
LMG8286_00766
LMG8286_00466
LMG8286_00503
LMG8286_00338
LMG8286_01380
LMG8286_00888
LMG8286_00720
LMG8286_00980
LMG8286_01174
LMG8286_01713
LMG8286_01796
LMG8286_01282
LMG8286_00127
LMG8286_01364
LMG8286_01367
LMG8286_00231
LMG8286_00680
LMG8286_00258
LMG8286_00288
LMG8286_00330
LMG8286_00328
LMG8286_00323
LMG8286_01442
LMG8286_00939
LMG8286_01814
LMG8286_00974
LMG8286_01603
LMG8286_01602
LMG8286_01131
LMG8286_01111
LMG8286_01101
LMG8286_00208

Gene

Annotation

IMPDH
kdsC
ribF
htpG
ctpA
metG
coaD
hemC
proS
dnaE
fba
metK
mnmG
ribE
gyrA
pheS
pckA
oadA
gatB
rny
dnaB
ydiK
serC
pheA
mreC
fabZ
bcp
dapB
comM
folE
cynT
yccA
dnaA
pyrG
thrZ
rplO
map
tcrA
ttcA
pgpA
gtaB
purA
group_2356
ribH
dapA
group_2365
aspS
lysC
xerH
czcO
group_2378
grpE
group_2380
smpB
guaB
uvrB
radA
group_2409
yfbR
thyX
recA
aroQ
group_2440
rplA
rpoBC_1
pyrH
fabL
ppa
group_2451
group_2458
ffh
glyQ
petB
ispG
group_2474
rnc
glmM
rpsT
rluB
rplV
rplF
rplU

Inosine-5'-monophosphate dehydrogenase
2-keto-3-deoxy-D-glycero-D-galacto-9-phosphonononic acid phosphatase
Bifunctional riboflavin kinase/FMN adenylyltransferase
Chaperone protein HtpG
Carboxy-terminal processing protease CtpA
Methionine--tRNA ligase
Phosphopantetheine adenylyltransferase
Porphobilinogen deaminase
Proline--tRNA ligase
DNA polymerase III subunit alpha
Fructose-bisphosphate aldolase
S-adenosylmethionine synthase
tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG
Riboflavin synthase
DNA gyrase subunit A
Phenylalanine--tRNA ligase alpha subunit
Phosphoenolpyruvate carboxykinase (ATP)
Oxaloacetate decarboxylase alpha chain
Aspartyl/glutamyl-tRNA(Asn/Gln) amidotransferase subunit B
Ribonuclease Y
Replicative DNA helicase
hypothetical protein
Phosphoserine aminotransferase
Bifunctional chorismate mutase/prephenate dehydratase
hypothetical protein
3-hydroxyacyl-[acyl-carrier-protein] dehydratase FabZ
Putative peroxiredoxin bcp
4-hydroxy-tetrahydrodipicolinate reductase
Competence protein ComM
GTP cyclohydrolase 1
Carbonic anhydrase 1
Modulator of FtsH protease YccA
Chromosomal replication initiator protein DnaA
CTP synthase
Threonine--tRNA ligase 2
50S ribosomal protein L15
Methionine aminopeptidase 1
Transcriptional regulatory protein TcrA
tRNA-cytidine(32) 2-sulfurtransferase
Phosphatidylglycerophosphatase A
UTP--glucose-1-phosphate uridylyltransferase
Adenylosuccinate synthetase
Carboxynorspermidine synthase
6,7-dimethyl-8-ribityllumazine synthase
4-hydroxy-tetrahydrodipicolinate synthase
hypothetical protein
Aspartate--tRNA(Asp/Asn) ligase
Aspartate kinase
Tyrosine recombinase XerH
Ferredoxin--NADP reductase
AP-4-A phosphorylase
Protein GrpE
hypothetical protein
SsrA-binding protein
Inosine-5'-monophosphate dehydrogenase
UvrABC system protein B
DNA repair protein RadA
hypothetical protein
5'-deoxynucleotidase YfbR
Flavin-dependent thymidylate synthase
Protein RecA
3-dehydroquinate dehydratase
Pyruvate:ferredoxin oxidoreductase
50S ribosomal protein L1
Bifunctional DNA-directed RNA polymerase subunit beta-beta'
Uridylate kinase
Enoyl-[acyl-carrier-protein] reductase [NADPH] FabL
Inorganic pyrophosphatase
hypothetical protein
hypothetical protein
Signal recognition particle protein
Glycine--tRNA ligase alpha subunit
Cytochrome b
4-hydroxy-3-methylbut-2-en-1-yl diphosphate synthase (flavodoxin)
hypothetical protein
Ribonuclease 3
Phosphoglucosamine mutase
30S ribosomal protein S20
Ribosomal large subunit pseudouridine synthase B
50S ribosomal protein L22
50S ribosomal protein L6
50S ribosomal protein L21
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Campylobacter
majalis
LMG7974
locus tag
LMG7974_00690
LMG7974_00516
LMG7974_01691
LMG7974_00180
LMG7974_01292
LMG7974_00990
LMG7974_00877
LMG7974_00776
LMG7974_01512
LMG7974_00046
LMG7974_00317
LMG7974_00550
LMG7974_00818
LMG7974_01141
LMG7974_01018
LMG7974_01017
LMG7974_01010
LMG7974_01007
LMG7974_01000
LMG7974_00475
LMG7974_00473
LMG7974_00687
LMG7974_00691
LMG7974_00608
LMG7974_00051
LMG7974_01065
LMG7974_01439
LMG7974_01019
LMG7974_01008
LMG7974_01005
LMG7974_00934
LMG7974_00966
LMG7974_01071
LMG7974_01546
LMG7974_01701
LMG7974_00012
LMG7974_01469
LMG7974_00933
LMG7974_01016
LMG7974_01013
LMG7974_01850
LMG7974_00391
LMG7974_01075
LMG7974_01785
LMG7974_00805
LMG7974_00893
LMG7974_01011
LMG7974_01849
LMG7974_00319
LMG7974_00031
LMG7974_00782
LMG7974_00936
LMG7974_01264
LMG7974_00683
LMG7974_00962
LMG7974_01012
LMG7974_00688
LMG7974_01015
LMG7974_00392
LMG7974_00740
LMG7974_00961
LMG7974_01002
LMG7974_00938
LMG7974_00937
LMG7974_01703
LMG7974_00861
LMG7974_01009
LMG7974_00739
LMG7974_00940
LMG7974_01020
LMG7974_00471
LMG7974_00741
LMG7974_00467
LMG7974_00189
LMG7974_00278
LMG7974_00775
LMG7974_00111
LMG7974_01498
LMG7974_00377
LMG7974_00752
LMG7974_00194
LMG7974_01050

Campylobacter
suis
LMG8286
locus tag
LMG8286_01365
LMG8286_00428
LMG8286_01443
LMG8286_00253
LMG8286_01072
LMG8286_00082
LMG8286_01150
LMG8286_00220
LMG8286_00250
LMG8286_00442
LMG8286_00831
LMG8286_00961
LMG8286_01031
LMG8286_01160
LMG8286_01115
LMG8286_01114
LMG8286_01107
LMG8286_01104
LMG8286_01097
LMG8286_00197
LMG8286_00195
LMG8286_01362
LMG8286_01366
LMG8286_00641
LMG8286_00778
LMG8286_00467
LMG8286_00045
LMG8286_01116
LMG8286_01105
LMG8286_01102
LMG8286_01047
LMG8286_01057
LMG8286_00333
LMG8286_00927
LMG8286_01454
LMG8286_00890
LMG8286_01667
LMG8286_01426
LMG8286_01113
LMG8286_01110
LMG8286_01276
LMG8286_00124
LMG8286_00329
LMG8286_00866
LMG8286_01473
LMG8286_00052
LMG8286_01108
LMG8286_01275
LMG8286_00829
LMG8286_01572
LMG8286_00176
LMG8286_01045
LMG8286_01022
LMG8286_01358
LMG8286_01163
LMG8286_01109
LMG8286_01363
LMG8286_01112
LMG8286_00123
LMG8286_01373
LMG8286_01162
LMG8286_01099
LMG8286_01043
LMG8286_01044
LMG8286_00207
LMG8286_01592
LMG8286_01106
LMG8286_01372
LMG8286_01042
LMG8286_01117
LMG8286_00193
LMG8286_01374
LMG8286_00189
LMG8286_00289
LMG8286_00390
LMG8286_00219
LMG8286_01671
LMG8286_00334
LMG8286_00846
LMG8286_00900
LMG8286_00413
LMG8286_00727

Gene

Annotation

rplJ
rpsO
petA
prs
ruvB_2
ahpC
infC
rbfA
pgk
cbpM
rpsF
group_2630
clpP
nrdB
rplD
rplW
rpsQ
rplE
secY
atpA
atpD_2
nusG
rplL
speA
hslV
dnaK
greA
rplC
rplX
rpsH
rplQ
acpP
rplS
groL
rpsB
group_2789
atpH
rpmE
rplB
rpsC
frdA
rpsI
rpsP
rpmB
dcd
rplY
rpmC
frdB
rpsR
efp
rpmF
rpsD
mreB
tufA
rplT
rplP
rplK
rpsS
rplM
rpsG
rpmI
rpsE
rpsM
rpsK
rpmA
mntB_2
rplN
rpsL
infA
rpsJ
tolQ_1
fusA
pal_2
gltX
mnmE
infB
sasA_2
pcrA
recG
mfd
yohD_1
yohD

50S ribosomal protein L10
30S ribosomal protein S15
Ubiquinol-cytochrome c reductase iron-sulfur subunit
Ribose-phosphate pyrophosphokinase
Holliday junction ATP-dependent DNA helicase RuvB
Alkyl hydroperoxide reductase C
Translation initiation factor IF-3
Ribosome-binding factor A
Phosphoglycerate kinase
hypothetical protein
30S ribosomal protein S6
putative transcriptional regulatory protein
ATP-dependent Clp protease proteolytic subunit
Ribonucleoside-diphosphate reductase subunit beta
50S ribosomal protein L4
50S ribosomal protein L23
30S ribosomal protein S17
50S ribosomal protein L5
Protein translocase subunit SecY
ATP synthase subunit alpha
ATP synthase subunit beta
Transcription termination/antitermination protein NusG
50S ribosomal protein L7/L12
Biosynthetic arginine decarboxylase
ATP-dependent protease subunit HslV
Chaperone protein DnaK
Transcription elongation factor GreA
50S ribosomal protein L3
50S ribosomal protein L24
30S ribosomal protein S8
50S ribosomal protein L17
Acyl carrier protein
50S ribosomal protein L19
60 kDa chaperonin
30S ribosomal protein S2
hypothetical protein
ATP synthase subunit c
50S ribosomal protein L31
50S ribosomal protein L2
30S ribosomal protein S3
Fumarate reductase flavoprotein subunit
30S ribosomal protein S9
30S ribosomal protein S16
50S ribosomal protein L28
dCTP deaminase
50S ribosomal protein L25
50S ribosomal protein L29
Fumarate reductase iron-sulfur subunit
30S ribosomal protein S18
Elongation factor P
50S ribosomal protein L32
30S ribosomal protein S4
Cell shape-determining protein MreB
Elongation factor Tu
50S ribosomal protein L20
50S ribosomal protein L16
50S ribosomal protein L11
30S ribosomal protein S19
50S ribosomal protein L13
30S ribosomal protein S7
50S ribosomal protein L35
30S ribosomal protein S5
30S ribosomal protein S13
30S ribosomal protein S11
50S ribosomal protein L27
Manganese transport system ATP-binding protein MntB
50S ribosomal protein L14
30S ribosomal protein S12
Translation initiation factor IF-1
30S ribosomal protein S10
Tol-Pal system protein TolQ
Elongation factor G
Peptidoglycan-associated lipoprotein
Glutamate--tRNA ligase
tRNA modification GTPase MnmE
Translation initiation factor IF-2
Adaptive-response sensory-kinase SasA
ATP-dependent DNA helicase PcrA
ATP-dependent DNA helicase RecG
Transcription-repair-coupling factor
hypothetical protein
Inner membrane protein YohD

305

Campylobacter
majalis
LMG7974
locus tag
LMG7974_00192
LMG7974_00503
LMG7974_01021
LMG7974_01036
LMG7974_00052
LMG7974_01263
LMG7974_00827
LMG7974_00110
LMG7974_01218
LMG7974_00318

Campylobacter
suis
LMG8286
locus tag
LMG8286_00411
LMG8286_01050
LMG8286_01014
LMG8286_01531
LMG8286_00779
LMG8286_01023
LMG8286_01601
LMG8286_01672
LMG8286_01469
LMG8286_00830

Gene

Annotation

ychF
nfuA_1
nfuA_2
ftsH_2
clpY
clpX
prfA
regX3
accC
ssb

Ribosome-binding ATPase YchF
Fe/S biogenesis protein NfuA
Fe/S biogenesis protein NfuA
ATP-dependent zinc metalloprotease FtsH
ATP-dependent protease ATPase subunit ClpY
ATP-dependent Clp protease ATP-binding subunit ClpX
Peptide chain release factor RF1
Sensory transduction protein regX3
Biotin carboxylase
Single-stranded DNA-binding protein
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